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ABSTRACT 
 
Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Colon 
Cancer. (August 2012) 
Satya Sreehari Pathi, B.V.M., Acharya N. G. Ranga Agricultural University, India; 
M.S., Texas A&M University, Kingsville 
Chair of Advisory Committee: Dr. Stephen H. Safe 
 
 Non-steroidal anti-inflammatory drugs (NSAIDs) and their NO derivatives (NO-
NSAIDs), and synthetic analogs are highly effective as anticancer agents that exhibit 
relatively low toxicity compared to most clinically used drugs. However, the mechanisms 
of action for NSAIDs and NO-NSAIDs are not well defined and this has restricted their 
clinical applications and applications for combined therapies. Earlier studies from our 
laboratory reported that specificity protein (Sp) transcription factors (Sp1, Sp3 and Sp4) 
are overexpressed in several types of human cancers including colon cancer and many 
Sp-regulated genes are pro-oncogenic and individual targets for cancer chemotherapy. 
Based on published results showing that NSAIDs downregulate several putative Sp-
regulated genes, we hypothesized that the anticancer properties of NSAIDs may be 
due, in part, to downregulation of Sp transcription factors. 
 NSAIDs and nitro derivatives of NSAIDs have been investigated in colon cancer 
cells and in vivo xenograft models. Aspirin and TA induced apoptosis and decreased 
colon cancer cell growth and tumor growth in vivo and downregulated genes associated 
with cell growth, survival, and angiogenesis. Previous RNA interference studies in this 
laboratory have shown that many of these genes are regulated, in part, by Sp 
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transcription factors Sp1, Sp3 and Sp4 that are overexpressed in colon and other 
cancer cell lines. Not surprisingly, these NSAIDs also decreased Sp1, Sp3 and Sp4 
proteins and Sp-regulated gene products in colon cancer cells and this was due to 
caspase-dependent proteolysis of Sp1, Sp3 and Sp4. Aspirin-induced activation of 
caspases and degradation of Spproteins was due to sequestration of zinc and could be 
reversed by addition of zinc sulphate, whereas TA mediated induction of caspases was 
independent of zinc ions and is currently being investigated.  
 GT-094 is a novel NO chimera-containing NSAID, which also inhibited colon 
cancer cell proliferation and induced apoptosis; these effects were accompanied by 
decreased mitochondrial membrane potential (MMP) and induction of reactive oxygen 
species (ROS), and were reversed after cotreatment with the antioxidant glutathione.  
GT-094 also downregulated Sp and Sp-dependent gene products and was due to 
decreased expression of microRNA-27a (miR-27a) and induction of ZBTB10, an Sp 
transcriptional repressor that is regulated by miR-27a in colon cancer cells.  Moreover, 
the effects of GT-094 on Sp1, Sp3, Sp4, miR-27a and ZBTB10 were also inhibited by 
glutathione suggesting that the anticancer activity of GT-094 in colon cancer cells is 
due, in part, to ROS-dependent disruption of miR-27a:ZBTB10. The importance of ROS 
induction in targeting Sp transcription factors was also confirmed using pro-oxidants 
such as ascorbic acid, hydrogen peroxide and t-butyl hydroperoxide and similar results 
have been observed in collaborative studies with other ROS inducers in colon cancer 
cells. Many cancer cell lines and tumors exhibit addiction to non-oncogenes such as 
Sp1, Sp3 and Sp4 for maintaining the oncogenic phenotype and future research will 
focus on the mechanisms of ROS-mediated targeting of Sp transcription factors which 
represents a novel approach for cancer chemotherapy. 
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CHAPTER I 
INTRODUCTION 
 
CANCER 
 Cancer is a group of diseases in which cells begin to proliferate in the absence 
of control and cancer cells typically exhibit increased growth and survival compared to 
normal cells. Cancer cells in one tissue can metastasize to other tissues/organs and 
this eventually leads to cancer related mortality. Cancer is a leading cause of death 
worldwide and deaths from cancer are projected to continue to increase, with an 
estimated 13.1 million deaths in 2030. In 2008, worldwide cancer deaths were nearly 
7.6 million and this accounted for 13% of all deaths and more than 12 million people 
were diagnosed with cancer.  
 The most commonly diagnosed cancers worldwide are lung (1.61 million, 12.7% 
of the total), breast (1.38 million, 10.9%) and colorectal cancers (1.23 million, 9.7%). 
The highest incidence of cancer deaths are from lung cancer (1.38 million, 18.2% of the 
total), stomach cancer (738,000 deaths, 9.7%) and liver cancer (696,000 deaths, 9.2%) 
and approximately 70% of all cancer deaths occur in low- and middle-income countries 
[1]. Cancer is the second highest cause of deaths in the US after heart disease and it 
accounts for 1 of every 4 deaths. In 2012, approximately 1,638,910 new cancer cases 
are expected to be diagnosed and 577,190 Americans are expected to die of cancer, 
i.e., more than 1,500 people a day (Fig. 1.1) [2].   
  
This dissertation follows the style of Carcinogenesis. 
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 The National Cancer Institute estimates that nearly 12 million Americans with a 
history of cancer were alive in January 2008 and some of these individuals were 
cancer-free, while others still had evidence of cancer and may be undergoing treatment. 
Since the risk of being diagnosed with cancer increases with age, most cases occur in 
middle aged or older people. About 77% of all cancers are diagnosed in persons 55 
years of age and older. Cancer researchers use the word ―risk‖ in different ways, most 
commonly expressing risk as lifetime risk or relative risk. Lifetime risk refers to the 
probability that an individual will develop or die from cancer over the course of a 
lifetime. 
  In the US, men have slightly less than a 1 in 2 lifetime risk of developing cancer; 
for women, the risk is a little more than 1 in 3. Relative risk is a measure of the strength 
of the relationship between risk factors and a particular cancer. It compares the risk of 
developing cancer for persons with a certain exposure or trait to the risk in persons who 
do not have this characteristic. For example, male smokers are about 23 times more 
likely to develop lung cancer than nonsmokers, so their relative risk is 23. Most relative 
risks are not this large. For example, women who have a first-degree relative (mother, 
sister, or daughter) with a history of breast cancer have about twice the risk of 
developing breast cancer, compared to women who do not have this family history. 
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Fig.1.1. Leading new cancer cases and deaths according to 2012 estimates [2]. 
 
 All cancers involve the malfunction of genes that control cell growth and division. 
About 5% of all cancers are strongly hereditary, in that an inherited genetic alteration 
confers a very high risk of developing one or more specific types of cancer. However, 
most cancers do not result from inherited genes but from damage to genes occurring 
during one‘s lifetime. Genetic damage may result from internal factors, such as 
hormones or the metabolism of nutrients within cells, or external factors, such as 
tobacco, chemicals, and excessive exposure to sunlight. These causal factors may act 
together or in sequence to initiate or promote the development of cancer. Ten or more 
years often pass between exposure to external factors and detectable cancer. Most 
importantly, development of cancer is due to genetic abnormalities in two classes of 
genes namely oncogenes and tumor suppressor genes. The first identified oncogenes 
were of viral origin with variable cellular functions ranging from their role as 
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transmembrane protein receptors to nuclear transcription factors. Tumor oncogenes are 
constitutive and activated by mutations and enhance cell proliferation and 
transformation, while tumor suppressor genes regulate apoptosis and cell division and 
are repressed in cancer cells. 
Mechanisms of Carcinogenesis. Carcinogenesis is the general term used for the 
development of cancer; and several well known cancer models show that tumor 
formation is a multistep process that can be categorized into different stages namely, 
initiation, promotion, progression, invasion and metastasis (Fig 1.2). 
 
 
Fig. 1.2. Different stages of carcinogenesis [3]. 
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 Initiation is the first stage of carcinogenesis and results from several studies 
indicate that initiation is caused by irreversible genetic changes which predispose 
susceptible normal cells to become malignant and immortalized. However, the 
efficiency of cancer initiation depends on cellular replicative DNA synthesis and cell 
division. DNA synthesis is primarly required for the fixation and the irreversibility of the 
initiated state [4, 5]. Genetic changes or DNA damage can result from ionizing radiation 
such as X-rays, chemical carcinogens and viruses like papilloma virus and Epstein-Barr 
virus. Exposure to mutagens does not cause observable changes in the cellular 
phenotype but increases the susceptibility for cancer formation. Several different 
models of cancer initiation have been proposed.  
 For example, mouse skin carcinogenesis involves genetic damage due to 
formation of covalent adducts between mutagens and DNA and these mutations are 
also observed in critical stem cell genes. Mutations of Ha-ras and N-ras oncogenes are 
responsible for development of benign papillomas and few papillomas become 
malignant squamous cell carcinomas (SCC) [6]. There is ample evidence that p53 acts 
as a tumor suppressor gene and mutations of p53 due to ultraviolet B radiation results 
in initiation of skin tumors in mouse models and humans [7, 8]. Loeb et al., [9] have 
proposed mutator phenotype hypothesis for  initiation and  suggest that the normal rate 
of mutations does not correlate with the number of mutations observed in cancer cells. 
It is hypothesized that mutations of genes involved in DNA synthesis, DNA repair, cell 
cycle, progression and apoptosis will amplify the basal mutation rate and are 
responsible for tumor initiation and promotion in a multi-hit model of carcinogenesis. 
 Tumor promotion is the second stage of carcinogenesis in which an initiated cell 
with mutations expands clonally and several pathways are involved in the promotion of 
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carcinogenesis. Induction of continuous proliferation and hyperplasia by direct activation 
of mitotic signaling pathways or indirectly in response to chronic wounding and/or 
inflammation, or due to a block in terminal differentiation or resistance to apoptosis is 
necessary to allow clonal expansion of mutated initiated cells to form tumors. In mouse 
models of carcinogenesis, tumor promotion involves mitotic pathways such as activation 
of epidermal growth factor receptor (EGFR) and Ras/Raf/mitogen-activated protein 
kinase (MAPK) signaling. Chronic inflammation results in inflammatory cell secretion of 
growth factors and cytokines such as tumor necrosis factor-α (TNF-α) and interleukins, 
as well as production of reactive oxygen species (ROS), all of which can stimulate cell 
proliferation. Persistent activation of these pathways leads to tumor promotion [10], 
which is dependent on favorable factors for cell growth such as tumor cell-stromal 
interactions, growth factors, angiogenesis, oxygen and many other factors. Even though 
DNA damage check points and apoptosis pathways may be activated by genetic events 
during initiation; >50% of human cancers  are defective in these pathways due to 
mutations in tumor suppressor genes such as p53, retinoblastoma (Rb), which regulate 
proapoptosis [11].  
 There are number of tumor promoters including phorbol esters, phenobarbitol, 
peroxisome proliferators, and biphenyls, many of which reversibly inhibit gap junctions 
[12]. A tumor promoter must be administered for weeks, months and even years and its 
effectiveness depends on the concentration in the target tissue. Tumor promotion is 
also reversible and after stopping promotion, cell growth decreases and apoptosis is 
increased. All cells exposed to promoters do not take part in the promotion stage, while 
cells  that are stimulated to divide, undifferentiated and survive apoptosis can contribute 
to instability and result in malignant neoplasia [13]. 
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 Tumor progression is the third stage of carcinogenesis in which preneoplastic 
and/or benign neoplasic cells are transformed into malignant lesions. The stage of 
progression is characterized by its karyotypic instability and development of irreversible, 
aneuploid malignant neoplasms which distinguishes tumor progression from both 
initiation and promotion [14]. These genomic alterations in neoplastic cells during 
progression are directly related to increased cell growth, invasiveness, metastatic 
instability and changes in the biochemical, morphological and physiological 
characteristics of the cells [15]. Angiogenesis is essential for neoplastic progression and 
contributes to malignancy and inhibition of angiogenesis delays neoplastic development 
[16]. Karyotypic alterations continue during progression in a variety of different 
neoplasms, such as multistage epidermal carcinogenesis, leukemia, lymphoma, 
hepatocarcinogenesis and colorectal carcinogenesis [17, 18].  
 Vogelstein et al., proposed a classical model of tumor progression in colorectal 
cancer progression, which involves successive waves of clonal selection [19]. 
According to this model, genetic alterations cause permanent genetic instability with 
high rate of chromosomal or base modification resulting in morphological and karyotypic 
changes that transform pre-neoplastic cells into neoplastic cells [20]. In colorectal 
cancers, there is a good correlation between gene mutations such as loss of 
chromosomes 8p and 18q and the severity of the disease measured by disease free 
survival at five years after surgery [21]. 
 Invasion and metastasis is fourth stage of carcinogenesis. The major reason for 
most cancer deaths is not due to the primary neoplasms, but secondary tumors 
metastasized to other sites. Drastic phenotypic and biochemical changes occur during 
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the metamorphosis of a normal cell into an invasive cancer cell due to changes in 
growth factor signaling, cell-cell adhesion, gene expression, motility or cell shape [22]. 
 
 
Fig. 1.3. Contribution of EMT to cancer progression and metastasis [23]. 
 
 
 Invasive cancer cells can secrete proteases which lyse barriers such as 
basement membranes in host cells and thereby facilitate migration of tumor cells to 
distant sites and angiogenesis at these sites [24]. Cancer cells of epithelial origin can 
adopt a mesenchymal-like phenotype and this is often referred to as an epithelial-
mesenchymal transition (EMT) which contributes to their metastatic phenotype (Fig. 
1.3). Various oncogenes, tumor suppressor genes and metastasis suppressor genes 
can affect the invasiveness and the metastatic potential of tumor cells. Due to the 
loosening of tissue structure as well as changes in the cytoskeleton such as the loss of 
cell adhesion molecules (CAM) and changes in integrin expression, epithelial cells may 
adopt a mesenchymal character. Dysregulation of the cadherin family and particularly 
the loss of E-cadherin and upregulation of N-cadherin are commonly observed in 
invasive cancer cells [23, 25]. The E-cadherin gene CDH-1 is also referred to as a 
metastasis suppressor gene, and loss of CDH1 induces an invasive phenotype in 
immortalized cells [26]. Cells of the innate and adaptive immune system, adjacent 
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stromal cells as well as chemokines and their receptors also play an important role in 
cancer cell metastasis and the tumor micro-environment, vascularization and the supply 
of cytokines also affect EMT.  
  It has recently been suggested that tumors consist of two types of cells – transit 
amplifying cells and cancer stem cells. Only cancer stem cells can proliferate 
indefinitely and these cells may play a critical and possibly essential role in tumor 
metastases [27]. Hanahan and Weinberg have six hallmarks of cancer (Fig. 1.4) that 
include sustained proliferative signaling, evading growth inhibitors, resisting apoptosis, 
enabling replicative immortality, sustained angiogenesis and tissue invasion and 
metastasis [28]. Recently two additional hallmarks of cancer namely reprogramming of 
energy metabolism and evading immune destruction are now considered as important 
determinants for cancer progression  [28] and these are discussed below. 
 
 
Fig.1.4. Characteristic features of malignant cell [29]. 
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Sustained proliferative signaling. The most important trait of cancer cells is their 
ability for sustained proliferative signaling through a number of different pathways. 
Cancer cells can also stimulate growth of normal cells within the tumor 
microenvironment and these cells secrete various growth factors that enhance cancer 
cell growth [30]. Overexpression of membrane growth factor receptors can also lead to 
enhanced cell proliferation; for example EGFR tyrosine kinase is overexpressed, 
amplified and dysregulated in many cancers and this receptor can engage in autocrine 
signaling and crosstalk with other kinase signaling cascades [31]. Somatic mutations 
also contribute to activation of signaling pathways usually activated by growth factor 
receptors. For example mitogen activated protein kinase (MAPK) pathway and 
phosphoinositide 3-kinase (PI3K) are constitutively activated in many tumor types due 
to activating mutations in B-Raf and the catalytic subunit of PI3K respectively [32, 33]. 
Evading growth inhibitors. Cancer cells can also circumvent powerful programs that 
negatively regulate cell proliferation and many of these programs include tumor 
suppressor genes. Two prototypical tumor suppressor genes, Rb and TP53 control two 
key cellular regulatory networks and govern the decisions of cells to proliferate or 
activate senescence and apoptosis. The Rb protein integrates signals from various 
extracellular and intracellular sources, while TP53 receives input from stress and 
abnormality sensors that decide whether a cell should or should not undergo cell cycle 
progression [34]. Cancer cells with defects in Rb and TP53 lose the services of these 
critical gate keepers of cell cycle progression and this result in continuous cell 
proliferation. For example, chimeric mice lacking the Rb gene exhibit proliferative 
abnormalities and continuous cell cycle progression leading to neoplasias, particularly 
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in the pituitary gland. TP53 null mice also develop abnormalities later in life in the form 
of leukemias and sarcomas [35, 36]. 
Resisting apoptosis. The concept of programmed cell death by apoptosis serves as a 
natural barrier to development of cancer and resistance to apoptosis is considered as 
an important hallmark of cancer. Tumor cells develop many strategies to circumvent 
apoptosis and most common among them is loss of TP53 tumor suppressor function, 
which eliminates the DNA damage sensor from inducing apoptosis. TP53 inhibits cell 
division by terminating the cell cycle at G1 or interphase for repair and in case of 
extensive DNA damage p53 activates apoptosis [37]. Inactivation of TP53 or TP53-
dependent genes leads to inhibition of apoptosis and formation of tumors. In addition 
cancer cells also inhibit apoptosis by overexpression of antiapototic regulators (bcl-2, 
Bcl-XL), survival signals (survivin, Igf1/2), and downregulation of proapoptotic factors 
(Bax, Bim, Puma) [38]. The multiplicity of pathways for inhibition of apoptosis in cancer 
cells demonstrates the importance of apoptosis inhibition as a hallmark of the 
progression of cells to malignancy. 
Enabling replicative immortality. Cancer cells require unlimited replicative potential in 
order to generate macroscopic tumors in contrast to non-cancer cells which usually 
have a definitive replicative potential. After a certain number of divisions, cells stop 
dividing and enter into nonproliferative viable state of senescence and/or 
crisis/apoptosis. Occasionally, cells emerge from a population in crisis and exhibit 
unlimited replicative potential and this transition is termed as immortalization and is well 
established in cell lines which proliferate in culture without senescence or crisis. Several 
studies indicate that telomeres which are repeat sequences at the end of chromosomes 
play an important role in cell replication. It is clear that all types of malignant cells and 
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90% of human cancers exhibit increased telomerase activity and addition of 
hexanucleotide repeats to the ends of telomeric DNA [39]. Telomere knockout mice 
have shortened telomeres and also shunt premalignant cells into senescence resulting 
in decreased tumorigenesis in mice that are genetically destined to develop cancer [40]. 
In human breast cancers, transient telomere deficiency results in malignant 
progression, while premalignant tumors did not express significant levels of telomerase 
and were characterized by shortening of telomeres and nonclonal chromosomal 
aberrations [41]. 
Sustained angiogenesis. Angiogenesis is required for physiological processes such 
as wound healing and female reproductive cycle, but only transiently. In contrast, during 
tumor development, angiogenesis is activated and continues to produce new blood 
vessels that facilitate neoplastic growth [42]. Angiogenesis is regulated by signaling 
proteins that binds to stimulatory or inhibitory cell surface receptors in vascular 
endothelial cells. For example vascular endothelial growth factor (VEGF) and fibroblast 
growth factor (FGF) regulate angiogenesis by binding to cell surface including VEGF-
receptor1 (VEGFR1) [43]. Many human tumors including renal and pancreatic 
adenocarcinomas are highly angiogenic and densely vascularized; tumors also 
overexpress VEGF and FGF compared to normal tissue and endogenous inhibitors of 
angiogenesis like thrombospondin, tumstatin are downregulated [44]. In some tumors, 
dominant oncogenes such as Ras and Myc upregulate expression of angiogenic 
factors, while in other tumors immune inflammatory cells induce angiogenesis. The 
direct induction of angiogenesis by oncogenes that also drive proliferative signaling 
indicates that distinct hallmark capabilities can be coregulated by some transcription 
factors. The VEGF gene is also regulated by different transcription factors and the role 
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of specificity protein (Sp) transcription factors in the regulation of VEGF has been 
reported in several cancers [45, 46]. 
Activating invasion and metastasis. Tissue invasion and metastasis is a hallmark for 
advanced stages of cancer with poor patient prognosis. In many human cancers 90% of 
cancer deaths are associated with invasion and metastasis and this phase is 
charectarized by EMT, loss of cell adhesion, gain of motility and stromal proteolysis 
[47]. Loss of E-cadherin and upregulation of N-cadherin is a prominent feature of EMT 
and is observed in most of the metastatic tumors.  Epidermal growth factor (EGF)- 
mediated downregulation of focal adhesion kinase (FAK) is required for early 
dissemination and cell detachment from the primary tumor. At distant sites, interactions 
with extracellular matrix through integrins activate FAK and mediate cell attachment 
which is required for establishing metastatic tumors. Matrix metalloproteases (MMPs) 
are stromal proteses that facilitate tumor invasion both in vitro and in vivo. 
Overexpression of urokinase plasminogen activator (uPA) positively correlates with 
invasive potential for a variety of human cancers because uPA plays an important role 
in tumor invasion and metastasis by initiating proteolytic cascades [48]. 
 After cancer cells are established at a distant site, they will not receive the same 
signals from their new environment. Hence, mesenchymal-epithelial-transition (MET, 
reversal of EMT) is induced and the original phenotype is adopted. Several factors such 
as TGF-s, TNF-, EGF, HGF, IGF-1, E47/e2A, FOXC2, Goosecoid, Snail, Slug, and 
Twist are known to induce the EMT [49]. Genomic instability and tumor promoting 
inflammation are also the enabling characteristics that facilitate evolving populations of 
premalignant cells to become malignant and metastatic. 
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COLON CANCER 
 Every year more than one million people will develop colorectal cancer (CRC) 
worldwide and the specific mortality of this disease is approximately 35% in the 
developing world. CRC is the 3rd most common malignancy and 4th most common 
cause of cancer mortality worldwide [50]. It was predicted that there will be 
approximately 1,000,000 new cases diagnosed in 2008, resulting in nearly 500,000 
deaths. CRC is major public health problem in the United States and nearly 150,000 
people are diagnosed with CRC every year and approximately one third of them die 
from the disease [51]. In the United States, among all cancers CRC incidence and 
mortality are 3rd and 2nd respectively. The lifetime risk for colorectal cancer life time is 
6% in the US and the average age of diagnosis of this disease is 66 years [52]. The 
causes of CRC and its mechanism of pathogenesis are complex and heterogeneous.  
Diet and lifestyle factors, somatic and hereditary mutations contribute to the 
development of CRC and risk factors include diets rich in unsaturated fats, processed 
meat & red meat, total energy intake & reduced physical activity, tobacco and excessive 
alcohol consumption. Most cases of CRC occur sporadically and contributing factors 
include increasing age, male sex, previous chromosome polymorphisms and family 
history of CRC [53]. 
 Inflammatory diseases such as Inflammatory bowel disease and ulcerative 
colitis are important risk factors for development of CRC and the risk increase with the 
duration of illness, severity and extent of inflammation [54, 55]. Inflammation induced 
CRC and sporadic CRC exhibit comparable similarities such as chromosomal (85%) 
and microsatellite instabilities (15%). Despite these similarities there are important 
differences between inflammation and sporadic-induced CRC. For example activation of 
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protooncogenes such as Ras and the inactivation of tumor suppressor genes such as 
adenomatous polyposis coli (APC) and p53 are important in the development of the 
majority of CRC, however the frequency and timing of these genetic alterations differ 
remarkably in sporadic CRC and colitis associated CRC [56, 57]. 
 
Table. 1.1. Molecular genetics of inherited colorectal cancer syndromes [58]. 
Syndrome Common features Gene defects 
FAP 
 
Multiple adenomatous polyps (>100) and 
carcinomas of the colon and rectum; 
duodenal polyps and carcinomas; fundic gland 
polyps in the stomach; congenital 
hypertrophy of retinal pigment epithelium 
APC (>90%) 
Gardner 
syndrome 
Same as FAP; also, desmoid tumors and 
mandibular osteomas 
 
Turcot‘s 
syndrome 
Polyposis and colorectal cancer with brain tumors 
(medulloblastomas); colorectal cancer and brain 
tumors (glioblastoma) 
APC 
MLH1, PMS2 
Attenuated 
adenomatous 
polyposis coli 
 
Fewer than 100 polyps, although marked variation 
in polyp number (from ∼5 to>1,000 polyps) 
observed in mutation carriers within a single 
family 
APC 
(predominantly 
5‘ 
mutations) 
Hereditary 
nonpolyposis 
colorectal 
cancer 
 
Colorectal cancer without extensive polyposis; 
other cancers include endometrial,ovarian and 
stomach cancer, and occasionally urothelial, 
hepatobiliary, and braintumor 
MSH2 
MLH1 
PMS2 
GTBP, MSH6 
 
Peutz-
Jeghers 
syndrome 
 
Hamartomatous polyps throughout the GI tract; 
mucocutaneous pigmentation;increased risk of GI 
and non-GI cancers 
LKB1, STK11 
(30–70%) 
 
Cowden 
disease 
Multiple hamartomas involving breast, thyroid, 
skin, central nervous system, and GItract; 
increased risk of breast, uterus, and thyroid 
cancers; risk of GI cancer unclear 
PTEN (85%) 
 
Juvenile 
polyposis 
syndrome 
 
Multiple hamartomatous/juvenile polyps with 
predominance in colon and stomach;variable 
increase in colorectal and stomach cancer risk; 
facial changes 
DPC4 (15%) 
BMPR1a 
(25%) 
PTEN (5%) 
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 Among the hereditary colorectal cancers (Table. 1.1), the Lynch syndrome also 
known as Hereditary Non Polypsis Colorectal Cancer (HNPCC), occurs approximately 
in one in 300 people with colorectal cancer. Familial adenomatous polyposis (FAP) is a 
hereditary CRC due to defects in the APC gene; the frequency of FAP is approximately 
one in 7000 people, whereas other syndromes such as MYH-associated polyposis 
occur in about one in 18000 individuals with colorectal cancer. Hereditary cases of 
colorectal cancer (Table. 1.1) account for nearly 6% of all colon cancer cases and this 
includes 3% with HNPCC, 2% with FAP and 1% with all other hereditary colon cancers 
including Peutz-Jeghers syndrome, familial juvenile polyposis and hereditary mixed 
polyposis syndrome. These syndromes are linked to mutations in LKB 1, STK11, SMAD 
4, PTEN, E-cadherin, cyclin D1 and TGF-β receptors [59]. 
 Colitis associated cancer (CAC), a subtype of colorectal cancer is associated 
with inflammatory bowel disease (IBD) and has high morbidity and mortality. More than 
20% of inflammatory bowel disease patients develop colitis associated cancer within 30 
years of disease onset and more than 50% of these patients will die from colitis 
associated cancer [60, 61]. Even though immune mediated mechanisms are 
responsible for colitis associated cancer; there are similarities between colitis 
associated cancer and other types of colorectal cancers that develop without any 
inflammatory signs. The important stages of colon cancer development such as 
formation of aberrant crypt foci, polyps, adenomas and carcinomas are similar between 
colorectal cancer and colitis associated cancer, even though different pathogenic 
sequences have been proposed for colitis associated cancer, such as chronic 
inflammation and injury-dysplasia carcinoma. 
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The Adenoma- Carcinoma sequence. The development of CRC via adenoma-
carcinoma sequence (Fig. 1.5) is a multistep process which slowly occurs over a period 
of several years and often decades. Benign tumors of the gastrointestinal tract are 
lesions that form above the surrounding mucosa and are generally known as polyps. 
Colorectal polyps, particularly polyps less than 5 mm in size are hyperplastic and these 
polyps are not CRC precursors, where as adenomatous polyps or adenomas are 
considered as important precursor lesions that can progress to CRC [62]. Adenomas 
are characterized by dysplastic morphology and abnormal differentiation of epithelial 
cells that arise from glandular epithelium. The frequency of occurrence of adenomatous 
polyps in the US is approximately 25% in individuals 50 years of age and 50% at the 
age of 70 and there is a high risk for developing CRC in patients whose adenomatous 
polyps are not removed [63, 64]. Individuals with diseases such as FAP are strongly 
predisposed for development of adenomatous polyps, present with CRC at 30-50 years 
of age [65]. Only a small fraction of adenomas slowly (years to decades) progress to 
CRC, for example adenomatous polyps with 1 cm size have an approximately 10-15% 
chance of progression to carcinoma within 10 years period. 
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Fig. 1.5. Development of CRC and CAC; adenoma-carcinoma sequence [66]. 
  
 Some of the essential stages of colon cancer development such as formation of 
aberrant crypt foci, polyps, adenomas and carcinomas are similar between non-
inflammatory colorectal cancer and colitis associated cancer. Common genetic and 
signaling pathways altered in colorectal cancer and colitis associated cancer include 
Wnt, β-catenin, K-Ras, p53, transforming growth factor-β (TGF- β), and the DNA 
mismatch repair proteins (MMR). 
The APC gene in colorectal cancer. FAP is an autosomal dominant syndrome that 
affects nearly 1 in 12000 individuals and accounts for approximately 0.5% of all 
colorectal cancers. Adenomas arise in the colon of affected individuals by 40 years of 
age, but only a few adenomas progress to colorectal cancer in a given FAP patient [65, 
67]. The incidence of colorectal cancer in an untreated FAP patient is 100% by the age 
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of 36 years, while prophylactic treatment provides good clinical management for FAP. 
One fourth of FAP cases are due to germline mutations and do not show autosomal 
pattern and inheritance [68]. A fraction of germline mutations in FAP patients results in 
silencing of APC gene expression, whereas 95% of the mutations are due to frameshift 
or nonsense mutations that lead to premature truncation of protein synthesis (Fig. 1.6) 
[68, 69]. 
 
 
Fig. 1.6. Schematic representation of APC and mutations in APC [58]. 
 
 
 The APC gene plays an important role in FAP and other syndromes, and also in 
sporadic colorectal cancer. Nearly 70-80% of sporadic colorectal cancers have somatic 
mutations that inactivate APC. Most somatic mutations lead to premature truncation of 
the APC protein and this is an early and rate limiting event in the development of 
adenomas [70, 71]. Frequencies of APC mutations in very small adenomas as well as 
advanced adenomas and carcinomas are similar, in contrast to mutations of other 
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somatic genes in colorectal tumors. Somatic mutations of APC are found even in 
earliest lesions such as microscopic adenomas which are comprised of few dysplastic 
glands [19]. According to the Knudson model for tumor suppressor genes, defects of 
both alleles in tumor suppressor genes (TSG) are required to promote tumor 
development. Both alleles of the APC appear to be inactivated in adenomas and 
carcinomas observed in FAP patients as well as patients with colorectal adenomas and 
carcinomas. 
APC protein functions in canonical Wnt signalling pathway. The APC tumor 
suppressor gene encodes an approximately 300-kDa protein that regulates cell 
migration, cell-cell interaction, chromosomal segregation and apoptosis in the colonic 
crypts [72]. Restoration of APC protein function in colorectal tumors that lack 
endogenous APC protein expression induces apoptosis [72]. The APC protein has 
some recognizable sequence motifs in the primary aminoacid sequence and these 
serve as binding sites for various cellular proteins (Fig. 1.6). Even though the APC 
protein has several important cellular functions, the most well established role for APC 
in formation of tumors is its interaction with β-catenin and subsequent regulation of Wnt 
signaling pathways [70, 72]. 
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Fig. 1.7. Model of APC and β-catenin in Wnt canonical signaling. (a). absence of Wnt 
ligands, (b). presence of Wnt ligands [73]. 
 
 β-Catenin plays an important role in linking cytoplasmic domains of  E-cadherin 
to the actin cytoskeleton via binding to the adaptor protein α-catenin. The major 
components of Wnt/β-catenin pathway is the β-catenin destruction complex which is 
composed of APC, AXIN, casein kinase 1 (CK 1), and glycogen synthase kinase 3 β 
(GSK 3 β).The proposed model for the biologic significance and interaction of APC and 
β-catenin shows that, in the absence of Wnt ligands, β-catenin is recruited into a 
destruction complex, which facilitates phosphorylation of β-catenin on conserved N-
terminal serine/threonine residues by CK1 and GSK3 β (Fig. 1.7). This leads to the 
ubiquitylation and proteasome-dependent degradation of β-catenin. In the nucleus, 
22 
 
prospective target genes of the Wnt signaling pathway are kept in a repressed state by 
interacting with T-cell factor (TCF) and lymphoid enhancer-binding protein (LEF) 
transcription factors with associated co-repressors. In the ‗off state‘, cells maintain low 
cytoplasmic and nuclear levels of β-catenin; β-catenin is associated with cadherins at 
the plasma membrane, an association that spares it from the degradative pathway. In 
the presence of Wnt, ligands interact with members of the Frizzled (FZ) family of 
serpentine receptors, and transmembrane protein low density lipoprotein receptor 
related proteins 5 and 6 (LRP5 and LRP6). The binding of Wnt to Fz receptors lead to 
activation and membrane recruitment of the phosphoprotein Dishevelled (DSH or DVL) 
and AXIN and the destruction complex to the plasma membrane, where AXIN directly 
binds to the cytoplasmic tail of LRP5/6. AXIN is then degraded, and this decreases β-
catenin degradation. The activation of DSH also leads to the inhibition of GSK3, which 
further decreases the phosphorylation and degradation of β-catenin. So, the ‗on state‘ 
involves increasing post-translational stability of β-catenin, through Wnt-dependent 
degradation of AXIN and inhibition of GSK3. As β-catenin levels rise, it accumulates in 
the nucleus, and interacts with DNA bound TCF and LEF family members to activate 
transcription of target genes including c-Myc and Cyclin D1 (Fig. 1.7). 
 In most colorectal cancers, both APC alleles are mutated and as a result 
coordinated phosphorylation and degradation of β-catenin is inhibited and this process 
mimics constitutive activation of Wnt ligand-mediated signaling and results in 
expression of several protooncogenes including c-Myc, Cyclin D1. In addition, the β -
catenin/TCF/LEF complex activates transcription of genes encoding membrane proteins 
such as matrix metalloproteinase 7 (MMP7), membrane type 1 MMP (MT1MMP), 
laminin 5, CD44 growth factors such as fibroblast growth factor (FGF) 20, FGF 9; and 
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negative Wnt regulators including AXIN 2, naked-1/2, dickkopf-1, and Wnt inhibitory 
factor [74, 75]. Induction of the β-catenin-dependent transcription program resembles 
the transcriptional program in presumptive tissue stem cells at the base of colonic 
crypts and β-catenin not only participates in establishment of the crypt progenitor 
phenotype but also in the spatial organization and migratory patterns of the cells in the 
continuous renewal of colonic crypts [76, 77]. 
 Wnt/ β-catenin/ TCF regulated genes are negatively regulated by feedback 
inhibitors such a Wnt inhibitory factor 1, dickkopf-1 and downstream Wnt ligand receptor 
signaling is inhibited by the homolog of the drosophila gene Naked as well as AXIN 2 
gene product. Dysregulation of Wnt/β-catenin signaling has been reported in several 
tumor types including colon tumors and overexpression of Wnt ligands are observed in 
both sporadic and familial colorectal cancer. APC gene mutations that encode a 
truncated protein result in a defective β-catenin destruction box, which is unable to bind 
to β-catenin and this results in decreased degradation of β-catenin and accumulation of 
high levels in the nucleus which activate Wnt target genes. Mutations in the β-catenin 
gene at various phosphorylation sites also prevent destruction of β-catenin by the 
proteasome pathway resulting in increased activation of Wnt signaling. 
DNA mismatch repair gene defects in colorectal cancer. Hereditary Nonpolyposis 
Colorectal cancer (HNPCC)- HNPCC was one of the first inherited cancer syndromes to 
be reported in the medical literature [78]. Many years later Lynch & co-workers [79, 80] 
proposed autosomal dominant patterns of colorectal cancer that were not accompanied 
by extensive polyposis. HNPCC accounts for approximately 5% of hereditary colorectal 
cancer causes and this genetic syndrome is caused by mutations in the family of 
mismatch repair genes (MMR) which include MLH 1, MSH 2, MSH 6, and PMS 2 [81, 
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82]. Germline mutations in one of these four MMR genes have been observed in 80% of 
affected families, with 50% of the mutations in MLH1, 40% in MSH2 and 10% in MSH6. 
The major role of MMR genes is to maintain genomic integrity, and mutations of these 
genes can lead to development of colorectal cancer and other solid tumors. MMR 
genes also function to mediate DNA damage-induced cell death; and colorectal cancer 
tumors with mutated MMR genes are resistant to a wide variety of cytotoxic agents such 
as cisplatin, carboplatin and several alkylating agents [83, 84]. Consequently colorectal 
cancer tumors expressing mutant MMR genes have a selective growth advantage when 
compared to other solid tumors expressing wild-type with intact MMR genes. Though 
FAP patients develop thousands of adenomatous polyps, there are other types of 
intestinal polyposis syndromes in which patients‘ exhibit several non-adenomatous 
polyps that increase the risk for colorectal cancer and these include juvenile polyposis 
syndrome (JPS), Cowden syndrome, Peutz-Jeghers syndrome and hereditary mixed 
polyposis syndromes. 
Oncogenic/ Tumor suppressor gene mutations in colorectal cancer. In contrast to 
hereditary colorectal cancer, which constitutes approximately 2-15% of all cases of 
colorectal cancer, sporadic cancer accounts for approximately 80-85% of colorectal 
cancer. The genetic alterations leading to dysregulation of key signaling pathways in 
hereditary colorectal cancer have also been implicated in the pathogenesis of sporadic 
colorectal cancer. The key pathways that are affected include Wnt/β-catenin, TGF-β 
receptor, Notch, Hedgehog, EGFR, Ras/Raf/MAPK and phosphoinositide 3-kinase 
PI3/Akt pathway. 
TGF-β/ SMAD. The TGF-β plays an important role in several biological processes such 
as cell proliferation, differentiation, migration and apoptosis [85, 86]. TGF-β ligands bind 
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to type II TGF-β receptors (TGFBR2) resulting in recruitment and activation of 
downstream factors include TGFBR1, SMAD 2, SMAD3, SMAD4 and heterodimeric 
SMAD complexes that translocate into the nucleus. SMAD complexes bind and activate 
or deactivate several different transcription factors including c-Jun, P300/CBP, c-Myc 
and cyclin associated protein CD1, cyclin dependent kinase inhibitors cdk 4, p21, p27, 
p15 and Rb in a cell specific manner. TGF-β acts as a tumor suppressor and inhibits 
growth by activation of cyclin-dependent kinase inhibitors p21, p27, p15; however TGF-
β also activates oncogenes such as TGF-α, FGF, EGFR and SMAD-independent 
pathways such as Ras/Raf/MAPK, JNK and PI3/Akt. In addition, TGF-β also promotes 
angiogenesis, cell adhesion and motility enhancing tumor invasion and mutagenesis. 
 The gene encoding TGFBR2 has A nucleotide repeats in exon 3, and GT 
repeats in exons 5 and 7, and these repeats are prone to DNA replication errors and 
frameshift mutations. Approximately 80% of colorectal cancers and 30% of sporadic 
colorectal cancers have frameshift matations in TGFBR2 and to date this is the most 
common pathway leading to alterations in TGF-β signaling [87]. Mutations of SMAD 
genes can also impair TGF-β signaling. Interestingly, SMAD2 and SMAD4 are localized 
on chromosome 18q, a region that is usually deleted in colorectal cancer and mutations 
of SMAD2 and 4 are observed in 10-25% of colorectal cancers. There is growing 
evidence that alterations of TGF-β signaling lead to development of colorectal cancer 
and this is an attractive target for cancer drug development. 
Notch signaling pathway. Notch signaling is important for proliferation of intestinal 
epithelium and under normal physiological conditions, Notch ligands bind to 
transmembrane receptors resulting in cleavage and the release of the intracellular 
domain of the Notch receptor. The cleaved Notch receptor translocates to the nucleus 
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and activates Notch target genes such as hairy/enhancer of split (Hes 1) a basic helix-
loop-helix transcription factor. Notch signaling is important for several physiological 
functions such as maintenance of stem cells, determination of cell fate, differentiation 
and oncogenesis. Notch signaling is constitutively activated in several cancers and 
there is increased expression of Notch ligand in colorectal cancers [88] . Moreover, 
crosstalk between Notch and Ras, where active Ras mutants activate Notch signaling 
and Notch activation is required for Ras-mediated cell transformation. 
Hedgehog Signaling Pathway. The hedgehog signaling plays an important role in 
proliferation, establishment of cell fates and embryonic development in Drosophila [89, 
90]. This pathway has also been identified in humans and is essential for development 
and patterning of various organs including gut epithelium. Hedgehog ligands bind to 
receptors of Patched Protein (Ptch) which suppress activity of smoothened receptor 
(Smoh), a G Protein-coupled receptor- like receptor. Hedgehog ligands bind to Ptch1 
and and activate GL1 transcription factor and regulate expression of several Hedgehog 
target genes. Aberrant activation of Hedgehog signaling is associated with enhanced 
cell proliferation and development of cancer [89]. Moreover Hedgehog signaling is 
involved in development and repair of colonic epithelial cells and this pathway is 
activated in colorectal cancer [91]. 
 Several studies have reported high expression of Hedgehog ligands, Hedgehog 
receptor ptch, and Hedgehog associated transmembrane receptor Smoh in hyperplastic 
polyps, adenomas and adenocarcinomas of colon [92, 93]. The exogenous Hedgehog 
ligand Snh, can promote the growth of colonocytes and colorectal cancer cells express 
high levels of Snh mRNA compared to normal colon cells [94]. 
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Ras signaling pathway. Ras is a member of a small G protein family which are critical 
for transmitting extra-cellular signals such as epidermal growth factors (EGFs) into 
intracellular signal transduction cascades [95]. Ras proteins have intrinsic GTPase 
activity and GDP/GTP-binding sites that are responsible for active (GTP-bound) and 
inactive (GDP-bound) confirmation. Ras proteins activate Raf/MEK/ERK signaling that 
mediate cell growth and cell cycle progression through phosphorylation of important 
transcription factors such as c-fos, Myc, RSK and MNK, and activation of the PI3K/Akt 
pathway. The role of Ras has been extensively investigated in cancer and 
approximately 15-20% of all human cancers exhibit Ras gene mutations. To date the 3 
Ras genes encode for 4 Ras proteins; namely, H-Ras, N-Ras, K-Ras4A, and K-Ras4B. 
Each of these Ras proteins is activated in different types of human cancers; K-Ras 
mutations are typically observed in CRC, pancreatic cancer, lung cancer and 
seminoma. In CRC, 30-40% of all patients have K-Ras gene mutation and >95% these 
mutations are observed in codons 12, 13 and 61. These mutations result in 
constitutively bound GTP in the active form of Ras which is independent of extracellular 
signals such as EGF. As a result K-Ras mutated tumors are resistant to anti-EGFR 
therapy with cetuximab or panitumumab which are antibodies that bind the EGFR with 
high affinity [96]. 
EGFR signaling pathway. The EGFR belongs to human epidermal growth factor 
receptor (HER) family that includes HER1 (ErbB1, EGFR), HER2 (ErbB2), HER3 
(ErbB3) and HER4 (ErbB4) [97]. Upon ligand binding, EGFR undergoes homo or 
heterodimerization with other members of HER family and regulates cell proliferation, 
survival, migration, invasion and angiogenesis through activation of several signaling 
networks [98]. Activation of EGFR is primarily responsible for development of resistance 
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to chemo and radiation therapies. EGFR is progressively upreglated from normal to 
malignant tissues and nearly 90% of metastatic CRC overexpresses the EGFR [99]. 
The role of EGFR in growth, proliferation and metastasis is well documented in several 
cancers and this receptor is an important target for drug development [100, 101]. Anti-
EGFR monoclonal antibodies such as, Cetuximab and Panitumumab are currently used 
for treatment of metastatic CRC; these drugs bind the EGFR with higher affinity than the 
natural ligands and inhibit phosphorylation and downstream signaling pathways and 
receptor internalization resulting in decreased cell surface expression of EGFR [102]. 
These drugs inhibit tumor angiogenesis and cell proliferation, induce apoptosis and cell 
cycle arrest. 
PI3K/Akt signaling pathways. PI3K signaling cascades play an important role in 
regulation of several key cellular processes including protein synthesis, glucose 
metabolism, cell proliferation, migration and angiogenesis [103]. PI3K is composed of a 
110-kDa catalytic subunit (PKC3A) and an 85-kDa adapter subunit. PI3K signaling is 
regulated by crosstalk with other extracellular signaling pathways activated by 
hormones, vitamins, integrins, intracellular calcium and Ras dependent MAPK. PI3K is 
constitutively activated in several cancers, such as CRC, breast cancer, prostate cancer 
and lung cancer [104]. Constitutive activation of PI3K is due to a mutation in PIK3CA 
resulting in a gain of function mutation affecting positive regulators of PI3K (HER2, 
EGFR, RAS and c-Src). Activation of PI3K function can also be due to mutations of 
tumor suppressor genes encoding negative regulators of PI3K such as PTEN. 
Activation of PI3K/Akt has been observed in several cancers including CRC, gastric 
cancer, breast cancer and ovarian cancer [105]. Moreover activation of various 
components of PI3K/Akt signaling has prognostic significance for several cancers and 
29 
 
PI3K activation contributes to resistance to chemotherapy, hormone and radiation 
therapy and several individual components of this signaling pathway are therapeutic 
targets for drug development [106]. 
EPIGENETIC CHANGES IN COLON CANCER 
 Epigenetics broadly refers to the heritable changes in gene expression that are 
not mediated by the changes in the DNA sequence. Epigenetic regulation of gene 
expression is important for embryonic development and tissue differentiation [107]. 
Aberrant epigenetic alterations were first discovered in CRC in 1982, and subsequent 
studies have revealed a complex array of epigenetic regulatory mechanisms that control 
gene expression in both normal and cancerous tissue [108, 109]. Epigenetic regulation 
of gene expression is determined by several factors, such as open and closed state of 
chromatin that leads to either gene transcription and silencing of gene transcription 
respectively [107]. 
 
 
Fig. 1.8. Epigenetic mechanisms in colorectal cancer [110]. 
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 The epigenetic mechanisms responsible for colon cancer development include 
methylation of CpG islands, post translational histone modifications, micro RNAs and 
non-coding RNAs and nucleosome positioning (Fig. 1.8). 
Methylation of CpG islands. Promoters of approximately 50% of all genes contain 
CpG islands and hypermethylation of these CpG islands is responsible for 
transcriptional silencing of gene expression [111, 112].  Decreased DNA methylation 
has been observed in CRC cells (compared to normal cells). Even though 
hypomethylation is commonly observed in CRC [113, 114], hypermethylation of CpG 
islands at specific gene promoters has been observed [115, 116]. 
 DNA hypomethylation was one of the first recognized epigenetic alterations in 
CRC, and its occurence is age-dependent and is observed early in the process of 
carcinogenesis [117]. Hypomethylation in CRC was assumed to be associated with 
activation of oncogenes such as CDH3, which is responsible for increased genomic 
instability. Experimental relevance of hypomethylation to genomic instability is 
supported by mouse models where DNMT hypomorphic ApcMIN/+ mice develop 
microadenomas associated with loss of heterozygocity of APC and increased genomic 
instability. DNA hypermethylation has been extensively characterized in CRC and is 
observed in nearly 60%of genes [118]. Hypermethylation of promoter CpG islands has 
been observed in several tumor suppressor- and DNA repair genes and leads to their 
inactivation or lack of function [112]. Hypermethylated genes include HIC1 
(hypermethylated in cancer 1) and Wnt signaling antagonists such as SFRPs (secreted 
Frizzled-related proteins), RTK, TP53, PI3K, retinoic acid and IGF signaling pathways 
and other pathways regulating  the cell cycle, transcription, DNA repair, stability, 
apoptosis, angiogenesis, invasion, metastasis and chromatin organization (Table. 1.2) 
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[115, 119]. Hypermethylated DNA is silenced through recruitment of methyl CpG 
binding proteins and associated repressors such as HDACs, which form repressive 
chromatin structure.  
 
Table 1.2. Promoter CpG island hypermethylated genes in colorectal cancer [110]. 
Promoter CpG island hypermethylated genes in colorectal cancer 
Signaling pathways/cancer 
hallmarks 
Promoter CpG island hypermethylated genes 
Wnt APC, SFRP1, SFRP2, SFRP4, SFRP5, SOX17, 
WNT5a, DKK1, DKK3, WIF1, AXIN2 
RTK RASSF1A, RASSF2A,EPHB2, RAB32, NORE1 
NOTCH NEURL 
TP53 P14ARF, HIC1DFNA5 
PI3K PIK3CG 
Estrogen receptor ER 
Retinoid acid receptor RAR, CRABP1 
IGF IGFBP3 , IGFBP7 
Cell cycle regulation P16INK4A , KLF4 
Transcription regulation GATA4, GATA5, RUNX3, CDX1, HLTF, FOXL2, 
ALX4 
DNA repair/stability MLH1, MGMT, WRN, CHFR 
Apoptosis BNIP3, IRF8, DAPK1, HRK 
Adhesion CDH4, CDH13 
Angiogenesis THBS1 
Invasion and metastasis TIMP3, RECK, CXCL12, TFPI2 
Axon guidance SLIT2 
Transmembrane (glyco)proteins MUC1, NMDAR2A, HPP1, SPARC, DCC, CD133 
Peptide hormones SST, TAC1 
Chromatin organization PRDM2 
Unknown function/pathway VIM, NDRG4 
Classical CIMP panel MINT1, MINT2, MINT31, P16INK4A, MLH1 
Weisenberger CIMP panel CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1 
NOTE: This table represents genes involved in major signaling pathways/cancer 
hallmarks that are epigenetically silenced by promoter CpG island hypermethylation. 
Abbreviations: WNT, wingless-type;  MMTV integration site family; RTK, receptor 
tyrosine kinase; NOTCH, neurogenic locus notch homolog protein; TP53, tumor protein 
53; IGF, insulin-like growth factor; CIMP, CpG island methylator phenotype. 
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 To date three types of  CpG binding proteins have been identified: methyl 
binding domain (MBD) family of proteins containing MBD1, MBD2 and MBD4, the zinc 
finger proteins Kaiso (ZBTB33), ZBTB4 and ZBTB38, and SET and RING finger 
associated proteins UHRF1 and UHRF2. Loss of MBD2 and Kaiso in APCmin/+ mice 
suppresses intestinal carcinogenesis and induces tumor suppressor gene expression 
resulting in cell cycle arrest and cell death [120, 121]. 
Post translational histone modifications. Post translational histone modifications 
regulate gene expression at the transcriptional level and these modifications dictate 
chromatin structure by disrupting contacts within or between nucleosomes. The most 
well-characterized histone modifications in CRC are histone deacetylation and histone 
demethylation. Active genes are enriched with di- and trimethylation of histone H3 
lysine 4 (H3K4me2/me3) and acetylation of key H3 and H4 aminoacids at the 
transcription startsite, while inactive genes lack these active modifications and are 
characterized by trimethylation of histone H3 lysines 9 and 27 (H3K9me3 and 
H3K27me3). Many genes hypermethylated in CRC include components of polycomb 
repressor complexes (PRC) such as EZH2 and CBX7 respectively and PRC-dependent 
DNA methyltransferases play a role in DNA methylation [122, 123]. 
Small, non-coding RNAs. Another important mechanism of epigenetic regulation 
involves the role of small non coding microRNAs (miRNAs) which are generated from 
precursor pre and pri-RNAs by successive cleavage by drosha and dicer nucleases. 
Depending on the degree of homology to their target sequence, miRNAs bind 3‘-UTRs 
of target mRNAs via base pairing and inhibit translation or induce mRNA degradation. 
Comprehensive analysis of miRNA expression in human cancers reveals differential 
miRNA expression in cancers [124]. Comparisons between CRCs, such as MSS CRC 
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and MSI-H CRC show differences in the abundance of specific miRNAs, for example 
miR-25 and miR-92 are highly expressed in MSS rather than MSI-H colon cancers (Fig. 
1.9) [125]. 
 
 
Fig. 1.9. Northern blot analysis of miRNAs miR-25 and miR-92. Northern blot analysis 
confirmed that these miRNAs were up-regulated in MSS samples. miRNA/U6 ratio of 
densitometric intensities is shown below each miRNA lane [125]. 
 
 
 Although many of the differences in miRNA expression in CRCs may be related 
to differential expression of the primary transcripts that contain the miRNAs, as 
indicated above, p53 mutations can affect processing of certain miRNAs. For example, 
tumor suppressor, p53, enhances the post-transcriptional maturation of several miRNAs 
with growth-suppressive function, including miR-16-1, miR-143 and miR-145, in 
response to DNA damage. In HCT116 colon cancer cells and human diploid fibroblasts, 
p53 interacts with the Drosha processing complex through the association with DEAD-
box RNA helicase p68 (also known as DDX5) and enhances processing of primary 
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miRNAs to precursor miRNAs. In contrast, transcriptionally inactive p53 mutants 
interfere with the functional assembly between the Drosha complex and p68, resulting 
in attenuation of miRNA processing [126]. In addition, oncogene and tumor suppressor 
gene signaling pathways that are normally dysregulated in CRC may also influence the 
expression of several miRNAs resulting in modulation of expression of different genes 
and proteins [127]. miRNAs are involved in different stages of colon carcinogenesis 
such as epithelial cell differentiation (miRNA-141, miRNA-200c), Wnt signaling (miRNA-
145, miRNA-135a and miRNA-135b), migration and invasion (miRNA-373, miRNA-
520c) [128-130]. miRNA-124a is involved in cell cycle regulation and is associated with 
CpG island hypermethylation, closed state of chromatin and occupancy of MeCp2 and 
MBD2. miRNA-34b and miRNA-34c that target TP53 pathways, undergo frequent 
promoter CpG island methylation in CRC. Certain metastatic CRCs are associated with 
promoter CpG methylation of miRNA-148a, miRNA-34b, miRNA-34c, and miRNA-9 
[131-133]. 
INFLAMMATION AND COLORECTAL CANCER 
 CAC is a type of CRC that is associated with IBD, which exhibits high mortality 
and more than 20% of IBD patients develop CAC within 30 years of disease onset and 
approximately 50% of these patients will die from CAC [61, 134]. Even though IBD and 
CAC are associated with immune mediated mechanisms, there are some similarities 
between CAC and other types of CRC that develop without any signs of inflammation. 
The important stages of colon cancer development such as formation of aberrant crypt 
cocci, polyps, adenoma and carcinomas are similar in between CRC and CAC, even 
though different pathogenic mechanisms including chronic inflammation and injury-
dysplasia carcinoma have been proposed for CAC. Moreover common genetic and 
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signaling pathways, such as Wnt, β-catenin, K-Ras, p53, TGF-β, and DNA mismatch 
repair genes are altered in both sporadic CRC and CAC, even though the timing of p53 
and APC inactivation and K-Ras activation differs in CRC and CAC [61, 135]. Finally, 
colorectal tumors that are not associated with IBD show infiltration of inflammatory 
cytokines and IBD patients with familial history for CRC, exhibit a higher risk for colon 
cancer development, suggesting overlapping mechanisms for development of CAC and 
CRC [136-140]. Moreover, a large number of CRC tumors exhibit constitutive activation 
of transcription factors that play an important role in inflammatory pathways and these 
include, NF-κB and STAT3 (signal transducer and activator of transcription 3) [141, 
142]. Therefore it is possible that inflammatory cytokines and immune mechanisms act 
through similar but also distinct pathways in the pathogenesis of CRC and CAC. 
Inflammation in initiation of CRC and CAC. For CRC, intratumoral immune cells are 
recruited after the tumor is formed therefore chronic inflammation does not precede 
tumor formation. Once the tumor is formed, localized inflammatory mediators promote 
additional mutations & epigenetic alterations and inflammatory cells produce reactive 
oxygen and nitrogen species that also induce mutations and DNA damage [143, 144]. 
Moreover immune mediated ROS production can diffuse into adjacent epithelial cells 
and cause mutations and epigenetic silencing of tumor suppressor genes. However, the 
contributions of immune-mediated mechanisms in cancer initiation is unclear [145]. In 
CAC, chronic inflammation precedes tumor development and the associated 
inflammation results in oxidative damage to DNA and p53 mutations with nondysplastic 
epithelium [146, 147]. In mouse models, inflammatory mediators such as dextran 
sodium sulfate (DSS) induce DNA damage and colonic adenomas; the number of 
36 
 
adenomas is increased and appeared much earlier if the procarcinigen azoxymethane 
(AOM) was administered to mice before DSS [148]. 
 
Table. 1.3. Incidence of large bowel neoplasms in mice treated with AOM and various 
doses of DSS [149]. 
  
  
 In mice receiving AOM plus 2% DSS, the incidence (multiplicity) of colonic 
tubular adenoma and adenocarcinoma was 75% (1.25 ± 1.26/mouse) and 100% (2.75 ± 
2.22/mouse), respectively. Mice administered AOM plus 1% DSS had an 80% incidence 
of adenoma (1.00 ± 0.71/mouse) and 60% incidence of adenocarcinoma (1.40 ± 
2.07/mouse) in the colon. In mice treated with AOM and 0.5% DSS, only one colonic 
adenoma (20% incidence with 0.20 ± 0.45 multiplicity) developed. A higher frequency of 
high-grade colonic dysplasia was noted in mice given AOM and 2% or 1% DSS when 
compared to mice treated with AOM and lower doses of DSS. Also, scoring for 
inflammation and nitrotyrosine immunoreactivity suggested that severe inflammation 
and nitrosation stress caused by high-doses (2% and 1%) of DSS enhanced AOM 
Group 
No 
TREATMENT 
(no. of mice) 
INCIDENCE (MULTIPLICITY) OF LARGE BOWEL NEOPLASMS 
Total Adenoma Adenocarcinoma 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
AOM®2%DSS (4) 
 
AOM®1%DSS (5) 
 
AOM®0.5%DSS (5) 
 
AOM®0.25%DSS(5) 
 
AOM®0.1%DSS (4) 
 
AOM (5) 
 
2%DSS (5) 
 
None (5) 
100%* (4.00±3.37) 
 
100%*** (2.40±2.19) 
 
20% (0.20±0.45) 
 
0% 
 
0% 
 
0% 
 
0% 
 
0% 
75%**(1.25±1.26) 
 
80%** (1.00±0.71) 
 
20% (0.20±0.45) 
 
0% 
 
0% 
 
0% 
 
0% 
 
0% 
100%* (2.75±2.22) 
 
60% (1.40±2.07) 
 
0% 
 
0% 
 
0% 
 
0% 
 
0% 
 
0% 
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initiated tumor formation (Table. 1.3). These findings indicate that the tumor-promoting 
activity of DSS was dose-dependent (1% or more) and the effects occurred under 
conditions of inflammation and nitrosation stress. In addition, inflammation induced 
mutations also inactivate MMR genes and activity of these mismatch repair enzymes is 
inhibited by ROS through oxidation [145, 150]. Epigenetic silencing facilitates 
development of CAC and CRC through reduced expression of proteins that maintain 
DNA stability during replication or act as tumor suppressors [65, 150-155]. Expression 
of several genes responsible for colon cancer development such as TGFBRII, TCF4, 
MSH1 & 2, APC, K-Ras, SMAD4, and PTEN is regulated by miRNAs and DNA methyl 
transferases [151]. The activity and expression of DNA methyl transferases such as 
Dnmt1 and Dnmt3 are induced during inflammation and are responsible for gene 
silencing in mouse and human colon cancers [156].  Inactivation of DNA methyl 
transferases in mouse CRC results in decreased tumor progression as well as inhibition 
of tumor formation [157]. Moreover inflammatory mediators can induce epigenetic 
changes that are responsible for cell transformation. 
Inflammation in promotion of CRC and CAC. Even though both sporadic CRC and 
CAC arise from dysplastic precursor lesions, the nature and timing of the dysplasia are 
sufficiently different to classify CRC and CAC as unique entities (Fig.1.10). In IBD, the 
premalignant lesion is not referred to as an adenomatous polyp, as is characteristic in 
sporadic CRC, because the histology of the lesion in IBD is usually not polypoid. 
Usually, colorectal cancer developed in the setting of IBD does not progress along the 
same adenomatous polyp to an invasive cancer pathway, but rather arises from flat 
dysplastic tissue [158]. Nearly, 80 to 85% of sporadic CRC involves chromosomal 
instability and loss of heterozygosity, which contributes to the loss of function of several 
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tumor suppressor genes including APC and p53. Loss of APC function is an early 
initiating factor in development of the adenoma, whereas the loss of p53 gene function 
occurs later and is the defining event that converts the adenoma to carcinoma. The 
remaining 15% of colorectal cancers arise through a pathway that involves 
microsatellite instability and microsatellite instability-positive sporadic colorectal cancers 
tend to occur in the proximal colon and have a better survival rate than cancers without 
microsatellite instability [159]. 
 
 
Fig. 1.10. Comparison of the carcinogenesis pathway of sporadic colorectal cancer and 
colitis-associated colorectal cancer [160]. 
 
  
 The same two major pathways of chromosomal instability and microsatellite 
instability are involved in the pathogenesis of CAC and in both CAC and sporadic CRC, 
80% of the cases involve chromosomal instability and 20% involve microsatellite 
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instability [161, 162]. However, the timing of the molecular changes are distinct. Loss of 
APC function is much less frequent in ulcerative CAC and usually occurs later than 
observed for sporadic CRC [163]. Loss of p53 gene function occurs early in CAC as 
cells progress toward dysplasia and cancer whereas in sporadic CRC, p53 is mutated 
late [164, 165]. Mutation of the p53 gene in both types of cancers may precede the 
development of aneuploidy. Further research is required to understand differences in 
the timing of the molecular changes in CAC compared to sporadic cases of CRC, and 
whether it is the chronic inflammatory changes in IBD that influence this alteration. 
 There are other mechanisms of carcinogenesis that distinguish between 
sporadic CRC and CAC. A study by Ezaki et al., [166] indicated that loss of 
heterozygosity on chromosome 6 is specific for ulcerative CAC and is not found in 
either sporadic CRC or other inflammatory lesions in the colon of patients with 
ulcerative colitis. This indicates that there are novel tumor suppressor genes on 
chromosome 6 related to the development of colorectal cancers in ulcerative CAC but 
not in sporadic cases. There is a lower apoptotic count in tumors from patients with 
ulcerative CAC compared to sporadic CRC patients, implying differences in regulation 
of apoptosis [167]. Identifying biomarkers for earlier detection of cancer or dysplasia is 
extremely important, since this would enhance effectiveness of early treatment. 
Methylation of the HPP1 gene, a gene found in hyperplastic polyps of the colon, 
appears to be a relatively common early event in ulcerative colitis-associated 
carcinogenesis that is not found in non-neoplastic ulcerative colitis mucosa [168]. CDH1 
promoter methylation may also be involved in the neoplastic progression from chronic 
inflammation to colorectal cancer in patients with ulcerative colitis [169]. Abnormal p53 
immunohistochemistry in tumors from patients with ulcerative colitis is associated with 
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an increased risk of cancer-related deaths and the adjusted relative risk was 3.03 [170]. 
These genes may prove to be attractive new biomarkers for detecting and predicting 
colorectal cancer in patients with ulcerative colitis. 
NF-B and Colon cancers. Nuclear factor- κB (NF-κB) belongs to NF-κB/Rel family of 
transcription factors, which can dimerize through the Rel homology domain to form a 
variety of transcription factor complexes. The most abundant form of NF-κB is the Rel A 
and p50 heterodimer which exists in the cytoplasm as a complex with I-κB inhibitory 
proteins. The classical mechanism of NF-κB activation in CAC and CRC is due to tumor 
promoting cytokines such as TNF- and interleukins. These cytokines activate the I-B 
kinase (IKK), which phosphorylates and degrades I-B through the ubiquitination-
proteasome pathway and this results in translocation of NF-κB into nucleus to enhance 
transcription of target genes [171, 172]. An alternative of NF-κB activation involves the 
IKK and p52/RelB transcription factor complex and cytokines such as RANKL and 
lymphotoxin-β in colorectal cancers. Prolonged retention of NF-κB in the nucleus is 
mediated by STAT-3, which is expressed constitutively in >50% of colorectal cancers 
[173]. No activating mutations of NF-κB or STAT-3 have been found in colorectal 
tumors suggesting that these transcription factors are activated through paracrine or 
autocrine pathways or activation of upstream components of their signaling pathways. 
 NF-κB is a commonly expressed inducible transcription factor that regulates 
expression of several genes involved in inflammation, proliferation, differentiation and 
apoptosis [174]. These functions are responsible for normal tissue homeostasis and the 
activity of NF-κB is tightly controlled in the regulation of cellular growth and apoptotic 
cell death [175, 176]. 
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Fig. 1.11. Regulation of NF-κB activity by tumor suppressors [175]. 
 
 The cellular consequences of NF-κB activation are complex and can result in 
cell context-dependent pro-apoptotic and anti-apoptotic effects [177]. NF-B subunits 
are inherently oncogenic and tumor promoting because of their ability to induce the 
expression of genes that promote resistance to apoptosis (e.g. Bcl-xL) and induce 
proliferation (e.g. cyclin D1) (Fig. 1.11). However, tumor suppressor proteins, such as 
p53 and ARF, can induce the association of NF-κB subunits with histone deacetylase 1 
(HDAC1) co-repressor complexes resulting in NF-κB -dependent repression of gene 
expression; in this mode NF-κB subunits facilitate apoptosis and cell-cycle arrest, and 
function as tumor suppressors (Fig 1.11) [175]. 
 Moreover, TNF-induced activation of NF-κB results in nuclear translocation of 
NF-κB resulting in activation of survival and growth pathways [178].  Aberrant activation 
of NF-κB pathway results in tumor formation and induces drug resistance due to 
increased binding NF-κB with DNA promoters [179]. In contrast, stress inducing agents 
such as UV radiation and serum deprivation activate NF-κB and induce cell death [180, 
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181]. Most of the tumor promoting cytokines activates NF-κB signaling in premalignant 
and immune cells. 
 
 
 
Fig. 1.12. Role of NF-κB in gastric and colorectal cancers [176]. 
  
 Aberrant activation of NF-κB which has been observed in more than 50% of 
CRC and CAC and plays a prominent role in colorectal and colitis associated 
tumorgenesis [182, 183]. Exposure to environmental carcinogens in the diet causes 
DNA damage of gastric or intestinal epithelial cells and these cells are normally 
eliminated by p53-mediated apoptosis. However, oncogene activation or loss of tumour-
suppressor activity, coupled with inflammation, can result in constitutive activation of 
NF-κB, production of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 
(COX-2) enzymes, which enhance production of ROS and ROS-mediated DNA 
damage. Growth factor and cytokine-dependent activation of NF-κB supports colon 
tumorigenesis by increasing cell proliferation and angiogenesis, inhibiting cell death and 
promoting cell invasion and metastasis [175] [184]. NF-κB activates several survival 
genes such as bcl-2, Bcl-xL and these genes play a role in radiation and drug 
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resistance and inactivation of NF-κB enhances the sensitivity to these agents [185, 
186]. 
 In IBD, persistent activation of NF-κB in myeloid & epithelial cells of the colonic 
mucosa is observed and inhibition of Rel A expression with antisense oligonucleotides 
alleviates many IBD symptoms [187, 188]. However, in DSS-induced intestinal injury-
dependent acute colitis, NF-κB is activated in intestinal epithelial cells and has a 
protective role [189]. Most of the drugs that are commonly used to treat acute IBD 
including sulfasalazine, mesalamine, glucocorticoids, and methotraxate, inhibit NF-κB or 
IKK kinases [190]. Conditional ablation of IKK-β in enterocytes decreased tumor 
incidence by 80% without affecting tumor size, indicating that NF-κB activation is 
involved in early stages of tumor promotion, rather than progression or growth [182]. 
Early pathogenic events in the AOM + DSS mouse model of colitis includes increased 
apoptosis in IKK-β deficient enterocytes and premalignant cells, which probably resulted 
from inactivation of Bcl-xL [191]. Increased activation of NF-B in epithelial cells 
increased tumor incidence and deletion of IKK-β in inflammatory cells (eg, DC, 
macrophages, neutrophils) decreased tumor size and tumor incidence by 50% [191]. 
Activation of NF-κB in myeloid cells (especially lamina propria macrophages and DC) 
enhanced production of cytokines including TNF-α, IL-6, IL-1β, and IL-11 that acted as 
growth factors for premalignant enterocytes [182]. Expression of TNF-α and IL-6, in 
serum samples from patients was associated with increased risk for colorectal adenoma 
[192]. 
Role of cyclooxygenases (COX) in colorectal cancers. Two isoforms of COX are 
known, and to date most studies have implicated COX-2, rather than COX-1, as the 
isoform involved in colon carcinogenesis [193]. COX-2 is an inducible mediator of 
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prostaglandin synthesis and the first evidence linking COX-2 to carcinogenesis 
emerged from studies on CRC. A significant elevation of COX-2 expression was seen in 
85% and 50% of human colorectal carcinomas and adenomas respectively (Fig. 1.13) 
[194]. 
 
 
Fig. 1.13. Western blots showing COX-2 protein levels (72-kilodalton band) in paired 
tissues from sporadic CRCs (T) and normal mucosa (N) (left panel). Increased COX-2 
expression was seen in tumors compared with normal tissue in which a low level of 
COX-2 was detected [195]. 
 
 
 
 Immunostaining shows expression of both COX-1 and COX-2 in mucosal 
epithelial cells, mononuclear cells, vascular endothelial cells and smooth muscle, while 
in human and animal models of colorectal cancer there is dramatic increase in COX-2 
expression in malignancies compared with adjacent normal mucosa. COX-1 expression 
appears to be unchanged or even decreased in human colonic cancers [196-198]. 
AOM-induced colon cancer, APCMin/+ mice [199] as well as in APCΔ716 mice (another 
Apc mutant model) exhibit increased expression of COX-2 mRNA and protein (but not 
COX-1) in colorectal tumors compared with normal adjacent tissue where as COX-2 
knockout results in decreased tumor formation in all models [200]. Transgenic mice 
overexpressing COX-2 in the colon did not develop tumors spontaneously, but did have 
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a higher tumor load compared with wild-type mice following AOM treatment [201]. 
Similar observations were found in skin and gastric cancers [202] [203]. Prostaglandin 
E2 (PGE2) a major COX-2 dependent prostaglandin is responsible for the 
protumorigenic effects of COX 2 and is highly expressed in CRC [204]. An enzyme 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) degrades PGE2 to inactive 15-keto 
PGE2 metabloite and loss of 15-PGDH expression correlates with tumor formation 
including colon and lung cancers [205-207]. Some studies indicate that 15-PGDH acts 
as tumor suppressor in colorectal cancers [208, 209]. PGE2 production is significantly 
higher in malignant tissues compared to normal tissues and several reports shows that 
chemopreventive actions of NSAIDs are mainly due to inhibition of PGE2 signaling 
[210, 211]. PGE2 contributes to the tumorigenesis by binding with PGE2 receptors 
(EP1-EP4), which belongs to G-protein coupled receptor superfamily. Sonoshita et al. 
[212] first reported the involvement of EP receptors in colorectal cancer progression by 
crossing APCMin/+ mice with various homozygous mutants of EP receptors. Crossing of 
EP-/- mice with APCMin results in decreased size and number of polyps and VEGF 
production is also significantly decreased in the polyps. Several other studies also 
investigated the role of EP receptors in cancer progression using various pharmacologic 
inhibitors of EP receptor signaling. In APCMin mice treated with an EP1-selective 
antagonist, a 40% reduction of polyp burden was observed, and EP1−/− mice treated 
with carcinogen resulted in 60% suppression of ACF formation [212]. APCMin mice 
treated with an EP4 selective antagonist exhibited decreased ACF formation by 67% 
and EP-/- mice treated with carcinogen led to 56% reduction of ACF [213]. Growth of 
sarcoma 180 and Lewis lung carcinoma xenografts in EP3 null mice was significantly 
reduced, indicating a role for EP3 [214]. Chang et al. reported high expression EP2 and 
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EP4 and low expression of EP3 in mammary tumors compared with normal mammary 
tissue [215]. To date, all four EP receptors have been implicated in promoting 
tumorigenesis in different contexts, and it is plausible that EP receptors may have 
divergent functions in different cell types. In addition to EP receptor signaling, PGE2 
also activates Wnt signaling, PPAR-, and EGFR pathways (Fig. 1.14). 
 
 
 
Fig.1.14. Crosstalk of PGE2 with other signaling networks during colorectal cancer 
progression [216]. 
 
 
 
 PGE2 increases the phosphorylation of GSK-3β to prevent β-catenin 
degradation resulting in nuclear accumulation of β-catenin and increased β-catenin/TCF 
mediated transcription of Wnt target genes such as cyclin D1, VEGF [217]. In addition 
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PGE2 stimulation of EP2 receptor results in association of G subunit with the regulator 
of G protein signaling (RGS) and AXIN. This binding causes inactivation of GSK-3β and 
results in accumulation of β-catenin in the nucleus and activation of Wnt target genes 
(Fig. 1.14) [218]. PGE2 indirectly transactivates PPAR- through PI3K/Akt.  PPAR-  is 
a direct transcriptional target of β-catenin/TCF and indicates an important role in 
bridging Wnt and PGE2 signaling downstream of β-catenin/TCF [219]. This suggests 
that PGE2 acts both upstream and downstream of β-catenin to regulate PPAR-  
function (Fig. 1.14). Other studies show that PGE2-induced migration and invasion of 
cancer cells through activation of EGFR. PGE2 stimulates EP4 receptors and form a 
complex with β-arrestin and c-Src and results in activation of EGFR and downstream 
Akt/protein kinase B (PKB) [220]. Overexpression of the EP4 receptor was observed in 
several cancers and adenomas and inhibition of EP4 with small molecule inhibitors 
decreased cell proliferation, invasion and motility in vitro [221, 222]. PGE2 interacts with 
EGFR pathways to promote tumor growth and induce apoptosis. PGE2 stimulates 
inhibition of apoptosis by activation of PI3K/Akt, while EGFR stimulates same pathway 
through Ras. PGE2 stimulates EGFR signaling through shedding of active EGFR 
ligands from the plasma membrane and PGE2 also activates EGFR directly via Src 
pathway stimulation (Fig. 1.14) [223-226]. In contrast, EGFR transactivation stimulates 
AP-1-mediated induction of COX-2 expression and thus PGE2 expression resulting in a 
loop of cross-stimulation [223]. In conclusion, all these mediators of inflammation are 
important components of colorectal tumorigenesis at least in sporadic CRC [227]. COX-
2 also promotes tumor angiogenesis by inducing production of angiogenic factors such 
as VEGF and basic fibroblast growth factor (bFGF),  increasing tumor dessimination by 
altering the cell adhesive properties and inducing matrix metalloproteinase activity [228, 
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229].  Finally in myeloid cells, PGE2 decreases expression of antitumorigenic IL-12 and 
increases expression of protumorigenic IL-23 [230]. 
Role of inflammation in metastasis of colorectal cancer. The role of inflammation in 
colon cancer metastasis is not well characterized due to the lack of suitable mouse 
models, however tumors from classical colon cancer models such as APCMin and 
AOM+DSS, rarely metastasize and, therefore models of colon cancer metastasis were 
developed. Implantation of colon cancer cells orthotopically under the skin and also as 
intrasplenic or intravenous administration of cells can result in metastatic colonization of 
target organs. The inflammatory environment plays an important role in metastasis 
[231] and the first step of metastasis is characterized by EMT, which allow cancer cells 
to invade epithelial linings/basal membranes and reach efferent blood vessels or 
lymphatics. This process of EMT is basically regulated by TGF-β and is characterized 
by loss of E-cadherin expression by malignant epithelial cells [23, 85]. 
 Overexpression of Fzd7, a Wnt receptor ligand increases motility & metastatic 
capabilities and activation of NF-κB and STAT-3 resulting in EMT in colon cancer cells 
(Fig. 1.15) [232, 233]. In addition to TGF-β, EMT is also regulated by several pro-
inflammatory cytokines, such as IL-1, IL-6, HIF-1, and TNF- [234-236] and ZEB1, 
ZEB2, Twist, Kiss and Snail transcription factors that play a role in EMT [237]. Activated 
snail inhibits E-cadherin in epithelial cells and TNF- stabilizes snail by preventing its 
degradation; this is one of the mechanism by which TNF- promotes colon cancer 
metastasis (Fig. 1.15) [234].  
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Fig.1.15. Signaling crosstalk between inflammatory cells and tumor cells. Tumor cells at 
the invasive front are surrounded by fibroblasts, macrophages, myeloid derived 
suppressors cells (MDSC) and neutrophils. Inflammatory cells produce TNF-α, TGF-β, 
IL-6, IL-1, and other pro-inflammatory factors and thus activate NFκB and STAT-3 
pathways and induce EMT and metastasis in tumor cells [231]. 
 
 
 
 Inflammatory signals also regulate the production and activity of proteases that 
facilitate invasion and metastasis by degradation of extracellular matrix. Human colon 
cancer cells express MMP 1, 2, 3, 7 & 9 and expression of various MMPs by stromal, 
immune and cancer cells provides the stimulus for cell migration and invasion [238]. 
DIAGNOSIS AND STAGING OF COLORECTAL CANCER 
 The diagnosis of colorectal cancer is based on symptoms, tissue biopsies, 
radiological techniques and biological markers. Except for obstructing or perforating 
cancers, the duration of these symptoms does not correlate with prognosis. The initial 
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stage of CRC does not produce any signs or symptoms and therefore intensive efforts 
for detection of CRC through screening tests are essential. Symptoms of colorectal 
cancer include but are not limited to bleeding, perforation, obstruction, intermittent 
abdominal pain, weakness, nausea and vomiting. CRC is also diagnosed by 
colonoscopy or sigmoidoscopy followed by tumor biopsies. Physical examination and 
complete colonoscopy is required to rule out metachronous tumor. Computed 
tomographic (CT) colonography of other organs such as chest, abdomen and pelvis is 
required to identify metastatic disease [239]. CT colonography is important for precise 
localization of the tumor and it also identifies other colon tumors or polyps that are 
undetected with colonoscopy due to obstructive lesions [240, 241]. For rectal cancers, it 
is essential to measure the tumor spread and high resolution MRI can be used to 
assess the spread of tumor in the surrounding mesorectum. In patients with suspected 
liver metastasis from colon cancers, spread of the tumors is determined by ultrasound, 
CT and MRI. Even though these imaging techniques are used to diagnose metastasis, 
new methods are required to characterize the liver metastasis. Biological markers are 
another tool for the diagnosis of colon cancer, but unfortunately reliable markers for 
colon cancer have not yet been identified [242]. CEA is the most widely studied marker 
that may be useful in preoperative staging and postoperative followup for large bowel 
cancers, however, CEA has low predictive value in diagnosis of asymptomatic patients 
[243]. Recently several carbohydrate antigens such as CA19-9 were examined and 
exhibit some promise regarding specificity for pre-neoplastic and early neoplastic 
lesions of colon [244]. Once diagnosis of CRC has been made, staging can be 
described based on tumor-node-metastasis (TNM) classification (Table. 1.4). 
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Table. 1.4. TNM classification of colorectal cancer based on clinical and pathological 
conditions [245]. 
 
  
 TNM is a dual system that includes both clinical and pathological classifications.                                                                                                                                  
This classification is based on two different methods of examination and serves different 
purposes. The clinical and pathological classifications are designated as cTNM and 
pTNM, While TNM without any prefix implies the clinical classification, usually cTNM is 
the basis for the choice of treatment and pTNM is the basis for prognostic assessment 
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[246]. CRC is classified into different stages based on the pTNM classification (Table. 
1.5). 
 
Table.1.5. Correlation between TNM stage and 5-year survival in colorectal carcinoma 
[245]. 
 
 
 
  
 Stage I CRC is equivalent to the Duke & Modified Astler-Coller (MAC) A or B1, 
in which the tumor is limited to bowel wall. Stage II is equivalent to the Duke & MAC B2 
or B3, in which tumor has spread to extramural tissue. Stage III is equivalent to Dukes & 
MAC C1-C3, in which the tumor has spread to regional lymph nodes [247]. Patients 
having potentially curable colorectal cancers are classified based on their history, 
physical examination, laboratory data, intestinal evaluation and instrumental work-up 
such as CT scan, NMR and PET [248, 249]. Surgical staging of colorectal cancer 
includes an assessment of liver metastases, nodal spread of disease, and extension of 
tumors through the bowel wall and onto adjacent structures [250]. 
TREATMENT OF COLORECTAL CANCER 
 Treatment of CRC is based upon the stage of CRC and surgery is the potential 
treatment option for patients with curable colorectal cancer. Adjuvant therapy, such as 
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chemotherapy is administered to reduce the risk of recurrence and death. The 
recurrence rate depends on pathological staging of CRC and adjuvant chemotherapy is 
the standard method of treatment for stage III patients, but it is not well established in 
stage II patients.  
Treatment of localized disease. Surgery is the common method of treatment for 
localized CRC. It includes wide resection of the involved bowel segment along with its 
lymphatic drainage. The extent of the resection is determined by the blood supply and 
distribution of regional lymph nodes [251]. Usually resection should include colon 
segments of at least 5 cm on either side of the tumor. Local excision or simple 
polypectomy is sufficient for treatment of stage 0 CRC, because the tumors limited to 
mucosa without invasion of the lamina propria. In stage I CRC, a wide surgical resection 
along with anastomosis is required because of its localized nature. In stage II CRC 
patients, wide surgical resection and anastomosis followed by adjuvant therapy is 
required in high risk patients, while in stage III CRC chemotherapy is the standard 
method of treatment because of the involvement of lymph nodes. Prognosis depends 
on the number of lymph nodes involved and patients have a decreased survival rate if 4 
or more lymph nodes are involved [252]. The standard treatment option for this stage is 
a combination of oxiplatinin and 5-FU/LV (FOLFOX4 or FLOX). In special 
circumstances, monotherapy with capecitabine, UFT/LV or 5-FU/LV is used as an 
alternative for adjuvant chemotherapy. In conclusion, standard treatment options for 
localized CRC include wide surgical resection and anastomosis followed by 
postoperative chemotherapy with FOLFOX. In addition to FOLFOX, other adjuvant 
chemotherapeutic options are also considered for high risk colon cancer patients who 
have advanced stage II or stage III colon cancers. These regimens include i. infusional 
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FU/LV and oxiplatinin (FOLFOX4), ii.  infusional 5-FU/LV alone for patients who cannot 
tolerate oxiplatinin, iii. Capecitabine alone may be considered for the patients who are 
not suited to FOLFOX and iv. Capecitabine/oxiplatinin (CAPOX) can be used instead of 
FOLFOX [245]. 
Treatment of metastatic CRC. Stage IV CRC is accompanied by distant metastatic 
disease and 25-30% of the patients will have metastasis at the time of colorectal cancer 
diagnosis. For stage IV, CRC therapy is primarily to prolong survival and maintain 
quality of life. A standard treatment option includes surgical resection of primary 
tumor/anastomosis, treatment of isolated metastasis, palliative chemotherapy, biological 
therapy and radiation therapy for the primary tumor and other sites of metastasis [253-
256]. Palliative chemotherapy for metastatic CRC can improve survival, lessen 
symptoms and decrease liver only or lung only metastasis in patients with potential 
resectable disease. Combinations of fluorouracil with irinotecan, oxiplatinin and targeted 
drugs increase survival of patients and this combination has reduced toxicity and hence 
is commonly used [257]. Fluorouracil can be safely substituted for capecitabine when 
combined with oxiplatinin with no loss of efficacy [258, 259]. The sequence of drugs 
used at first presentation of disease and as the disease progresses seems to be less 
important in increasing the survival rather than exposure to all active drugs during 
treatment [260]. Even though an initial drug combination is commonly used, 
fluropyrimidine monotherapy is suitable for some patients [261, 262]. Treatment is 
continued until the disease regression or for a fixed duration depending upon the toxic 
side-effects, tumor response and preference of the patient [263, 264]. Progress in the 
management of metastatic CRC in the past 5 years has been made by addition of 
targeted treatments. Novel targeted therapies with drugs/ agents such as Bevacizumab, 
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a vascular endothelial growth factor inhibitor; Cetuximab and Panitumumab, monoclonal 
antibodies against the EGFR have increased the efficacy of treatment for metastatic 
CRC. In chemorefractory patients, cetuximab alone was active and reversal of 
irinotecan resistance can be observed when used with irinotecan [253]. The activity of 
cetuximab alone or in combination with irinotecan also gave improved responses in 
other studies [265, 266]. First line of treatment with combinations of cetuximab, 
fluorouracil and irinotecan marginally improved progression free survival [267]. 
Panitumumab has been approved as a monotherapy for pretreated patients and 
significantly improved progression free and survival rates when given in combination 
with fluorouracil and oxyplatinin to patients with tumors expressing wild-type K-Ras 
[268, 269]. Combinations of panitumumab, irinotecan and fluorouracil also improve 
progression-free but not overall survival in pretreated patients with wild type K-Ras 
tumors [270]. K-Ras mutation status is consistently used to monitor the response of 
patients to EGFR directed monoclonal antibodies and now cetuximab & panitumumab 
are the only drugs offered to patients with wild type K-Ras colorectal cancers. Rashes, 
diarrhea and hypomagnesemia are characteristic toxicities observed with anti EGFR 
drugs. Bevacizumab is a VEGF inhibitor which also causes normalization of tumor 
vasculature and improves delivery of the drug. Its side-effects include hypertension, 
gastrointestinal proliferation, bleeding, delayed wound healing and thromboembolism. 
Combinations of Bevacizumab, irinotecan and fluorouracil improves the response rates 
by 10% in untreated metastatic colon cancer patients, and significantly prolonged the 
survival rates in pretreated patients [254]. Bevacizumab was approved as first line of 
treatment for metastatic colorectal cancers in combination with fluoropyrimidine-based 
chemotherapy and is widely considered as the standard first-line treatment. Cetuximab 
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received regulatory approval in 2004 as a monotherapy for chemotherapy-resistat 
patients and panitumumab was approved in 2006 for patients having wild type K-Ras 
pretreated tumors. Despite the use of active targeted drugs for treatment of metastatic 
CRC in the past decade, improvement in overall survival has increased by 2 years; 
however, overall cure rates have remained low. The parallel development of predictive 
molecular and clinical biomarkers will help to achieve the best outcomes for targeted 
therapies and K-Ras is currently the only validated molecular biomarker in CRC for 
predicting a positive response to EGFR-directed monoclonal antibodies. Clinical and 
translational research that is in progress will hopefully provide personalized medicine 
and other predictive biomarkers for management of CRC. 
MECHANISM BASED ANTICANCER DRUGS 
 Most current chemotherapeutic drugs are accompanied by severe side effects 
and toxicity, and thus have lead to development of new target therapies with decreased 
toxicity. These mechanism based anticancer drugs are highly promising for treatment of 
several cancers, since these agents are more tumor-specific and include drugs such as 
kinase inhibitors, antibodies that block various signaling modules, immunotherapies and 
genomic therapies that involve knock down of specific oncogenes and re-expression of 
tumor suppressor genes. Applications of mechanism based drugs are highly tumor-
specific such as treatment of non small cell lung cancer patients with specific EGF 
receptor mutations with EGF receptor inhibitors erlotinib and gefetinib [271, 272]. 
Targeted therapy of colon cancer. Currently there are 7 FDA approved drugs for 
treatment of metastatic CRC (Table. 1.6). These drugs are usually used in combination 
however; some drugs are administered as single agents. Recently the national 
comprehensive cancer network (NCCN) proposed 12 possible different drug 
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combinations for first line of treatment in metastatic CRC patients. Given the availability 
of these drugs and their complexity in the current treatment paradigms, it is important to 
understand the efficacy and toxicity profile of these agents in order to provide better 
therapies for individual patients. 
 
Table. 1.6. Drugs approved for treatment of metastatic colon cancer [273]. 
Drug Category Mechanism of action FDA indication 
5-FU/LV 
 
Antimetabolite 
(pyrimidine analog) 
Non-competitive 
inhibition of thymidylate 
synthase 
1991: palliative treatment 
of colon cancer 
Oxaliplatin Alkylating agent 
(platinum) 
Inhibits DNA synthesis 
by forming inter and 
intra strand crosslinks 
with DNA 
2002: 2nd line with 5-FU, 
after irinotecan failure 
2004: 1st line with 5-FU 
Irinotecan Camptothecin Inhibits topoisomerase I, 
producing DNA breaks 
1998: 2nd after failure of 
5-FU based therapy 
2000: 1st line with 5-
FU/LV 
Capecitabine Antimetabolite 
(pyrimidine analog) 
Prodrug of 5-FU 2001: 1st line when 
treatment with 
fluoropyrimidine therapy 
alone is preferred 
Bevacizumab Humanized 
monoclonal 
antibody 
Binds to VEGF, 
inhibiting interaction 
between VEGF and its 
receptor 
2004: 1st line with 5-FU 
based therapy 
2006: 2nd line with 5-FU 
based therapy 
Cetuximab Recombinant, 
chimeric, 
monoclonal 
antibody 
Binds to EGFR, 
inhibiting binding of 
EGF 
2004: single agent or with 
irinotecan, on irinotecan 
refractory or intolerant 
2009: amended only for 
patients with KRAS 
lacking mutations in codon 
12 and 13 
Panitumumab Recombinant, 
human, 
monoclonal 
antibody 
Binds to EGFR, 
inhibiting binding of 
EGF 
2006: single agent on 
chemorefractory 
2009: amended only for 
patients with KRAS 
lacking mutations in codon 
12 and 13 
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1. 5-Fluorouracil (5-FU). It is a pyrimidine analog which belongs to a group of 
antimetabolite drugs and works through non-competitive inhibition of the enzyme, 
thymidylate synthase. It requires ribosylation and phosphorylation to form specific 
metabolites associated with its cytotoxicity. Metabolites of 5-FU such as, 
triphosphatefluxoridine (FUTP) are incorporated into RNA and fluorodeoxyuridine 
monophosphate (FdUMP) inhibits thymidylate synthesis, which is necessary for 
DNA replication. 5-FU also inhibits activity of an exoribonuclease complex essential 
for cell survival. 5-FU is an S-phase specific drug and induces cell cycle arrest and 
apoptosis. 5-FU is administered as an infusion and/or intravenous bolus every 2 
weeks and the dose will depend on the combination of drugs used. Typically 5-FU is 
used in combination with folinic acid (leucovorin (LV)), which enhances its 
cytotoxicity by increasing formation of ternary complexes with thymidylate synthase. 
Metabolic degradation of 5-FU occurs in liver by dihydropyrimidine dehydrogenase 
(DPD). The most common adverse side-effects with this drug are fatigue, stomatitis, 
diarrhea, nausea, myelosupression, increased pigmentation and atrophy of the skin. 
Several studies have evaluated the role of 5-FU/LV in metastatic CRC treatment 
with different regimens and methods of administration and show that 5-FU/LV 
should be administered as continuous infusion in order to obtain maximum efficacy. 
This combination of 5-FU/LV is frequently in clinical trials as a reference comparison 
with newer drug combinations [274, 275]. 
2. Oxaplatinin. This platinum analog belongs to third generation diaminocyclohexane 
(DACH). Platinum analogs which are converted to their active metabolites such as 
monoaquo and diaquodiaminocyclohexane platinum which covalently bind to DNA. 
Oxiplatinin interchelates with DNA through interstrand and intrastand crosslinks and 
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inhibits DNA synthesis & function resulting in tumor cell death in all stages of cell 
cycle. Oxiplatinin also binds to both cytoplasmic and nuclear proteins and induces 
cytotoxicity and antitumor effects. Oxiplatinin is rapidly distributed to the tissues and 
undergoes biotransformation; the major route of elimination is via renal clearance. 
The most common observable side-effects with platinum analogs are nausea, 
vomiting, diarrhea, fatigue, myelosuppression and peripheral neuropathy. Oxiplatinin 
is considered as a second line therapy for treatment of colon cancers, since 
FOLFOX4 (5-FU/LV+oxiplatinin) is superior when compared to 5-FU/LV (reference). 
Oxiplatinin was considered to be inactive as a single agent and is administered in 
combination with 5-FU/LV. The adverse effects of FOLFOX4 include diarrhea, 
neuropathy and neutropenia which interfere with patient‘s quality of life [276-278]. 
3. Irinotecan. Irinotecan is derived from camptothecin, a natural phytochemical 
obtained from Campathotheca acuminate. Irinotecan is an S-phase specific drug 
which binds and inhibits the topoisomerase I-DNA complex and induces single and 
double stranded DNA breaks leading to cell death. Irinotecan is activated by 
hydrolysis to SN-38, which is 1000 times more potent than irinotecan as an inhibitor 
of topoisomerase I and conversion of irinotecan to SN-38 is mediated by a 
carboxylesterase enzyme in the liver; SN-38 is conjugated in the liver by the 
enzyme glucuronosyltransferase 1A1 (UGT1A1) to form an inactive metabolite SN-
38 glucuronide that is eliminated through urine and bile. SN-38 metabolism is 
affected in patients with hepatic dysfunction and/or inherited UGT1A1 mutations 
(Gilbert‘s syndrome). Therefore patients with these disorders are at increased risk 
for irinotecan induced toxicity.  SN-38 glucoronide is in turn converted into active 
SN-38 by beta-glucuronidases in the human intestine. The most observable side 
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effects include diarrhea, myelosupression, nausea, vomiting and fatigue. Initially this 
drug was adopted as second line therapy, but it is highly effective as first line 
therapy, in IFL, FOLFERI regimens, which is a combination of irinotecan with 5-
FU/LV [279, 280]. 
4. Capecitabine. Prodrug Capecitaninbe is an orally administered 
fluoropyrimidinecarbamate which is absorbed in gastrointestinal tract and rapidly 
metabolized to 5-FU. Thymidine phosphorylase which is highly expressed in several 
cancers is the enzyme involved in the final conversion to 5-FU. This approach has 
some advantages over infusional 5-FU, since the active drug attains maximal 
concentrations in tumors with high efficacy and less toxicity. The mechanism of 
action of this drug is the same as 5-FU and is administered along with oxiplatinin 
and irinotecan. The commonly observed side-effects are nausea, diarrhea, 
stomatitis and fatigue. Unfortunately capecitabine has higher incidence of hand foot 
syndrome when compared to intravenous 5-FU.There are significant interactions 
with other drugs such as warfarin and phenytoin and  capecitabine should be used 
with caution in patients with liver dysfunction. Several studies on capecitabine as a 
replacement for 5-FU in combination with oxiplatinin and also compared with 
FOLFOX gave similar results. 
5. Bevacizumab. Bevacizumab (Avastin) is a humanized monoclonal antibody that 
targets VEGF. Angiogenesis is the process of development of new blood vessels 
and is important in wound repair, tissue remodling and inflammation. It is a multistep 
process involving vasodilation, increased vascular permeability, stromal 
degradation, endothelial cell proliferation and migration which results in formation of 
new capillaries [281]. The process of angiogenesis is regulated by several factors 
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and their cognate receptors such as VEGF, PDGF, FGF and TGF- (Fig. 1.16). The 
most studied pathway in the process of angiogenesis involves VEGF and its 
receptors (VEGFR) [282]. 
 
 
Fig.1.16. VEGF signaling pathway [283]. 
 
 The VEGF family contains VEGF A-E with VEGF-A being the most important 
mediator of angiogenesis. VEGF-A expression is regulated by differentiation, 
transformation and hypoxia. It is also regulated by a number of cytokines, 
hormones, and growth factors such as EGFR, IL-1b, PGE2, IGF-1 [284, 285]. VEGF 
is a soluble growth factor secreted by tumor cells and stromal cells and acts by 
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binding to the extracellular domain of VEGFRs and the intracellular domain of these 
receptors contains the catalytic tyrosine kinase domains. VEGF-A primarily binds to 
VEGFR2 and activates endothelial cell survival, proliferation, migration, 
differentiation and increases vascular permeability. VEGF expression plays an 
important role in metastasis and overexpression of VEGF correlates with tumor 
progression and poor prognosis in CRC patients [286, 287]. In CRC, increased 
VEGF expression was observed in human liver metastases from primary CRC and 
expression of VEGFR was also increased in liver metastases compared with 
adjacent normal hepatic tissue [288]. 
 A number of anti-angiogenic agents are undergoing clinical trials. Bevacizumab 
is a monoclonal antibody against VEGF-A that inhibits VEGF interactions with its 
receptors on the surface of endothelial cells thus inhibiting growth of blood vessels 
and the supply of blood, oxygen and nutrients to tumors. Bevacizumab in 
combination with chemotherapy is highly effective due to additive suppression of 
tumor growth, induction of apoptosis and enhanced the delivery of anticancer 
agents to the tumor by normalization of blood vessel architecture [289]. 
Bevacizumab was first approved based on its ability to increase the survival in 
metastatic CRC patients and is administered as an intravenous infusion every 2 
weeks; bevacizumab is usually administered along with bolus IFL or with FOLFOX. 
Gastrointestinal perforation, impaired wound healing, bleeding, myocardial 
infarctions, strokes and nephritic syndrome are the side-effects of bevacizumab and 
the antibody [290]. Bevacizumab should not be administered   for at least 4 weeks 
prior and 4 weeks after surgical procedures due to impaired wound healing. Other 
minor adverse effects include diarrhea, hypertention, asthenia, headache, 
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stomatitis, and leucopenia. Bevacizumab was the first biological agent approved by 
the US-FDA as a component of anticancer therapy in 2004. This approval was 
based upon pivotal study conducted by Hurwitz et al [254] which showed increased 
response rates and progression free survival, when bevacizumab was given along 
with IFL regimen (Irinotecan, 5-FU bolus, Leucovorin) in previously untreated 
metastatic CRC patients. Addition of bevacizumab to chemotherapeutic drugs 
increased the response and survival rates in most regimens including second and 
third line therapies. However there are a few exceptions such as addition of 
bevacizumab to FOLFOX failed to increase the response rate in previously 
untreated metastatic CRC and resected non-metastatic CRC patients [291]. 
Other anti-angiogenesis drugs and their targets. Several other angiogenesis 
inhibitors are being investigated. Aflibercept is a potent VEGF inhibitor produced by 
recombinant fusion of human VEGFR extracelluar domain and Fc portion of human 
IgG1. It was active as a single agent for metastatic CRC and effective in 
combination with other standard chemotherapies [292]. Vatalinib is another 
antiangiogenesis agent which inhibits VEGFR-1, 2, &3 mediated angiogenesis and 
decreased tumor growth and metastasis in preclinical models of CRC [293, 294]. 
Sunitinib is multi tyrosine kinase inhibitor targeting VEGFR, PDGFR, c-KIT, RET, & 
LT3 and is approved for renal cancer patients [295]. Additional anti-angiogenic 
agents, such as cediranib (AZD2171), and AMG706 stabilize metastatic CRC 
patients in phase I trials and are now being investigated in phase II trials [296, 297]. 
6. Cetuximab and Panitumumab. Cetuximab and Panitumumab are inhibitors of 
EGFR which belongs to the HER family of receptor tyrosine kinases that includes 
EGFR (ErbB1/HER1), ErbB2 (HER2/neu), ErbB3 (HER3) and ErbB4 (HER4) [298]. 
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These receptor tyrosine kinases are activated by ligands such as EGF, TGF-. 
Receptor activation induces receptor homo/hetero dimerization and 
autophosphorylation of C-terminal tyrosine residues and results in activation of 
downstream signaling cascades such as the Ras/Raf/MAPK, the PI3K-Akt pathway, 
PKC, STAT, and src kinase pathways, which are responsible for cell proliferation, 
invasion, migration, and inhibition of apoptosis (Fig. 1.17). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.17. EGFR signaling pathway [283]. 
 
EGFR activation activates multiple signaling pathways [299] and anti-EGFR therapy 
includes EGFR mAb‘s and small molecule inhibitors of EGFR tyrosine kinase 
activity (TKIs) [299]. Cetuximab (Erbitux) is a recombinant human/mouse chimeric 
monoclonal antibody that binds specifically to the extracellular domain of EGFR. It is 
made up of Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and 
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kappa light chain constant region. Panitumumab (Vectibix) is recombinant human 
IgG2 kappa monoclonal antibody which binds the extracellular domain of EGFR. 
EGFR is highly constitutively expressed in several human cancers including CRC 
and cetuximab mAb binds specifically to EGFR and inhibits the binding of EGF and 
other ligands, thereby inhibiting phosphorylation and activation of receptor 
associated kinases and this result in induction of apoptosis, growth inhibition and 
decreased VEGF & MMP production. It also prevents receptor dimerization through 
steric inhibition of the extracellular domain and promotes receptor internalization, 
resulting in receptor degradation and reduced cell surface expression of EGFR. 
Cetuximab also kills the tumor cells by cell-mediated cytotoxicity (ADCC) and 
complement fixation. The mechanism of action of panitumimab is similar to 
cetuximab. The most common side effects with these drugs include acneiform, rash, 
fatigue, dyspnea, nausea, hypomagnesemia and diarrhea. 
Cetuximab and panitumumab are approved for treatment of CRC. Cetuximab 
was approved by US-FDA in 2004 in combination with irinotecan for irinotecan-
resistant disease or as a single agent in irinotecan intolerant patients [253]. 
Panitumumab received FDA approval based on similar study with fluoropyrimidine-, 
oxaliplatinin-, irinotecan-containing chemotherapy regimens in EGFR expressing 
CRC patients [300]. Even though, anti-EGFR antibodies are clinically safe and 
active in CRC, tyrosine kinase inhibitors (TKIs) as single agents exhibit minimal 
activity in metastatic CRC. Combinations of TKIs with fluoropyrimidine-, 
oxaliplatinin-, irinotecan-containing chemotherapy regimens increased the clinical 
response rates in phase II trials, but the trials closed prematurely because of severe 
adverse effects. However, Anti-EGFR therapy in combination with cetuximab, 
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irinotecan and oxaliplatin increased the response rate by 77%. Combinations of 
panitumumab with standard chemotherapy resulted in worse outcomes in patients 
who received panitumumab. Thus anti-EGFR therapy as firstline therapy for 
metastatic CRC is unclear and several trials are ongoing to address the unanswered 
questions. Similarly the role of cetuximab in the adjuvant treatment of CRC is 
currently under study in phase III clinaical trials. 
7. Novel therapies 
mTOR inhibitors. Mammalian target of Rapamycin (mTOR) is a serine threonine 
kinase which belongs to PI3K family of kinases. mTOR is activated in response to 
growth factors and results in phosphorylation of translational regulators such as 
eukaryotic initiation factor 4E-binding protein and p70s6 kinase. Inhibitors of mTOR 
induce apoptosis and arrest cell cycle in late G1 by down regulation of cyclin/CDK 
complexes and activation of the cell cycle inhibitor p27. mTOR inhibitors also inhibit 
angiogenesis by preventing endothelial and vascular smooth muscle cell 
proliferation. mTOR inhibitors are analogs of rapamycin that bind to immunophilin 
FK506/rapamycin-binding protein to inhibit its function. The efficacy of mTOR 
inhibitors has been demonstrated in preclinical models and recently temsirolimus, 
an mTOR inhibitor was approved for treatment of metastatic renal cancer [301]. 
RAD-001, another mTOR inhibitor was in phase II clinical trials and showed 
promising effects in treatment of metastatic CRC [302]. The mTOR inhibitors are 
likely to be more effective when combined with traditional chemotherapy and several 
clinical trilas of mTOR inhibitors in combination with other agents is underway. 
Protein kinase C (PKC) inhibitors. PKC is a serine thronine kinase activated 
downstream from EGFR and VEGFR receptor tyrosine kinases. Activation of PKC 
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plays an important role in cell signaling pathways that lead to tumor growth and 
survival, and PKC activity and expression is highly elevated in several cancers and 
tumors including CRC. Enzastaurin is a potent inhibitor of serine/threonine kinases 
and targets PKC, PI3K/AKT and GSK3. It was considered to be safe as single agent 
or in combination with 5-FU or bevacizumab [303, 304]. Currently combinations of 
enzastaurin, bevacizumab and 5-FU are in phase II clinical trials and show great 
promise. 
Src inhibitors. The proto-oncogene Src is a non receptor tyrosine kinase which 
plays an important role in cancer cell proliferation, angiogenesis, invasion, 
metastatsis and regulation of apoptosis [305]. Src is activated downstream of 
several signaling cascades including growth factor receptor activation and enhanced 
Src activity has been observed in 80% of CRC patients. Src activity levels correlate 
with enhanced metastasis, and resistance to chemotherapy. AZD0530 is an orally 
administered Src inhibitor that prevents CRC metastasis in stabilized disease in 
phase II clinical trials [306]. Another src inhibitor, dasatinib in combination with 
FOLFOX and erbitux is currently in clinical trials. 
Kinesin spindle protein (KSPs). Mitotic kinesins, such as KSP are important for 
the mitotic spindle, providing the propulsive forces required to separate 
centrosomes during prophase [307]. These proteins are expressed in proliferating 
cells and provide an attractive target for anticancer therapy [308]. Ispinesib (SB-
715992) is a potent small molecule inhibitor of KSP and has been in phase II clinical 
trials as a single agent, but combination chemotherapy studies have  not been 
performed [309]. 
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 In conclusion, the treatment options and the expectations for CRC patients has 
changed dramatically over the last 10 years and an increasing number of new 
agents aimed at a variety of targets are being investigated. Some of these agents 
include tyrosine kinase and histone deacetylase inhibitors, and PPAR agonists. 
Promising pre-clinical effects and activity have been observed in phase I CRC 
studies. Furthermore, many phase II clinical trials on these novel agents in 
combination with standard chemotherapy are also highly effective. 
TRANSCRIPTION FACTORS AS DRUG TARGETS 
 Many current targeted therapies have focused at cell surface proteins, however, 
recent studies show that intracellular proteins, such as transcription factors can also be 
drug targets. A single transcription factor activates multiple signaling cascades and also 
regulates expression of genes involved in the oncogenic process, and therefore 
modulating the activity of a transcription factor can be a highly effective treatment 
modality. In order to consider a protein as therapeutic target, it has to satisfy important 
criteria such as, 
a. The target protein should be expressed/overexpressed in cancer cells 
but not in normal cells 
b. The target protein should be involved in one or more malignant pathways 
including cell proliferation, resistance to apoptosis, invasion, metastasis 
and angiogenesis 
c. Inhibition of target protein expression/function should inhibit the 
malignanct process 
d. Exogenous expression of the target protein should enhance the 
tumorigenesis. 
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e. The target protein should be ―druggable‖. 
f. The target should have limited homology with related genes/proteins to 
avoid cross reactivity and undesirable off-target effects. 
 In general, gene transcription is regulated by the transcriptional machinery (TF‘s, 
RNA polymerase II, activators and co-activators) and transcriptional regulatory 
elements such as promoters, enhancers, silencers, insulators and locus control regions 
[310, 311]. Dysregulation of transcription and subsequent post transcriptional processes 
can result in cancer initiation, persistence, repression and temporal/spatial 
dyscoordination as well as structural changes including mutations and translocations 
[311]. Several TF‘s are associated with cancer and the transcriptional machinery & 
transcriptional regulatory elements are novel therapeutic targets and understanding 
transcriptional regulatory networks has revealed their critical role in the development of 
cancer. Several TF‘s are associated with hallmarks of cancer and contribute to the 
development of tumor specific phenotypes (Table.  1.7). 
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Table.1.7. Hallmark characteristics of transcription factors [312]. 
Transcription factor Hallmark traits 
 
 
S
e
lf
-s
u
ff
ic
ie
n
c
y
 
in
 g
ro
w
th
 
s
ig
n
a
ls
 
In
s
e
n
s
it
iv
it
y
 t
o
 
g
ro
w
th
- 
in
h
ib
it
o
ry
 s
ig
n
a
l 
E
v
a
s
io
n
 o
f 
p
ro
g
ra
m
m
e
d
 
c
e
ll
 d
e
a
th
 
L
im
it
le
s
s
 
re
p
li
c
a
ti
v
e
 
p
o
te
n
ti
a
l 
S
u
s
ta
in
e
d
 
a
n
g
io
g
e
n
e
s
is
 
T
is
s
u
e
 i
n
v
a
s
io
n
 
a
n
d
 m
e
ta
s
ta
s
is
 
AP-1 X 
 
X 
 
X X 
AR X 
     
ATF-1 
     
X 
BRN-3b 
 
X 
    
C/EBP  
 
X 
    
CREB 
  
X 
 
X 
 
E2F-1 
   
X 
  
ETS-1 
    
X X 
EWS/ETS 
   
X 
  
FOX03a 
  
X 
   
HIF-1 /HIF-1 (ARNT) 
    
X X 
Myc X 
   
X X 
NF- B X 
 
X 
 
X X 
PEA3 
     
X 
RAR  X 
     
RB1 
   
X 
  
Sp-1 
 
X X 
 
X X 
STAT3 
 
X X 
 
X 
 
STAT5 
 
X X 
   
TP53 
  
X 
   
 
71 
 
 
Fig.1.18. Transcription factors are attractive targets for cancer treatment. (a) 
Transcription factors play a critical role in carcinogenesis. (b) Transcription factors can 
be targeted at multiple levels. 
 
 
 Extracellular signals, cytotoxic exposures or cytokines that bind to their 
receptors, initiate signaling cascades that result in activation of nuclear transcription 
factors. In some cases, TF‘s including STAT proteins, NF-κB, hypoxia inducible factor-1 
(HIF-1) and β-catenin are latent in the cytoplasm until activated by an appropriate 
signal. Once activated, the TFs undergo homo/heterodimerization (e.g. STAT dimers, 
NF-κB dimers or β-catenin/T-cell factor complexes) and translocate into the nucleus. 
Inside the nucleus, the TF complex binds to specific DNA response elements and 
regulates expression of genes that promote pro-oncogenic pathways (Fig. 1.18). 
Transcription factors can be targeted at multiple levels; the mRNA encoding the 
targeted TF can be bound in the nucleus by antisense oligonucleotide (ON) or 
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alternatively, the TF mRNA can be targeted by morpholino antisense ONs, which 
sterically inhibit translation in the cytoplasm. RNA interference with short inhibitory RNA 
(siRNA) duplexes leads to degradation of the mRNA by RNA-induced silencing complex 
(RISC). Small molecules commonly exert their action by keeping the latent TF‘s 
sequestered in the cytoplasm or by preventing a critical activation event, such as 
recruitment of an activated receptor complex, phosphorylation or dimerization. Activated 
TFs in the nucleus can be prevented from binding DNA response elements by decoy 
ONs that mimic the DNA sequence of the response element. For example, G-quartet 
ONs inhibit the binding of STAT-3 to the DNA response element. In vitro experiments 
with primary cell lines, tumor cells and in vivo experiments with animal models are 
necessary for determining efficacy of specific transcription factors in clinical trials and 
Table. 1.8 summarizes details regarding TF‘s involved in preclinical studies. 
 
 
Table. 1.8. Summary of preclinical studies involving transcription factors as drug targets 
[312]. 
 
Transcription 
factor 
Justification summary Reference 
AP-1 (c-Jun) Inhibition-reduced breast cancer cell proliferation in mice Liu et al. [313] 
AR Downregulation resulted in prostate tumor size reduction in 
mouse xenografts 
Eder et al. 
[314] 
ATF-1/CREB Knockdown in mice resulted in subcutaneously transplanted 
tumor-size reduction through apoptosis 
Jean [315] 
BRN-3b (POU) Results suggest that Brn-3b elevation in breast cancer is a 
significant transcription factor in regulating mammary cell 
growth 
Dennis et al. 
[316] 
C/EBPa C/EBPa knockout mice showed abnormal lung cancer cell 
proliferation 
Halmos et al. 
[317] 
CREB Transfected mice with CREB300/310 dramatically enhances 
tumor growth, whereas CREB300/310/133 inhibits the 
growth of the implanted tumor cells 
Abramovitch et 
al. [318] 
E2F-1/RB1 Knockdown of E2F of mouse embryonic fibroblast leads to 
phosphorylation of RB1. The result is cell proliferation 
Wu et al. [319] 
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Transcription 
factor 
Justification summary Reference 
ETS-1 Overexpression in a rat hind limb ischemia model led to 
angiogenesis by increasing HGF and VEGF 
Hashiya et al. 
[320] 
EWS/ETS EWS/ETS fusion activated telomerase in Ewing's sarcoma 
cells and appears to activate the transcription of hTERT as a 
transactivator 
Takahashi et 
al. [321] 
FOX03a C. elegans Daf16, an ortholog to FKHRL1, FKHR and AFX, 
is the major output of insulin signaling 
Lee et al. [322] 
HIF-1a/HIF-1b 
(ARNT) 
Shown to enhance neovascularization in the rabbit ischemic 
hindlimb model 
Vincent et al. 
[323] 
Myc Overexpression in mice resulted in downregulation of IL-6- 
and VEGF-induced rabbit corneal angiogenesis 
Hatzi et al. 
[324] 
NF-kB Bortezomib has completed phase II trials where the NF-kB 
pathway was downregulated in refractory multiple myeloma 
and relapsed myeloma patients 
Richardson et 
al. [325] 
PEA3 Use of a dominant-negative PEA3 delayed onset, reduced 
number and size of mammary tumors in mice 
Bieche et al. 
[326] 
RARa Downregulation of RARa resulted in lymphoma in 44% of 
homozygous transgenic mice 
Manshouri et 
al. [327] 
SP-1 Nude mice trial using celecoxib-affected Sp1-binding sites 
on VEGF gene expression and limited metastasis 
Wei et al. [328] 
STAT3 Nude mice xenografts provide a method of knocking down 
STAT3 
Sun et al. [329] 
STAT5 Downregulation of STAT5b mediates proliferation of SCCHN 
cancer cells 
Leong et al. 
[330] 
p53 Adenovirus-mediated wild-type p53 gene transfer with 
chemotherapy and radiation therapy inhibits progression of 
lung cancer growth in animal models with minimal toxicity 
Nishizaki et al. 
[331] 
 
  
 Targeting TFs as a therapeutic option in cancer patients depends on selectivity 
and specificity. TFs from the same family also have similar or shared motifs, or 
structures, but different functions, (for example STAT-1 versus STAT-3, c-jun versus jun 
B) and this presents a challenge for the treatment to be effective. Increased knowledge 
of mechanisms of transcription and the transcription regulatory networks has led to a 
better understanding of their role in cancer and has facilitated rational drug design. 
Computer modeling can also help to improve the affinity and specificity in targeting TFs 
and Table. 1.9 summarizes the advantages and disadvantages of different approaches. 
 
Table. 1.8 continued 
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Table. 1.9. Comparision of different technologies in targeting TF‘s. 
Targeting 
method 
Stage of 
development 
Advantages Disadvantages Refs 
Small 
molecules 
Clinical 
• Can usually be 
administered 
without delivery 
vehicle 
• Affinity and/or 
specificity may be 
relatively low 
• screening process 
required 
[332] 
Antisense 
Clinical trials for c-
Myc and some non-
TF targets 
• High specificity 
and affinity for 
target mRNA 
• Degraded unless 
modified 
• Delivery vehicle is 
required to get into 
cells 
[333] 
RNAi 
Clinical for 
intravitreous 
injection; preclinical 
for systemic use 
• High specificity 
and affinity for 
target mRNA 
• Highly efficient 
degradation of 
target mRNA 
• Degraded unless 
modified 
• Delivery vehicle is 
required to get into 
cells 
[334] 
Decoy Preclinical 
• High specificity 
and affinity for 
TF
b
 
• Degraded unless 
modified 
• Delivery vehicle is 
required to get into 
cells 
[335, 
336] 
G-quartet Preclinical 
• Long half-life 
within cell due to 
nuclease-
resistant 
structure 
• Delivery vehicle is 
required to get into 
cells 
[337, 
338] 
 
  
 Recent advances in delivery vehicles and directed targeting (for example, 
liposomes, nanoparticles and aptomers) along with more accurate and potent effectors 
(for example, shRNA, siRNA, ribozymes, antisense ONs, and small molecule inhibitors) 
will be important for targeting TFs in a clinical setting. 
SPECIFICITY PROTEIN (Sp) TRANSCRIPTION FACTORS AS DRUG TARGETS 
Sp transcription factors. Sp transcription factors belong to Sp/KLF (kruppel-like factor) 
family of transcription factors which contains three conserved Cys2His2 zinc fingers in 
the DNA binding domain. 
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Fig. 1.19. The zinc fingers of Sp/KLF transcription factors. Individual fingers (F1, F2, 
and F3) are depicted as a β-sheet (arrows) and a -helix (cylinder) held together by a 
zinc ion (dark grey sphere). GC box is shown as a double array of beads on strings with 
the nucleotide pairs partially overlapping. The amino acids in the a-helices are 
indicated, and interactions between critical residues (black) in each finger and a specific 
triplet of nucleotides of the GC box are shown with dotted lines [339]. 
 
 
 
 Sp1 was the first transcription factor identified and binds to DNA with KHA, RER 
and RHK aminoacids in the three zinc fingers respectively. Both Sp and KLF family of 
transcription factors binds to GC-(GGGGCGGGG) and GT-(GGTGTGGGG) boxes, but 
with different affinities due to alterations in the amino acid sequences in the zinc fingers 
(Fig. 1.19). This accounts for the interaction of Sp1 with diverse GC rich promoters and 
regulation of several of Sp-dependent genes in normal and transformed cells [340-342]. 
All Sp proteins have similar zinc finger domains and N-terminal motifs. Sp1-Sp9 
transcription factors have been grouped under the Sp subfamily based upon homology 
and chromosomal localization which is adjacent to the HOX gene cluster. Genetic 
regulation of transcription by Sp proteins is tightly controlled. 
Structural and functional characteristics of Sp proteins. Sp proteins have similar 
modular structures and Sp1-Sp4 form a subgroup among Sp proteins based on their 
similarity. Of their respective glutamine rich transactivation domains A and B, serine 
76 
 
threonine rich sequences and C-terminal zinc finger DNA-binding region. All Sp proteins 
have a conserved button head (btd) and Sp boxes that are involved in transactivation 
and regulation of proteolysis respectively [343, 344]. Sp2 has only one glutamine rich 
domain and a different consensus binding site due to the substitution of histidine by 
leucine in zinc finger 1 [345]. Sp5-Sp8 proteins have several small domains in common 
with other Sp proteins and appear to be truncated forms of Sp1-Sp4 due to lack of their 
N-terminal regions. With the exception of the btd and Sp boxes, the N-terminal regions 
of Sp5-Sp8 are different from other Sp proteins and are closely related to each other 
(Fig. 1.20). 
 
 
Fig.1.20. Structural motifs in Sp family proteins [339]. 
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 Sp1 regulates transcription from proximal promoters as well as distal enhancers 
and activation of domain B is important for multimerization and along with Domain A 
mediates superactivation of Sp1-dependent transcription [344, 346, 347]. Sp2 has a 
different binding specificity than other Sp proteins and therefore it is unable to activate 
transcription through GC boxes and its functions are cell specific. Sp2 has different 
characteristics compared to other Sp proteins due to single a tranactivation domain, 
whereas two domains are necessary for superactivation and synergestic activation by 
Sp1 [347-349]. Although Sp3 and Sp4 are structurally similar to Sp1, some functional 
differences exist between these proteins.  Sp3 exhibits additive and synergistic effects 
with Sp1 and also represses some Sp1 regulated genes. Sp4 was super activated with 
fingerless Sp1 and repressed by Sp3 [350-352]. Sp1 proteins regulate expression of 
several genes in combination with other transcription factors such as Oct-1, NF-κB, 
E2F-1, GATA and SMAD3 [353-355]. Sp1 and E2F-1 synergistically interact on the 
dihydrofolatereductase (DHFR) and thymidine kinase promoters and other Sp proteins 
such as Sp2, Sp3 and Sp4 also interact with E2F-1 for regulation of specific genes such 
as murine thymidine kinase [349]. Sp1 also interacts with the basic transcription 
machinery including TATA binding protein (TBP), TBP assosciated factors (TAFs) and 
other basal TFs through glutamine rich activation domains A, B and C-terminal domains 
[356, 357]. Sp1 also requires CRSP (cofactor required for Sp1) for efficient activation of 
transcription and it mediates Sp1 activation of GC rich promoters by interacting with 
TATA box, initiator sequences and RNA polymerase pre initiation complex [358, 359]. 
 Sp proteins play an important role in the regulation of key biological process 
such as cell proliferation, differentiation, survival and angiogenesis [339, 360, 361]. 
Even though the specific physiological functions of Sp proteins are not clear, some 
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gene knockout studies show that knockdown of Sp1, Sp3 and Sp4 results in 
embryolethality and severe abnormalities in the offspring including retarded 
development, reproductive abnormalities and defective tooth formation [362-365]. Thus 
the Sp gene family plays an important role in the normal development of organs and 
tissues. However expression of Sp1 and other Sp proteins is decreased in mature 
animals and decreases with age [366, 367]. 
Role of Sp proteins in cancer. Even though, Sp proteins are required for embryonic 
and postnatal development, there is emerging evidence that Sp protein expression 
plays a critical role in tumor development, growth and metastasis. Sp proteins such as 
Sp1, Sp3 and Sp4 are overexpressed in tumors compared to other tissues [368-372]. 
Lou and co workers [373] reported that carcinogen-induced transformation of fibroblasts 
increased expression of Sp1 by 8-18 fold and these transformed fibroblasts formed 
tumors in xenograft mouse models, while untransformed cells with low levels of Sp1 did 
not form tumors. Along with Sp1, other oncogenic genes such as VEGF are also highly 
expressed in gastric tumors and gastric tumor cells have elevated levels of nuclear Sp1 
compared to adjacent non glandular/stromal cells. Sp1 is a poor prognostic factor for 
gastric cancer patients and high levels of Sp1 predicted decreased patient survival 
compared to patients with low-non detectable levels of Sp1. Moreover, there is positive 
correlation between Sp1 and VEGF suggesting that patients with high VEGF expression 
also have poor survival rates [374]. In addition, ribozyme dependent knockdown of Sp1 
in transformed cells also decreases VEGF and induces apoptosis. Shi and coworkers 
[371]  reported high expression of Sp1and VEGF in pancreatic cancer cells and these 
results are consistent with studies indicating that Sp1 plays a critical role in VEGF 
regulation and knockdown of Sp1 along with Sp3 and Sp4 in pancreatic cancer cells 
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confirmed that Sp proteins regulate VEGF and its receptors [45, 46, 375]. Sp1 protein is 
also highly expressed in breast cancers and thyroid tumors [372, 376] and knockdown 
of Sp1 by small inhibitory RNAs inhibits G0/G1- S-phase progression in MCF-7 breast 
cancer cells [377]. Furthermore DNA-dependent protein kinases, such as Ku70 and 
Ku80 are highly upregulated in colon cancer tumors along with Sp1 and constitutive 
expression of these genes is regulated by interaction of Sp1 with their corresponding 
GC rich promoters resulting in tumor growth and metastasis [370]. In addition, Sp3 also 
plays an important role in cell proliferation and angiogenesis along with Sp1 by 
repressing p27, a CDK inhibitor in pancreatic cancer cells. 
Mechanism of Sp protein action in cancer. Sp proteins regulate constitutive 
expression of several genes involved in multiple functions in both normal and cancer 
cells. Sp proteins bind to GC rich promoters and subsequent interactions with 
components of the basal transcription machinery activates gene transcription. Sp 
dependent activation of genes is a highly complex process which depends on several 
factors such as gene promoter, cell context and interaction with other nuclear factors. 
Sp1 and Sp3 are commonly used models to investigate the mechanism of Sp proteins 
in the activation of several genes. 
 Courey et al., [378] first reported the synergistic interactions of Sp1 which forms 
homooligmeric complexes on GC rich promoters; this can be further attenuated by 
interaction of Sp1 with other nuclear factors on the same GC rich elements.  Sp1 and 
Sp3 proteins bind to same GC promoters and work cooperatively or Sp3 inhibits Sp1 
dependent transactivation and this depends on Sp1/Sp3 ratios for expression of some 
genes [379]. 
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Fig.1.21. Sp depenedent transactivation in cancer cells [369]. 
 
 Sp1 and Sp3 cooperatively activate several genes by interacting with other TFs 
as previously indicated. In addition Sp1 also interacts with several nuclear receptors 
such as estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), 
retinoic acid receptor (RAR), retinoic X receptor (RXR), peroxisome proliferator-
activated receptor- (PPAR-), vitamin D receptor (VDR) and others [380]. All these 
interactions occur at the C-terminal domain C/D domain of Sp1 which is the major site 
for interaction with other proteins. Thus Sp1 and other Sp proteins also function as 
modulators of gene expression through interactions with different nuclear proteins and 
other DNA bound transcription factors (Fig. 1.21). 
 Several studies also have shown that modification of Sp proteins such as 
phosphorylation, glycosylation, and acetylation also plays an important role in the Sp-
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dependent activation of some genes and this forms another layer of complexity in the 
function of Sp transcription factors (Fig. 1.21). In most prostate cancer cell lines, VEGF 
is regulated by PI3K and this is linked to increased phosphorylation of Sp1 and 
enhanced binding of the phosphoprotein to the GC rich promoter sequence [381], while 
MAPK dependent phosphorylation of Sp1 is critical for 6-integrin gene expression 
[382]. In addition, cyclin dependent kinases also increase phosphorylation of Sp1 and 
Sp1-dependent responses/gene expression and this is also associated with increased 
DNA binding of Sp1 [383-385]. Acetylation of Sp1 and Sp3 also increases 
transactivation; for example, Sp3 inhibits TGFBR in late passage MCF-7 cells, while, 
acetylation of Sp3 induces transactivation of TGFBR [386, 387]. Similarly, 
topoisomerase II inhibitors activate SV40 promoter through acetylation of Sp1 and 
acetylation of these proteins is regulated by p300, which exhibits histone 
acetyltransferase activity [388]. In contrast serine threonine O-linkage with N-
acetylglucosamine inhibits Sp1-dependent transactivation and is another factor that 
modifies Sp1 function [389]. 
Regulation of oncogenes by Sp proteins. Genes that regulate growth, proliferation, 
angiogenesis and cell cycle frequently contain GC rich elements in their proximal 
promoters, and their interaction with Sp and other TFs is important for their expression. 
Several reports have shown that Sp proteins regulate VEGF through proximal GC rich 
motifs and Sp1-mediated angiogenesis through induction of VEGF is cell context 
dependent [45, 371, 390]. Results of RNA interference studies showed that Sp proteins 
are involved in regulation of VEGF and this was due to binding of Sp1, Sp3 and Sp4 
with the VEGF promoter. RNA interference studies have also shown that Sp1, Sp3 and 
Sp4 regulate genes involved in cell growth and cell cycle progression such as cyclins 
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and cyclin dependent kinases. For example transfection of pancreatic cancer cells with 
iSp3 results in upregulation of cyclin dependent kinase inhibitor p27 indicating that Sp3 
enhances growth of pancreatic cancer cells by inhibiting p27 mRNA and protein 
expression through interaction with GC rich promoter elements. Sp proteins also 
regulate the expression of TGF-β/TGFBR signaling in cancer cells [391-393] and the 
TF‘s also regulate several genes associated with cell growth and cell cycle progression 
(CD1, E2F1, c-fos, TGF-), purine/pyramidine synthesis and metabolism [thymidylate 
synthase, adenosine deaminase, DNA polymerase , carbamylphosphate 
synthase/aspertatecarbamyltransferase/dihydroorotase (CAD)], angiogenesis (VEGF) 
and anti-apoptosis (bcl-2)) [341, 342, 390, 394-399]. Several other reports have also 
shown that Sp proteins regulate transcription of genes involved in the growth and 
metastasis of cancer cells and must be considered as prognostic factors for the disease 
and as potential targets of chemotherapy. 
Strategies of Sp protein targeting in cancer cells. In some human cancers, Sp 
protein overexpression is a negative prognostic factor for survival and contributes 
towards proliferative and metastatic tumor phenotype. There are several possible 
strategies for targeting Sp proteins in cancer cells and these include drugs that 
inactivate GC-rich DNA motifs, oligonucleotides and peptide nucleic acid-DNA chimeras 
(Sp1 decoys) and chemicals that modulate Sp1 protein expression (Fig. 1.22). 
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Fig. 1.22. Strategies for targeting Sp proteins in cancer cells. 
 
 Drugs such as mithramycin and hedamycin bind GC-rich motifs and decrease 
Sp1-DNA binding and Sp1-dependent gene expression [400, 401]. For example, TNF- 
induction of  thymidine kinase in colon cancer cells is due to enhanced Sp1-DNA 
binding and this was inhibited by mithramycin [401], while hedamycin inhibits survivin 
transcription by interacting with proximal GC-rich Sp1 binding site in the survivin gene 
promoter [402]. Double stranded GC rich oligonucleotides (Sp1 decoys) have been 
developed for inhibiting Sp1-dependent gene expression [403, 404] and TNF- induced 
VEGF and TGF-β1 gene/protein expression, cell proliferation and invasiveness is 
decreased by Sp1 decoys. Mutant Sp1 decoys are also being developed and there may 
be potential clinical applications for this technology for treatment of specific cancers 
[405, 406]. 
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 COX-2 inhibitors such as celecoxib are potent anticancer drugs because of their 
anti-angiogenic activity which has been linked to modulation of Sp1 transcription activity 
in pancreatic cancer cell lines [407-409] and this was due to decreased Sp1 protein 
phosphorylation and decreased P-Sp1/Sp1 ratios which binds the GC-rich VEGF 
promoter. This suggested that the anti-angiogenic activity of celecoxib in pancreatic 
cancer cells was due to targeted dephosphorylation of Sp1. Recent studies from our 
laboratory also investigated the anti cancer activity of non steroidal anti-inflammatory 
drugs (NSAIDs) and COX-2 inhibitors in pancreatic, colon and other cancer cell lines. 
The growth inhibitory effect of celecoxib, nimesulide and NS-398 in SW480 colon 
cancer cells was due to downregulation of Sp1 and Sp4 but not Sp3 proteins. It was 
further shown that down regulation of Sp1 and Sp4 was COX independent and due to 
activation of proteasomes which specifically targeted degradation of Sp1 and Sp4 in 
colon cancer cells [410]. These results indicated an opportunity for development of 
small molecule drugs that target Sp TF‘s and Sp-regulated genes that are important for 
cancer cell growth arrest, inhibition of angiogenesis and metastasis for several cancers. 
 In conclusion, Sp transcription factors play an important role in tumor 
development, growth and metastasis. The complexity of Sp-regulated gene expression 
depends on domain specific interaction of Sp1 with other transcription & nuclear factors, 
and also chemical and enzyme induced modifications. This complexity may be highly 
advantageous for treating some cancers since combined targeting of different pathways 
that modulate Sp protein expression and activity may enhance the selectivity and 
efficacy of this type of therapy. 
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NSAIDs AS ANTI-CANCER AGENTS 
 NSAIDs are a chemically diverse group of drugs that are available over the 
counter or by prescription world-wide. These drugs are commonly used to treat a variety 
of acute and chronic inflammatory conditions including pain, fever and arthritis. Fig. 1.23 
represents the chemical structure of aspirin, the most widely used NSAID which was 
discovered over 150 years ago. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.23. Chemical structures of commonly used NSAIDs. 
 
 The pharmacological basis for the anti-inflammatory activity of NSAIDs is due to 
inhibition of COX enzymes which prevents the conversion of arachidonic acid to 
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prostaglandin H2, a precursor of prostaglandins, prostacyclins and thromboxanes (Fig 
1. 24) [411]. 
 
 
Fig.1.24. NSAIDs, COX inhibition and prostaglandins [412]. 
 
 COX is a key regulatory enzyme in prostaglandin biosynthesis and is 
responsible for induction of inflammation [413]. COX-1 is a constitutive enzyme required 
for the regulation of prostaglandin biosynthesis and prostaglandin-dependent effects on 
blood flow & tissue integrity. COX-2 is an inducible enzyme expressed in inflammatory 
cells & cancer cells and hence, considered to be an ideal target for inhibition of 
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inflammation and tumorigenesis. This property makes NSAIDs valuable for treatment of 
diseases associated with inflammation and cancer. Several studies have shown 
increased levels of COX enzymes & prostaglandins in various tumors suggesting that 
inflammation plays an important role in tumorigenesis and that the suppression of 
prostaglandin synthesis is essential for activity of NSAIDs in disease prevention [194, 
197, 414, 415]. However many responses induced by NSAIDs cannot be explained by 
COX inhibition indicating that COX-dependent and independent mechanisms play an 
important role in the biological and anticancer activity of NSAIDs. Several clinical, 
epidemiological & experimental studies have shown that aspirin and other NSAIDs are 
promising anti-cancer agents and prolonged continuous use of NSAIDs decreases the 
risk of cancer of the colon and other gastrointestinal organs as well as breast, prostate, 
lung and skin cancers [416-422].  Recent studies and reviews have assessed the 
association of NSAIDs with the reduced risk of gastric cancer and suggested that 
continuous long-term administration of aspirin results in a significant dose dependent 
reduction of gastric and colon cancers and it was protective in all age groups of men 
and women [423]. Continuous use of NSAIDs in cancers seem to have protective effect, 
while infrequent use is not associated with reduced risk for both colorectal cancers and 
adenomas [419, 424]. NSAIDs reduce precancerous adenomas in patients with familial 
or sporadic adenomatous polyposis and the non-selective COX inhibitor sulindac and 
the COX-2 selective inhibitor celecoxib prevent formation and regression of adenomas 
in patients with familial polyposis [425-428]. NSAIDs also exhibit anti-carcinogenic 
effects in experimental animal models such as chemically induced gastric tumors in 
mice which can be decreased by aspirin, sulindac, indomethacin and ibuprofen [429-
432]. NSAIDs also exhibit anti-tumorogenic activity in xenograft mouse models and 
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inhibit growth of transplanted tumors and carcinogen induced skin tumors in mice & rats 
[429-432]. Several NSAIDs also decrease polyp multiplicity, tumor incidence and colon 
cancer cell growth (Table. 1.10). 
 
Table. 1.10. Effects of COX-2 selective inhibitors in animal models of colorectal 
cancers 
(* Non-selective NSAID inhibitors, ** Selective COX-2 inhibitors) [433]. 
 
NSAID treatment Outcome 
Apcmin mouse  
Sulindac*  polyp multiplicity 
Piroxicam*  polyp multiplicity 
Celecoxib**  polyp multiplicity 
Apc 716 mouse  
Rofecoxib**  polyp multiplicity 
Azoxymethane-treated rat  
Celecoxib**  tumor incidence 
 multiplicity 
NS-398**  tumor incidence 
 multiplicity 
Nimesulide**  tumor incidence 
 multiplicity 
Aspirin*  tumor incidence 
 multiplicity 
Nude mouse xenograft  
SC-58125**  colon carcinoma cell growth 
Celecoxib**  colon carcinoma cell growth 
Meloxicam*  colon carcinoma cell growth 
 
 
 Both experimental and epidemiological studies show that the anti-tumorogenic 
effects of NSAIDs are reversible and tumor recurrence increases shortly after 
discontinuous use of NSAIDs [434]. Aspirin and several other NSAIDs also induce 
apoptosis & inhibit proliferation of various cancer cell lines [418, 435, 436] and it has 
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been reported that both COX-2 dependent and independent mechanisms are involved 
in NSAID induced apoptosis [418, 435]. 
 
 
Fig.1. 25. COX2-depenedent and –independent mechanisms of NSAID induced 
apoptosis [437]. 
 
 
Inhbition of cancer: COX-2-dependent mechanisms. Constitutive expression of 
COX-1 in mammalian tissues is responsible for homeostasis and maintenance of 
gastrointestinal mucosal integrity [438]. In contrary, COX-2 is largely induced during 
inflammation and several studies show overproduction of COX-2 and PGE2 in gastric & 
colon tumors, suggesting that overexpression of COX-2 plays a role in gastric cancers 
[439-442]; and it was hypothesized that anti-carcinogenic activity of NSAIDs was due to 
inhibition of COX-2 [216]. Overexpression of COX-2 contributes to carcinogenesis by 
increasing cell proliferation, inhibiting apoptosis, and enhancing angiogenesis and these 
effects are thought to be mediated through induction of PGE2 [418, 435, 440]. COX2 
overexpression also increases cellular levels of bcl-2 and this results in the resistance 
to apoptosis of premalignant cells [443], whereas induction of apoptosis by COX-2 
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inhibition is not well understood. Other studies show that decreased cellular PGE2 and 
increased arachidonic acid levels might be involved in induction of apoptosis and 
inhibition of cell proliferation (Fig. 1.25) [436]. Increased levels of arachidonic acid can 
alter mitochondrial membrane potential & permeability and releases of cytochrome C, 
leading to apoptosis [444, 445] and arachidonic acid also increases production of 
ceramide, a potent inducer of apoptosis (Fig. 1.25) [446]. COX-2 is also involved in the 
promotion of angiogenesis in several experimental systems and is critical for 
progression of many cancers [44, 447]. Importantly, NSAIDs inhibit both COX-1 and 
COX-2 to varying degrees; the therapeutic effects of traditional NSAIDs are due to 
inhibition of COX-2 and adverse effects such as gastrointestinal toxicity are due to 
inhibition of COX-1 activity. This has led to the development of selective COX-2 
inhibitors, which are relatively less toxic than conventional NSAIDs [438, 439]. 
 Apoptosis caused by NSAIDs is not fully explained by COX inhibition, because 
anti-proliferative and apoptotic effects were also observed in cell lines irrespective of 
their COX levels [448]. Moreover, NSAIDs also inhibit growth of colon cancer cell lines 
that are negative for COX enzymes and mouse embryo fibroblasts that are null for both 
COX enzymes [449, 450]. Interestingly, the dose of NSAIDs required to give anti-
carcinogenic effects is much higher than required for inhibition of inflammation (Table. 
1.11). The difference in the clinical activities of low and high dose of aspirin has led to 
the speculation that not only COX inhibition but also COX independent effects are 
responsible for the benefits of aspirin [451]. 
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Table. 1.11. Tumor cell growth and COX inhibitory activity of different NSAIDs. 
NSAID Growth 
IC50 (μM) 
COX-1 
IC50 (μM) 
COX-2 
IC50 (μM) 
Serum levels 
(μM) 
Celecoxib 50 >30 2.25 2 
Sulindac sulfide 60 1.02 10.4 15 
Diclofenac 160 0.14 0.05 6 
Indomethacin 180 0.16 0.46 1.4 
Piroxicam 900 0.76 8.9 17 
Ibuprofen 975 4.75 >30 40 
Flurbiprofen 1800 0.44 6.42 53 
Aspirin 5000 4.5 13.9 10 
 
 
COX-2-independent mechanisms of NSAIDs. At higher concentrations, NSAIDs 
activate a number of COX-1 and COX-2-independent pathways including 
downregulation of NF-κB activity [452-454], changes in expression of pro- and anti-
apoptotic proteins [455-457], activation of extrinsic and intrinsic apoptosis 
pathways[458-461], inhibition of proteasome function [462, 463], cell cycle arrest [462-
466], and activation of stress kinases and generation of the stress response (Fig. 1.26) 
[467-471]. For example, Sulindac and other NSAIDs induce apoptosis in colon cancer 
cells and this process is mediated by 15-lipoxygense 1 [472-474]. NSAIDs also activate 
peroxisome proliferator activated receptor (PPAR) subtypes-,  and  and PPAR   
interacts with APC/β-catenin signaling in colorectal cancer [219, 475, 476]. In addition 
NSAIDs also target multidrug resistance protein 4 (MRP4), which modulates release of 
prostaglandins from cells and this function is inhibited by NSAIDs (Fig. 1.26) [477]. 
92 
 
 
Fig. 1.26. NSAIDs and non-COX targets [412]. 
 
Some of these mechanisms are also regulated through COX-2 dependent pathways, 
since NSAIDs induced cell death, suppression of NF-κB activation and inhibition of 
expression of COX-2 is dependent on cell context and dose [478, 479]. Indomethacin, 
ibuprofen and sulindac are more potent inducers of apoptosis compared to aspirin in a 
variety of cancer cells such as pancreatic and lung cancer cells [478, 479]. 
Downregulation of NF-B pathway. Activation of NF-κB stimulates different pathways 
that promote cell death and cell survival [480-482]. NF-κB activity is elevated in several 
cancers, especially advanced cancers that have been treated previously; and high NF-
κB activity plays a critical role in chemo-resistance of many cancers [480, 483]. Several 
NSAIDs including aspirin induce apoptosis through inhibition of NF-κB activity and also 
inhibit TNF--induced activation of NF-κB and sensitizes gastric cell lines to TNF- 
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[452, 453, 484]. NSAIDs also inhibit I-B kinase β, an enzyme responsible for activation 
of NF-κB through phosphorylation and subsequent proteasomal degradation of I-B- 
[453]. Other reports have shown that aspirin-induced apoptosis is through enhanced 
degradation of IB- and increased NF-κB activity [485, 486]. Therefore the effect of 
NSAIDs on NF-κB activity is contradictory and also dependent on cell context and dose. 
NSAIDs also inhibit AP-1 activity and this is related to the induction of apoptotic signals 
[470]. 
Activation of apoptotic pathway. Aspirin and other NSAIDs induce apoptosis through 
both intrinsic and extrinsic pathways. In some cells NSAIDs alter mitochiondrial 
membrane permeability and release cytochrome c and activate caspase 8 & 9, thus 
leading to apoptosis [455, 458-461]. The release of cytochrome c from mitochondria is 
considered as a central event in apoptosis and it is an early event in NSAID-induced 
apoptosis [487] [459, 462, 487]. Cytochrome c binds with apoptotic protease activating 
factor-1 (apaf-1) and subsequent activation of caspase-9 & caspase-3. In human cancer 
(gastric, ovarian) cells, aspirin-induced apoptosis is partially blocked by caspase 
inhibitors and overexpression of anti-apoptotic bcl-2 [455, 459, 460]. Knockout of apaf-1 
in HeLa cells resulted in resistance to aspirin-induced apoptosis [459]. In addition to 
caspase 9 and caspase 3, caspase 8 also plays a role in aspirin induced apotosis by 
direct activation of downstream caspases or by cleaving the BH3 interacting domain 
death agonist (Bid); tBid then translocates to mitochondria and induces the release of 
cytochrome c. NSAIDs also mediate apoptosis through upregulation of pro-apoptotic 
and downregulation of anti-apoptotic proteins [455-457]. NSAIDs downregulate bcl-2 
expression and induce the expression of bcl-2 associated X protein (Bax), bcl-2 
antagonist of cell death (Bad) and p53 [455-457, 462]. For example, COX-2-selective 
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inhibitors SC-58125 and NS-398 sensitize colon and prostate cancer cells to apoptosis 
by downregulating bcl-2 [488], while aspirin and indomethacin induced apoptosis by 
upregulation of Bax & Bak and activation of caspase 3 [457]. Bax translocates from the 
cytosol to the outer mitochondrial membrane to facilitate release of cytochrome c 
through formation of pores [489]. Release of cytochrome c from mitochondria is also 
due to downregulation of bcl-2, arachidonic acid and ceramide, which are increased due 
to inhibition of COX-2. Thus, the mitochondria is a common target of both COX-2-
dependent and -independent apoptotic pathways induced by NSAIDs. NSAIDs also 
induce apoptosis by downregulation of protein kinase C-b1 (PKC-b1) [490], a survival 
mediator. 
Inhibition of proteasome function and cell cycle arrest. NSAIDs induce cell cycle 
arrest and cause apoptosis through inhibition of proteasome function [462-466]. The 
ubiquitin proteasome system (UPS) is a major extra lysosomal pathway responsible for 
intracellular protein degradation in eukaryotes and this pathway is involved in the 
degradation of several important regulatory proteins associated with regulation of the 
cell cycle and differentiation [491, 492]. The target proteins are conjugated with ubiquitin 
through covalent attachment and the tagged protein is recognized and degraded by the 
proteasomal machinery. The UPS is involved in degradation of many short-lived 
proteins that are required for cell survival and modulation of this pathway can promote 
cell context-dependent cell death [493-495]. Some reports show that proteasome 
inhibition also generates stress responses and induces various heat-shock proteins 
which increase tolerance to stressful conditions [496]. Proteasome inhibitors also inhibit 
NF-κB activity, induce oxidative and endoplasmic (ER) stress, and activate various 
stress kinases. Treatment of different cell lines (neuro-2a, COS-1, and HeLa) with 
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aspirin decreases proteasome function and increases accumulation of ubiquitinated 
proteins and is accompanied by apoptosis [462]. Aspirin and other NSAIDs increase 
intracellular accumulation of various proteasomal substrates, such as Bax, IkB-, p53, 
p21waf1/Cip1 and p27kip1, which are pro-apoptotic [455, 457, 462, 464, 465] and also 
increase accumulation of p27kip1 or p21waf1/Cip1 which cause cell cycle arrest at the G1/S 
phase and induce apoptosis. The mechanisms of proteasome inhibition by aspirin and 
other NSAIDs is not known, however NSAIDs-induced proteasomal dysfunction 
explains many of the growth inhibitory and proapoptotic effects of NSAIDs. 
Induction of stress response. NSAIDs also induce oxidative & ER stress, and these 
stress responses are involved in the initiation of apoptotic signals [467-469]. ER stress 
response is induced by accumulation of unfolded proteins in the ER in which activating 
transcription factor (ATF) 4- and 6-dependent activate C/EBP homologous transcription 
factor (CHOP). ER stress also activates apoptosis signal regulating kinase 1 (ASK1), 
and activated ASK1 induces apoptosis through cJun N-terminal kinase (JNK) [497]. ER 
stress also activates caspase-12 and activated caspase-12 further activates caspase-9 
and -3 [497]. Indomethacin induces both glucose-regulated protein-78 and CHOP [469] 
and also activates ATF6, ATF4, X box binding protein-1, ASK1 and JNK [469-471, 498]. 
NSAID-induced apoptosis is also initiated by generation of oxidative stress, through 
activation of the intrinsic apoptosis pathway involving mitochondria [467, 468]. NSAID 
induced ER or oxidative stress most likely depends on the concentrations and the types 
of drugs used [499]. Nitric oxide-donating NSAIDs, which are safer than their NSAIDs 
counterpart, are more potent inducers of oxidative stress and apoptosis than NSAIDs 
[499]. 
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 In conclusion, aspirin and other NSAIDs induce COX-2-dependent or –
independent pathways in cancer cells and further understanding of the mechanisms of 
NSAID-induced apoptosis will greatly facilitate the design of more potent and safer 
drugs for the treatment of gastric, colon and other cancers. One of the major problems 
with NSAIDs is that they require higher doses to produce their anti-carcinogenic effects 
and to induce apoptosis. Selective COX-2 inhibitors or nitric oxide-donating NSAIDs 
with minimum gastrointestinal side effects are also promising anti-cancer drugs that can 
also be combined with drugs targeting multiple oncogenic pathways to enhance their 
clinical efficacy. Examples of this combination therapy include combining selective 
COX-2 inhibitors with EGF receptor inhibitors and/or protein kinase A inhibitors [500], 
coupling inhibitors of COX-2 with compounds that block matrix metalloproteinases 
[501], combining specific COX-2 inhibitors with herceptin [502], or simply adding COX-2 
inhibitors to standard colon cancer chemotherapy regimens. 
Aspirin and human cancer - Epidemiological studies. The first epidemiological 
evidence that aspirin acts as a chemoprevention agent came from a case control study, 
in which aspirin use was associated with a significantly lower risk of colorectal cancer 
even after adjustment for other risk factors [503]. In 2005, Bosetti et al., [504] reviewed 
all case–control and cohort reports  (100 studies) regarding the chemopreventive 
activity of aspirin; the pooled relative risk (RR) for developing colorectal cancer was 
0.71 (95% CI: 0.67–0.75), even though there was significant heterogeneity between 
trials and study designs. There was limited evidence that aspirin prevented cancers of 
the esophagus (RR 0.72, 95% CI: 0.62–0.84), stomach (RR 0.84, 95% CI: 0.76–0.93), 
breast (RR 0.91, 95% CI: 0.88–0.95) and lung (RR 0.94, 95% CI: 0.89–1.00) [504]. 
Recently, two large cohort studies have highlighted that the magnitude of the response 
97 
 
depends on both the dose and duration of aspirin use, with the maximum decrease in 
colorectal cancer incidence seen when > 14 aspirin tablets (325 mg) were taken per 
week for 6–10 years [505, 506]. 
 Two recent non-randomised studies have examined the use of aspirin after a 
diagnosis of cancer as a chemotherapeutic drug. Regular use of aspirin after diagnosis 
of colorectal cancer decreased colorectal cancer-specific mortality (HR 0.71, 95% CI: 
0.53–0.95) and overall mortality (HR 0.79, 95% CI: 0.65–0.97) in aspirin users when 
compared to non-users [434, 505, 506]. Notably, patients with primary tumors 
overexpressing COX-2 had the most benefit with an HR of 0.39 (95% CI: 0.20–0.76) for 
colorectal cancer-specific mortality compared with an HR of 1.22 (95% CI: 0.36–4.18) 
for those whose primary tumors had weak or absent COX-2 expression. In addition, 
those who had taken aspirin before diagnosis did not seem to benefit (HR 0.89, 95% CI: 
0.59–1.35) compared with those with no previous use (HR 0.53, 95% CI: 0.51–0.92) 
[434]. Similar results have been reported for breast cancer, with aspirin use after breast 
cancer diagnosis associated with decreased distant recurrence and breast cancer 
mortality [507]. Three small randomised-controlled trials have assessed the effects of 
aspirin in combination with traditional chemotherapy. Three hundred small cell lung 
cancer patients were assigned to take 1g of aspirin per day for 18 months or no aspirin 
in addition to their chemotherapy [508] and it was reported that there was no significant 
difference in survival between the groups and aspirin was well tolerated. Another trial 
found no evidence of a survival benefit when 176 patients with advanced renal cell 
carcinoma received interferon- with or without aspirin 2400 mg daily [509]. Another 
small trial of 66 patients evaluated 1200 mg of aspirin daily compared with placebo as 
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adjuvant treatment for Duke‘s B2 and C colorectal cancer (HR for survival 0.65, 95% CI: 
0.02–18.06, P¼0.90) [510]. 
 In conclusion, aspirin continues to be evaluated in vitro and in pre-clinical 
models as to the mechanisms of action as anti-neoplastic agent. Recent evidence from 
randomized trials shows a decrease in cancer incidence with long-term follow-up and 
colorectal & breast cancer studies show that aspirin use post-diagnosis increases 
cancer survival and decreases the time to recurrence. The development of new 
combination therapies that include aspirin should provide effective, low cost cancer 
treatment options. 
Tolfenamic acid (TA) as anticancer agent. TA is a widely used NSAID for treatment 
of migraines, headaches and alcohol induced hangovers [511]. It is a potent, well 
tolerated NSAID with relatively few side effects and a high therapeutic index [512]. It 
has antipyretic and analgesic properties as evidenced in several animal models and 
also shows promising results for treatment of osteoarthritis and rheumatoid arthritis 
[513, 514]. Fig. 1.27 represents the structure of TA. 
 
 
Fig. 1.27. The structure of TA [515]. 
 
 The commercial names for TA are Clotam Rapid and Tufnil for use in humans 
(not in the United States) and Tolfedine for veterinary use. The systematic (IUPAC) 
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name for TA is ‗‗2-[(3-chloro-2-methylphenyl)amino]benzoic acid)‘‘ and it belongs to the 
‗‗fenamates‘‘ class of NSAIDs [516, 517]. NSAIDs are known to cause side-effects, 
which include gastrointestinal bleeding and ulceration and high oral doses of TA 
exhibits a decreased incidence of these. In rare cases, other reported side effects such 
as fatigue, headache, vertigo, tremors, euphoria, and anemia may occur.  In one study 
conducted on wistar rats, TA caused only low gastro-ulcerogenicity when compared 
with 10 other NSAIDs including ketoprofen, indomethacin, and naproxen [512]. 
Recently, several reports have shown the efficacy of this drug for cancer chemotherapy 
[375, 518]. Studies from our laboratory identified TA as a novel anti-cancer agent in 
pancreatic, breast, esophageal and lung cancer models [519, 520] [518, 521]. The anti-
cancer activity of TA is COX-independent and related to the degradation of Sp 
transcription factors. TA inhibits pancreatic cancer cell growth and tumor growth through 
induction of proteasome-dependent degradation of Sp transcription factors [45, 375, 
518]. Recent evidence shows that TA induces apoptosis in colon cancer cells and also 
inhibits metastasis & tumorigenesis in pancreatic cancer models [375, 522, 523]. TA 
decreases the expression of angiogenic genes such as VEGF and VEGF receptors, 
which are mediated through downregulation of Sp transcription factors. The anti-
angiogenic activity of TA is associated with the inhibition of liver metastasis in an 
orthotropic model of pancreatic cancer [518]. TA also inhibits lung, esophageal, breast 
and ovarian cancer cell growth and with the exception of breast cancer cells, TA also 
induced downregulation of Sp1, Sp3, Sp4 and Sp-regulated genes [516, 519-522, 524]. 
However, the molecular basis for the induction of apoptosis and scope of its action in 
colorectal cancer has not been reported and will be investigated as part of my thesis 
research.  
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NO-NSAIDs AND CANCER 
 Design of pharmacological agents includes modification of known compounds in 
order to optimize their pharmacological properties, such as safety and efficacy. Nitric 
oxide-donating nonsteroidal anti-inflammatory drugs (NO-NSAIDs) represent an 
emerging class of drugs and their design was based on the known properties of 
NSAIDs and the newly discovered NO, a molecule that plays an important role in the 
cardiovascular system and in human physiology. It was expected that, NO-NSAIDs 
would exhibit properties of both NSAIDs and NO groups. Since release of NO group 
would mimic the effects of antihypertensive agents and prostaglandin analogs. NO-
donating compounds are also promising for treatment of other diseases, including 
cardiovascular diseases, asthma, hypoxic–ischemic brain injury, glaucoma, and 
alzheimer's disease because of their antioxidant activity [525-529].  
 NO-NSAIDs consist of a conventional NSAID to which an NO-releasing moiety 
is attached covalently, often via a spacer molecule (Fig. 1.28).  
 
 
Fig. 1.28. The chemical structure of NO-aspirin. The aspirin derivative designated NCX 4016 [2-
(acetyloxy)benzoicacid 3-(nitrooxymethyl)phenyl ester] is shown with its three structural components 
highlighted. The spacer molecule links traditional aspirin to -NO2, which can release NO [530]. 
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 Del Soldato et al .,[531] first synthesized NO-NSAIDs and a large number of 
NO-NSAIDs can be generated by varying the spacer molecules (Fig. 1.29), which can 
include aliphatic and aromatic molecules and the latter were more effective as spacers. 
Positional isomerism also influences the pharmacological efficiency of NO-ASA in colon 
cancer cells [530]. 
 
 
Fig.1.29. The structure of representative NO-NSAIDs.NO-NSAIDs consist of a 
conventional NSAID, the spacer molecule and the NO-releasing moiety (–ONO2). The 
conventional NSAID is in the boxed area [532]. 
 
 
 
 The rationale for the initial synthesis of NO-NSAIDs was based on the fact that 
NSAIDs damage the gastrointestinal mucosa by inhibiting the synthesis of 
cytoprotective prostaglandins [7], whereas the action of NO on this mucosa is similar to 
that of prostaglandins. Several in vivo studies showed that both prostaglandins and NO 
modulate mucosal blood flow, mucus release, mucosal injury repair, inhibit neutrophil 
adherence and activation, and of suppress mast cell degranulation [533, 534]. Thus 
release of NO by NO-NSAID provides locally generated NO and thereby protects from 
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NSAID-induced mucosal damage and this has been demonstrated in several animal 
and some human studies (Fig. 1.30) [535, 536]. For example, NO-donating aspirin 
maintains cyclooxygenase-1 and platelet inhibitory activity with minimal gastrointestinal 
damage. NMI-1182 and AZD3582 are NO-derivatives of naproxen that exhibit inhibition 
of COX activity similar to that naproxen, but cause significantly fewer gastric lesions 
than naproxen. The safety of NO-ASA was established in randomized studies 
conducted on 40 healthy subjects who were treated with NO-ASA or ASA or placebo for 
a week. Toxicity was determined using endoscopic injury scores which were lower for 
NO-ASA compared to that of ASA [536]. NO-NSAIDs exhibit a significantly higher 
cytostatic and cytocidal activity than that of the parent NSAID in different experimental 
in vitro and in vivo cancer models [537-549]. 
 
 
Fig. 1.30. Mechanism of gastric cytoprotection by NO-NSAIDs. While the NSAID moiety inhibits gastric PG 
production, the NO released from the NO-NSAID compensates for the loss of the PG synthesis. This 
mechanism is thought to account for the protection of gastric mucosa by NO-NSAIDs [530]. 
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 The hypothesized release of the cytoprotective NO group from NO-NSAIDs 
within the stomach is not accurate, since NO-ASA traverses the stomach intact, thus 
ruling out this mechanism, at least in the case of NO-ASA [550, 551]. An alternative 
explanation is that NO is released beyond the upper GI tract and can reach the gastric 
mucosa via the circulation; however this route of NO delivary to mucosa is unknown; 
even though elevated NO levels in the circulation have been observed following 
administration of NO-NSAIDs [551].  
 The chemotherapeutic properties of NO-NSAIDs such as NO-ASA, NO-sulindac 
and NO-ibuprofen have been reported in colon cancer cells; these compounds 
decreased growth of cultured HT-29 human colon adenocarcinoma cells more 
effectively compared to that of their related NSAIDs [548] and this was subsequently 
shown in several cancer cell lines [543, 545, 547, 552]. NO-NSAIDs inhibited cell 
proliferation, induced apoptosis and DNA degradation and caused a G0/G1 to S phase 
block in cell cycle progression [530]. The anticancer activity NO-NSAIDs was also 
observed in Min mice and in azoxymethane induced colon cancer. For example, NO-
ASP decreased incidence, multiplicity and size of tumor in Min mice and in 
azoxymethane induced colon tumors [538, 540, 542, 553] and NCX-4016 (NO-ASA) 
decreased the number of aberrant cryptic foci in the colon by 85%, where as only a 
64% was observed for aspirin [552]. 
 The anticancer activity of NO-NSAIDs has been observed not only in the colon 
cancer models but also in animal models for pancreatic, ovarian and bladder cancer 
[541, 552, 554, 555]. Other reports show that positional isomers of NO-NSAIDs also 
influence their anticancer activity. For example, the IC50 for growth inhibition of HT-29 
colon cancer cells differed between p-NO-ASP (12 uM) and m-NO-ASP (230 uM); meta 
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NO-ASA (3000 ppm) decreased pancreatic tumor growth and incidence (89.5%) where 
as ASA (3000 ppm) was not active [556]. NO-ASA also inhibited growth of BxPC-3 
human pancreatic cancer cells by increasing intracellular ROS, activation of MAPKs 
and induction of p21cip-1 resulting in suppression of cyclin D1 and growth inhibition [554]. 
NCX-4016 inhibited EGFR and STAT3 signaling, modulated Bcl-2 expression, induced 
apoptosis and inhibited cell cycle progression in cisplatin-resistant human ovarian 
cancer cells & xenografts [555]. A short 6 hour exposure to NCX-4040, a NO-ASP 
induced apoptosis due to caspase activation and mitochondrial membrane protein 
depolarization in HT1376 and MCR bladder cancer cell lines [541]. 
 
Table. 1.12. Growth inhibitory IC50 values of NSAIDs and NO-NSAIDs in colon cancer 
cells [552]. 
 
Compound 
IC50 (µM) 
HT-29 HCT-15 
Aspirin 
NO-Aspirin 
Ratio 
3500 ± 300 
5 ± 2 
689 ± 115 
3000 ± 250 
3 ± 1 
1083 ± 114 
Sulindac 
NO-sulindac 
Ratio 
682 ± 35 
33 ± 5 
21 ± 1 
487 ± 50 
35 ± 4 
14 ± 0.7 
Indomethacin 
NO-indomethacin 
Ratio 
580 ± 50 
35 ± 4 
17 ± 0.7 
436 ± 40 
25 ± 3 
18 ± 0.8 
Salicylic acid 
NO-salicylic acid 
Ratio 
>1000 
143 ± 28 
>7 
>1000 
112 ± 18 
>9 
Ibuprofen 
NO-Ibuprofen 
Ratio 
>1000 
48 ± 15 
>21 
>1000 
57 ± 20 
>18 
Flurbiprofen 
NO-flurbiprofen 
Ratio 
782 ± 35 
98 ± 10 
9 ± 0.4 
450 ± 50 
285 ± 75 
1.7 ± 0.2 
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 Several NO-NSAIDs including NO-ASA, NO-salicylic acid, NO-indomethacin, 
NO-sulindac, NO-ibuprofen and NO-flurbiprofen were more potent than their parent 
NSAIDs (Table.1.12) as inhibitors of HT-29 and HCT-15 colon cancer cell growth and 
the IC50s for these NO-NSAIDs were between 7-and -689 fold and 1.7- to 1083 fold 
lower than their corresponding NSAIDs in these cells respectively [552]. The activity 
NO-NSAIDs was COX-independent since HT-29 cells express COX enzymes whereas 
HCT-15 cells do not. NO-NSAIDs also cause morphological changes which include 
nuclear condensation, extensive vacuolization of cytoplasm, loss of cell membrane 
integrity, loss of volume and texture of the nucleus indicative of apoptosis and necrosis 
[552]. 
 
 
Fig. 1.31. Working model of the effect of nitric oxide (NO)-donating aspirin on signalling 
pathways and other molecular targets [557]. 
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  NO-ASA induces oxidative stress resulting in activation of the intrinsic apoptosis 
pathway and inhibition of Wnt (β-catenin) signaling (Fig. 1.31) [468]. Inhibition of Wnt 
signaling is a dual mechanism; the dominant mechanism operates at lower 
concentrations, NO-ASA, which blocked formation of β-catenin/TCF complexes; at 
higher concentrations β-catenin is cleaved. NO-NSAIDs also inhibit both inducible nitric 
oxide synthase (iNOS) [558] and NF-κB activation (Fig.1.33) [559]. However their action 
on cyclooxygenases was ambiguous since different studies show conflicting results 
[560]. NO-NSAIDs also modulate drug metabolizing enzymes such as induction of 
expression and activity of NAD(P)H:quinone oxireductase (NQO) and glutathione S-
transferase (GST) and translocation of Nrf2 into nucleus by binding to Keap1 [561]. NO-
ASA also suppressed microsatellite instability in mismatch repair-deficient cell lines 
suggesting that it can be used effectively for chemoprevention of HNPCC [562].  
GT-094 as anticancer agent. GT-094 (ethyl 2-((2, 3-bis (nitroxy) propyl) 
disulfanyl)benzoate) (Fig. 1.32) is a novel NO chimera containing three key structural 
features which include, an NSAID (thiosalicylate) and NO moieties and a disulfide 
pharmacophore. It was anticipated that GT-094 would be a prototype for the design of 
novel anticancer agents for treatment of colon and other cancers [563]. The use of 
thiosalicylate derivatives in colon cancer therapy has previously been documented and 
the thiosalicylate component of GT-094 was expected to be a COX-2 inhibitor which 
would in turn contribute to the chemopreventive activity of this compound in CRC [564, 
565]. The disulfide pharmacophore is responsible for the anti-inflammatory and anti-
proliferative activity and induction of cytoprotective phase II enzymes by GT-094 [563]; 
and other disulfides are reported to inhibit HCT-115 and Caco-2 cell proliferation by 
inducing a G2-M cell cycle arrest [566-569].  
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Fig. 1.32. Structure of GT-094. GT-094 releases nitrate and a NSAID moieties by rapid 
thiol/disulfide exchange with protein sulfhydryl groups [570]. 
 
 
 The anticancer activity of GT-094 was observed in azoxymethane-induced colon 
tumors in rats [570]. GT-094 decreased azoxymethane induced colon crypt proliferation 
by 30 to 69%, decreased inducible NO synthase levels by 33 to 67% and also 
decreased aberrant crypt foci by 45% compared to untreated animals [570]. GT-094 
also decreased poly (ADP-ribose) polymerase (PARP) and increased cleaved PARP (2- 
to 4-fold) and p27 expression in the distal colon [570]. GT-094 also decreased 
biomarkers of inflammation and DNA damage, such as iNOS and PARP-1 and 
differences between GT-094 and other NO-ASP analogs suggested that the nitrate 
structure influenced activity and this may be due to the activity of NO to activate both 
pro- and anti-apoptotic activities which is dependent on NO flux, cell type, and other 
factors [571]. 
 The antiproliferative and anti-inflammatory activities of GT-094 were further 
confirmed in Caco-2, HT-29 human colon cancer cell lines and murine macrophage-like 
RAW264.7 cells [570]. GT-094 inhibits iNOS protein expression, and synthesis of PGD2 
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& PGE2. GT-094 also inhibits induction of several cytokines and iNOS and induces 
detoxifying phase 2 enzymes (NQO1) in Hepa 1c1c7 cells [563]. The mechanisms of 
action of GT-094 as an anticancer agent was further investigated as part of this thesis 
research [572]. 
ASCORBIC ACID AND CANCER 
 Ascorbic acid (Vitamin C) deficiency results in scurvy, a disease which occurs in 
humans whose diets lack fresh fruits and vegetables; in the mid-18th century James 
Lind demonstrated that the juice of fresh citrus fruits cures scurvy. The active agent was 
a new glucose derivative (enolic form of 3-oxo-L-gulofuranolactone) named ‗‗hexuronic 
acid‘‘ by the Hungarian physician Szent-Gyorgyi [573]. Szent-Gyorgyi described the 
antiscorbutic activity of this compound which was given the trivial name, ascorbic acid 
(AA) (Fig. 1.33) to designate its function in preventing scurvy [574, 575]. Ascorbic acid 
can be generated de novo by many species and is synthesized via gulonolactone 
oxidase in the hexuronic acid pathway in the liver or the kidney. Since humans (as well 
as other primates, guinea pigs and a few bat species) lack this enzyme, they cannot 
synthesize ascorbic acid which must be provided in the diet from fruits and vegetables 
[576]. 
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Fig. 1.33. Different states of ascorbic acid [577]. 
 
Ascorbic acid as an anticancer agent. Several studies have demonstrated that 
ascorbic acid, an essential micronutrient in living systems, possesses chemopreventive 
and chemotherapeutic properties against cancer [578-581]. However, the role of 
ascorbic acid in cancer treatment and its mechanism of action have remained 
controversial [582, 583]. The reasons for this controversy are the lack of reproducibility 
of the therapeutic effects of ascorbate in cancer patients [584], a problem compounded 
by uncertainties associated with deficiencies of independent pathologic confirmation 
and failure to include appropriate placebo groups in clinical studies [585-588]. However, 
recent studies clarified, in part, the anticancer activity of ascorbic acid. McCormick, 
Cameron and Rotman, postulated two hypotheses regarding the use of ascorbate for 
cancer treatment [589-591]; namely that, ascorbate exerts an antitumor effect by 
110 
 
increasing collagen synthesis [590, 591] and that ascorbate inhibits hyaluronidase, an 
enzyme which breaks down hyaluronic acid [589]. Pauling, Cameron and Leibovitz 
subsequently provided a scientific basis to support these hypotheses [581, 592]. 
 Based on an initial study with 50 advanced cancer patients, Cameron et al., 
concluded that high-dose ascorbate enhanced patient survival [581]. In 1978, Cameron 
and Pauling subsequently showed that the long-term survival of cancer patients who 
received high-dose ascorbate was 20 times greater than patients in the control group 
(Fig.1.34) [584, 593]. 
 
 
Fig. 1.34. Comparison of survival times in patients administered with or without 
ascorbate. Adapted from Cameron and Pauling [594]. 
 
 
 In 1991, another prospective study showed that the survival of ascorbate-treated 
patients was 343 days compared to 180 days for controls who did not receive ascorbate 
[595]. However, Moertel and Mayo concluded that there was no significant difference in 
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the survival between ascorbate-treated and -untreated groups [587, 588]. The 
discrepancy between these findings may reflect differences in the route of ascorbate 
administration; Cameron administered ascorbate both orally and intravenously, while 
Moertel administered ascorbate exclusively through the oral route and these findings 
are summarized in Fig. 1.35 [596-598]. 
 
 
Fig. 1.35. Anticancer effects of ascorbate in cancer patients, comparision of different 
studies [594]. 
 
 
 However, in the Moertel and Mayo study, most of the patients had received prior 
chemotherapy, whereas only few patients (4/100) in the Cameron study received prior 
treatment with radiation and chemotherapy [593]. It is reported that there were clinical 
benefits and improved survival rates using both oral and intravenously administered 
ascorbate in the treatment of terminal cancer [581, 584]. Later on, two double blind, 
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placebo-controlled trials at the Mayo clinic showed that a high oral dose of ascorbate 
had no effect on cancer survival [587, 588]. These trials were considered definitive, 
possibly because of the difference in the in vivo levels of ascorbic acid achieved 
between the oral and intravenous administration, which was not adequately 
appreciated. Plasma levels of ascorbic acid are tightly controlled and are around 50 µM 
[599]. Padayatty et al. have shown that intravenous administration of ascorbic acid 
bypasses such tight control and results in approximately a 70-fold higher concentration 
than those achieved by maximum oral dose [600]. Recently, Levine and coworkers 
have demonstrated that pharmacologic ascorbic acid concentrations achievable through 
intravenous administration were cytotoxic to many types of cancer cells in vitro and 
significantly inhibit tumor progression in vivo without being toxic to normal tissues [601]. 
A possible mechanism of action was proposed that involves ascorbic acid-induced 
formation of H2O2 in the extracellular fluid leading to the cytotoxic effects [602-604]. 
Mechanism of action of ascorbate. Several studies have shown that pharmacological 
(mM) concentrations of ascorbic acid kill cancer cells but not normal cells in a hydrogen 
peroxide (H2O2)-dependent manner [578, 601, 605] and these concentrations are 
attained in humans by i.v. infusion but not through oral administration of ascorbate 
[600]. Hence, ascorbic acid is hypothesized to exert local pro-oxidant effects in the 
interstitial fluid surrounding tumor cells, thereby inhibiting their growth or killing them, 
while leaving normal cells intact [578, 601, 605]. 
 In normal physiological conditions, ascorbic acid, acts as an effective biologic 
antioxidant, however, ascorbate readily donates an electron (e- ) to redox-active 
transition metal ions, such as cupric (Cu2+) or ferric (Fe3+) ions, reducing them to 
cuprous (Cu+) and ferrous (Fe2+) ions, respectively (Reaction 1) (Fig. 1.38). In fact, 
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.- . . .- 
reduction of copper or iron in the catalytic site of certain enzymes contribute to the 
biologic functions of acsorbate as a co-substrate in procollagen, carnitine, and 
catecholamine biosynthesis [606]. Reduced transition metal ions, in contrast to ascorbic 
acid, readily react with O2, reducing it to superoxide radicals (Reaction 2), which in turn 
dismutate to form H2O2 and O2 (Reaction 3) (Fig. 1.36). 
AscH- + Me(n+1)+             Asc
.- + Men+ + H+    [Reaction 1] 
Men+ + O2             Me
(n+1)+ + O2    [Reaction 2]
 
HO2 + O2 + H
+            H2O2+O2    [Reaction 3] 
2AscH- + O2             2Asc
.- + H2O2  [Sum of Reactions 1-3] 
 The production of H2O2 (Reactions 1–3) is important for the anticancer activity of 
ascorbate since H2O2 causes tumor cells to undergo apoptosis, necrosis and pyknosis 
[578]. In contrast, normal cells are less susceptible to H2O2 and the reason for the 
increased sensitivity of cancer cells to H2O2 is not clear but may be due to lower 
antioxidant defenses [607]. In fact, a lower capacity to destroy H2O2—e.g., by catalase, 
peroxiredoxins, and GSH peroxidases—may cause tumor cells to grow and proliferate 
more rapidly than normal cells in response to low concentrations of H2O2.  
 It is well known that H2O2 induces dose-dependent effects on several cell 
functions, including growth stimulation at very low concentrations to growth arrest, 
apoptosis, and eventually necrosis at higher concentrations [608]. This dose-
dependency may be shifted in tumor cells, making them more sensitive to both the 
growth stimulatory and cytotoxic effects of H2O2. The increased sensitivity of tumor cells 
to H2O2 –induced death may provide the specificity and the ―therapeutic window‖ for the 
anticancer activity of extracellular ascorbate [578, 601]. 
Me 
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Fig. 1.36. Proposed mechanism for formation of Asc•− and H2O2 in extracellular fluid 
compared with blood [605]. After oral and parenteral administration, ascorbic acid 
achieves equivalent concentrations in blood (left side) and extracellular fluid (right side). 
In extracellular fluid, pharmacologic concentrations of ascorbic acid lose one electron 
and form Asc•−. The electron reduces a protein-centered metal (Fe3+ to Fe2+) and Fe2+ 
donates an electron to oxygen, forming active oxygen such as superoxide (O2
•−) with 
subsequent dismutation to H2O2 [609]. In blood (left side), it is proposed that these 
reactions are damped or inhibited (dashed lines). Asc•− appearance will be inhibited by 
red blood cell membrane-reducing proteins [610] and/or by large plasma proteins that 
do not distribute to the extracellular space. Any formed H2O2 will be immediately 
destroyed by plasma catalase and red blood cell GSH peroxidase, so that no H2O2 will 
be detectable [587, 588, 611]. The identities of the metal-centered proteins are 
unknown. 
 
 
 
 The conversion of ascorbate to H2O2, as explained above (Reactions 1–3), 
requires a redox-active transition metal and without which ascorbate cannot exhibit pro-
oxidant activity. Chen et al. [578] proposed that there is an extracellular ―metalloprotein 
catalyst‖ (10-30 kDa) that interacts with ascorbate; identification of this metalloprotein 
will be important because it is responsible for the action of millimolar concentrations of 
ascorbate as a pro-oxidant in interstitial fluid. In contrast, the metalloprotein must be 
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absent or inactive in blood, otherwise ascorbate would become oxidized to the ascorbyl 
radical or become unstable and this is not observed [601]. If this putative metalloprotein 
can be identified and characterized, it may also serve as an additional target for 
anticancer therapy. For example, other naturally occurring reducing agents, such as 
certain flavonoids or thiol compounds, may be particularly effective in reducing the 
protein's metal center, or drugs may be developed to specifically target this center. 
However, there is no direct evidence for the existence of the metalloprotein or formation 
of reduced transition metal ions by extracellular ascorbate. Chen et al. [601] measured 
the other reaction product formed between ascorbate and the putative metal center, i.e., 
the ascorbyl radical (Reaction 1). They also showed formation of this radical is time-
dependent and dose-dependent in interstitial fluid of tissues, including tumor xenografts, 
but not in the blood (Fig. 1.38) [601, 605]. They also showed that the concentration of 
the ascorbyl radical correlates with the concentration of H2O2 in the interstitial fluid, 
whereas no H2O2 can be detected in the blood or plasma (Fig. 1.38) [605, 612]. These 
observations, combined with the inhibitory effects of ascorbate on xenograft growth, 
provide the proof of the concept that millimolar concentrations of extracellular 
ascorbate, achievable by i.p. injection or i.v. infusion in experimental animals and 
humans respectively, exhibits pro-oxidant and antitumorigenic activity in vivo. The 
mechanism of ascorbate-induced ROS (H2O2) and ROS-induced downstream effects in 
cancer cells will be investigated in this thesis research.  
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CHAPTER II 
ASPIRIN INHIBITS COLON CANCER CELL AND TUMOR GROWTH AND 
DOWNREGULATES SPECIFICITY PROTEIN (Sp) TRANSCRIPTION FACTORS 
 
INTRODUCTION 
 Acetylsalicylic acid or aspirin is a non-steroidal anti-inflammatory drug (NSAID) 
widely used for treatment of pain, fever and other inflammatory conditions [613] and the 
role of aspirin and other NSAIDs in cancer has been extensively investigated [614, 615]. 
Aspirin use is associated with decreased risk for colorectal, breast, esophageal, lung, 
stomach and ovarian cancer, and aspirin is both a chemopreventive and 
chemotherapeutic agent for breast and colon cancer [616-620].  A recent report on the 
chemopreventive effects of aspirin showed that the incidence of colon cancer in 
Scotland was significantly decreased in the general population at the lowest daily dose 
of aspirin (75 mg) and the decreased incidence was observed even after only 5 yr of 
aspirin use [619].  In another study on the chemotherapeutic effects of aspirin in colon 
cancer patients, a hazard ratio of 0.53 (for mortality) was observed in patients who did 
not use the drug prior to diagnosis and this value decreased to 0.39 for a subset of 
patients overexpressing COX-2 [617]. 
 Several studies on colon cancer cells and colon tumor models have confirmed 
that aspirin inhibits growth and induces apoptosis in these systems; however, the 
specific effects of aspirin are somewhat variable in these reports.  For example, aspirin 
downregulates bcl-2 expression [621], inhibits vascular endothelial growth factor, 
exhibits antiangiogenic activity [622, 623], and inhibits the Wnt/-catenin pathway [624].  
Dunlop and coworkers have also demonstrated that aspirin-induced downregulation of 
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IB in colon cancer cells results in enhanced nuclear accumulation of the NF-κB 
complex (p65/p50) and this has been linked to a pro-apoptotic pathway in colon cancer 
cells [485, 625, 626]. 
 GT-094 is a synthetic nitro-non-steroidal anti-inflammatory drug (NO-NSAID) 
and like aspirin, GT-094 also inhibits colon cancer cell and tumor growth [570, 627].  
Mechanistic studies indicate that the anticancer activity of GT-094 is due, in part, to 
ROS-dependent downregulation of specificity protein (Sp) transcription factors Sp1, 
Sp3, Sp4 and Sp-regulated genes which include bcl-2, survivin, hepatocyte growth 
factor receptor (c-MET), VEGF and its receptor VEGFR1 [627].  Other drugs including 
NSAIDs such as tolfenamic acid and COX-2 inhibitors also inhibit cancer cell growth 
and downregulate Sp transcription factors [628-636] and, in this study, we have 
investigated the effects of aspirin on Sp proteins and other Sp-regulated genes 
including -catenin.  Our results show that aspirin and salicylate downregulate Sp1, 
Sp3, Sp4 and several Sp-regulated gene products in colon cancer cells and identifies 
an important pathway for the anticancer activity of aspirin that is consistent with RNA 
interference (RNAi) studies in which knockdown Sp1, Sp3 and Sp4 in cancer cells also 
inhibits growth and induces apoptosis [634-636].  Knockdown of Sp proteins also 
demonstrated that -catenin is an Sp-regulated gene in colon cancer cells.  Results of 
this study, coupled with previous reports on the mechanisms of aspirin-mediated 
inhibition of colon cancer cell growth, will also facilitate development of therapies with 
aspirin and NSAID analogs in combination with other agents used to treat colon cancer.  
The reported high serum salicylate/aspirin ratios observed in human studies using 
aspirin [637] suggest that salicylate may be an important contributor to the anticancer 
activity of aspirin in colon cancer patients. 
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MATERIALS AND METHODS 
Cell lines, reagents and antibodies. RKO, SW480, HT-29 and HCT-116 human colon 
carcinoma cell lines were obtained from American Type Culture Collection (Manassas, 
VA).  RKO and SW480 cells were maintained in Dulbecco‘s modified/Ham‘s F-12 
(Sigma-Aldrich, St. Louis, MO) with phenol red supplemented with 0.22% sodium 
bicarbonate, 5% fetal bovine serum, and 10ml/L 100X antibiotic/antimycotic solution 
(Sigma).  HT-29 and HCT-116 cells were maintained in McCoy‘s 5A medium (Sigma-
Aldrich, St. Louis, MO) with phenol red supplemented with 0.22% sodium bicarbonate, 
10% fetal bovine serum, and 10 ml/L 100X anti-biotic anti-mycotic solution (Sigma).  
The cells were grown in 150 cm2 culture plates in an air/CO2 (95:5) atmosphere at 37C 
and passaged approximately every 3-5 days.  All antibodies were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA), except cleaved poly (ADP) ribose 
polymerase (PARP) and c-Met (Cell Signaling Technology, Danvers, MA), Sp1, survivin 
and VEGF-R2 (Millipore, Temecula, CA), VEGFR1 and p65 (Abcam Inc. Cambridge, 
MA), and -actin antibodies (Sigma-Aldrich). -Catenin was purchased from Epitomics, 
Inc., Burlingame, CA. The NSAIDs acetylsalicylic acid and sodium salicylate were 
purchased from Sigma-Aldrich. N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine 
(TPEN), glutathione (98%) (GSH), and lactacystin were purchased from Sigma-Aldrich 
(St Louis, MO). Dithiothretol (DTT) (98%) was obtained from Boehringer Mannheim 
Corp, (Indianapolis, IN).Caspase inhibitors 2, 8 and 9 and pancaspase inhibitor (Z-VAD-
fmk) are purchased from Calbiochem (SanDiego, CA). Leptomycin B was inhibitor of 
nuclear export purchased from Enzo Life Sciences International, Inc. (Plymouth 
Meeting, PA). Lipofectamine and Lipofectamine 2000 were purchased from Invitrogen. 
Luciferase reagent was from Promega (Madison, WI). β-Galactosidase reagent was 
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obtained from Tropix (Bedford, MA). NFB promoter construct was purchased from 
Stratagene (Cedar Creek, TX). The VEGF and survivin promoter constructs were 
provided by Drs. Gerhard Siemeister and Gunter Finkenzeller (Institute of Molecular 
Medicine, Tumor Biology Center, Freiburg, Germany) and Dr. M. Zhou (Emory 
university, Atlanta, GA), respectively. Sp1 and Sp3 promoter constructs were kindly 
provided by Drs. Carlos Cuidad and Veronique Noe (University of Barcelona, 
Barcelona, Spain). 
Cell proliferation assays. RKO, SW480, HT-29 and HCT-116 colon cancer cell lines 
were plated (3 x 104 per well) using DMEM:Ham‘s F-12 medium containing 2.5% 
charcoal stripped fetal bovine serum (FBS) in 12-well plates and left to attach for 24 hr.  
Cells were then treated with either vehicle or the indicated concentrations of aspirin and 
sodium salicylate.  After 24, 48 and 72 hr of treatment, cells were counted using a 
Coulter Z1 particle counter.  Each experiment was carried out in triplicate and results 
are expressed as meansSE for each determination. 
Annexin V staining. Apoptosis, necrotic and healthy cell detection kit was purchased 
from Biotium, Inc (Hayward, CA). RKO, SW480, HT-29 and HCT-116 colon cancer cells 
(7.5 x 104) were seeded in Lab-Tek two chambered cover glass slides and allowed to 
attach overnight.  After treatment with aspirin (10 mM) for 24 hr, cells were washed with 
cold phosphate-buffered saline (PBS) twice and incubated with FITC Annexin V, 
ethidium homodimer III and Hoechst 33342 in Annexin V binding buffer for 20 min 
according to the manufacturer‘s instructions in the protocol. The cells were then washed 
twice with Annexin V binding buffer and flouroscence was analyzed with a digital 
fluorescence microscope. 
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siRNA interference assays. SiRNAs for Sp1, Sp3, Sp4, and Lamin werepurchased 
from Sigma-Aldrich.  The siRNA complexes used in this study are indicated as follows: 
Lamin: SASI_Hs02_00367643 
Sp1:  SASI_Hs02_00363664 
Sp3   5'-GCG GCA GGU GGA GCC UUC ACU TT 
Sp4   5'-GCA GUG ACACAU UAG UGA GCT T 
RKO and SW480 colon cancer cell lines were seeded (6 x 104 per ml) in 6-well plates in 
DMEM:Ham's F-12 medium supplemented with 2.5% charcoal-stripped FBS without 
antibiotic and left to attach for 1 d.  Knockdown of Sp1,Sp3, Sp4 individually or a 
combination of all 3 proteins was carried out using appropriate siRNA along with iLamin 
as control was performed using LipofectAMINE 2000 transfection reagent as per the 
manufacturer's instructions. 
Transfection and luciferase assay. RKO and SW480 colon cancer cells (1x105 per 
well) were plated in 12-well plates in DMEM/Ham‘s F-12 medium supplemented with 
2.5% charcoal-stripped FBS.  After 24 hr, various amounts of DNA [i.e., 0.4 g PGL3-
Luc, 0.04 g -galactosidase, and 0.4 g pNFκB-Luc (4)-Luc] were transfected using 
LipofectAMINE 2000 reagent according to the manufacturer‘s protocol.  After 5 hr of the 
transfection, the transfection mix was replaced with complete medium containing either 
vehicle (DMSO) or the indicated compound in DMSO. 
 For RNA interference studies, RKO and SW480 colon cancer cells were 
cotransfected with siRNA for Sp1, Sp3, Sp4 or Lamin along with various amounts of 
DNA for PGL3-Luc or 0.4 g pNFκB-Luc. After 22 hr, cells were then lysed with 100 L 
of 1X reporter lysis buffer, and cell extracts (30 µL) were used for luciferase and -
galactosidase assays.  A Lumicount luminometer was used to quantitate luciferase and 
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-galactosidase activities, and the luciferase activities were normalized to -
galactosidase activity. 
Western blots. RKO, SW480, HT-29 and HCT-116 colon cancer cells were seeded in 
DMEM:Ham‘s F-12 medium containing 2.5% charcoal-stripped FBS and, after 24 hr, 
cells were treated with either vehicle (DMSO) or the indicated compounds.  Cells were 
collected using high-salt buffer (50 mM HEPES, 0.5 mol/L NaCl, 1.5 mM MgCl2, 1 mM 
EGTA, 10% glycerol, and 1% Triton-X-100) and 10 ml/L Protease Inhibitor Cocktail 
(Sigma-Aldrich). After centrifugation of the lysates at 15,000 g for 15 min at 4oC, the 
supernatants were recovered, and protein was quantified by the Bradford protein assay. 
Protein lysates (15-60 µg) were incubated for 5 min at 100C along with 5X loading 
buffer and then separated by electrophoresis on 7.5-12% sodium dodecyl sulphate-
polyacrylamide gels at 120 V for 3 to 4 hr.  Proteins were transferred onto 
polyvinylidenedifluoride membranes by wet electroblotting in a buffer containing 25 
mMTris, 192 mM glycine, and 20% methanol for 1.5 hr at 180 mÅ.  Membranes were 
blocked for 45 min with 5% TBST-Blotto (10 mMTris-HCl, 150 mMNaCl, pH 8.0, 0.05% 
Triton X-100, and 5% nonfat dry milk) and incubated in fresh 5% TBST-Blotto with 
1:500 primary antibody overnight with gentle shaking at 4C.  After washing twice with 
TBST for 10 min, the membrane was incubated with secondary antibody (1:5000) in 5% 
TBST-Blotto for 3-4 hr by gentle shaking.  The membrane was washed twice with TBST 
for 10 min, incubated with 2 ml of chemiluminescence substrate (Millipore, Temecula, 
CA) for 1 min, and exposed to Kodak image station 4000 mm Pro (Carestream Health, 
Rochester, NY). 
Xenograft studies in athymic mice. Female athymic (nude) mice were purchased 
from Harlan Laboratories (Indianapolis, IN). The mice were housed and maintained 
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under specific pathogen-free conditions in facilities approved by the American 
Association for Accreditation of Laboratory Animal Care and in accordance with current 
regulations and standards of the United States Department of Agriculture, United States 
Department of Health and Human Services. The mice were used in accordance with 
institutional guidelines. To produce tumors, RKO cells were harvested from 
subconfluent cultures by a brief exposure to 0.25% trypsin and 0.02% 
ethylenediaminetetraacetic acid. Trypsinization was stopped with medium containing 
10% fetal bovine serum, and the cells were washed once in serum-free medium and 
resuspended in serum free medium. Only suspensions consisting of single cells with 
90% viability were used for the injections. A xenograft was established by subcutaneous 
injection of the cells (3×106) into the flanks of individual mice. Tumors were allowed to 
grow for 6 d until they were palpable. Mice were then randomized into two groups of 6 
mice per group and dosed by oral gavage in corn oil 200 mg/kg/day (neutralized with an 
equimolar concentration of NaOH) of aspirin on every day for 14 d. The mice were 
weighed, and tumor size was measured every second day with calipers to permit 
calculation of tumor volumes: V=LW2/2, where L and W were length and width, 
respectively. After 14 d, the animals were sacrificed; final body and tumor weights were 
determined and plotted. At the end of the experiment, major visceral organs and tumors 
were collected and analyzed for Sp protein expression and induction of apoptosis using 
western blots and TUNEL staining respectively. 
Statistical analysis. Statistical significance of differences was determined by analysis 
of variance and student t-test, and the levels of probability were noted. All statistical 
tests were two-sided.  IC50 values were calculated using non-linear regression analysis 
and expressed in M, at 95% confidence intervals. 
123 
 
RESULTS 
Aspirin inhibits growth and induces apoptosis in colon cancer cells. In this study, 
different concentrations (2.5-10 mM) of aspirin inhibited growth of SW480, RKO, HT-29 
and HCT-116 cells over a  period of 3 days (Figs. 2.1A and 2.1B), and IC50 values for 
aspirin-induced growth inhibition were in the range of 2.5-5 mM in all 4 cell lines.  The 
high dose (10 mM) of aspirin was used to determine the proapoptotic effects of this 
compound after treatment for only 24 hr and the results show that aspirin increased 
Annexin V staining in all 4 colon cancer cell lines (Fig. 2.1C).  The proapoptotic effects 
of aspirin (5 and 10 mM) were further investigated in colon cancer cells by determining 
changes in expression in the survival proteins bcl-2 and survivin and induction of 
caspase-dependent PARP cleavage. Aspirin induced a concentration- and time-
dependent downregulation of survivin and bcl-2 and induced of PARP cleavage, a 
marker of apoptosis (Figs. 2.1D and 2.1E). 
Aspirin and salicylate downregulates Sp1, Sp3, Sp4 and Sp-regulated genes. 
Previous studies by RNA interference (RNAi) show that both survivin and bcl-2 are 
regulated by Sp1, Sp3 and Sp4 in cancer cells [627, 632, 634-636].  Therefore, RKO, 
SW480, HT-29 and HCT-116 cells were treated with 5 and 10 mM aspirin for 24 or 48 
hr and western blot analysis showed that there was a concentration- and time-
dependent decrease in Sp1, Sp3 and Sp4 proteins in all 4 cell lines (Figs. 2.2A and 
2.2B). 
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Fig. 2.1. Aspirin inhibits colon cancer cell growth and induces apoptosis.  Inhibition of SW480 and RKO (A) 
and HT-29 and HCT-116 (B) cell proliferation.  Cells were treated with DMSO or 2.5-10 mM aspirin for 3 
days, and cell numbers were determined as described in the Experimental Procedures.  Induction of 
Annexin V staining (C) and apoptotic responses in RKO and SW480 (D) and HT-29 and HCT-116 (E) cells.  
Annexin V staining was determined as described in the Experimental Procedures.  The expression of 
apoptotic proteins PARP cleavage was determined by western blot analysis of whole cell lysates as 
described in the Experimental Procedures.  Results in (A) and (B) are means  SE for 3 replicate 
determination for each treatment group, and significant (p < 0.05) inhibition is indicated (*). 
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Moreover, treatment of RKO, SW480, HT-29 and HCT-116 colon cancer cells with 5 or 
10 mM aspirin for 24 or 48 hr also decreased expression of several gene products 
regulated by Sp1, Sp3 and Sp4 [634-639] and these include VEGF, VEGFR1, cyclin D1 
and c-MET proteins, and the effects of aspirin on their expression were both 
concentration- and time-dependent.  
 We also investigated the effects of 5 and 10 mM aspirin on luciferase activity in 
RKO and SW480 cells transfected with constructs containing GC-rich promoter inserts 
from the Sp1 (pSp1For4, -751 to -20), Sp3 (pSp3For5, -417 to -38), VEGF (pVEGF, 
-2018 to +50), and survivin (pSurvivin, -269 to +49) genes (Fig. 2.2E).  With the 
exception of the VEGF construct, 5 and 10 mM aspirin significantly decreased 
luciferase activity and these results correlated with the decreased expression of the 
corresponding Sp1, Sp3, VEGF and survivin proteins in RKO and SW480 cells.  The 
increase in luciferase activity in RKO cells treated with 5 mM aspirin and transfected 
with pVEGF may be due to the relatively slow downregulation of this protein which was 
only observed after 48 hr at the 10 mM concentration, suggesting that other aspirin-
induced pathways may also be activating VEGF. 
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Fig. 2.2. Aspirin decreases expressions of Sp1, Sp3, Sp4 and Sp-regulated gene products in colon cancer 
cells.  Downregulation of Sp proteins in RKO and SW480 (A) and HT-29 and HCT-116 (B) and Sp-
regulated gene products in RKO and SW480 (C) and HT-29 and HCT-116 (D) cells.  Cells were treated 
with 5 or 10 mM aspirin for 24 or 48 hr, and whole cell lysates were analyzed by western blot analysis as 
described in the Experimental Procedures.  Results are typical of duplicate experiments.  (E) Aspirin 
decreases reporter gene activity.  Cells were transfected with pSp1For4, pSp3For5, pVEGF and pSurvivin 
and treated with DMSO or aspirin (5 or 10 mM).  Luciferase activity was determined as described in the 
Experimental Procedures.  Results are expressed as means ± SE (3 replicates) and significant (p < 0.05) 
inhibition is indicated (*). 
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Fig. 2.3. Salicylate inhibits colon cancer cell growth and downregulates Sp1, Sp3, Sp4 and Sp-regulated 
genes.  Inhibition of RKO and SW480 (A) and HCT-116 and HT-29 (B) cell growth.  Cells were treated with 
2.5-10 mM sodium salicylate for up to 3 days, and cell numbers were determined as described in the 
Experimental Procedures.  Protein downregulation in RKO and SW480 (C) and HCT-116 and HT-29 (D) 
cells.  Cells were treated with 5 or 10 mM salicylate for 24 or 48 hr, and whole cell lysates were analyzed by 
western blot analysis as described in the Experimental Procedures. 
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Aspirin is rapidly metabolized to salicylate [637] and the effects of salicylate on colon 
cancer cell growth, Sp proteins and Sp-regulated genes was also investigated (Fig. 
2.3).  Salicylate (sodium salt) (2.5-10 mM) also inhibited growth of all 4 cell lines (Figs. 
2.3A and 3B), and the growth inhibitory effects were similar to that observed for aspirin 
(Figs. 2.2A and 2.2B).  Growth inhibition was accompanied by the time-dependent 
downregulation of Sp1, Sp3, Sp4 and Sp-regulated gene products (bcl-2, cyclin D1, 
survivin and VEGF) in RKO and SW480 (Fig. 2.3C) and HCT-116 and HT-29 (Fig. 
2.3D) cells.  This pattern of responses for sodium salicylate was comparable to that 
observed for aspirin (Figs. 2.1 and 2.2) and similar effects were also observed for 
methyl salicylate (data not shown) which is also rapidly metabolized to salicylate. 
Aspirin-induced suppression of NF-κB and -catenin is due, in part, to Sp-
downregulation. It has previously been reported that aspirin enhanced nuclear NF-κB 
accumulation [485, 625, 626] and this was further investigated in RKO and SW480 cells 
treated with 5 and 10mM aspirin for 48 hr.  Levels of cytosolic p65 and p50 levels were 
decreased, whereas nuclear p65 and p50 levels were relatively unchanged after 
treatment with aspirin (Figs. 2.4A and 2.4B) and these results differed with previous 
studies [485, 625, 626].  Moreover, overall levels of nuclear proteins were <10% of 
cytosolic proteins and this was confirmed by western blot analysis of whole cell lysates 
from cells treated with 5 or 10 mM aspirin which showed that both p65 and p50 proteins 
were decreased in both cell lines within 48 hr after treatment with aspirin (Figs. 2.4A 
and 2.4B).  Aspirin also decreased luciferase activity in SW480 and RKO cells 
transfected with a pNF-κB-luc construct (Fig. 2.4C) and these results were consistent 
with the observed downregulation of both p65 and p50 proteins (Figs. 2.4A and 2.4B). 
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Fig. 2.4. Aspirin decreases expression of NFB and -catenin in colon cancer cells.  
Decreased p65/p50 in RKO (A) and SW480 (B) cells.  Cells were treated for 48 hr with 
5 or 10 mM, and whole cell, nuclear and cytosolic extracts were analyzed by western 
blot analysis as described in the Experimental Procedures.  (C) Aspirin decreases NF-
κB-luc.  The construct was transfected into RKO and SW480 cells treated with DMSO 
or aspirin, and luciferase activity determined as described in the Experimental 
Procedures.  Results are means  SE (3 replicates) and significant (p < 0.05) inhibition 
is indicated (*).  (D) Downregulation of -catenin.  Cells were treated with 5 or 10 mM 
aspirin for 48 hr, and whole cell lysates were analyzed by western blot analysis as 
described in the Experimental Procedures. 
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Previous studies reported that aspirin decreased -catenin expression in colon cancer 
cells [624] and our results confirmed that 5-10 mM aspirin also decreases -catenin 
expression in RKO and SW480 colon cancer cells (Fig. 2.4D). 
 Since NF-κB (p65) and the -catenin promoters contain GC-rich Sp binding sites 
[638, 639], we used RNAi to determine the role of Sp1, Sp3 and Sp4 in regulation of 
p65, p50 and -catenin in colon cancer cells.  RKO and SW480 cells were transfected 
with small inhibitory RNAs targeting Sp1 (iSp1), Sp3 (iSp3), and Sp4 (iSp4) alone and 
in combination (iSp1/3/4).  Figure 2.5A shows that each individual oligonucleotide 
decreased expression of its individual target (Sp1, Sp3 and Sp4) and iSp1/3/4 knocked 
down all three proteins.  iSp1 also decreased expression of Sp4 (but not Sp3) and this 
is consistent with previous studies showing cross-regulatory interactions among the Sp 
transcription factors due to their GC-rich promoters [632, 635]. Fig. 2.5B illustrates cell 
context-dependent differences in the effects of iSp1, iSp3 and iSp4 on p65 expression 
in RKO and SW480 cells where Sp1, Sp3 and Sp4 knockdown resulted in small 
changes in p65 in RKO cells and Sp1 and to a lesser extent Sp4 knockdown decreased 
p65 in SW480 cells.  iSp1/3/4 (combined oligonucleotides) decreased p65 expression in 
both cell lines, whereas minimal effects were observed for p50.  Thus, aspirin-induced 
downregulation of p50 (Figs. 2.4A and 2.4B) was Sp-independent.  Fig 2.5C shows that 
iSp1/3/4 also decreased luciferase activity in RKO (90%) and SW480 (40%) cells 
transfected with the NF-κB-luc construct, and the different effects of Sp knockdown in 
these cells suggest a more dominant role for Sp-dependent regulation of NF-κB in RKO 
than SW480 cells.  Sp knockdown (combined) also decreased -catenin protein in RKO 
and SW480 cells and results of knockdown of individual Sp proteins suggest that Sp1 
and Sp4 are the dominant transcription factors required for constitutive expression of -
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catenin in RKO cells, whereas knockdown of Sp1, Sp3 and Sp4 decrease -catenin 
protein levels in SW480 cells (Fig. 2.5D). 
 
 
Fig. 2.5. Knockdown of Sp1, Sp3 and Sp4 (alone and combined) by RNA interference. 
Knockdown of Sp1, Sp3, Sp4 and Sp1/3/4 (A) and p65/p50 (B) in colon cancer cells.  
Cells were transfected with various oligonucleotides, and whole cell lysates were 
analyzed by western blot analysis as outlined in the Experimental Procedures.  (C) 
Knockdown of Sp1/3/4 (combined) inhibits NFB-luc.  Cells were transfected with 
iLamin (control) and iSp1/3/4 (combined oligonucleotides) and NFB-luc, and luciferase 
activity was determined as described in the Experimental Procedures.  Results are 
expressed as means  SE (3 replicates), and significantly (p < 0.05) decreased activity 
is indicated (*).  (D) Sp knockdown decreases -catenin.  Cells were transfected with 
various oligonucleotides, and whole cell lysates were analyzed by western blot analysis 
as described in the Experimental Procedures. 
132 
 
Mechanism of aspirin-induced downregulation of Sp1, Sp3 and Sp4. Several 
pathways have been described for enhanced Sp degradation in cancer cell lines and 
these include activation of proteasomes, caspases and ROS [627-630, 632-636] and 
also a pathway which involves nuclear export of Sp1 followed by proteolytic degradation 
in the cytosol [640]. Western blot analysis of nuclear and cytosol fractions from RKO 
and SW480 cells show that Sp1, Sp3 and Sp4 are localized in the nucleus and 
treatment with aspirin decreased Sp1, Sp3 and Sp4 protein levels in the nucleus without 
any apparent translocation to the cytosol (Fig. 2.6A).  Similar results were observed 
after cotreatment with aspirin and the nuclear export inhibitor leptomycin B (combined), 
indicating that nuclear export of Sp1, Sp3 or Sp4 was not required for aspirin-induced 
downregulation of Sp1, Sp3 and Sp4.  Other agents such as the nitro-NSAID GT-094 
and betulinic acid decreased Sp proteins in RKO and SW480 cells through ROS-
dependent induction of Sp transcriptional repressor ZBTB10 and this response was 
attenuated by antioxidants such as GSH or DTT [627, 641]; however, results in Fig. 
2.6B show that these antioxidants do not block aspirin-induced downregulation of Sp 
proteins.  Results of preliminary studies show that aspirin-induced downregulation of Sp 
proteins was also not blocked by proteasome inhibitors (data not shown) but was 
affected by cotreatment with the pancaspase inhibitor Z-VAD-fmk.  Figs. 2.6C and 2.6D 
show that aspirin-induced Sp downregulation in RKO and SW480 cells was inhibited 
after cotreatment with the pancaspase inhibitor (Z-VAD-fmk), caspase-2 (Z-VDVAD-
fmk), and caspase-8 (Z-IETD-fmk) inhibitors but only partially blocked with the caspase-
9 (Z-LEHD-fmk) inhibitor. 
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Fig. 2.6. Mechanisms of aspirin-induced Sp protein degradation. (A) Effects of 
leptomycin B.  Cells were treated with 10 mM aspirin in the presence or absence of 
leptomycin B for 48 hr, and whole cell lysates were analyzed by western blot analysis 
as described in the Experimental Procedures.  Effects of antioxidants (B) and caspase 
inhibitors (C, D) on aspirin-induced Sp protein downregulation.  Cells were treated with 
DMSO, aspirin alone or in combination with antioxidants or caspase inhibitors, and after 
48 hr, whole cell lysates were analyzed by western blots analysis as described in the 
Experimental Procedures. 
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Fig.2.7. Zinc depletion results in downregulation of Sp proteins.  TPEN decreases levels of Sp1, Sp3 and 
Sp4 proteins (A) and induces activation (cleavage) of caspases(B).  Cells were treated with 25 or 50 M 
TPEN for 18 hr, and whole cell lysates were analyzed by western blots as described in the Experimental 
Procedures.  (C) Zinc sulfate blocks the effects of TPEN on Spdownregulation.  Cells were treated with 50 
M ZnSO4 for 18 hr, and whole cell lysates were analyzed by western blots.  (D) Aspirin activates 
caspases.  Cells were treated with aspirin for 48 hr, and whole cell lysates were analyzed by western blots 
as outlined in the Experimental Procedures.  (E) Effects of ZnSO4 on aspirin-induced downregulation of Sp 
proteins.  RKO or SW480 cells were treated with 10 mM aspirin alone or in combination with 50 M ZnSO4 
for 48 hr, and whole cell lysates were analyzed by western blots as outlined in the Experimental 
Procedures. 
135 
 
Favier and coworkers [642, 643] previously reported in HeLa cells that zinc chelation by 
the permeable metal ion chelator TPEN activated multiple caspases (3-, 8- and 9-) and 
decreased expression of Sp1, Sp3 and Sp4 proteins that contain zinc ions in their 
catalytic sites.  Results in Fig. 2.7A show that after treatment of RKO and SW480 cells 
with 25 or 50 M TPEN for 18 hr, there was a dramatic decrease in Sp1, Sp3 and Sp4 
protein expression and this was accompanied by induction of PARP cleavage and 
activation (cleavage) of caspases 8, 9, 3, and 7 (Fig. 2.7B).  The critical role of zinc 
depletion in mediating this response was confirmed by treating the colon cancer cells 
with TPEN alone or in combination with 50 M ZnSO4 (Fig. 2.7C).  The addition of 
ZnSO4 completely reversed the TPEN-dependent downregulation of Sp1, Sp3 and Sp4 
proteins.  Like TPEN, aspirin also induced PARP cleavage and activation (cleavage) of 
caspases 8, 9, 3 and 7 (Fig. 2.7D).  Moreover, treatment of RKO and SW480 cells with 
aspirin alone or in combination with 50 M ZnSO4 and the results show that ZnSO4 also 
decreased aspirin-mediated downregulation of Sp1, Sp3 and Sp4 (Fig. 2.7E), thus 
confirming that aspirin, like TPEN, induces caspase-dependent cleavage of Sp proteins 
that is due to zinc ion depletion. 
In vivo studies. In athymic nude mice bearing RKO cells as xenografts, aspirin was 
administered when the tumors were initially palpable.  The sodium salt of aspirin (200 
mg/kg/d) was administered daily by oral gavage and this resulted in decreased tumor 
volumes and weights (Figs. 2.8A and 2.8B) and due to the lack of toxicity of the sodium 
salt, the treatment was continued for several days without any apparent signs of toxicity.  
Tumor lysates from control and treated animals were analyzed by western blot analysis 
for Sp1, Sp3 and Sp4, and levels were quantified relative to -actin and showed 
significant decreases in expression of Sp1, Sp3 and Sp4 in aspirin vs. control animals 
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(Fig. 2.8C).  Fig. 2.8D shows increased apoptosis (TUNEL staining) in tumors from 
aspirin-treated mice compared to controls and these results complement in vitro studies 
showing that aspirin induced apoptosis in colon cancer cells (Fig. 2.1). 
 
Fig. 2.8. Aspirin inhibits colon tumor growth in athymic nude mice (xenografts).  Inhibition of tumor weight 
(A) and volume (growth) (B) in athymic nude mice administered the sodium salt of aspirin.  Athymic nude 
mice bearing RKO cells as xenografts were treated with the sodium salt of aspirin, and tumor volumes and 
weights were determined after sacrifice as described in the Experimental Procedures.  (C) Expression of 
Sp1, Sp3 and Sp4 in colon tumors.  Tumor lysates from solvent (control) and aspirin-treated mice were 
analyzed by western blot analysis as described in the Experimental Procedures.  Expression of Sp1, Sp3 
and Sp4 in aspirin-treated tumors compared to solvent (control)-treated tumors (set at 100%) was 
determined by densitometry, and -actin was used to normalize protein expression.  Results are means  
SE (6 replicates) and significant (p < 0.05) inhibition of Sp1, Sp3 and Sp4 protein levels by aspirin is 
indicated (*).  (D) Induction of apoptosis.  Fixed tumor tissue from control and aspirin-treated mice were 
analyzed for TUNEL staining as outlined in the Experimental Procedures. 
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These data confirm that aspirin-mediated inhibition of colon cancer cell and tumor 
growth was accompanied by downregulation of Sp transcription factors and this 
response contributes to the anticancer activity of aspirin. 
DISCUSSION 
 Aspirin and other NSAIDs reduce the incidence and increase survival of colon 
cancer patients and similar results have been observed for aspirin as a 
chemotherapeutic agent for treatment of breast cancer patients [616-620].  These 
results indicate that aspirin has significant potential as a chemotherapeutic agent, 
although there is concern regarding the adverse gastrointestinal side-effects of aspirin 
[614, 615, 644] and in the future, these may be circumvented by using NO-NSAIDs.  
The effective doses of aspirin in most in vitro studies in colon cancer cells vary from 1-
10 mM [485, 621-626] and we observed significant inhibition of SW480, RKO, HT-29 
and HCT-116 cell growth at  2.5 mM aspirin (Fig. 2.1) and 10 mM aspirin completely 
inhibited cell growth without causing seeded cells to detach.  In children with 
autoimmune disease, treatment with aspirin (25 mg/kg) exhibited maximum serum 
concentrations of 5.2 mM aspirin with a range of 0.38-10.26 mM [637], suggesting that 
the dose range of aspirin used in this and many previous studies in colon cancer cells 
(1-10 mM) is within the range of serum levels achieved in studies using 
pharmacological doses of aspirin [637]. RNA interference studies in several cancer cell 
lines show that knockdown of Sp1, Sp3 and Sp4 (singly or in combination) results in 
decreased expression of growth promoting (EGFR, c-MET, cyclin D1), survival (bcl-2, 
survivin), angiogenic (VEGF and its receptors), and pro-inflammatory [p65 (NF-κB)] 
genes or gene products [628, 631-636].  Moreover, several anticancer agents including 
NSAIDs and GT-094 (a NO-NSAID), curcumin, betulinic acid and synthetic 
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triterpenoids, and arsenic trioxide decrease expressionof Sp1, Sp3, Sp4 and Sp-
regulated genes in cancer cells and these effects contribute to their anticancer activity 
[627, 628, 630, 645].The reported growth inhibitory and antiangiogenic activity of aspirin 
and the downregulation of bcl-2 expression [621-623] suggested that one of the 
mechanisms of action of aspirin may also be due to downregulation of Sp1, Sp3 and 
Sp4 transcription factors.  Results in Figs 2.1 and 2.2 show that aspirin induced a time- 
and concentration-dependent downregulation of Sp1, Sp3, Sp4 and Sp-regulated gene 
products in RKO, SW480, HT-29 and HCT-116 cells.  There was some variability 
among the different cell lines in terms of their sensitivity to aspirin; however, after 
treatment for 48 hr, downregulation of Sp1, Sp3 and Sp4 was observed at 
concentrations of aspirin that were  5 mM (HT-29 and HCT-116 cells) or 5-10 mM 
(RKO and SW480 cells).  These results, coupled with in vivo data showing that the 
sodium salt of aspirin decreased colon tumor growth in a xenograft model (RKO cells) in 
athymic nude mice and also decreased levels of Sp1, Sp3 and Sp4 proteins in tumors 
(Fig. 2.7), suggest that aspirin-induced downregulation of Sp proteins plays a role in the 
anticancer activity of this compound. 
 Aspirin-induced inhibition of -catenin and NFB have also been associated with 
the anticancer activity of aspirin [485, 624-626], and we have previously identified that 
p65-NF-κB expression was regulated by Sp transcription factors in colon and bladder 
cancer cells [632, 635].  One study reported that aspirin induced rapid phosphorylation 
and inactivation of -catenin within 60 min after treatment and this was accompanied by 
decreased expression of several putative -catenin-regulated gene products (e.g. cyclin 
D1 and c-MET) after treatment for 24-72 hr [624]. Our results confirm that aspirin also 
decreased expression of -catenin protein (Fig. 2.4D); however, results of knockdown 
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of Sp proteins by RNAi showed that -catenin itself is an Sp-regulated gene, 
demonstrating that the effects of aspirin on -catenin are also due to downregulationof 
Sp proteins. 
 It was also reported that aspirin increased nuclear p65 levels and induced 
apoptosis in colon cancer cells within 24 hr after treatment, and this former response 
has been linked to decreased expression of IB [485, 625, 626]. In contrast, our 
results show that aspirin treatment had minimal effects on nuclear p65 or p50 levels and 
the dominant effect was a dramatic decrease in p65 and p50 proteins in whole cell 
lysates (Figs. 2.4A and 2.4B).  RNAi shows that p65 is an Sp-regulated gene (Fig. 2.5B) 
as previously reported in other cancer cell lines [632, 635].  The maximal (>50%) 
decrease was only observed in cells transfected with iSp1/3/4 (combined); however, the 
overall decrease in p65 in this experiment (Fig. 2.5B) was less than observed in other 
cancer cell lines [632, 635] and aspirin-induced inhibition of NF-κB was only due, in 
part, to downregulation of Sp1, Sp3 and Sp4 transcription factors.  Thus, although 
aspirin induces a dramatic downregulation of p65 and p50 in colon cancer cells, Sp 
protein downregulation contributes to decreased p65 levels, whereas effects on p50 are 
Sp-dependent.  Results of transfection assays with an NF-κB-luc contruct (Fig. 2.5C) 
also suggest that Sp1, Sp3 and Sp4 differentially affect NF-κB-dependent 
transactivation in RKO and SW480 cells and this is currently being investigated. 
 The NO-NSAID GT-094 also decreased expression of Sp proteins and Sp-
regulated genes in RKO and SW480 cells and this was due to induction of ROS and 
ROS-dependent downregulation of miR-27a and induction of the Sp transcriptional 
repressor ZBTB10 [627].  These responses were inhibited by antioxidants, whereas 
aspirin induced Sp downregulation was not affected by antioxidants (Fig. 2.6B); 
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however, the pan-caspase inhibitor Z-VAD-fmk inhibited aspirin-induced effects on Sp1, 
Sp3 and Sp4 (Fig. 2.6D).  Arsenic trioxide also induced caspase-dependent cleavage of 
Sp3 and Sp4 in bladder cancer cells [636] and retinoid (CD437)-induced Sp1 
degradation was also caspase-dependent in EL-4 cells [646]. It has also been reported 
that zinc depletion induces apoptosis and decreases Sp1, Sp3 and Sp4 in cancer cell 
lines [642, 643], and we confirmed that aspirin-induced downregulation of Sp1, Sp3 and 
Sp4 was inhibited in RKO and SW480 cells cotreated with aspirin plus ZnSO4 (Fig. 
2.7D).The physical interactions of zinc ions with aspirin have previously been observed 
[647], and functional interactions between zinc ions and aspirin in terms of zinc-induced 
neurotoxicity and the fetal toxicity have also been reported [648, 649].  Results of this 
study show a novel pathway for aspirin-induced effects on Sp1, Sp3 and Sp4 in colon 
cancer cells, and current studies are focused on specific enzymes and pathways 
associated with the effects of aspirin on zinc homeostasis. 
 Previous studies on the pharmacokinetics of aspirin (25 mg/kg) administered to 
children with autoimmune disease showed that maximum serum concentrations of 
aspirin were 5.20 mM (range of 0.38 - 10.26 mM), whereas the maximum concentration 
of the major aspirin metabolite salicylate was 172 mM with a range of 59.8-312.2 
mM[637].  Thus, pharmacologic doses of aspirin that give low mM serum concentrations 
can be accompanied by > 30-fold higher concentrations of salicylate which are more 
than sufficient to inhibit colon cancer cell growth and decrease Sp1, Sp3, Sp4 and Sp-
regulated genes (Fig. 2.3).  Our studies with salicylate show that both aspirin and 
salicylate induced similar responses with comparable potencies in colon cancer cells 
(Figs. 2.1-2.3) and this is consistent with previous reports [615, 622, 623, 650]. The high 
salicylate/aspirin serum ratios observed in children administered pharmacological doses 
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of aspirin (25 mg/kg) [637] suggests that the salicylate metabolite may be a major 
contributor to the reported chemotherapeutic effects of aspirin in colon cancer patients.
 In summary, this study demonstrates that aspirin induces caspase-dependent 
proteolysis of Sp1, Sp3 and Sp4 proteins in colon cancer cells and tumors and, this was 
accompanied by downregulation of several Sp-regulated genes involved in cell 
proliferation, survival and angiogenesis.  Aspirin-induced Sp downregulation was due to 
activation of nuclear caspases and perturbation of zinc homeostasis, and the 
mechanisms that regulate this pathway are unknown and are currently being 
investigated.  Based on the similar effects of aspirin and salicylate as anticancer agents 
observed in Figs 2.1-2.3 and other studies [615, 622, 623, 650] and the high serum 
salicylate/aspirin ratios [637], the cancer chemotherapeutic effects of aspirin observed 
in human cancer studies  [615-617, 619, 620] may primarily be due to the salicylate 
metabolite.  
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CHAPTER III 
TOLFENAMIC ACID (TA) INHIBITS COLON CANCER CELL AND TUMOR GROWTH 
AND DOWNREGULATES SPECIFICITY PROTEIN (Sp) TRANSCRIPTION FACTORS 
 
INTRODUCTION 
 Non-steroidal anti-inflammatory drugs (NSAIDs) are used traditionally as 
inhibitors of pain, fever and inflammation, however, there is evidence that NSAIDs also 
act as cancer chemopreventive and chemotherapeutic agents [615, 651, 652]. The 
anticancer activity of acetylsalicylic acid (ASA or aspirin) has been extensively 
characterized both in epidemiological and laboratory-based studies [408, 419, 615, 652, 
653]. Several case-control studies have shown that aspirin use is associated with 
decreased incidence of several cancers including colon and breast cancer and it has 
also been reported that aspirin use after diagnosis of colon and breast cancer 
decreases subsequent recurrence of these cancers [434, 507, 619, 654-657]. NSAIDs 
such as sulindac induce colon polyp regresssion in high risk individuals with familial 
adenomatous polyposis who prematurely develop colon polyps and are a high risk 
group for colon cancer [427, 658]. Cyclooxygenase-2 (COX-2) inhibitors are also highly 
promising drugs for treatment of colon cancer, however, their effectiveness is tempered 
by an increase in adverse cardiovascular side-effects [410, 659]. 
 NSAIDs such as aspirin and COX-2 inhibitors block cyclooxygenase activity and 
the subsequent production of prostanoids including prostaglandins and thromboxanes 
which act as inflammatory mediators. However, the mechanisms of action of NSAIDs as 
anticancer agents are complicated and involve activation of multiple pathways resulting 
in inhibition of cell growth, survival and angiogenesis [408, 419, 615, 651-653]. Initial 
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studies in this laboratory showed that the COX-2 inhibitors celecoxib, nimesulide and 
NS-398 inhibited colon cancer cell growth and induced proteasome-dependent 
degradation of the specificity proteins (Sps), Sp1 and Sp4 that are overexpressed in 
these cancer cells [434]. These compounds also decreased expression of vascular 
endothelial growth factor (VEGF) an Sp-regulated gene and the effects of these COX-2 
inhibitors were COX-2-independent [410]. Subsequent screening of different structure 
classes of NSAIDs in pancreatic cancer cells identified tolfenamic acid as a relatively 
potent anticancer agent that also induced proteasome-dependent degradation of Sp1, 
Sp3 and Sp4 in cell lines [518]. TA decreased Sp transcription factors, VEGF and 
angiogenesis in pancreatic tumors and also inhibited tumor growth and metastasis to 
the liver in an orthotropic model of pancreatic cancer [518]. TA also inhibits lung, 
esophageal, breast and ovarian cancer cell growth and with the exception of breast 
cancer cells, TA also induced downregulation of Sp1, Sp3, Sp4 and Sp-regulated genes 
[516, 519-522, 524]. 
 Since NSAIDs have been strongly linked to colon cancer chemoprevention and 
chemotherapy, we have investigated the anticancer activity and mechanism of action of 
TA in colon cancer cell lines and in nude mice bearing colon cancer cells as xenografts. 
TA inhibits colon cancer cell and tumor growth and this was accompanied by decreased 
expression of Sp1, Sp3, Sp4 and Sp-regulated gene products that play a role in cancer 
cell growth, survival, angiogenesis and inflammation. However, in contrast to studies in 
pancreatic cancer [518], TA-induced downregulation of Sp transcription factors was 
proteasome-independent and involved induction of caspase-dependent pathways. 
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MATERIALS AND METHODS 
Cell lines, reagents and antibodies. RKO, SW480, HT-29 and HCT-116 human colon 
carcinoma cell lines were obtained from American Type Culture Collection (Manassas, 
VA).  RKO and SW480 cells were maintained in Dulbecco‘s modified/Ham‘s F-12 
(Sigma-Aldrich, St. Louis, MO) with phenol red supplemented with 0.22% sodium 
bicarbonate, 5% fetal bovine serum, and 10ml/L 100X anti-biotic anti-mycotic solution 
(Sigma).  HT-29 and HCT-116 cells were maintained in McCoy‘s 5A medium (Sigma-
Aldrich, St. Louis, MO) with phenol red supplemented with 0.22% sodium bicarbonate, 
10% fetal bovine serum, and 10 ml/L 100X anti-biotic anti-mycotic solution (Sigma). 
Cells were grown in 150 cm2 culture plates in an air/CO2 (95:5) atmosphere at 37C and 
passaged approximately every 3-5 days.  All antibodies were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA), except cleaved poly (ADP) ribose polymerase 
(PARP) and c-Met (Cell Signaling Technology, Danvers, MA), Sp1, survivin and VEGF-
R2 (Millipore, Temecula, CA),  VEGFR1 and P65 (Abcam Inc. Cambridge, MA), and -
actin antibodies (Sigma-Aldrich).  The NSAIDs tolfenamic acid, diclofenac and 
ampiroxicam were purchased from LKT laboratories, Inc. (St. Paul, MN). Glutathione, 
98% (-glu-cys-gly, GSH), zinc sulphate and lactacystin were purchased from Sigma-
Aldrich (St Louis, MO). Dithiothretol (DTT, 98%) was obtained from Boehringer 
Mannheim Corp, (Indianapolis, IN). Caspase inhibitors 2, 8, 9 and pancaspase inhibitor 
(Z-VAD-fmk) are purchased from Calbiochem (sandiago, CA). Caspase 12 inhibitor was 
purchased from BioVision Inc, (Milpitas, CA). Leptomycin B was inhibitor of nuclear 
export purchased from Enzo Life Sciences International, Inc. (Plymouth Meeting, PA). 
AM251 and AM630 were purchased from Cayman Chemical Company (Ann Arbor, 
Michigan) and Tocris Bioscience (Ellisville, MO) respectively. Gliotoxin was kindly 
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provided by Dr. Alan Taylor (National Research Council of Canada, Halifax, NS, 
Canada). 
Cell proliferation assays. RKO, SW480, HT-29 and HCT-116 colon cancer cell lines 
were plated (3 x 104 per well) using DMEM:Ham‘s F-12 medium containing 2.5% 
charcoal stripped fetal bovine serum (FBS) in 12-well plates and left to attach for 24 hr.  
Cells were then treated with either vehicle or the indicated concentrations of tolfenamic 
acid.  After 24, 48 and 72 hr of treatment, cells were counted using a Coulter Z1 particle 
counter.  Each experiment was carried out in triplicate and results are expressed as 
means  SE for each determination. 
Annexin V staining. Apoptosis, necrotic and healthy cell detection kit was purchased 
from Biotium, Inc, (Haywrd, CA). RKO, SW480, HT-29 and HCT-116 colon cancer cells 
(7.5 x 104) were seeded in Lab-Tek two chambered cover glass slides and allowed to 
attach overnight.  After treatment with tolfenamic acid (100 µM) for 24 hr, cells were 
washed with cold phosphate –buffered saline (PBS) twice and incubated with FITC 
Annexin V, ethidium homodimer III  and Hoechst 33342 in Annexin V binding buffer for 
20 min according to the manufacturer‘s  instructions. The cells were then washed twice 
with Annexin V binding buffer and flouroscence was analyzed with a digital fluorescence 
microscope. 
Western blots. RKO, SW480, HT-29 and HCT-116 colon cancer cells were seeded in 
DMEM:Ham‘s F-12 medium containing 2.5% charcoal-stripped FBS and, after 24 hr, 
cells were treated with either vehicle (DMSO) or the indicated compounds.  Cells were 
collected using high-salt buffer (50 mM HEPES, 0.5 mol/L NaCl, 1.5 mM MgCl2, 1 mM 
EGTA, 10% glycerol, and 1% Triton-X-100) and 10 ml/L Protease Inhibitor Cocktail 
(Sigma-Aldrich). After centrifugation of the lysates at 15,000 g for 15 min at 4oC, the 
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supernatants were recovered, and protein was quantified by the Bradford protein assay. 
Protein lysates (15-60 µg) were incubated for 5 min at 100C along with 5X loading 
buffer and then separated by electrophoresis on 7.5-12% sodium dodecyl sulphate -
polyacrylamide gels at 120 V for 3 to 4 h.  Proteins were transferred onto polyvinylidene 
difluoride membranes by wet electroblotting in a buffer containing 25 mM Tris, 192 mM 
glycine, and 20% methanol for 1.5 h at 180 mA. Membranes were blocked for 45 min 
with 5% TBST-Blotto (10 mM Tris-HCl, 150 mM NaCl, pH 8.0, 0.05% Triton X-100, and 
5% nonfat dry milk) and incubated in fresh 5% TBST-Blotto with 1:500 primary antibody 
overnight with gentle shaking at 4C.  After washing twice with TBST for 10 min, the 
membrane was incubated with secondary antibody (1:5000) in 5% TBST-Blotto for 3-4 
hr by gentle shaking.  The membrane was washed twice with TBST for 10 min, 
incubated with 2 ml of chemiluminescence substrate (Millipore, Temecula, CA) for 1 
min, and exposed to Kodak image station 4000 mm Pro (Carestream Health, 
Rochester, NY). 
Xenograft studies in athymic mice. Female athymic nude mice were purchased from 
Harlan Laboratories (Indianapolis, IN). The mice were housed and maintained under 
specific pathogen-free conditions in facilities approved by the American Association for 
Accreditation of Laboratory Animal Care and in accordance with current regulations and 
standards of the United States Department of Agriculture, United States Department of 
Health and Human Services. The mice were used in accordance with institutional 
guidelines. To produce tumors, RKO cells were harvested from subconfluent cultures by 
a brief exposure to 0.25% trypsin and 0.02% ethylenediaminetetraacetic acid. 
Trypsinization was stopped with medium containing 10% fetal bovine serum, and the 
cells were washed once in serum-free medium and resuspended in serum free medium. 
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Only suspensions consisting of single cells with 90% viability were used for the 
injections. A xenograft was established by subcutaneous injection of the cells (3×106) 
into the flanks of individual mice. Tumors were allowed to grow for 6 days or until they 
were palpable. Mice were then randomized into two groups of six mice per group and 
dosed by oral gavage in corn oil or 50 mg/kg/day tolfenamic acid (TA) on every 
alternate day for 14 days. The mice were weighed, and tumor size was measured every 
second day with calipers to permit calculation of tumor volumes: V=LW2/2, where L and 
W were length and width, respectively. After 14 days, the animals were sacrificed; final 
body and tumor weights were determined and plotted. At the end of the experiment, 
major visceral organs and tumors were collected and analyzed for Sp protein 
expression levels using western blots. 
Statistical analysis. Statistically significant differences were determined by analysis of 
variance and Student t-test, and the levels of probability were noted. All statistical tests 
were two-sided.  IC50 values were calculated using non-linear regression analysis and 
expressed in M, at 95% confidence intervals. 
RESULTS 
TA induces apoptosis, inhibits colon cancer cell proliferation and decreases 
expression of Sp1, Sp3 and Sp4 proteins. The effects of tolfenamic acid on growth of 
colon cancer cells was investigated in SW480, RKO, HCT-116 and HT-29 cell lines 
(Figs. 3.1A and 3.1B).  
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 After treatment for 72 hr, significant growth inhibition was observed in all cell 
lines treated with 50-100 µM TA; after 24 hr ≤ 100 µM TA also inhibited proliferation of 
SW480, RKO and HCT-116 but not HT-29 cells which were the most resistant among 
the four colon cancer cell lines. In addition, treatment of SW480, RKO, HCT-116 and 
HT-29 cells with 100 µM TA for 24 hr enhanced annexin V staining (Figs. 3.1C and 
3.1D) confirming that TA also induced apoptosis in colon cancer cells as previously 
observed in lung, esophageal and pancreatic cancer cells treated with TA [518, 520, 
521]. Treatment of the colon cancer cell lines with TA also induced PARP cleavage and 
this was accompanied by downregulation of the pro-survival genes bcl-2 and survivin 
(Figs. 3.2A and 3.2B). Previous studies indicated that bcl-2 and survivin are regulated 
by Sp1, Sp3 and Sp4 transcription factors that are overexpressed in colon and other 
cancer cell lines  [410, 516, 518-522, 524] and Fig 3.2C and 3.2D demonstrate that TA 
decreased expression of Sp1, Sp3 and Sp4 proteins in RKO, SW480, HT-29 and HCT-
116 cells. Downregulation of Sp1, Sp3 and Sp4 proteins is both time- and dose-
dependent and these results are consistent with the reported effects of TA on levels of 
Sp1, Sp3 and Sp4 proteins in other cancer cell lines [410, 516, 518-522, 524]. 
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Fig. 3.1. Tolfenamic acid inhibits colon cancer cell growth and induces apoptosis. 
Inhibition of SW480 and RKO (A) and HCT-116 and H-T29 (B) colon cancer cell 
proliferation.  Cells were treated with DMSO or 50-100 µM tolfenamic acid for 3 days, 
and cell numbers were determined as described in the Materials and Methods.  C. 
Induction of Annexin V staining and apoptotic responses in RKO, SW480, HT-29 and 
HCT-116 cells.  Annexin V staining was determined as described in the Materials and 
Methods. Results in (A) and (B) are means  SE for 3 replicate determination for each 
treatment group, and significant (p < 0.05) inhibition is indicated (*). 
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Fig. 3.2. Western blot analysis of Sp-regulated survival and Sp proteins in colon cancer 
cells. Tolfenamic acid decreases expression of survival proteins (survivin, bcl-2), and 
increases expression of apoptotic proteins (cleaved PARP) in RKO and SW480 (A), HT-
29 and HCT-116 (B) colon cancer cells. Tolfenamic acid decreases the expression of 
Sp proteins (Sp1, Sp3 and Sp4) in RKO and SW480 (C) and HT-29 and HCT-116 (D) 
colon cancer cells. Cells were treated with 50 or 100 µM tolfenamic acid for 24 or 48 hr, 
and whole cell lysates were analyzed by western blot analysis as described in the 
Materials and Methods.  Results are typical of duplicate experiments. 
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TA decreases expression of Sp-regulated genes including NF-κB. Treatment of 
RKO and SW480 cells with 75 or 100 µM TA for 24 or 48 hr resulted in a time- and 
concentration-dependent decrease in several Sp-regulated genes including VEGF, 
VEGFR1, cyclin D1 and c-MET (Fig. 3.3A). Similar results were observed in HT-29 and 
HCT-116 cells (Fig. 3.3B) however, it was apparent that HT-29 cell were the most 
resistant cell line to the effects of TA on downregulation of Sp and Sp-regulated gene 
products. Since tolfenamic acid is an anti-inflammatory drug and p65 is an Sp-regulated 
gene (26, 27) we also investigated the effects of TA on p65 and p50 in RKO (Fig. 3.3C) 
and SW480 (Fig. 3.3D) cells. After treatment of both cell lines with 75 and 100 µM TA 
for 24 or 48 hr there was a decrease in both p65 and p50 proteins and this 
corresponded to decreased NF-κB-dependent tranactivation (data not shown). 
TA inhibits colon tumor growth in a xenograft model. The effects of TA (50 
mg/kg/day) on colon tumor growth were investigated in athymic nude mice bearing RKO 
cells as xenografts. TA significantly inhibited tumor volumes over the 3 week period of 
administration (Fig. 3.4A) and after sacrifice, TA treated mice exhibited significantly 
lower tumor volumes and weights (Fig. 3.4B) compared to corn oil treated controls. We 
also examined expression of Sp1, Sp3, Sp4 and Sp-regulated gene products on 
individual mice by western blot analysis of tumor lysates (Fig. 3.4C). Although there was 
some interindividual differences in expression of these proteins in the control and 
treated group (Fig. 3.4C), quantitation of the results relative to β-actin (relative 
expression in controls was set at 1.0) showed that treatment with TA significantly 
decreased protein levels of Sp1, Sp3, Sp4 and Sp-regulated genes (Fig. 3.4D). 
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Fig. 3.3. Western blot analysis of Sp-regulated angiogenic and proliferative proteins in 
colon cancer cells. Tolfenamic acid decreases the expression of angiogenic proteins 
(VEGF, VEGFR1) and proliferative proteins (cyclin D1, C-Met) in RKO, SW480 (A) and 
HT-29 and HCT-116 (B) colon cancer cells. Tolfenamic acid decreases the expression 
of NF-κB (p65 and p50) in RKO and SW480 (C) colon cancer cells. Cells were treated 
with 50 or 100 µM tolfenamic acid for 24 or 48 hr, and whole cell, nuclear and cytosolic 
extracts were analyzed by western blot analysis as described in the Materials and 
Methods. Results are typical of duplicate experiments. 
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Fig. 3.4. Tolfenamic acid inhibits colon tumor growth in athymic nude mice (xenografts).  A, Inhibition of 
tumor growth in athymic nude mice administered with tolfenamic acid.  B, Athymic nude mice bearing RKO 
cells as xenografts were treated with tolfenamic acid, and tumor volumes and weights were determined 
after sacrifice as described in the Materials and Methods.  (C) Expression of Sp1, Sp3 and Sp4 in colon 
tumors.  Tumor lysates from solvent (control) and tolfenamic acid-treated mice were analyzed by western 
blot analysis as described in the Materials and Methods.  D, Expression of Sp1, Sp3 and Sp4 proteins in 
tolfenamic acid-treated tumors compared to solvent (control)-treated tumors (set at 100%) was determined 
by densitometry, and -actin was used to normalize protein expression.  Results are means  SE (6 
replicates) and significant (p < 0.05) inhibition of Sp1, Sp3 and Sp4 protein levels by tolfenamic acid is 
indicated (*). 
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Mechanism of TA-induced downregulation of Sp1, Sp3 and Sp4 proteins. TA 
induces proteasome-dependent downregulation of Sp1, Sp3 and Sp4 in pancreatic 
cancer cells [518] however, results in Fig. 3.5A show that the proteasome inhibitors 
lactacystin and gliotoxin did not affect TA-induced downregulation of Sp1, Sp3 or Sp4 
proteins in RKO and SW480 cells. Drug-induced ROS also decreased Sp protein 
expression in several cancer cell lines [572, 660-662], however Fig. 3.5B shows that the 
antioxidants DTT or GSH did not affect downregulation of Sp1, Sp3 and Sp4 in colon 
cancer cells treated with 100 µM TA. These results are in contrast to the effects of 
antioxidants on Sp downregulation by ROS inducers in colon and other cancer cell lines 
(pancreatic, bladder). Cannabinoid (CB) receptor agonists also downregulate Sp1, Sp3 
and Sp4 and these responses are inhibited by the CB1 and CB2 receptor antagonists 
AM251 and AM630 respectively [663] however these antagonists did not affect TA-
mediated effects on Sp proteins (Fig. 3.5C). Previous studies with arsenic trioxide [662] 
have also linked activation of caspases to degradation of Sp1, Sp3 and Sp4 and 
therefore we initially investigated the effects of inhibitors of caspases 2, 8 and 9 and the 
pan-caspase inhibitor Z-VAD-fmk on TA-mediated degradation of Sp proteins (Fig. 
3.6A). In RKO cells only the pan-caspase inhibitor Z-VAD-fmk blocked TA-induced 
degradation of Sp1, Sp3 and Sp4 and in a second experiment the caspase-12 inhibitor 
was also active as an inhibitor in RKO cells (figure/data not shown). In contrast, TA-
induced degradation of Sp1, Sp3 and Sp4 in SW480 cell was inhibited not only by Z-
VAD-fmk but also inhibitors of caspases 2, 8, 9 and 12 (Fig. 3.6B). 
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Fig. 3.5. Mechanisms of tolfenamic acid -induced Sp protein degradation. Effect of 
proteasome inhibitors (A), antioxidants (B) and cannabinoid receptor inhibitors (C) on 
tolfenamic acid-induced Sp protein downregulation.  Cells were treated with DMSO, 
tolfenamic acid alone or in combination with proteasome inhibitors or antioxidants or 
cannabinoid receptor inhibitors, and after 48 hr, whole cell lysates were analyzed by 
western blots analysis as described in the Materials and Methods. 
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Fig. 3.6. Mechanisms of tolfenamic acid-induced Sp protein degradation. Effects of 
caspase inhibitors (A, B) on tolfenamic acid-induced Sp protein downregulation.  Cells 
were treated with DMSO, tolfenamic acid alone or in combination with caspase 
inhibitors, and after 48 hr, whole cell lysates were analyzed by western blots analysis as 
described in the Materials and Methods. Effects of leptomycin B (B) on tolfenamic acid-
induced Sp protein downregulation. Cells were treated with 100 uM tolfenamic acid in 
the presence or absence of leptomycin B for 48 hr, and cytoplasmic and nuclear lysates 
were analyzed by western blot analysis as described in the Materials and Methods. 
Effects of ZnSO4 (D) on tolfenamic acid-induced Sp protein downregulation.  Cells were 
treated with DMSO, tolfenamic acid alone or in combination with ZnSO4, and after 48 hr, 
whole cell lysates were analyzed by western blots analysis as described in the Materials 
and Methods. 
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Fig. 3.6. Continued. 
 
 Previous studies show that retinoid-induced transglutaminase-2 (TG2) and 
caspase-3 resulted nuclear TG2-Sp1 crosslinking and subsequent degradation of Sp1 
[664] and in this study we also observed that TA-induced degradation of nuclear Sp1, 
Sp3 and Sp4 (Fig. 3.6C). Moreover, similar results were observed in the presence or 
absence of leptomycin β (LMB, nuclear protein export inhibitor), confirming that Sp 
protein degradation was nuclear. However, we did not observe formation of any high 
molecular weight Sp1/Sp3/Sp4-TG2 crosslinked bands and the detection of subsequent 
Sp degradation products was inconsistent (data not shown). It has also been reported 
that zinc chelation induces caspase-dependent cleavage of Sp1, Sp3 and Sp4 which is-
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reversed by excel zinc sulfate (ZnSO4) [665] and Fig. 3.6D shows that ZnSO4 only 
partially inhibits TA-mediated Sp degradation in SW480 and not in RKO cells. Current 
studies are focused on further investigation of the mechanism of caspase induction by 
TA and the subsequent mechanism identification of specific amino acid targets in Sp1, 
Sp3 and Sp4 that are required for degradation. 
DISCUSSION 
 Sp1, Sp3 and Sp4 transcription factors are highly expressed in cancer cells and 
tumors [516, 519-522, 524, 632, 660, 661]  and studies focused on Sp1 show that this 
protein is a negative prognostic factor for pancreatic and gastric cancer patient survival 
[666, 667]. Sp1 expression is also critical for malignant transformation of human 
fibroblast cells [373] and expression of Sp1 in rodents and humans decrease with age 
[367, 668]. The high tumor/non-tumor ratio of Sp1 and other Sp transcription factor 
suggests that these transcription factors are potentially important drug targets for 
cancer chemotherapy. Knockdown of Sp1, Sp3 and Sp4 alone or in combination by 
RNAi also decreased expression of several genes involved in cancer cell growth (cyclin 
D1, C-MET, EGFR), survival (bcl-2 and survivin), angiogenesis (VEGF and VEGF 
receptors), and inflammation (p65, NF-κB) [375, 520, 632, 641, 660-662, 669, 670], and 
many of these genes are themselves individual targets for anticancer drugs. Moreover, 
knockdown of Sp transcription factors by RNAi in cancer cells alone also induces 
apoptosis and growth inhibition [660-662]. Studies in this laboratory have identified 
several anticancer agents such as curcumin, arsenic trioxide, betulinic acid and 
synthetic triterpenoids and non-steroidal antiinflammatory drugs (NSAIDS) that act, in 
part, by downregulating Sp1, Sp3, Sp4 and Sp-regulated genes [375, 518, 572, 632, 
641, 660-663, 669, 670]. 
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 Several reports show that TA inhibits cancer cell and tumor growth of multiple 
tumor types and these responses are due, in part, to downregulation of Sp1, Sp3, Sp4 
and Sp-regulated genes [516, 518-522, 524]. In this study we have also demonstrated 
the effectiveness of TA as an inhibitor of colon cancer cell (Fig. 3.1) and tumor growth 
(Fig. 3.4) and as an inducer of apoptosis (Fig. 3.1C). Moreover these responses are 
consistent with TA-mediated effects on decreased expression of Sp1, Sp3 and Sp4 and 
also decrease levels of growth promoting (CD1, c-MET), angiogenic (VEGF and 
VEGFR) survival (survivin and bcl-2) and inflammatory (p65/p50) genes (Figs. 3.2 and 
3.3). Results of this study with TA in colon cancer cells are similar to comparable 
studies with TA in other cell lines however, the mechanism of TA-induced effects on Sp 
protein expression differed from previous reports. For example, the proteasome 
inhibitors gliotoxin and lactacystin did not inhibit TA-induced degradation of Sp1, Sp3 
and Sp4 as previously reported in pancreatic cancer cells [518]. Several proteasome-
independent pathways for drug-induced repression of Sp1, Sp3 and Sp4 have 
previously been reported and include ROS-, CB receptor- and caspase-dependent 
pathways which vary with respect to the drug and cell context [572, 632, 641, 660-663, 
669, 670]. For example, betulinic acid–mediated downregulation of Sp1, Sp3 and Sp4 
was proteasome-dependent in LNCaP prostate cancer cells [671], ROS-dependent in 
RKO and SW480 colon cancer cells [641] and we recently showed that in breast cancer 
cells betulinic acid-induced responses were CB receptor-dependent [663]. TA-induced 
downregulation of Sp1, Sp3 and Sp4 proteins was not affected by antioxidants (Fig. 
3.5B) or CB receptor antagonists (Fig. 3.5C) however, the pan-caspase inhibitor Z-
VAD-fmk inhibited TA-mediated degradation of Sp proteins in both RKO and SW480 
cells (Figs. 3.6A and 3.6B). We also observed that the caspase-12 inhibitor (Z-ATAD-
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FMK) reversed the effects of TA in both cell lines whereas the caspase-2, 8 and 9 
inhibitors were active only in SW480 but not RKO cells indicating some mechanistic 
differences between the two cell lines. 
 It has previously been reported that induction of TG2 and caspase-3 leads to 
crosslinking of TG2 with Sp1 and the subsequent proteolytic cleavage of Sp1 [664]. We 
observed that TA decreased expression of nuclear Sp1, Sp3 and Sp4 in the presence 
or absence of leptomycin B, the nuclear export inhibitor (Fig. 3.6C) indicating that 
caspase-dependent cleavage of Sp proteins was primarily nuclear. However, we did not 
observe induction of TG2 by TA in RKO or SW480 cells nor did we detect any higher 
molecular weight crosslinked bands (data not shown). Another possible caspase-
dependent degradation pathway for Sp1, Sp3 and Sp4 involves zinc chelation which 
can be rescued by adding excess ZnSO4 [665] and ongoing studies in this laboratory 
indicate that other NSAIDs induce Sp protein degradation through this pathway. Fig. 
3.6D shows that ZnSO4 only partially rescues SW480 cells from TA-mediated 
degradation of Sp1, Sp3 and Sp4 suggesting that other mechanisms of caspase 
activation are induced by TA in colon cancer cells and these are currently being 
investigated. 
 In summary, results of this study demonstrate the anticancer activity of TA in 
colon cancer cells and the potential clinical utility of using this drug for chemotherapy 
(alone or in combination) of colon cancer patients. TA has previously been used for pain 
relief and as an antiinflammatory agent in human studies [671, 672] and can be readily 
adapted for clinical applications. TA induces proteasome-dependent and independent 
degradation of Sp1, Sp3 and Sp4 and for the first time we have demonstrated that 
activation of caspases by TA is required for Sp protein degradation and current studies 
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are focused on identifying the mechanisms of TA-induced caspase activation that is 
required for degradation of Sp1, Sp3 and Sp4.  
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CHAPTER IV 
GT-094, A NO-NSAID, INHIBITS COLON CANCER CELL GROWTH BY ACTIVATION 
OF A REACTIVE OXYGEN SPECIES (ROS)-MICRORNA-27A:ZBTB10-SPECIFICITY 
PROTEIN (Sp) PATHWAY 
 
 
INTRODUCTION 
 Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are invaluable 
for treatment of fever, pain, arthritis, other inflammatory diseases, and cancer, and 
applications for these compounds continues to increase [419, 615, 655, 673].  Several 
epidemiology studies have reported decreased incidence of multiple cancers associated 
with NSAIDs (primarily aspirin) intake, and these drugs have been extensively 
investigated for their chemopreventive and chemotherapeutic activities [419, 507, 655].  
A recent study reported that aspirin use among women with breast cancer decreased 
the subsequent incidence of metastasis and cancer-related deaths [507].  Aspirin and 
other NSAIDs play a role in colon cancer prevention and therapy [417, 434, 656, 657, 
674-678], and specific NSAIDs and other cyclooxygenase (COX) inhibitors also 
decrease the risk of colon cancer among high risk individuals [676-678]. 
 Nitric oxide (NO) plays an important role in the suppression of GI-induced 
inflamation and toxicity, and this has led to development of nitro-NSAIDs (NO-NSAIDs) 
which combine the anti-inflammatory activities of NSAIDs with the NO-dependent 
protection from NSAID-induced GI toxicity.  NO-aspirin and other NO-NSAIDs exhibit 
anticancer activity in a wide range of cancer cell lines and in vivo models [468, 531, 
538, 544, 547, 553, 560, 563, 570, 679-682], and these compounds are invariably more 
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potent than their corresponding NSAID analogs.  For example, the NO-NSAID analog 2-
(acetyloxybenzoic acid 4-nitrooxymethyl)-phenyl ester (NO-ASA) is 700 times more 
potent than aspirin as an inhibitor of pancreatic cancer cell growth which is due to 
inhibition of cell proliferation and induction of apoptosis by both compounds [547].  The 
mechanism of action of NO-NSAIDs as cancer chemotherapeutic agents is unclear; 
however, these compounds clearly inhibit cancer and tumor cell growth, induce 
apoptosis, and exhibit antiangiogenic and antimetastatic activity. 
 Ethyl 2-((2,3-bis(nitrooxy)propyl)disulfanyl)benzoate (GT-094) [563, 570] is a 
novel NO chimera containing an NSAID and NO moieties and also a disulfide 
pharmacophore that in itself exhibits cancer chemopreventive activity [566].  GT-094 
significantly decreases aberrant crypt foci, proliferation and inducible NO synthase 
(iNOS) levels in azoxymethane-induced rat colon cancer [570] and decreases 
proliferation and arrests Caco-2 colon cancer cells in the G2/M phase of the cell cycle 
[563, 570]. 
 In this study, we investigated the mechanism of action of NO-NSAIDs using GT-
094 as a model in RKO and SW480 colon cancer cells. GT-094 inhibited colon cancer 
cell proliferation and induced apoptosis, and this was accompanied by downregulation 
of genes associated with cell growth [cyclin D1, hepatocyte growth factor receptor (c-
Met), epidermal growth factor receptor (EGFR)], survival (bcl-2, survivin), and 
angiogenesis [vascular endothelial growth factor (VEGF) and its receptors (VEGFR1 
and VEGFR2)].  Previous RNA interference studies in this laboratory has shown that all 
of these genes are regulated, in part, by specificity protein (Sp) transcription factors 
Sp1, Sp3 and Sp4 that are overexpressed in colon and other cancer cell lines [45, 46, 
410, 518, 632, 670, 671, 683, 684].  GT-094 also decreased Sp1, Sp3 and Sp4 in colon 
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cancer cells and this was dependent on a decrease in mitochondrial membrane 
potential (MMP) and induction of reactive oxygen species (ROS).  ROS-mediated 
repression of Sp and Sp-dependent genes involves downregulation of microRNA-27a 
(miR-27a) and induction of ZBTB10, an Sp repressor, and comparable results have also 
been observed for synthetic triterpenoid anticancer drugs in pancreatic and colon 
cancer cells [661, 683]. 
MATERIALS AND METHODS 
Cell lines, reagents and antibodies. RKO and SW480 human colon carcinoma cell 
lines were obtained from American Type Culture Collection (Manassas, VA).  RKO and 
SW480 cells were maintained in Dulbecco‘s modified/Ham‘s F-12 (Sigma-Aldrich, St. 
Louis, MO) with phenol red supplemented with 0.22% sodium bicarbonate, 5% fetal 
bovine serum, and 10 ml/L 100X antibiotic antimycotic solution (Sigma).  Cells were 
grown in 150 cm2 culture plates in an air/CO2 (95:5) atmosphere at 37C and passaged 
approximately every 3-5 days.  GT-094 was synthesized in the laboratory of Dr. 
Gregory R. Thatcher (University of Illinois, Chicago).  All antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA), except cleaved poly (ADP) ribose 
polymerase (PARP) and c-Met (Cell Signaling Technology, Danvers, MA), Sp1 and 
VEGFR2 (Millipore, Temecula, CA), survivin (R&D Systems, Minneapolis, MN), 
VEGFR1 (Abcam Inc. Cambridge, MA), and -actin antibodies (Sigma-Aldrich).  
Glutathione, 98% (-glu-cys-gly, GSH) and carbonyl cyanide 3-chlorophenylhydrazone 
(CCCP) were purchased from Sigma-Aldrich.  Dithiothretol (DTT, 98%) was obtained 
from Boehringer Mannheim Corp, (Indianapolis, IN).  CM-H2DCFDA was purchased 
from Invitrogen.  MG132 and lactacystin are the proteasomal inhibitors purchased from 
Calbiochem (Sandiago, CA) and Sigma Chemicals Co. (St Louis, MO), respectively. 
165 
 
Cell proliferation assays. RKO and SW480 cancer cell lines were plated (3 x 104 per 
well) using DMEM:Ham‘s F-12 medium containing 2.5% charcoal stripped fetal bovine 
serum (FBS) in 12-well plates and left to attach for 24 h.  Cells were then treated with 
either vehicle or the indicated concentrations of GT-094.  After 24, 48 and 72 h of 
treatment, cells were counted using a Coulter Z1 particle counter [377].  Each 
experiment was carried out in triplicate and results are expressed as means  SE for 
each determination. 
Western blots. RKO and SW480 cancer cells were seeded in DMEM:Ham‘s F-12 
medium containing 2.5% charcoal-stripped FBS and, after 24 h, cells were treated with 
either vehicle (DMSO) or the indicated compounds.  Cells were collected using high-salt 
buffer (50 mM HEPES, 0.5 mol/L NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol, and 
1% Triton-X-100) and 10 ml/L Protease Inhibitor Cocktail (Sigma-Aldrich). Protein 
lysates were incubated for 3 min at 100C before electrophoresis and then separated 
on 10% SDS-polyacrylamide gel electrophoresis 120 V for 3 to 4 h.  Proteins were 
transferred onto polyvinylidene difluoride membranes by wet electroblotting in a buffer 
containing 25 mM Tris, 192 mM glycine, and 20% methanol for 1.5 h at 180 mA. 
Membranes were blocked for 30 min with 5% TBST-Blotto (10 mM Tris-HCl, 150 mM 
NaCl, pH 8.0, 0.05% Triton X-100, and 5% nonfat dry milk) and incubated in fresh 5% 
TBST-Blotto with 1:500 primary antibody overnight with gentle shaking at 4C.  After 
washing with TBST for 10 min, the polyvinylidene difluoride membrane was incubated 
with secondary antibody (1:5000) in 5% TBST-Blotto for 2 h by gentle shaking.  The 
membrane was washed with TBST for 10 min, incubated with 6 ml of 
chemiluminescence substrate for 1 min, and exposed to Kodak image station 4000 mm 
Pro (Carestream Health, Rochester, NY). 
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ROS estimation. Cellular ROS levels were evaluated with the cell permeant probe CM-
H2DCFDA (5-(and-6)-chloromethyl-2',7'
 dichlorodihydrofluorescein diacetate acetyl 
ester).  CM-H2DCFDA is nonfluorescent until removal of the acetate groups by 
intercellular esterases and oxidation occurs within the cell.  Following treatment of the 
cells for 12 h, 48-well cell culture plates were loaded with 10 M CM-H2DCFDA  for 30 
min, washed once with serum-free medium, and analyzed for ROS levels using Bio Tek 
Synergy 4 plate reader (Bio Tek Instruments, Inc., Winooski, VT) set at 480 nm and 525 
nm excitation and emission wavelength, respectively.  Cells were then washed twice 
with PBS and fixed with methanol for 3 min at room temperature.  Methanol was then 
completely removed and 1 mg/ml Janus green was added to the cultures for 3 min.  
Following removal of Janus green, cultures were washed twice with PBS and 100 l of 
50% methanol was added to each well.  Cell counts were then determined with the 
plate reader set to an absorbance of 654 nm, and ROS intensities were corrected 
accordingly.  Three experiments were performed and analyzed on different days using 8 
wells per treatment group, and results are expressed as means  SE for each 
determination.  
Terminal deoxyribonucleotide transferase-mediated nick-end labeling (TUNEL) 
assay. RKO and SW480 cells (10 × 104) were seeded in two-chambered glass slides 
and left overnight to attach.  After treatment with indicated compounds for 12 h, the in 
situ cell death detection POD kit was used for the terminal deoxyribonucleotide 
transferase-mediated nick-end labeling (TUNEL) assay according to the instructions in 
the protocol manual for fixed cells.  The percentage of apoptotic cells was calculated by 
counting the stained cells in eight fields, each containing 50 cells.  The total number of 
apoptotic cells was plotted as a percentage in both cell lines. 
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Measurement of MMP. MMP was measured with the Mitochondrial Membrane 
Potential Detection Kit (Stratagene, Cedar Creek, TX) according to manufacturer‘s 
protocol using JC-1 dye.  RKO and SW480 colon cancer cells were plated on two-well 
Lab-Tex Coverglass slides (NUNC A/S, Roskilde, Denmark) and, after 24 h, cells were 
treated with DMSO, CCCP (25 mol/L), GT-094 (50 mol/L) alone or with GSH (5 
mmol/L) for 12 h.  Cells were then incubated with 1× JC-1 dye at 37C for 15 min and 
washed twice with assay buffer according to manufacturer‘s protocol, and then cells 
were subjected to microscopic analysis using Zeiss Stallion Dual Detector Imaging 
System (Carl Zeiss Microimaging Inc., Thornwood, NY).  J-aggregates are detected as 
red fluorescence, and J-monomers are detected as green fluorescence.  The ratio of 
red fluorescence to green fluorescence was measured using ImageJ Software.  Cells 
were examined in more than 10 fields per slide on multiple slides.  Data represent the 
average of all the fields and results are expressed as means  SE for each 
determination. 
Quantitative real-time PCR analysis of mRNAs and miRNAs. miRNA was extracted 
using the mirvaRNA extraction kit (Applied Biosystems).  Quantification of miRNA 
(RNU6B, miRNA-27a) was performed using the Taqman miRNA kit (Applied 
Biosystems) according to the manufacturer‘s protocol with real-time PCR.  U6 small 
nuclear RNA was used as a control to determine relative miRNA expression.  Total 
RNA was isolated using the RNeasy Protect Mini kit (Qiagen) according to the 
manufacturer‘s protocol.  RNA was reverse transcribed using Superscript II reverse 
transcriptase (Invitrogen) according to the manufacturer‘s protocol.  PCR was carried 
out with the SYBR Green PCR Master Mix from PE Applied Biosystems on an ABI 
Prism 7700 Sequence Detection System (PE Applied Biosystems) using 0.5 mol/L of 
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each primer and 2 l cDNA template in each 25 l reaction.  TATA binding protein 
(TBP) was used as an exogenous control to compare the relative amount of target gene 
in different samples.  The PCR profile was as follows: one cycle of 95C for 10 min, 
then 40 cycles of 95C for 15 s, and 60C for 1 min.  The comparative CT method was 
used for relative quantitation of samples, and results are expressed as means  SE for 
at least 3 separate determinations.  Primers were purchased from Integrated DNA 
Technologies. The following primers were used. 
TBP (F): 5-TGCACAGGAGCCAAGAGTGAA-3 
TBP (R): 5-CACATCACAGCTCCCCACCA-3 
ZBTB10 (F): 5-GCTGGATAGTAGTTATGTTGC-3 
ZBTB10 (R): 5-CTGAGTGGTTTGATGGACAGA-3 
Statistical analysis. Statistical significance of differences was determined by analysis 
of variance and student t-test, and the levels of probability were noted. All statistical 
tests were two-sided.  IC50 values were calculated using non-linear regression analysis 
and expressed in M, at 95% confidence intervals. 
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RESULTS 
 GT-094 is a model nitro-NSAID analog (NO-chimera) that contains both the 
aliphatic nitro group and a disulfide linker, and this compound exhibits cancer 
chemoprevention activity in an in vivo model for colon cancer.  In this study, we initially 
investigated the concentration and time-dependent effects of GT-094 on proliferation of 
RKO and SW480 colon cancer cells (Fig. 4.1A).  Significant growth inhibition was 
observed in both cell lines and the 24-h IC50 values for growth inhibition were 36 and 44 
mol/L in RKO and SW480 cells, respectively.  In addition, the proapoptotic effects 
were examined in RKO and SW480 cells, and GT-094 induced caspase-dependent 
PARP cleavage in both cell lines (Fig. 4.1B).  GT-094 decreased expression of pro-
survival survivin and bcl-2 proteins, and this was consistent with the observed caspase-
dependent PARP cleavage.  GT-094 inhibited cell proliferation and induced apoptosis in 
RKO and SW480 cells and therefore, the effects of GT-094 on gene products 
associated with cell proliferation and apoptosis were also investigated.  Results in Fig. 
4.1C show that GT-094 decreased expression of several proteins involved in cell 
proliferation and these included cyclin D1, c-Met and EGFR in both RKO and SW480 
cells.  In addition, we observed that GT-094 decreased expression of the angiogenic 
growth factor VEGF and its receptor VEGFR1 in RKO and SW480 cells (Fig. 4.1D). 
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Fig. 4.1. GT-094 inhibits growth and induces apoptosis in colon cancer cells. (A) 
Inhibition of RKO and SW480 cell growth. Cells were treated with different 
concentrations of GT-094, and cell numbers were determined on days 1, 2 and 3 as 
described in the Materials and Methods. Western blot analysis of Sp-regulated survival 
(B), proliferative (C), and angiogenic (D) gene products in RKO and SW480 cells 
treated with GT-094. Cells were treated with GT-094 (20 and 50 μmol/L) for 24 h, and 
whole cell lysates were analyzed by western blots as described in the Materials and 
Methods. 
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Fig. 4.2. GT-094-mediated effects on Sp protein and Sp-regulated gene products. (A) GT-094 decreases 
Sp1, Sp3 and Sp4 protein expression in colon cancer cells. RKO and SW480 cells were treated with 20 or 
50 μmol/L GT-094 for 24 h, and whole cell lysates were analyzed by western blots as described in the 
Materials and Methods. (B) Effects of proteasome inhibitors on Sp downregulation. Cells were treated with 
50 μmol/L GT-094, MG132 or lactacystin alone or in combination, and whole cell lysates were analyzed by 
western blots as described in the Materials and Methods. Results in Figure 2 are typical of replicate (at 
least 2) experiments. Time-course effects of GT-094 (50 μM) in RKO (C) and SW480 (D) cells. Cells were 
treated with DMSO (0 time) or GT-094 for 6, 12, 18, 24 and 36 h, and whole cell lysates were analyzed by 
western blots as outlined in the Materials and Methods. 
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 Previous studies with agents such as curcumin, betulinic acid, synthetic 
triterpenoid anticancer drugs, and the NSAID tolfenamic acid show that these 
compounds decrease expression of bcl-2, survivin, c-Met, EGFR, cyclin D1, VEGF and 
VEGFR1 protein in several cancer cell lines, including colon cancer cells, and RNA 
interference studies confirmed that these genes are regulated by Sp1, Sp3 and Sp4 
transcription factors which are overexpressed in cancer cells [518, 632, 661, 670, 671, 
683].  Treatment of RKO and SW480 cancer cells with 20 and 50 mol/L GT-094 
decreased expression of Sp1, Sp3 and Sp4 proteins (Fig. 4.2A) and these results were 
consistent with decreased expression of Sp-regulated proteins illustrated in Fig. 4.1.  
However, in contrast to the effects of betulinic acid and tolfenamic acid in prostate or 
pancreatic cancer cells, the effects of GT-094 on downregulation of Sp1, Sp3 and Sp4 
proteins were not reversed by the proteasome inhibitors MG132 or lactacystin (Fig. 
4.2B).  MG132 alone decreased expression of Sp1, Sp3 and Sp4 in RKO and SW480 
cells, whereas lactacystin alone slightly decreased Sp protein levels only in SW480 
cells; however, a combination of lactacystin plus GT-094 did not reverse Sp 
downregulation but appeared to enhance this response.  The time-dependent effects of 
GT-094 on Sp1, Sp3, Sp3 and Sp4 protein expression and levels of Sp-regulated genes 
were also determined in RKO (Fig. 4.2C) and SW480 (Fig. 4.2D) cells.  In RKO cells, 
Sp1, Sp3 and Sp4 proteins decreased between 6-12 h after treatment and after 12 h, 
there was almost complete loss of these transcription factors.  The time-dependent 
decrease in expression of bcl-2, survivin, c-MET, and VEGFR-R1 and induction of 
cleaved PARP followed a pattern similar to that observed for Sp proteins.  However, 
cyclin D1 was significantly decreased within 6 h, whereas decreased VEGF expression 
was delayed (> 18 h), suggesting that other GT-094-mediated pathways may also be 
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involved.  In SW480 cells, the time-dependent pattern of GT-094-induced 
downregulation of Sp1, Sp3, Sp4 and Sp-regulated gene products was similar with 
decreased expression observed within 6-12 h and highly significant downregulation 
after 18 h.  The major exceptions were the rapidly decreased responses (within 6 h) for 
bcl-2, VEGF and the low molecular weight Sp3 protein. 
 
 
Fig. 4.3. GT-094 decreases MMP in colon cancer cells. Effects of GT-094 in RKO (A) 
and SW480 (B) cells. Cells were treated with 50 μmol/L GT-094, 25 μmol/L CCCP, and 
GT-094 plus GST for 12 h and analyzed for changes in MMP as outlined in the 
Materials and Methods. Quantitative changes in MMP in RKO (C) and SW480 (D) cells. 
Changes in MMP were determined as described in the Materials and Methods. 
Significant (p<0.05) decreases by GT-094 or CCCP (*) and reversal of these effects by 
GSH (**) are indicated. 
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 Ongoing studies with arsenic trioxide and other pro-oxidants that also decrease 
expression of Sp transcription factors suggest that mitochondria are the initial targets for 
these agents [660, 662].  Figure 4.3A illustrates the effects of 50 mol/L GT-094 and the 
mitochondriotoxic carbonyl cyanide 3-chlorphenyl hydrazone (CCCP) (24 mol/L) which 
depolarizes mitochondria and decreases MMP.  In RKO cells treated with the 
fluorescent dye JC-1 and DMSO or GSH, JC-1 formed a red fluorescent aggregate 
which is characteristic of high MMP.  However, after treatment with GT-094 or CCCP, 
there was a decrease in red and an increase in green fluorescence of JC-1 which is 
typical of low MMP, and this was accompanied by a decreased red/green fluorescence 
ratio.  However, cotreatment of RKO cells with GT-094 and the cellular antioxidant GSH 
(5 mmol/L) reversed the effects of GT-094 and restored MMP.  Similar responses were 
observed in SW480 cells (Fig. 4.3B) and the results were quantitated in both cell lines 
(Figs. 4.3C and 4.3D). 
 Drug-induced opening of the mitochondrial pore is associated with induction of 
ROS, and  Figure 4.4A shows that treatment of RKO cells with 50 M GT-094 
significantly induced ROS levels as determined by hydrolysis of the cell permeant probe 
to give a fluorescent product.  In addition, cotreatment of these cells with thiol 
antioxidants (DTT or GSH) significantly decreased induction of ROS by GT-094.  In 
parallel experiments in SW480 cells, we also observed that GT-094 induced ROS and 
this response was also attenuated after cotreatment with the thiol antioxidants (Fig. 
4.4B).  The role of ROS in mediating GT-094-dependent downregulation of Sp1, Sp3 
and Sp4 proteins was investigated in RKO and SW480 cells.  Treatment of RKO (Fig. 
4.4C) and SW480 (Fig. 4.4D) cells with GT-094 decreased expression of Sp1, Sp3 and 
Sp4 proteins in both cell lines and this response was attenuated in cells cotreated with-
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GT-094 plus the thiol antioxidants.  These results demonstrate that GT-094-mediated 
downregulation of Sp1, Sp3 and Sp4 proteins in  colon cancer cells is dependent on 
decreased MMP and induction of ROS, and we have observed similar effects for 
arsenic trioxide and curcumin in bladder and pancreatic cancer cells, respectively [661, 
662]. 
 
Fig. 4.4. Role of ROS in GT-094-mediated downregulation of Sp1, Sp3 and Sp4 proteins. Induction of ROS 
in RKO (A) and SW480 (B) cells. Cells were treated with 50 μmol/L GT-094, 1 mmol/L DTT, and 5 mmol/L 
GSH alone or in combination for 12 h, and ROS was determined as described in the Materials and 
Methods. Significant (p<0.05) induction by GT-094 (*) and inhibition of this response by GSH or DTT (**) 
are indicated. Effects of GSH or DTT on GT-094-mediaited Sp downregulation in RKO (C) and SW480 (D) 
cells. Cells were treated with different concentrations as indicated for 24 h, and whole cell lysates were 
analyzed by western blots as outlined in the Materials and Methods. Results are typical of replicate (2) 
experiments. 
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Fig. 4.5. GSH blocks GT-094-induced growth inhibition and apoptosis. Inhibition of RKO (A) and SW480 (B) 
cell growth by GT-094 blocked by GSH. Cells were treated with 50 μmol/L GT-094 or 5 mmol/L GSH alone 
or in combination for 24 h, and cell numbers were determined as described in the Materials and Methods. 
Significant (p<0.05) inhibition by GT-094 (*) or reversal of this effect by GSH (**) are indicated. Induction of 
apoptosis by GT-094 ± GSH in RKO (C) and SW480 (D) cells. Cells were treated with GT-094 ± GSH for 
24 h, and apoptosis was determined by TUNEL staining as described in the Materials and Methods. 
Significant (p<0.05) induction of apoptosis by GT-094 (*) and inhibition after cotreatment with GSH (**) are 
indicated. 
 
 
 Since GT-094-induced mitochondrial disruption and induction of ROS mediates 
downregulation of Sp1, Sp3 and Sp4, the role of this pathway on inhibition of colon 
cancer cell growth and induction of apoptosis was investigated.  Treatment of RKO and 
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SW480 cells with 50 M GT-094 for 24 h significantly inhibited proliferation of both cell 
lines; however, in cells cotreated with GT-094 and the antioxidant GSH, the growth 
inhibitory effects of the nitro-NSAID was attenuated (Figs. 4.5A and 4.5B).  The results 
also show that the role of ROS-induced growth inhibition was more dominant in RKO 
than in SW480 cells, suggesting that other ROS-independent pathways are involved in 
the inhibitory effects of GT-094 in SW480 cells.  Figures 4.5C and 4.5D show that GT-
094 enhanced TUNEL staining, indicative of apoptosis in RKO and SW480 cells, and 
this effect was inhibited in cells cotreated with GT-094 plus GSH.  These results confirm 
that GT-094-dependent activation of ROS plays an important role in the observed 
downregulation of Sp1, Sp3 and Sp4 transcription factors, decreased cell proliferation, 
and induction of apoptosis in colon cancer cells. 
 A recent report shows that downregulation of Sp transcription by methyl 2-
cyano-3,11-dioxo-18-oleana-1,12-dien-30-oate (CDODA-Me) is due to disruption of 
miR-27a:ZBTB10 interactions in colon cancer cells, resulting in decreased expression 
of miR-27a and induction of ZBTB10, an Sp repressor [683].  Treatment of RKO and 
SW480 cells with GT-094 decreased miR-27a expression in both cell lines (Fig. 4.6A) 
and cotreatment with GSH reversed this effect.  In parallel experiments, we observed 
that GT-094 induced ZBTB10 mRNA levels in RKO and SW480 cells (Fig. 4.6B) cells 
and this response was also attenuated after cotreatment with GSH.  Downregulation of 
miR-27a was only observed using 50 M GT-094, whereas 20 and 50 M GT-094 
induced ZBTB10 and this was particularly evident in RKO cells, suggesting that other 
microRNAs or other factors that play a role in regulating ZBTB10 expression may be 
affected by GT-094. 
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Fig. 4.6. GT-094 modulates miR-27a and ZBTB10 expression. (A) GT-094 decreases miR-27a expression 
in RKO and SW480 cells. Cells were treated with 20 or 50 μmol/L GT-094 and 5 mmol/L GSH alone or in 
combination for 24 h, and miR-27a was determined by real time PCR as outlined in the Materials and 
Methods. (B) GT-094 induces ZBTB10 in RKO and SW480 cells. Cells were treated with 20 or 50 μmol/L 
GT-094 and 5 mmol/L GSH alone or in combination for 24 h, and ZBTB10 mRNA levels were determined 
by real time PCR as outlined in the Materials and Methods. Significant (p<0.05) inhibition of miR-27a and 
induction of ZBTB10 (*) and inhibition of these responses by GSH (**) are indicated. (C) Proposed 
molecular mechanism for GT-094-induced ROS and ROS-dependent disruption of the miR-27a:ZBTB10-
Sp/Sp-regulated gene axis. 
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The time-dependent effects of GT-094 (50 M) on miR-27a and ZBTB4 were also 
investigated (Fig. 4.7).  GT-094 decreased miR-27a expression in both cell lines within 
6 h, whereas ZBTB10 was induced after 6-12 and 12-18 h in RKO and SW480 cells, 
respectively, indicating some cell context-dependent differences. 
 
 
Fig. 4.7. Time course effects of GT-094 on miR-27a (A) and ZBTB10 (B). 
RKO and SW480 cells were treated with DMSO or GT-094 for 6, 12, 18, 24 and 36 h, 
and expression of miR-27a and ZBTB10 was determined by real time PCR as outlined 
in the Materials and Methods. Results are mean ± SE for replicate (3) experiments, and 
significant (p < 0.05) inhibition/induction is indicated ( * ). 
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DISCUSSION 
 Nitro-NSAIDs are a new class of NSAIDs that have been developed to provide 
the prototypical anti-inflammatory and analgesic effects of NSAIDs but have minimal 
toxic gastrointestinal side-effects observed for aspirin and related drugs.  The NO 
moiety enhances gastric mucosal repair and ulcer healing and ameliorates NSAID-
induced toxicity.  NO-NSAIDs have also been investigated for their anticancer activities 
and the results of in vitro cell culture and in vivo animal studies have been promising 
[468, 531, 538, 544, 547, 553, 560, 563, 570, 679-682],.  These compounds typically 
inhibit cell growth and induce apoptosis in various cancer cell lines and this includes 
inhibition of -catenin/Tcf complexes and downregulation of cyclin D1 in colon cancer 
cells [560].  Nitro-aspirin derivatives inhibit growth of tumors in mouse xenograft 
experiments using HT-29 colon cancer cells and this is accompanied by decreased 
vascularity in the tumors and downregulation of VEGF [679].  GT-094 also inhibits 
cancer cell and tumor growth and, in both Caco-2 and HT-29 colon cancer cells, there 
was no evidence for induction of apoptosis [563, 570]. 
 Studies in this laboratory have shown that COX-2 inhibitors such as celecoxib 
decreased colon cancer cell growth and the NSAID tolfenamic acid decreased 
pancreatic cancer cell growth, and these effects were due, in part, to downregulation of 
Sp1, Sp3 and Sp4 transcription factors [410, 518].  GT-094 inhibited growth of RKO and 
SW480 colon cancer cells (Fig. 4.1A), induced PARP cleavage (Fig. 4.1B), and TUNEL 
staining (Fig. 4.5C) consistent with induction of apoptosis.  Moreover, GT-094 also 
decreased expression of the antiapoptotic survivin and bcl-2 proteins and this was 
consistent with induction of apoptosis.  GT-094 decreased expression of other proteins 
that play a role in cell growth (cyclin D1, c-Met and EGFR) and angiogenesis (VEGF 
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and VEGFR1) (Figs. 4.1C and 4.1D) and this was consistent with previous studies on 
NO-NSAIDs which report downregulation of cyclin D1 and VEGF [679, 680]. Previous 
studies in this laboratory have demonstrated by RNA interference that knockdown of 
Sp1, Sp3 and Sp4 individually or in combination decreases expression of the 
prosurvival, growth promoting, and angiogenic proteins [45, 46, 377, 632, 660-662, 
670].  Results shown in Fig. 4.1 suggest that an underlying mechanism for these 
responses in RKO and SW480 cells may be related to downregulation of Sp1, Sp3 and 
Sp4 proteins and this was observed in these cells treated with GT-094 (Fig. 4.2A).  The 
time-dependent decrease in expression of Sp1, Sp3, Sp4 and Sp-regulated genes was 
also determined in RKO and SW480 cells treated with GT-094 (Figs. 4.2C and 4.2D).  
Although the rate of decrease in expression of these proteins was similar in each of the 
cell lines, there were also notable exceptions, particularly for some putative Sp-
regulated genes which have previously been characterized by Sp1, Sp3 and Sp4 
knockdown in RNA interference studies [45, 46, 377, 632, 660-662, 670].  For example, 
expression of cyclin D1 (RKO cells) and bcl-2 (SW480 cells) was rapidly decreased (< 6 
h) prior to Sp transcription factors or most other Sp-regulated genes, suggesting that 
GT-094 also induced other pathways that repress genes independent of Sp 
downregulation. 
 At least two different pathways have been linked to drug-dependent 
downregulation of Sp transcription factors, namely via activation of proteasomes [518, 
632, 671] or through downregulation of miR-27a and the subsequent induction of the Sp 
repressor ZBTB10 [671, 683].  GT-094-dependent downregulation of Sp1, Sp3 and Sp4 
was not reversed by proteasome inhibitors (Fig. 4.2B), whereas the NSAID tolfenamic 
acid and the triterpenoid betulinic acid induce proteasome-dependent degradation of Sp 
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transcription factors in pancreatic and prostate cancer cells, respectively [518, 671].  In 
contrast, CDODA-Me-dependent downregulation of Sp1, Sp3 and Sp4 in colon cancer 
cells was proteasome-independent as observed in this study, and the effects of 
CDODA-Me were due to decreased miR-27a and the subsequent induction of ZBTB10, 
a miR-27a-regulated mRNA [683].  Moreover, in SW480 and RKO cells transfected with 
antisense-miR-27a or ZBTB10 expression plasmid, there is also a decrease in Sp1, 
Sp3, Sp4 and Sp-regulated genes [683].  This pathway was also relevant for GT-094 
which induced ZBTB10 and decreased miR-27a in colon cancer cells (Fig. 4.6 and Fig. 
4.7).  ZBTB10 is a member of the POK family of transcriptional repressors [685] and 
was first identified as an inhibitor of gastrin gene expression [686].  ZBTB10 binds to the 
GC-rich gastrin gene promoter and inhibits Sp1-dependent transactivation and 
presumably inhibits expression of Sp1, Sp3, Sp4 and Sp-regulated genes through 
similar interactions with their GC-rich promoters. 
 In ongoing studies with arsenic trioxide [662] and other pro-oxidants including 
curcumin and CDDO-Me in pancreatic cancer cells [660, 661], we have observed that 
these compounds decreased MMP and increased ROS and ROS-induced 
downregulation of Sp and Sp-regulated gene products.  Results illustrated in Fig 4.3 
and 4.4 indicate that GT-094 decreased MMP and induced ROS in RKO and SW480 
cells and this was reversed in cells cotreated with the thiol antioxidant GSH.  The 
effects of GT-094 on MMP and ROS were similar to the induction of ROS by NO-ASA in 
colon cancer cell lines [468].  However, induction of ROS by GT-094 in this study was 
also related to modulation of the miR-27a:ZBTB10-Sp1/Sp3/Sp4 axis since cotreatment 
with GSH attenuated GT-094-mediated downregulation of miR-27a and induction of 
ZBTB10 (Fig. 4.6) decreased expression of Sp1, Sp3 and Sp4 (Figs. 4.4C and 4.4D), 
183 
 
increased TUNEL staining (Figs. 4.5C and 4.5D), and decreased growth (Figs. 4.5A 
and 4.5B).  It was also apparent from the cotreatment studies (GT-094 + GSH) that 
there were cell context-dependent differences in the inhibitory effects of GSH.  For 
example, GSH almost totally reversed GT-094-mediated inhibition of RKO cell 
proliferation but only partially reversed these effects in SW480 cells (Figs. 4.5A and 
4.5B), suggesting that other GT-094-induced growth inhibitory responses were 
important in the latter cell line.  In RKO cells, 20 M GT-094 induced ZBTB10 mRNA 
but did not downregulate miR-27a (Figs. 4.6A and 4.6B), suggesting that other miRs or 
other factors contributed to expression of this gene and these are currently being 
investigated. 
 In summary, this study shows that like CDODA-Me, GT-094 decreases miR-27a 
and induces ZBTB10 expression in colon cancer cells and the subsequent 
downregulation of Sp1, Sp3, Sp4 and Sp-regulated proteins contributes to the 
anticancer activities of this compound.  Moreover, GT-094 disruption of mitochondria 
and induction of ROS are critical elements for the subsequent ROS-dependent 
downstream disruption of the miR-27a:ZBTB10-Sp transcription factor axis (Fig. 4.6C).  
In addition, this study and a previous report in pancreatic cancer cells demonstrate that 
ROS suppresses miR-27a, and we have also observed similar ROS-dependent effects 
on the miR-27a promoter.  We are currently investigating the specific cis-elements and 
trans-acting factors responsible for ROS-miR-27a interactions.  These results 
demonstrate a hitherto unknown mechanism of action for GT-094 and other NO-
NSAIDs in cancer cells (data not shown), and current studies are focused on the role of 
Sp transcription factors as targets for NO-NSAIDs and NSAIDs in cancer cells and 
tumors. 
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CHAPTER V 
PHARMACOLOGIC DOSES OF ASCORBIC ACID REPRESS SPECIFICITY 
PROTEIN (Sp) TRANSCRIPTION FACTORS AND Sp-REGULATED GENES IN 
COLON CANCER CELLS 
 
INTRODUCTION 
 Vitamin C (ascorbic acid) is an essential dietary nutrient and highly effective 
antioxidant that is a critical cofactor required for the activity of multiple enzymes.  As a 
pharmacological agent, vitamin C has a controversial history, particularly with respect to 
the effectiveness of high doses of this compound for treating the common cold and 
cancer [577, 687, 688].  Cameron, Pauling and coworkers summarized a series of 
studies on the anticancer effects of high doses of ascorbic acid and concluded that this 
regimen improved the quality of life and extended the lifespan of cancer patients [584, 
689]. In contrast, results of two trials carried out by Moertel and coworkers at the Mayo 
Clinic did not observe any benefit for patients taking vitamin C versus patients who did 
not receive the drug [587, 588].  Thus, the anticancer activity of vitamin C is 
controversial and it is possible that, in common with many other mechanism-based 
drugs, only select sub-sets of cancer patients may respond to ascorbic acid alone or in 
combination with other agents. 
 The use of vitamin C or any other drug for cancer chemotherapy is predicated, 
in part, by an understanding of the underlying mechanism of action in both in vitro and 
in vivo models.  Several studies show that vitamin C inhibits growth of a number of 
cancer cell lines [580, 587, 588, 601, 690-693], and it was recently reported that EC50 
values using the MTT reduction assays ranged from 3 to 7 mM in 5 different human 
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cancer cell lines and that both intravenous and intraperitoneal administration of 
ascorbate in mice could result in blood levels of ascorbate as high as 20 mM [694].  
Moreover, intravenous administration of ascorbate in humans can also give low mM 
concentrations of this compound in serum [596, 695].  It was also reported that ascorbic 
acid-dependent decreases in cancer cell viability was attenuated after cotreatment with 
catalase and the antioxidant N-acetylcysteine (NAC) and this observation was 
consistent with the induction of reactive oxygen species (ROS) [694].  The results also 
correlated with studies demonstrating the pro-oxidant activity of ascorbic acid and the 
identification of hydrogen peroxide in extracellular fluid of mice administered 
pharmacologic doses of ascorbic acid [578, 601, 605, 696]. 
 The pro-oxidant activity induced by ascorbic acid is comparable to that observed 
for many other anticancer drugs such as arsenic trioxide which is currently being used 
for treatment of acute promyelocetic leukemia (APL) and is also being evaluated for 
treating solid tumors [697-699].  Ongoing studies in this laboratory confirm that arsenic 
trioxide decreases mitochondrial membrane potential (MMP) and induces ROS in 
bladder and pancreatic cancer cell lines [662].  Moreover, arsenic trioxide-induced ROS 
decreased expression of specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 
and several Sp-regulated genes associated with cancer cell proliferation, survival and 
angiogenesis [662].  We therefore hypothesized that the anticancer activity of ascorbic 
acid may also be related to ROS-dependent downregulation of Sp transcription factors.  
Using colon cancer cells as a model, we have now confirmed that ascorbic acid 
decreases expression of Sp1, Sp3, Sp4 and Sp-dependent genes and these responses 
are ROS-dependent and blocked by antioxidants such as glutathione.  Similar effects 
were observed after treating colon cancer cells with other pro-oxidants such as 
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hydrogen peroxide (H2O2). This study identifies for the first time an important ascorbic 
acid-induced pathway that contributes to the pro-oxidant anticancer activity of this 
compound. 
MATERIALS AND METHODS 
Cell lines, reagents and antibodies. RKO and SW480 human colon carcinoma cell 
lines were obtained from American Type Culture Collection (Manassas, VA).  RKO and 
SW480 cells were maintained in Dulbecco‘s modified/Ham‘s F-12 (Sigma-Aldrich, St. 
Louis, MO) with phenol red supplemented with 0.22% sodium bicarbonate, 5% fetal 
bovine serum, and 10ml/L 100X antibiotic antimycotic solution (Sigma) containing 
10,000 units penicillin, 10,000 g streptomycin and 25 g amphotericin B/ml, in 0.85% 
saline.  The cells were grown in 150 cm2 culture plates in an air/CO2 (95:5) atmosphere 
at 37C and passaged approximately every 3-5 days.  All antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA), except cleaved poly (ADP) ribose 
polymerase (PARP) and c-Met (Cell Signaling Technology, Danvers, MA), Sp1 and 
VEGF-R2 (Millipore, Temecula, CA), survivin (R&D Systems, Minneapolis, MN), 
VEGFR1 (Abcam Inc. Cambridge, MA), and -actin antibodies (Sigma-Aldrich).  L-
Ascorbic acid (99%) and glutathione, 98% (-glu-cys-gly, GSH) were purchased from 
Sigma-Aldrich.  Dithiothretol (DTT, 98%) was obtained from Boehringer Mannheim 
Corp, (Indianapolis, IN). 
Cell proliferation assays. RKO and SW480 cancer cell lines were plated (3 x 104 per 
well) using DMEM:Ham‘s F-12 medium containing 2.5% charcoal stripped fetal bovine 
serum (FBS) in 12-well plates and left to attach for 24 hr.  Cells were then treated with 
either vehicle or the indicated concentrations of ascorbate (pH 7) for 3 hr and washed 
and further grown for additional 24 hr in growth medium in the absence of ascorbate.  
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Ascorbic acid was neutralized to pH 7.0 with sodium hydroxide and prepared 
immediately before use.  After 24 hr, cells were counted using a Coulter Z1 particle 
counter.  Each experiment was done in triplicate and results are expressed as means  
SE for each determination. 
WST-1 cell survival assay. RKO or SW480 cells were seeded in 96-well plates and 
then treated with H2O2 or t-butylhydroperoxide (T-BOOH) (Sigma) alone or co-treated 
with GSH for 24 hr.  The WST-1 assay kit was obtained from Roche (Indianapolis, IN) 
and the assay was carried out according to the manufacturer‘s instructions.  Cell 
viability was determined by the absorbance of the formazan product at 440 nm.  The 
rate of cell survival was calculated as the percentage of the absorbance of the treated 
samples divided by the controls.  All experiments were determined in triplicate and 
repeated at least two times and results are expressed as means  SD for each 
treatment group. 
Apoptotic and Necrotic assays. RKO and SW480 cells (10 x 104) were seeded in two 
chambered glass slides and left to attach overnight.  The apoptotic and necrotic assay 
kit was obtained from Biotium, Inc. (Hayward, CA) and contained FITC-Annexin V, 
ethidium homodimer III and Hoechst 3342.  Cells were treated with ascorbate for 3 hr 
and further grown for additional 12 hr, and the apoptotic, necrotic and healthy cell 
detection kit was used according to the instructions provided by the manufacturer for 
analysis of adherent cells. 
Western blot assays. RKO and SW480 cancer cells were seeded in DMEM:Ham‘s F-
12 medium containing 2.5% charcoal-stripped FBS.   After 24 hr, cells were treated with 
either vehicle or ascorbate for 3 hr, media was changed, and cells were incubated for 
24 hr.  Western blot analysis on whole cell lysates was determined using -actin as a 
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loading control.   Cells were cotreated with dithiothreitol (DTT) and glutathione (GSH) in 
the presence or absence of ascorbate, H2O2 or T-BOOH for the indicated times and 
harvested 24 hr after treatment, and whole cell lysates were obtained for analysis by 
western blots as previously described [632, 670, 683].  Briefly, cells were collected 
using high-salt buffer (50 mmol/L HEPES, 0.5 mol/L NaCl, 1.5 mmol/L MgCl2, 1 mmol/L 
EGTA, 10% glycerol, and 1% Triton-X-100, pH 7.5) and 10 L/mL of Protease Inhibitor 
Cocktail (Sigma Aldrich).  Protein lysates were incubated for 3 min at 100C and then 
separated by electrophoresis on 10% SDS-PAGE 120 V for 3 to 4 hr.  Protein lysates 
were transferred onto polyvinylidene difluoride (PVDF) membranes by wet 
electroblotting in a buffer containing 25 mmol/L Tris, 192 mmol/L glycine, and 20% 
methanol for 1.5 hr at 180 mÅ.  Membranes were blocked for 30 min with 5% TBST-
Blotto [10 mmol/L Tris-HCl, 150 mmol/L NaCl (pH 8.0), 0.05% Triton X-100, and 5% 
nonfat dry milk] and incubated in fresh 5% TBST-Blotto with 1:500 primary antibody 
overnight with gentle shaking at 4C.  The PVDF membrane was washed with TBST for 
10 min and then incubated with secondary antibody (1:5000) in 5% TBST-Blotto for 2 hr 
by gentle shaking.  After washing with TBST for 10 min, the membrane was incubated 
with 6 mL of chemiluminescence substrate for 1 min and exposed to Kodak image 
station 4000 mm Pro (Carestreamhealth, Woodbridge, CT). 
ROS estimation. Cellular ROS levels were evaluated with the cell permeant probe CM-
H2DCFDA (5-(and-6)-chloromethyl-2',7'
 dichlorodihydrofluorescein diacetate acetyl 
ester).  CM-H2DCFDA is nonfluorescent until removal of the acetate groups by 
intercellular esterases and oxidation occurs within the cell.  Following treatment for 12 
hr, 48-well cell culture plates containing cells were loaded with 10 M CM-H2DCFDA  
for 30 min, washed once with serum free medium, and analyzed for ROS levels using 
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Bio Tek Synergy 4 plate reader (Bio Tek Instruments, Inc., Winooski, VT) set at 480 nm 
and 525 nm excitation and emission wavelength, respectively.  Cells were then washed 
twice with PBS and fixed with methanol for 3 min at room temperature.  Methanol was 
then completely removed and 1 mg/ml Janus green was added to the cultures for 3 min.  
Following removal of Janus green, cultures were washed twice with PBS and 100 l of 
50% methanol was added to each well.  Cell counts were then determined with the 
plate reader set to an absorbance of 654 nm, and ROS intensities were then corrected 
accordingly.  Three experiments were performed and analyzed on different days using 8 
wells per treatment group. 
Statistical analysis. All statistical tests were two-sided and statistical significance in 
the differences between treatment groups was determined by analysis of variance and 
Student's t-test.  Results are expressed as means  SD for replicate (at least three) 
experiments and levels of significance are noted. 
RESULTS 
 RKO and SW480 cells were treated with 1 - 3 mM ascorbic acid for 3 hr and 
after 24 hr, cells were counted to determine effects on cell survival.  The results 
(Fig.5.1A) show that 1, 2 and 3 mM ascorbic acid significantly inhibited cell proliferation 
and the growth inhibitory concentrations were similar to those previously reported in 
other cancer cell lines [601, 694].  Growth inhibitory IC50 values were 1.62 and 1.64 mM 
in RKO and SW480 cells, respectively  The effects of ascorbate on caspase-dependent 
PARP cleavage were cell context-dependent (Fig. 5.1B).  In RKO cells, 2 and 3 mM 
ascorbate increased PARP cleavage; however, at the higher concentrations, there was 
a decrease in PARP cleavage and similar results were observed in SW480 cells.  
These results are consistent with previous studies showing that ascorbate also induces 
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necrosis in cancer cells and this is due, in part, to the induction of H2O2 which inhibits 
apoptosis (27, 28).  The cell death pathways were further investigated using a kit 
containing FITC-Annexin V, ethidium homodimer III, and Hoechst 3342 that 
simultaneously stains apoptotic cells (green), necrotic cells (red), and healthy cells 
(blue).  Compared to control (solvent-treated) RKO cells, ascorbate induced both 
apoptosis (green) and necrosis (red) and cotreatment with GSH decreased both death 
pathways (Fig. 5.1C).  Ascorbate also induced apoptosis and necrosis in SW480 cells 
and these effects were also inhibited after cotreatment with GSH, demonstrating that 
ascorbate-induced cell death is associated with its pro-oxidant activity.  Green staining 
(apoptosis) was more evident in SW480 cells, whereas necrosis (red staining) was 
more enhanced in RKO cells. Since ascorbate inhibits cell proliferation and is cytotoxic 
to colon cancer cells, we also investigated expression of several genes that mediate 
these responses.  For example, treatment of RKO and SW480 cells with 2 or 3 mM 
ascorbate resulted in decreased expression of EGFR, c-Met and cyclin D1 proteins 
(Figs. 5.2A and 5. 2B).  We also observed that ascorbate decreased levels of the 
survival genes bcl-2 and survivin in RKO and SW480 cells (Figs. 5.2C and 5.2D, 
respectively), and loss of these gene products is likely associated with induction of 
apoptosis in cancer cells as observed in the PARP cleavage and fluorescent staining 
assays (Figs. 5.1B and 5.1C).   
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Fig. 5.1. Ascorbate is cytotoxic to colon cancer cells. A: Cell growth inhibition. RKO and 
SW480 cells were treated with 1–3 mM ascorbate for 3 h and, after 24 h, cell number 
was determined as described in the Materials and Methods. Results are expressed as 
means ± SE for 3 replicate determinations, and significant (P < 0.05) growth inhibition is 
indicated (*). Induction of poly (ADP) ribose polymerase (PARP) cleavage (B) and 
necrosis and apoptosis (C) in RKO and SW480 cells. RKO and SW480 cells were 
treated with 3 mM ascorbate for 3 h and, after 24 h, cell lysates were analyzed by 
Western blots for PARP cleavage (B) or were stained with the fluorescent dye kit 
containing FITC-annexin V, ethidium homodimer III, and Hoechst 3342 and analyzed for 
apoptosis and necrosis as described in the Materials and Methods. 
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 Previous RNA interference studies in this laboratory indicate that individual 
knockdown of Sp1, Sp3 or Sp4 and their combination decreased expression of cyclin 
D1, c-Met, EGFR, bcl-2 and survivin [45, 46, 377, 410, 632, 662, 670], indicating that 
these genes are regulated by Sp1, Sp3 and Sp4 transcription factors [45, 46, 377, 410, 
632, 662, 670]. These results suggest that ascorbate may also affect expression of 
these proteins by downregulation of Sp transcription factors.  Fig. 5.3A demonstrates 
that after treatment of RKO and SW480 cells with 2 and 3 mM ascorbate, levels of Sp1, 
Sp3 and Sp4 proteins were decreased in both cells lines.  The angiogenic proteins 
VEGF, VEGFR1 and VEGFR2 are Sp-regulated genes [45, 46] and ascorbate also 
decreased expression of these proteins in RKO and SW480 cells (Fig. 5.3B) further 
confirming that Sp1, Sp3, Sp4 and Sp-regulated genes are critical targets of ascorbate 
in colon cancer cells and similar results have been observed in other cancer cell lines 
including KU7 (bladder), L3.6pL (pancreatic), and LNCaP and PC3 (prostate) cancer 
cells (data not shown).  Since ascorbate treatment results in formation of hydrogen 
peroxide (H2O2) in both in vitro and in vivo models [578, 601, 605, 696], we also 
investigated the effects of H2O2 and the pro-oxidant t-butyl hydroperoxide (T-BOOH) on 
Sp protein expression in RKO and SW480 colon cancer cells. 
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Fig. 5.2. Ascorbate-induced effects on proteins involved in cell growth and cell death. 
The effects of ascorbate on expression of epidermal growth factor receptor (EGFR), c-
Met, and cyclin D1 proteins in RKO (A) and SW480 (B) cells and also on levels of 
survivin and bcl-2 and cleaved poly (ADP) ribose polymerase in RKO (C) and SW480 
(D) cells were determined on whole cell lysates by Western blots as described in the 
Materials and Methods. Results are typical of duplicate experiments. 
 
 Both H2O2 and T-BOOH decreased expression of Sp1, Sp3 and Sp4 proteins 
and induced PARP cleavage in RKO and SW480 cells (Figs. 5.3C and 5.3D) and these 
results are comparable to the effects of ascorbate on expression of these proteins (Fig. 
5.3A). 
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Fig. 5.3. Ascorbate, H2O2, and t-butylhydroperoxide (T-BOOH) downregulate specificity protein (Sp)1, Sp3, 
and Sp4. RKO and SW480 cells were treated with ascorbate (A, B), H2O2 (C), and T-BOOH (D), and whole 
cell lysates were analyzed for Sp1, Sp3, and Sp4 proteins or vascular endothelial growth factor (VEGF), 
VEGFR1, and VEGFR2 proteins by Western blots as described in the Materials and Methods. Gels are 
typical of results obtained in multiple (2–3) experiments. Cleaved poly (ADP) ribose polymerase (PARP) 
was also determined in cells treated with H2O2 or T-BOOH. 
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 We also investigated the induction of ROS 12 hr after incubation of RKO and 
SW480 cells with ascorbate for 3 hr.  The results indicate that ROS was induced by 
ascorbate in RKO and SW480 cells at this time point and in cells cotreated with 
ascorbate plus the thiol antioxidants GSH and DTT, the ascorbate-induced ROS 
response was attenuated (Figs. 5.4A and 5.4B).  Figures 4C and 4D show that GSH 
inhibited ascorbate-induced cell death and these results also correlated with the 
inhibitory effects of GSH on ascorbate-induced inhibition of RKO and SW480 cell 
proliferation (Figs. 5.4C and 5.4D). 
 Since the antioxidant GSH inhibited ascorbate-induced cytotoxicity, we also 
investigated the role of ROS in mediating downregulation of Sp1, Sp3 and Sp4 and Sp-
regulated genes in colon cancer cells treated with 3 mM ascorbate.  Figure 5.5A shows 
that ascorbate-induced downregulation of Sp1, Sp3 and Sp4 in RKO and SW480 cells 
was attenuated after cotreatment with GSH, whereas minimal effects were observed in 
cells cotreated with DTT.  The effects of antioxidants on ascorbate-induced 
downregulation of growth inhibitory (Fig. 5.5B) and angiogenic/survival (Fig. 5.5C) gene 
products was also determined.  GSH inhibited ascorbate-induced downregulation of 
EGFR, c-Met and cyclin D1 protein expression (Fig. 5.5C) and also VEGF, VEGFR1, 
VEGFR2 and survivin protein expression (Fig. 5.5B) in RKO and SW480 cells.  DTT 
was relatively ineffective as an inhibitor in these assays and this was consistent with 
results summarized in Fig. 5.5A. 
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Fig. 5.4. Antioxidants inhibit ascorbate-induced ROS and growth inhibition. Induction of 
ROS in RKO (A) and SW480 (B) cells. Cells were treated with buffer, 3 mM ascorbate 
alone or in combination with antioxidants and, after 12 h, ROS was determined as 
described in the Materials and Methods. Cell proliferation in RKO (C) and SW480 (D) 
cells. Cells were treated with DMSO, ascorbate alone, or in combination with 
antioxidants (3 h) and, after 24 h, cell numbers were counted as described in the 
Materials and Methods. Results (A, B) are means ± SE for at least 3 separate 
experiments per treatment group and significant (P < 0.05) responses induced by 
ascorbate (*) and inhibited after cotreatment with antioxidants (**) are indicated. 
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Fig. 5.5. Antioxidants inhibit ascorbate-induced repression of specificity protein (Sp)1, Sp3, Sp4, 
and Sp-regulated gene products. RKO and SW480 cells were treated with 3 mM ascorbate for 3 
h in the presence or absence of thiol antioxidants and, after 24 h, the expression of Sp1, Sp3, 
and Sp4 proteins (A), Sp-regulated growth promoting (B), and angiogenic (C) proteins were 
determined by Western blot analysis of whole cell lysates. The blots are representative of 
replicated (2–3) experiments. GSH indicates glutathione; DTT, dithiothretol. 
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 The role of antioxidants in attenuating the effects of H2O2 and T-BOOH were 
also investigated.  Figure 6A shows that H2O2 and T-BOOH inhibit growth of RKO cells 
and cotreatment with the antioxidants significantly blocks the growth inhibitory effects of 
the pro-oxidants.  Similar results were observed in SW480 cells (Fig. 5.6A).  Treatment 
of RKO and SW480 cells with 150 M H2O2
 (Fig. 5.6B) or 160 M T-BOOH (Fig. 5.6C) 
decreased expression of Sp1, Sp3, Sp4 and cyclin D1 (an Sp-regulated gene); 
however, cotreatment with thiol antioxidants (GSH or DTT) inhibited H2O2-mediated 
effects and GSH blocked T-BOOH-dependent downregulation of Sp1, Sp3, Sp4 and 
cyclin D1 (Fig. 5.6C).  Thus, ascorbate and prototypical pro-oxidants such as H2O2 and 
T-BOOH inhibit growth of colon cancer cells, and this is accompanied by decreased 
expression of Sp1, Sp3 and Sp4 transcription factors and Sp-regulated genes that are 
important for to cancer cell growth (c-Met, EGFR, cyclin D1) and angiogenesis (VEGF, 
VEGFR1 and VEGFR2).  This suggests that the anticancer activity of ascorbate is due, 
in part, to ROS-dependent downregulation of Sp transcription factors. 
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Fig. 5.6. Antioxidants block H2O2- and T-BOOH-induced responses in colon cancer cells. A: Cell 
proliferation. RKO and SW480 cells were treated with H2O2 (24 h) or T-BOOH (24 h) alone or in 
the presence of antioxidants. Cells were then counted as described in the Materials and 
Methods. Results are expressed as means ± SE for at least 3 replicate experiments for each 
treatment group and significant (P < 0.05) H2O2- and t-butylhydroperoxide (T-BOOH)-induced 
responses (*) and inhibition by antioxidant (**) are indicated. Effects of antioxidants on H2O2 (B) 
and T-BOOH (C)-dependent downregulation of Sp transcription factors. Cells were treated as 
described in (A) and whole cell lysates were analyzed by Western blots. Gels are typical of 
replicate (at least 2) experiments. GSH indicates glutathione; DTT, dithiothretol. 
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DISCUSSION 
 Sp/Krüppel-like factors (KLFs) are an important family of transcription factors 
that regulate mammalian and viral genes through high affinity interactions with GC-rich 
promoter elements [339, 360, 369].  Sp/KLF proteins contain three zinc fingers in their 
C-terminal DNA-binding domains and Sp1 was the first transcription factor identified 
[700].  Sp1 and other Sp transcription factors are critically important in embryonic 
development [339, 360, 369]; however, their expression decreases with age [366, 367, 
668].  Studies in this laboratory have demonstrated high expression of Sp1, Sp3 and 
Sp4 proteins in cancer cell lines and in tumors (xenografts) but minimal levels were 
detected in non-tumor tissues in rodent models [632, 671, 683, 684] and in cells [518], 
and the differential expression contributes to the selectivity of agents that target Sp 
transcription factors.  Lou and coworkers showed differences in expression of Sp1 in 
normal human fibroblasts (low), a non-transformed immortalized cell line (medium), and 
an H-Ras transformed cell line (high), and oncogene- or carcinogen-induced 
transformation of human fibroblasts resulted in an 8- to 18-fold increase in Sp1 protein 
[373].  Moreover, knockdown of Sp1 in these transformed fibroblasts markedly 
decreased their tumorigenicity in mouse xenografts [373].  RNA interference studies in 
which Sp1, Sp3 or Sp4 are knocked down individually or in combination also decreased 
expression of several Sp-regulated genes involved in cancer cell growth (c-Met, EGFR, 
cyclin D1), survival (survivin and bcl-2), and angiogenesis (VEGF, VEGFR1 and 
VEGFR2) [45, 46, 377, 410, 632, 662, 670].  These results clearly demonstrate the pro-
oncogenic activity of Sp transcription factors and their potential importance as a drug 
target for cancer chemotherapy. 
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 Ongoing studies with arsenic trioxide show that this anticancer drug induced 
ROS and ROS-dependent downregulation of Sp1, Sp3, Sp4 and Sp-regulated genes in 
several different cancer cell lines including RKO and SW480 colon cancer cells [662].  
Ascorbate has also previously been identified as a pro-oxidant drug that inhibits growth 
of multiple cancer cell lines; however, the underlying mechanisms of action of this 
compound are unclear.  Using RKO and SW480 colon cancer cells as models, it was 
apparent that ascorbate inhibited cell proliferation and induced cell death was due to 
both necrosis and apoptosis (Fig. 5.1), and these results are consistent with previous 
studies [580, 601, 690-694].  A survey of 43 cancer cell lines demonstrate variability in 
the IC50 values for growth inhibition by ascorbate (low mM to > 10 mM) [601] and our 
results suggest that RKO and SW480 cells are among the more sensitive cancer cell 
lines [601].  Induction of apoptosis was somewhat variable between the cell lines, even 
though ascorbate significantly decreased expression of the antiapoptotic genes bcl-2 
and survivin (Fig. 5.2) in both cell lines and this may be due, in part, to the reported 
inhibitory effects of H2O2 on apoptosis [601, 605, 696].  However, the effects of 
ascorbate on bcl-2, survivin, cyclin D1, c-Met, EGFR, VEGF, VEGFR1 and VEGFR2 
suggested that the underlying anticancer activity of this compounds may be due, in part, 
to targeting downregulation of Sp1, Sp3 and Sp4 transcription factors that are 
overexpressed in cancer cell lines and tumors [373, 518, 671, 683, 684].  Other 
compounds such as arsenic trioxide, curcumin and some triterpenoid anticancer agents 
[518, 632, 662, 671, 683] decrease expression of many of the same gene products 
downregulated by ascorbate (Fig. 5.2), and RNA interference studies show that 
expression of these genes is regulated by Sp1, Sp3 and Sp4 in cancer cells [45, 46, 
377, 410, 632, 670].  Not surprisingly, we also observed that ascorbate decreased 
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expression of Sp1, Sp3 and Sp4 proteins in RKO and SW480 cells (Fig. 5.3), and this 
response correlated with the downregulation of several Sp-regulated genes (Fig. 5.2).  
However, it should also be noted that 1 mM ascorbate decreased colon cancer cell 
growth, whereas  2 mM ascorbate was required for decreased expression of Sp1, Sp3 
and Sp4 proteins.  Thus, ascorbate-induced Sp downregulation is not the only pathway 
associated with the anticancer activity of this compound. 
 Ascorbate-induced cytotoxicity has been associated with generation of H2O2 
[601, 605, 662, 696-699, 701, 702], and our results with the pro-oxidants H2O2 and T-
BOOH show that like ascorbate, these compounds are also cytotoxic and decrease 
proliferation and downregulate Sp1, Sp3 and Sp4 expression in RKO and SW480 cells 
(Figs. 5.3 and 5.6).  The linkage between the pro-oxidant activities of ascorbate, H2O2 
and T-BOOH and their effects on cell proliferation and expression of Sp transcription 
factors was confirmed in studies showing that these effects were partially reversed in 
cells after cotreatment with the antioxidant GSH which also exhibits many other 
activities (Figs. 5.5 and 5.6).  Previous studies with hydrogen peroxide in normal cells 
and in cancer cell lines were mixed and have reported both increased and decreased 
effects on Sp1 and/or Sp-regulated genes [703-707].  However, these studies primarily 
attributed these effects to modulation of Sp1 phosphorylation or Sp1 DNA binding.  
Results in this paper clearly demonstrate that ascorbate and pro-oxidants induced 
downregulation of Sp1, Sp3 and Sp4 proteins and Sp-regulated gene products, and we 
have observed similar results for arsenic trioxide [662].  The effectiveness of DTT as an 
antioxidant was variable since GSH but not DTT inhibited ascorbate-induced 
downregulation of Sp1, Sp3 and Sp4 proteins (Fig. 5.5A), whereas both GSH and DTT 
blocked downregulation of Sp proteins by H2O2 (Fig. 5.6B).  The specificity of DTT and 
203 
 
other antioxidants for inhibiting drug-induced Sp downregulation has previously been 
observed [662]. 
 In previous studies, the triterpenoid methyl 2-cyano-3,11-dioxo-18-olean-1,12-
dien-30-oate (CDODA-Me) decreased expression of Sp1, Sp3, Sp4 and Sp-regulated 
genes through induction of an Sp-repressor protein ZBTB10 in RKO and SW480 cells 
[683].  The effects of CDODA-Me were dependent on downregulation of microRNA-27a 
(miR-27a) which suppresses ZBTB10 [683, 684].  Ascorbate did not affect expression of 
miR-27a or ZBTB10 in RKO and SW480 cells, and other possible downstream targets 
are currently being investigated.  In summary, results of this study show for the first time 
that the anticancer activity of ascorbate is due, in part, to downregulation of Sp1, Sp3 
and Sp4 transcription factors and Sp-regulated genes.  Many Sp-dependent genes such 
as EGFR, c-Met, bcl-2, VEGF and its receptors are themselves drug targets in specific 
cancers because of their critical role in tumor growth, survival and angiogenesis.  
Results of this study with ascorbate and previous reports with arsenic trioxide, 
curcumin, betulinic acid and CDODA-Me [518, 632, 662, 671, 683] demonstrate that 
many of these genes can be repressed at the same time by targeting Sp transcription 
factors, and we are currently developing this approach for single agent and combined 
therapies for cancer treatment. 
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CHAPTER VI 
SUMMARY 
 
 Previous studies from our laboratory investigated the mechanisms of action of 
several synthetic and natural compounds such as tolfenamic acid, betulinic acid and 
curcumin as anticancer drugs that inhibit proliferation of pancreatic, prostate and 
bladder cancer cells in culture and tumor growth in murine xenograft or orthotopic 
models, respectively [518, 632, 671]. These compounds also decrease expression of 
Sp1, Sp3 and Sp4 proteins and several Sp-dependent genes and proteins such as 
VEGF, VEGFR1, survivin, cyclin D1 and bcl-2, and these responses contribute to their 
anticancer activity. Here we demonstrate the anticancer activity of aspirin, tolfenamic 
acid, GT-094 and ascorbic acid in colon cancer cells and in vivo animal models. 
 Aspirin is a widely used NSAID for treatment of pain, fever and inflammation and 
it has been extensively investigated as a chemopreventive and chemotherapeutic agent 
in cancer. Aspirin use is associated with decreased incidence of several cancers such 
as colon, breast, esophagus, lung, stomach and ovarian cancers; however, the 
mechanism of action of aspirin as anticancer agent is still unknown. Using colon cancer 
cells as a model, we investigated the mechanism of action of aspirin as 
chemotherapeutic agent. Aspirin inhibited the growth of RKO, SW480, HT-29 and HCT-
116 colon cancer cells and also downregulated Sp1, Sp3 and Sp4 and Sp-dependent 
genes including the angiogenic, proliferative and survival genes, NF-κB-p65 and β-
catenin. Aspirin induces apoptosis in all cell lines and inhibited tumor growth in athymic 
nude mice bearing RKO cells as xenografts. This study demonstrates that aspirin 
activates caspases and caspase-dependent proteolysis of Sp1, Sp3 and Sp4 proteins in 
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colon cancer cells and tumors and, this was accompanied by downregulation of several 
Sp-regulated genes.  Aspirin-induced Sp downregulation was due to cellular depletion 
of zinc and activation of nuclear caspases. Based on the similar effects of aspirin and 
salicylate as anticancer agents [615, 622, 623, 650] and the high serum 
salicylate/aspirin ratios observed in patients after treatment with aspirin [637], the 
cancer chemotherapeutic effects of aspirin [615-617, 619, 620] may primarily be due to 
the salicylate metabolite. 
 Tolfenamic acid has been used for pain relief as an anti-inflammatory drug [671, 
672] and is currently being studied as an anticancer agent. TA induces proteosome-
dependent degradation of transcription factors Sp1, Sp3, Sp4 and Sp-regulated genes 
in pancreatic cancer cells [518] and in this study we have investigated the effects of TA 
on colon cancer using both in vitro and in vivo models. TA inhibited colon cancer cell 
proliferation and cell viability and induced apoptosis in four different colon cancer cells, 
RKO, SW480, HT-29 and HCT-116. TA also decreased expression of Sp1, Sp3 and 
Sp4 and also several growth promoting (CD1, c-MET), angiogenic (VEGF and VEGFR) 
survival (survivin and bcl-2) and inflammatory (p65/p50) genes. The effects of TA in 
colon cancer cells and tumors was comparable to those observed for TA in other cancer 
cells, however, the mechanism of TA-induced effects on Sp protein expression differed 
from previous studies.  TA-induced downregulation of nuclear Sp1, Sp3 and Sp4 and 
Sp dependent genes is mediated by activation of caspases and this contrasts to the 
proteasome dependent and independent effects of TA in other cancer cells [518-521]. 
Results of this study show that activation of caspases by TA is required for Sp protein 
degradation and current studies are focused on identifying the mechanisms of TA-
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induced caspase activation and the rationale for specifically targeting Sp1, Sp3 and Sp4 
proteins.  
 GT-094 is a prototypical NO-NSAID that acts as antiinflammatory, 
antiproliferative and cytoprotective agent in vitro and in vivo models [563]. In this study, 
we investigated the action of GT-094 in colon cancer cells and GT-094 inhibited RKO 
and SW480 colon cancer cell growth, induced PARP cleavage, and TUNEL staining 
consistent with induction of apoptosis. Moreover, GT-094 decreased expression of Sp1, 
Sp3 and Sp4 and Sp-dependent antiapoptotic survivin and bcl-2 proteins and this was 
consistent with decreased expression of other Sp-regulated gene products that play a 
role in cell growth (cyclin D1, c-Met, and EGFR) and angiogenesis (VEGF and 
VEGFR1). GT-094 also decreases mitochondrial membrane potential and induced ROS 
and this was accompanied by downregulation of miR-27a and upregulation of ZBTB-10, 
an Sp repressor. Thus like CDODA-Me [661] GT-094 inhibits miR-27a-dependent 
suppression of ZBTB10 in colon cancer cells and the transcriptional repressor 
subsequently downregulates expression of Sp1, Sp3, Sp4, and Sp-regulated proteins 
and this significantly contributes to the anticancer activities of this compound. Moreover, 
GT-094-mediated perturbation of mitochondria and induction of ROS are critical 
elements for the subsequent ROS-dependent disruption of the miR-27a:ZBTB10-Sp 
transcription factor axis. We are currently investigating the specific cis-elements and 
trans-acting factors responsible for ROS-dependent repression of miR-27a. 
  Ascorbate has previously been identified as a prooxidant drug that inhibits 
growth of multiple cancer cell lines; however, the underlying mechanisms of action of 
this compound are unclear. Using RKO and SW480 colon cancer cells as models, it 
was apparent that ascorbate inhibited cell proliferation and induced cell death was due 
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to both necrosis and apoptosis and these results are consistent with previous studies 
[580, 601, 690-694]. Induction of apoptosis was somewhat variable between the cell 
lines, even though ascorbate significantly decreased expression of the antiapoptotic 
genes bcl-2 and survivin in RKO and SW480 cells and this may be due, in part, to the 
reported inhibitory effects of H2O2 on apoptosis [601, 605, 696]. Not surprisingly, we 
also observed that ascorbate decreased expression of Sp1, Sp3, and Sp4 proteins in 
RKO and SW480 cells and this response was accompanied by downregulation of 
several Sp-regulated genes such as bcl-2, survivin, cyclin D1, c-Met, EGFR, VEGF, 
VEGFR1, and VEGFR2 suggesting that the underlying anticancer activity of this 
compounds may be due, in part, to targeting downregulation of Sp1, Sp3, and Sp4 
transcription factors that are overexpressed in cancer cell lines and tumors [373, 518, 
671, 683, 684]. Ascorbate-induced cytotoxicity has been associated with generation of 
H2O2 [601, 605, 662, 696-699, 701, 702], and our results with the prooxidants H2O2 and 
T-BOOH show that like ascorbate these compounds are also cytotoxic and decrease 
colon proliferation and downregulate Sp1, Sp3, and Sp4 expression in RKO and SW480 
cells. The linkage between the prooxidant activities of ascorbate, H2O2, and T-BOOH 
and their effects on cell proliferation and expression of Sp transcription factors was 
confirmed in studies showing that these effects were partially reversed in cells after 
cotreatment with the antioxidant GSH, which also exhibits many other activities. 
However, Unlike CDDO-Me and GT-094 [572, 661], ascorbate did not affect expression 
of miR-27a or ZBTB10 in RKO and SW480 cells, and other possible downstream 
targets are currently being investigated. 
  
208 
 
REFERENCES 
 
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of 
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 
127(12):2893-2917. 
 
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 
2012, 62(1):10-29. 
 
3. Yokota J: Tumor progression and metastasis. Carcinogenesis 2000, 21(3):497-
503. 
 
4. Boutwell RK: Some biological aspects of skin carcinogenisis. Prog Exp Tumor 
Res 1964, 4:207-250. 
 
5. McCormick PJ, Bertram JS: Differential cell cycle phase specificity for neoplastic 
transformation and mutation to ouabain resistance induced by N-methyl-N'-nitro-
N-nitrosoguanidine in synchronized C3H10T 1/2 C18 cells. Proc Natl Acad Sci U 
S A 1982, 79(14):4342-4346. 
 
6. Quintanilla M, Brown K, Ramsden M, Balmain A: Carcinogen-specific mutation 
and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986, 
322(6074):78-80. 
 
7. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human 
cancers. Science 1991, 253(5015):49-53. 
 
8. Weihrauch M, Bader M, Lehnert G, Wittekind C, Tannapfel A, Wrbitzky R: 
Carcinogen-specific mutation pattern in the p53 tumour suppressor gene in UV 
radiation-induced basal cell carcinoma. Int Arch Occup Environ Health 2002, 
75(4):272-276. 
 
9. Loeb LA: A mutator phenotype in cancer. Cancer Res 2001, 61(8):3230-3239. 
 
10. Rundhaug JE, Fischer SM: Molecular mechanisms of mouse skin tumor 
Promotion. Cancers (Basel) 2010, 2(2):436-482. 
 
11. Sarasin A: An overview of the mechanisms of mutagenesis and carcinogenesis. 
Mutat Res 2003, 544(2-3):99-106. 
 
12. Yuspa SH, Dlugosz AA, Denning MF, Glick AB: Multistage carcinogenesis in the 
skin. J Investig Dermatol Symp Proc 1996, 1(2):147-150. 
 
13. Trosko JE: Commentary: is the concept of "tumor promotion" a useful paradigm? 
Mol Carcinog 2001, 30(3):131-137. 
209 
 
14. Pitot HC: The molecular determinants of carcinogenesis. Symp Fundam Cancer 
Res 1986, 39:187-196. 
 
15. Dixon K, Kopras E: Genetic alterations and DNA repair in human 
carcinogenesis. Semin Cancer Biol 2004, 14(6):441-448. 
 
16. Hawighorst T, Velasco P, Streit M, Hong YK, Kyriakides TR, Brown LF, 
Bornstein P, Detmar M: Thrombospondin-2 plays a protective role in multistep 
carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J 2001, 
20(11):2631-2640. 
 
17. Sargent L, Xu YH, Sattler GL, Meisner L, Pitot HC: Ploidy and karyotype of 
hepatocytes isolated from enzyme-altered foci in two different protocols of 
multistage hepatocarcinogenesis in the rat. Carcinogenesis 1989, 10(2):387-
391. 
 
18. Nowell PC: Mechanisms of tumor progression. Cancer Res 1986, 46(5):2203-
2207. 
 
19. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 
1990, 61(5):759-767. 
 
20. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100(1):57-70. 
 
21. Zhou W, Goodman SN, Galizia G, Lieto E, Ferraraccio F, Pignatelli C, Purdie 
CA, Piris J, Morris R, Harrison DJ et al: Counting alleles to predict recurrence of 
early-stage colorectal cancers. Lancet 2002, 359(9302):219-225. 
 
22. Leber MF, Efferth T: Molecular principles of cancer invasion and metastasis 
(review). Int J Oncol 2009, 34(4):881-895. 
 
23. Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin 
Invest 2009, 119(6):1420-1428. 
 
24. Kerbel RS, Viloria-Petit A, Okada F, Rak J: Establishing a link between 
oncogenes and tumor angiogenesis. Mol Med 1998, 4(5):286-295. 
 
25. Herzig M, Savarese F, Novatchkova M, Semb H, Christofori G: Tumor 
progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-
mediated Wnt signaling. Oncogene 2007, 26(16):2290-2298. 
 
26. Guilford P: E-cadherin downregulation in cancer: fuel on the fire? Mol Med 
Today 1999, 5(4):172-177. 
 
27. Gupta PB, Chaffer CL, Weinberg RA: Cancer stem cells: mirage or reality? Nat 
Med 2009, 15(9):1010-1012. 
 
210 
 
28. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 
144(5):646-674. 
 
29. Oliveira PA, Colaco A, Chaves R, Guedes-Pinto H, De-La-Cruz PL, Lopes C: 
Chemical carcinogenesis. An Acad Bras Cienc 2007, 79(4):593-616. 
 
30. Cheng N, Chytil A, Shyr Y, Joly A, Moses HL: Transforming growth factor-beta 
signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in 
mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res 
2008, 6(10):1521-1533. 
 
31. Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, Smith DA, 
Zhang H, Komisopoulou E, Huang J et al: Oncogene-specific activation of 
tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci 
U S A 2012, 109(5):1643-1648. 
 
32. Davies MA, Samuels Y: Analysis of the genome to personalize therapy for 
melanoma. Oncogene 2010, 29(41):5545-5555. 
 
33. Jiang BH, Liu LZ: PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv 
Cancer Res 2009, 102:19-65. 
 
34. Burkhart DL, Sage J: Cellular mechanisms of tumour suppression by the 
retinoblastoma gene. Nat Rev Cancer 2008, 8(9):671-682. 
 
35. Lipinski MM, Jacks T: The retinoblastoma gene family in differentiation and 
development. Oncogene 1999, 18(55):7873-7882. 
 
36. Ghebranious N, Donehower LA: Mouse models in tumor suppression. 
Oncogene 1998, 17(25):3385-3400. 
 
37. Junttila MR, Evan GI: p53--a Jack of all trades but master of none. Nat Rev 
Cancer 2009, 9(11):821-829. 
 
38. Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 
35(4):495-516. 
 
39. Blasco MA: Telomeres and human disease: ageing, cancer and beyond. Nat 
Rev Genet 2005, 6(8):611-622. 
 
40. Artandi SE, DePinho RA: Telomeres and telomerase in cancer. Carcinogenesis 
2010, 31(1):9-18. 
 
41. Raynaud CM, Hernandez J, Llorca FP, Nuciforo P, Mathieu MC, Commo F, 
Delaloge S, Sabatier L, Andre F, Soria JC: DNA damage repair and telomere 
length in normal breast, preneoplastic lesions, and invasive cancer. Am J Clin 
Oncol 2010, 33(4):341-345. 
 
211 
 
42. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic 
switch during tumorigenesis. Cell 1996, 86(3):353-364. 
 
43. Shinkaruk S, Bayle M, Lain G, Deleris G: Vascular endothelial cell growth factor 
(VEGF), an emerging target for cancer chemotherapy. Curr Med Chem 
Anticancer Agents 2003, 3(2):95-117. 
 
44. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 
2002, 29(6 Suppl 16):15-18. 
 
45. Abdelrahim M, Smith R, 3rd, Burghardt R, Safe S: Role of Sp proteins in 
regulation of vascular endothelial growth factor expression and proliferation of 
pancreatic cancer cells. Cancer Res 2004, 64(18):6740-6749. 
 
46. Higgins KJ, Abdelrahim M, Liu S, Yoon K, Safe S: Regulation of vascular 
endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp 
proteins. Biochem Biophys Res Commun 2006, 345(1):292-301. 
 
47. Klymkowsky MW, Savagner P: Epithelial-mesenchymal transition: a cancer 
researcher's conceptual friend and foe. Am J Pathol 2009, 174(5):1588-1593. 
 
48. Johnsen M, Lund LR, Romer J, Almholt K, Dano K: Cancer invasion and tissue 
remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell 
Biol 1998, 10(5):667-671. 
 
49. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Hofler H, Becker 
KF: Differential expression of the epithelial-mesenchymal transition regulators 
snail, SIP1, and twist in gastric cancer. Am J Pathol 2002, 161(5):1881-1891. 
 
50. Tenesa A, Dunlop MG: New insights into the aetiology of colorectal cancer from 
genome-wide association studies. Nat Rev Genet 2009, 10(6):353-358. 
 
51. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA 
Cancer J Clin 2009, 59(4):225-249. 
 
52. Hawk ET, Levin B: Colorectal cancer prevention. J Clin Oncol 2005, 23(2):378-
391. 
 
53. Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, 
Woodward M: The impact of dietary and lifestyle risk factors on risk of colorectal 
cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 
2009, 125(1):171-180. 
 
54. Eaden JA, Abrams KR, Mayberry JF: The risk of colorectal cancer in ulcerative 
colitis: a meta-analysis. Gut 2001, 48(4):526-535. 
 
55. Itzkowitz SH, Harpaz N: Diagnosis and management of dysplasia in patients 
with inflammatory bowel diseases. Gastroenterology 2004, 126(6):1634-1648. 
212 
 
56. Triantafillidis JK, Nasioulas G, Kosmidis PA: Colorectal cancer and inflammatory 
bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and 
prevention strategies. Anticancer Res 2009, 29(7):2727-2737. 
 
57. Jass JR: Colorectal cancer: a multipathway disease. Crit Rev Oncog 2006, 12(3-
4):273-287. 
 
58. Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol 2011, 
6:479-507. 
 
59. Bodmer W: The somatic evolution of cancer. The Harveian Oration of 1996. J R 
Coll Physicians Lond 1997, 31(1):82-89. 
 
60. Goel GA, Kandiel A, Achkar JP, Lashner B: Molecular pathways underlying IBD-
associated colorectal neoplasia: therapeutic implications. Am J Gastroenterol 
2011, 106(4):719-730. 
 
61. Lakatos PL, Lakatos L: Risk for colorectal cancer in ulcerative colitis: changes, 
causes and management strategies. World J Gastroenterol 2008, 14(25):3937-
3947. 
 
62. Jass JR: Classification of colorectal cancer based on correlation of clinical, 
morphological and molecular features. Histopathology 2007, 50(1):113-130. 
 
63. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye 
JD, Schapiro M, Bond JH, Panish JF et al: Prevention of colorectal cancer by 
colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 
1993, 329(27):1977-1981. 
 
64. Rex DK, Lehman GA, Ulbright TM, Smith JJ, Pound DC, Hawes RH, Helper DJ, 
Wiersema MJ, Langefeld CD, Li W: Colonic neoplasia in asymptomatic persons 
with negative fecal occult blood tests: influence of age, gender, and family 
history. Am J Gastroenterol 1993, 88(6):825-831. 
 
65. Rustgi AK: The genetics of hereditary colon cancer. Genes Dev 2007, 
21(20):2525-2538. 
 
66. Terzic J, Grivennikov S, Karin E, Karin M: Inflammation and colon cancer. 
Gastroenterology 2010, 138(6):2101-2114 e2105. 
 
67. Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med 2003, 
348(10):919-932. 
 
68. Galiatsatos P, Foulkes WD: Familial adenomatous polyposis. Am J 
Gastroenterol 2006, 101(2):385-398. 
 
69. Segditsas S, Tomlinson I: Colorectal cancer and genetic alterations in the Wnt 
pathway. Oncogene 2006, 25(57):7531-7537. 
213 
 
70. Polakis P: The many ways of Wnt in cancer. Curr Opin Genet Dev 2007, 
17(1):45-51. 
 
71. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996, 
87(2):159-170. 
 
72. Aoki K, Taketo MM: Adenomatous polyposis coli (APC): a multi-functional tumor 
suppressor gene. J Cell Sci 2007, 120(Pt 19):3327-3335. 
 
73. Moon RT, Kohn AD, De Ferrari GV, Kaykas A: WNT and beta-catenin signalling: 
diseases and therapies. Nat Rev Genet 2004, 5(9):691-701. 
 
74. Huang M, Wang Y, Sun D, Zhu H, Yin Y, Zhang W, Yang S, Quan L, Bai J, 
Wang S et al: Identification of genes regulated by Wnt/beta-catenin pathway and 
involved in apoptosis via microarray analysis. BMC Cancer 2006, 6:221. 
 
75. Mosimann C, Hausmann G, Basler K: Beta-catenin hits chromatin: regulation of 
Wnt target gene activation. Nat Rev Mol Cell Biol 2009, 10(4):276-286. 
 
76. Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G, 
Meeldijk J, Robertson J, van de Wetering M, Pawson T et al: Beta-catenin and 
TCF mediate cell positioning in the intestinal epithelium by controlling the 
expression of EphB/ephrinB. Cell 2002, 111(2):251-263. 
 
77. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van 
der Horn K, Batlle E, Coudreuse D, Haramis AP et al: The beta-catenin/TCF-4 
complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 
2002, 111(2):241-250. 
 
78. Warthin AS: Heredity with reference to carcinoma - As shown by the study of the 
cases examined in the Pathological Laboratory of the University of Michigan, 
1895-1913. Arch Intern Med 1913, 12(5):546-555. 
 
79. Lynch HT, Krush AJ: Cancer family "G" revisited: 1895-1970. Cancer 1971, 
27(6):1505-1511. 
 
80. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ: Hereditary factors 
in cancer. Study of two large midwestern kindreds. Arch Intern Med 1966, 
117(2):206-212. 
 
81. Lynch HT, Lynch JF: What the physician needs to know about Lynch syndrome: 
an update. Oncology (Williston Park) 2005, 19(4):455-463; discussion 463-454, 
466, 469. 
 
82. Peltomaki P: Role of DNA mismatch repair defects in the pathogenesis of 
human cancer. J Clin Oncol 2003, 21(6):1174-1179. 
214 
 
83. Valentini AM, Armentano R, Pirrelli M, Caruso ML: Chemotherapeutic agents for 
colorectal cancer with a defective mismatch repair system: the state of the art. 
Cancer Treat Rev 2006, 32(8):607-618. 
 
84. Pors K, Patterson LH: DNA mismatch repair deficiency, resistance to cancer 
chemotherapy and the development of hypersensitive agents. Curr Top Med 
Chem 2005, 5(12):1133-1149. 
 
85. Xu Y, Pasche B: TGF-beta signaling alterations and susceptibility to colorectal 
cancer. Hum Mol Genet 2007, 16 Spec No 1:R14-20. 
 
86. Massague J, Blain SW, Lo RS: TGFbeta signaling in growth control, cancer, and 
heritable disorders. Cell 2000, 103(2):295-309. 
 
87. Biswas S, Chytil A, Washington K, Romero-Gallo J, Gorska AE, Wirth PS, 
Gautam S, Moses HL, Grady WM: Transforming growth factor beta receptor 
type II inactivation promotes the establishment and progression of colon cancer. 
Cancer Res 2004, 64(14):4687-4692. 
 
88. Miele L: Notch signaling. Clin Cancer Res 2006, 12(4):1074-1079. 
 
89. Rubin LL, de Sauvage FJ: Targeting the Hedgehog pathway in cancer. Nat Rev 
Drug Discov 2006, 5(12):1026-1033. 
 
90. Kalderon D: Transducing the hedgehog signal. Cell 2000, 103(3):371-374. 
 
91. Qualtrough D, Buda A, Gaffield W, Williams AC, Paraskeva C: Hedgehog 
signalling in colorectal tumour cells: induction of apoptosis with cyclopamine 
treatment. Int J Cancer 2004, 110(6):831-837. 
 
92. Douard R, Moutereau S, Pernet P, Chimingqi M, Allory Y, Manivet P, Conti M, 
Vaubourdolle M, Cugnenc PH, Loric S: Sonic Hedgehog-dependent proliferation 
in a series of patients with colorectal cancer. Surgery 2006, 139(5):665-670. 
 
93. Oniscu A, James RM, Morris RG, Bader S, Malcomson RD, Harrison DJ: 
Expression of Sonic hedgehog pathway genes is altered in colonic neoplasia. J 
Pathol 2004, 203(4):909-917. 
 
94. Monzo M, Moreno I, Artells R, Ibeas R, Navarro A, Moreno J, Hernandez R, 
Granell M, Pie J: Sonic hedgehog mRNA expression by real-time quantitative 
PCR in normal and tumor tissues from colorectal cancer patients. Cancer Lett 
2006, 233(1):117-123. 
 
95. Barbacid M: ras genes. Annu Rev Biochem 1987, 56:779-827. 
 
96. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG: Post-translational 
modifications and regulation of the RAS superfamily of GTPases as anticancer 
targets. Nat Rev Drug Discov 2007, 6(7):541-555. 
215 
 
 
97. Bos JL: ras oncogenes in human cancer: a review. Cancer Res 1989, 
49(17):4682-4689. 
 
98. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, 
Landi B, Louvet C et al: KRAS mutations as an independent prognostic factor in 
patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 
2008, 26(3):374-379. 
 
99. Arteaga CL: The epidermal growth factor receptor: from mutant oncogene in 
nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001, 
19(18 Suppl):32S-40S. 
 
100. Lee JJ, Chu E: First-line use of anti-epidermal growth factor receptor 
monoclonal antibodies in metastatic colorectal cancer. Clin Colorectal Cancer 
2007, 6 Suppl 2:S42-46. 
 
101. Vokes EE, Chu E: Anti-EGFR therapies: clinical experience in colorectal, lung, 
and head and neck cancers. Oncology (Williston Park) 2006, 20(5 Suppl 2):15-
25. 
 
102. Kim ES, Khuri FR, Herbst RS: Epidermal growth factor receptor biology (IMC-
C225). Curr Opin Oncol 2001, 13(6):506-513. 
 
103. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD: Cellular 
function of phosphoinositide 3-kinases: implications for development, 
homeostasis, and cancer. Annu Rev Cell Dev Biol 2001, 17:615-675. 
 
104. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in 
human cancer. Nat Rev Cancer 2002, 2(7):489-501. 
 
105. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-
Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 
30(2):193-204. 
 
106. LoPiccolo J, Granville CA, Gills JJ, Dennis PA: Targeting Akt in cancer therapy. 
Anticancer Drugs 2007, 18(8):861-874. 
 
107. Sharma S, Kelly TK, Jones PA: Epigenetics in cancer. Carcinogenesis 2010, 
31(1):27-36. 
 
108. Suzuki MM, Bird A: DNA methylation landscapes: provocative insights from 
epigenomics. Nat Rev Genet 2008, 9(6):465-476. 
 
109. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer 2004, 
4(2):143-153. 
 
216 
 
110. van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG: Colorectal cancer 
epigenetics: complex simplicity. J Clin Oncol 2011, 29(10):1382-1391. 
 
111. Miranda TB, Jones PA: DNA methylation: the nuts and bolts of repression. J Cell 
Physiol 2007, 213(2):384-390. 
 
112. Herman JG, Baylin SB: Gene silencing in cancer in association with promoter 
hypermethylation. N Engl J Med 2003, 349(21):2042-2054. 
 
113. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M: Reduced genomic 5-
methylcytosine content in human colonic neoplasia. Cancer Res 1988, 
48(5):1159-1161. 
 
114. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP: Hypomethylation of DNA 
from benign and malignant human colon neoplasms. Science 1985, 
228(4696):187-190. 
 
115. Kim MS, Lee J, Sidransky D: DNA methylation markers in colorectal cancer. 
Cancer Metastasis Rev 2010, 29(1):181-206. 
 
116. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP: Alterations in DNA 
methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998, 72:141-
196. 
 
117. Suzuki K, Suzuki I, Leodolter A, Alonso S, Horiuchi S, Yamashita K, Perucho M: 
Global DNA demethylation in gastrointestinal cancer is age dependent and 
precedes genomic damage. Cancer Cell 2006, 9(3):199-207. 
 
118. Wajed SA, Laird PW, DeMeester TR: DNA methylation: an alternative pathway 
to cancer. Ann Surg 2001, 234(1):10-20. 
 
119. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP: Aging and DNA methylation in 
colorectal mucosa and cancer. Cancer Res 1998, 58(23):5489-5494. 
 
120. Lopes EC, Valls E, Figueroa ME, Mazur A, Meng FG, Chiosis G, Laird PW, 
Schreiber-Agus N, Greally JM, Prokhortchouk E et al: Kaiso contributes to DNA 
methylation-dependent silencing of tumor suppressor genes in colon cancer cell 
lines. Cancer Res 2008, 68(18):7258-7263. 
 
121. Prokhortchouk A, Sansom O, Selfridge J, Caballero IM, Salozhin S, Aithozhina 
D, Cerchietti L, Meng FG, Augenlicht LH, Mariadason JM et al: Kaiso-deficient 
mice show resistance to intestinal cancer. Mol Cell Biol 2006, 26(1):199-208. 
 
122. Mohammad HP, Cai Y, McGarvey KM, Easwaran H, Van Neste L, Ohm JE, 
O'Hagan HM, Baylin SB: Polycomb CBX7 promotes initiation of heritable 
repression of genes frequently silenced with cancer-specific DNA 
hypermethylation. Cancer Res 2009, 69(15):6322-6330. 
217 
 
123. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van 
Eynde A, Bernard D, Vanderwinden JM et al: The Polycomb group protein EZH2 
directly controls DNA methylation. Nature 2006, 439(7078):871-874. 
 
124. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero 
A, Ebert BL, Mak RH, Ferrando AA et al: MicroRNA expression profiles classify 
human cancers. Nature 2005, 435(7043):834-838. 
 
125. Lanza G, Ferracin M, Gafa R, Veronese A, Spizzo R, Pichiorri F, Liu CG, Calin 
GA, Croce CM, Negrini M: mRNA/microRNA gene expression profile in 
microsatellite unstable colorectal cancer. Mol Cancer 2007, 6:54. 
 
126. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K: 
Modulation of microRNA processing by p53. Nature 2009, 460(7254):529-533. 
 
127. Slaby O, Svoboda M, Michalek J, Vyzula R: MicroRNAs in colorectal cancer: 
translation of molecular biology into clinical application. Mol Cancer 2009, 8:102. 
 
128. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz 
T: A reciprocal repression between ZEB1 and members of the miR-200 family 
promotes EMT and invasion in cancer cells. EMBO Rep 2008, 9(6):582-589. 
 
129. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, 
Huang G, Klein-Szanto AJ et al: The microRNAs miR-373 and miR-520c 
promote tumour invasion and metastasis. Nat Cell Biol 2008, 10(2):202-210. 
 
130. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R: Micro 
RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon 
cancer cells. J Biol Chem 2007, 282(45):32582-32590. 
 
131. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco 
D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ et al: A microRNA DNA 
methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 
2008, 105(36):13556-13561. 
 
132. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, Tokino T: 
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is 
associated with CpG island methylation in colorectal cancer. Cancer Res 2008, 
68(11):4123-4132. 
 
133. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, Casado S, 
Suarez-Gauthier A, Sanchez-Cespedes M, Git A et al: Genetic unmasking of an 
epigenetically silenced microRNA in human cancer cells. Cancer Res 2007, 
67(4):1424-1429. 
 
134. Feagins LA, Souza RF, Spechler SJ: Carcinogenesis in IBD: potential targets for 
the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 2009, 
6(5):297-305. 
218 
 
135. Sheng H, Shao J, Williams CS, Pereira MA, Taketo MM, Oshima M, Reynolds 
AB, Washington MK, DuBois RN, Beauchamp RD: Nuclear translocation of 
beta-catenin in hereditary and carcinogen-induced intestinal adenomas. 
Carcinogenesis 1998, 19(4):543-549. 
 
136. Waldner MJ, Neurath MF: Cytokines in colitis associated cancer: potential drug 
targets? Inflamm Allergy Drug Targets 2008, 7(3):187-194. 
 
137. Atreya I, Atreya R, Neurath MF: NF-kappaB in inflammatory bowel disease. J 
Intern Med 2008, 263(6):591-596. 
 
138. Atreya I, Neurath MF: Immune cells in colorectal cancer: prognostic relevance 
and therapeutic strategies. Expert Rev Anticancer Ther 2008, 8(4):561-572. 
 
139. Clevers H: At the crossroads of inflammation and cancer. Cell 2004, 118(6):671-
674. 
 
140. Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A: 
Family history as a risk factor for colorectal cancer in inflammatory bowel 
disease. Gastroenterology 2001, 120(6):1356-1362. 
 
141. Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading 
role for STAT3. Nat Rev Cancer 2009, 9(11):798-809. 
 
142. Sakamoto K, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y, Shibata W, Yanai 
A, Ogura K, Omata M: Constitutive NF-kappaB activation in colorectal 
carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin 
Cancer Res 2009, 15(7):2248-2258. 
 
143. Westbrook AM, Wei B, Braun J, Schiestl RH: Intestinal mucosal inflammation 
leads to systemic genotoxicity in mice. Cancer Res 2009, 69(11):4827-4834. 
 
144. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, Rickman BH, 
Rogers AB, Moroski-Erkul CA, McFaline JL et al: DNA damage induced by 
chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 
2008, 118(7):2516-2525. 
 
145. Hussain SP, Hofseth LJ, Harris CC: Radical causes of cancer. Nat Rev Cancer 
2003, 3(4):276-285. 
 
146. Kraus S, Arber N: Inflammation and colorectal cancer. Curr Opin Pharmacol 
2009, 9(4):405-410. 
 
147. Choi J, Yoon SH, Kim JE, Rhee KH, Youn HS, Chung MH: Gene-specific 
oxidative DNA damage in Helicobacter pylori-infected human gastric mucosa. Int 
J Cancer 2002, 99(4):485-490. 
219 
 
148. Neufert C, Becker C, Neurath MF: An inducible mouse model of colon 
carcinogenesis for the analysis of sporadic and inflammation-driven tumor 
progression. Nat Protoc 2007, 2(8):1998-2004. 
 
149. Suzuki R, Kohno H, Sugie S, Tanaka T: Dose-dependent promoting effect of 
dextran sodium sulfate on mouse colon carcinogenesis initiated with 
azoxymethane. Histol Histopathol 2005, 20(2):483-492. 
 
150. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A: Cancer-related 
inflammation, the seventh hallmark of cancer: links to genetic instability. 
Carcinogenesis 2009, 30(7):1073-1081. 
 
151. Yang L, Belaguli N, Berger DH: MicroRNA and colorectal cancer. World J Surg 
2009, 33(4):638-646. 
 
152. Grady WM, Carethers JM: Genomic and epigenetic instability in colorectal 
cancer pathogenesis. Gastroenterology 2008, 135(4):1079-1099. 
 
153. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer 
H, Laczko E, Kurowski MA, Bujnicki JM, Menigatti M et al: Transcriptome profile 
of human colorectal adenomas. Mol Cancer Res 2007, 5(12):1263-1275. 
 
154. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, Jr., Sjoblom T, Barad O, 
Bentwich Z, Szafranska AE, Labourier E et al: The colorectal microRNAome. 
Proc Natl Acad Sci U S A 2006, 103(10):3687-3692. 
 
155. Oving IM, Clevers HC: Molecular causes of colon cancer. Eur J Clin Invest 
2002, 32(6):448-457. 
 
156. Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD, Chu FF, Pfeifer 
GP: Methylation of polycomb target genes in intestinal cancer is mediated by 
inflammation. Cancer Res 2008, 68(24):10280-10289. 
 
157. Eads CA, Nickel AE, Laird PW: Complete genetic suppression of polyp 
formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-
hypomorphic Mice. Cancer Res 2002, 62(5):1296-1299. 
 
158. Podolsky DK: Inflammatory bowel disease (2). N Engl J Med 1991, 
325(14):1008-1016. 
 
159. Chung DC: The genetic basis of colorectal cancer: insights into critical pathways 
of tumorigenesis. Gastroenterology 2000, 119(3):854-865. 
 
160. Itzkowitz S: Colon carcinogenesis in inflammatory bowel disease: applying 
molecular genetics to clinical practice. J Clin Gastroenterol 2003, 36(5 
Suppl):S70-74; discussion S94-76. 
 
220 
 
161. Willenbucher RF, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH, 2nd, 
Waldman FM: Genomic instability is an early event during the progression 
pathway of ulcerative-colitis-related neoplasia. Am J Pathol 1999, 154(6):1825-
1830. 
 
162. Suzuki H, Harpaz N, Tarmin L, Yin J, Jiang HY, Bell JD, Hontanosas M, 
Groisman GM, Abraham JM, Meltzer SJ: Microsatellite instability in ulcerative 
colitis-associated colorectal dysplasias and cancers. Cancer Res 1994, 
54(18):4841-4844. 
 
163. Tarmin L, Yin J, Harpaz N, Kozam M, Noordzij J, Antonio LB, Jiang HY, Chan O, 
Cymes K, Meltzer SJ: Adenomatous polyposis coli gene mutations in ulcerative 
colitis-associated dysplasias and cancers versus sporadic colon neoplasms. 
Cancer Res 1995, 55(10):2035-2038. 
 
164. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, 
Burmer GC: Mutations in the p53 gene: an early marker of neoplastic 
progression in ulcerative colitis. Gastroenterology 1994, 107(2):369-378. 
 
165. Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, Hontanosas M, 
Newkirk C, Meltzer SJ: p53 point mutations in dysplastic and cancerous 
ulcerative colitis lesions. Gastroenterology 1993, 104(6):1633-1639. 
 
166. Ezaki T, Watanabe M, Inoue N, Kanai T, Ogata H, Iwao Y, Ishii H, Hibi T: A 
specific genetic alteration on chromosome 6 in ulcerative colitis-associated 
colorectal cancers. Cancer Res 2003, 63(13):3747-3749. 
 
167. Mikami T, Yoshida T, Akino F, Motoori T, Yajima M, Okayasu I: Apoptosis 
regulation differs between ulcerative colitis-associated and sporadic colonic 
tumors. Association with survivin and bcl-2. Am J Clin Pathol 2003, 119(5):723-
730. 
 
168. Sato F, Shibata D, Harpaz N, Xu Y, Yin J, Mori Y, Wang S, Olaru A, Deacu E, 
Selaru FM et al: Aberrant methylation of the HPP1 gene in ulcerative colitis-
associated colorectal carcinoma. Cancer Res 2002, 62(23):6820-6822. 
 
169. Azarschab P, Porschen R, Gregor M, Blin N, Holzmann K: Epigenetic control of 
the E-cadherin gene (CDH1) by CpG methylation in colectomy samples of 
patients with ulcerative colitis. Genes Chromosomes Cancer 2002, 35(2):121-
126. 
 
170. Lashner BA, Bauer WM, Rybicki LA, Goldblum JR: Abnormal p53 
immunohistochemistry is associated with an increased colorectal cancer-related 
mortality in patients with ulcerative colitis. Am J Gastroenterol 2003, 98(6):1423-
1427. 
 
171. Karin M: How NF-kappaB is activated: the role of the IkappaB kinase (IKK) 
complex. Oncogene 1999, 18(49):6867-6874. 
221 
 
172. Thanos D, Maniatis T: NF-kappa B: a lesson in family values. Cell 1995, 
80(4):529-532. 
 
173. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, 
Pardoll DM, Yu H: Persistently activated Stat3 maintains constitutive NF-kappaB 
activity in tumors. Cancer Cell 2009, 15(4):283-293. 
 
174. Baeuerle PA: Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle? 
Curr Biol 1998, 8(1):R19-22. 
 
175. Perkins ND: NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 2004, 
14(2):64-69. 
 
176. Karin M, Cao Y, Greten FR, Li ZW: NF-kappaB in cancer: from innocent 
bystander to major culprit. Nat Rev Cancer 2002, 2(4):301-310. 
 
177. Fan C, Yang J, Engelhardt JF: Temporal pattern of NFkappaB activation 
influences apoptotic cell fate in a stimuli-dependent fashion. J Cell Sci 2002, 
115(Pt 24):4843-4853. 
 
178. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr.: Control of inducible 
chemoresistance: enhanced anti-tumor therapy through increased apoptosis by 
inhibition of NF-kappaB. Nat Med 1999, 5(4):412-417. 
 
179. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I: p53 stabilization is 
decreased upon NFkappaB activation: a role for NFkappaB in acquisition of 
resistance to chemotherapy. Cancer Cell 2002, 1(5):493-503. 
 
180. Campbell KJ, Rocha S, Perkins ND: Active repression of antiapoptotic gene 
expression by RelA(p65) NF-kappa B. Mol Cell 2004, 13(6):853-865. 
 
181. Ryan KM, Ernst MK, Rice NR, Vousden KH: Role of NF-kappaB in p53-
mediated programmed cell death. Nature 2000, 404(6780):892-897. 
 
182. Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer 
development and progression. Nat Rev Immunol 2005, 5(10):749-759. 
 
183. Kojima M, Morisaki T, Sasaki N, Nakano K, Mibu R, Tanaka M, Katano M: 
Increased nuclear factor-kB activation in human colorectal carcinoma and its 
correlation with tumor progression. Anticancer Res 2004, 24(2B):675-681. 
 
184. Naugler WE, Karin M: NF-kappaB and cancer-identifying targets and 
mechanisms. Curr Opin Genet Dev 2008, 18(1):19-26. 
 
185. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T: 
Requirement for NF-kappaB signalling in a mouse model of lung 
adenocarcinoma. Nature 2009, 462(7269):104-107. 
 
222 
 
186. Wang CY, Mayo MW, Baldwin AS, Jr.: TNF- and cancer therapy-induced 
apoptosis: potentiation by inhibition of NF-kappaB. Science 1996, 
274(5288):784-787. 
 
187. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, 
Baeuerle PA, Scholmerich J, Gross V: Nuclear factor kappaB is activated in 
macrophages and epithelial cells of inflamed intestinal mucosa. 
Gastroenterology 1998, 115(2):357-369. 
 
188. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W: Local 
administration of antisense phosphorothioate oligonucleotides to the p65 subunit 
of NF-kappa B abrogates established experimental colitis in mice. Nat Med 
1996, 2(9):998-1004. 
 
189. Eckmann L, Nebelsiek T, Fingerle AA, Dann SM, Mages J, Lang R, Robine S, 
Kagnoff MF, Schmid RM, Karin M et al: Opposing functions of IKKbeta during 
acute and chronic intestinal inflammation. Proc Natl Acad Sci U S A 2008, 
105(39):15058-15063. 
 
190. Majumdar S, Aggarwal BB: Methotrexate suppresses NF-kappaB activation 
through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 
2001, 167(5):2911-2920. 
 
191. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin 
M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-
associated cancer. Cell 2004, 118(3):285-296. 
 
192. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, 
Halabi S, Sandler RS: Circulating levels of inflammatory cytokines and risk of 
colorectal adenomas. Cancer Res 2008, 68(1):323-328. 
 
193. Koehne CH, Dubois RN: COX-2 inhibition and colorectal cancer. Semin Oncol 
2004, 31(2 Suppl 7):12-21. 
 
194. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: 
Up-regulation of cyclooxygenase 2 gene expression in human colorectal 
adenomas and adenocarcinomas. Gastroenterology 1994, 107(4):1183-1188. 
 
195. Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y, Frazier ML: 
Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis 
colorectal cancers relative to sporadic cancers. Gastroenterology 1999, 
117(2):350-358. 
 
196. Dixon DA: Regulation of COX-2 expression in human cancers. Prog Exp Tumor 
Res 2003, 37:52-71. 
 
223 
 
197. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, 
Kato H, Kondo M, Hla T: Expression of cyclooxygenase-1 and -2 in human 
colorectal cancer. Cancer Res 1995, 55(17):3785-3789. 
 
198. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S: Expression 
of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer 
Res 1995, 55(12):2556-2559. 
 
199. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, 
Morham SG, Smithies O, Langenbach R: Genetic disruption of Ptgs-1, as well 
as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000, 
60(17):4705-4708. 
 
200. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, 
Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in Apc 
delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 
87(5):803-809. 
 
201. Al-Salihi MA, Terrece Pearman A, Doan T, Reichert EC, Rosenberg DW, 
Prescott SM, Stafforini DM, Topham MK: Transgenic expression of 
cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate 
tumorigenesis but promotes tumor progression. Cancer Lett 2009, 273(2):225-
232. 
 
202. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G: 
Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for 
carcinogenesis. Proc Natl Acad Sci U S A 2002, 99(19):12483-12488. 
 
203. Leung WK, Wu KC, Wong CY, Cheng AS, Ching AK, Chan AW, Chong WW, Go 
MY, Yu J, To KF et al: Transgenic cyclooxygenase-2 expression and high salt 
enhanced susceptibility to chemical-induced gastric cancer development in 
mice. Carcinogenesis 2008, 29(8):1648-1654. 
 
204. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K: Enhancement of colon 
carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003, 
24(5):985-990. 
 
205. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, 
Lutterbaugh J, Lu S, Willson JK et al: 15-Hydroxyprostaglandin dehydrogenase, 
a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human 
gastrointestinal cancers. Proc Natl Acad Sci U S A 2004, 101(50):17468-17473. 
 
206. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, 
Katkuri S, DuBois RN: 15-Hydroxyprostaglandin dehydrogenase is down-
regulated in colorectal cancer. J Biol Chem 2005, 280(5):3217-3223. 
 
224 
 
207. Ding Y, Tong M, Liu S, Moscow JA, Tai HH: NAD+-linked 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor 
suppressor in lung cancer. Carcinogenesis 2005, 26(1):65-72. 
 
208. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, 
Dannenberg AJ, Lovgren AK, Luo G et al: 15-Hydroxyprostaglandin 
dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad 
Sci U S A 2006, 103(32):12098-12102. 
 
209. Mann JR, Backlund MG, Buchanan FG, Daikoku T, Holla VR, Rosenberg DW, 
Dey SK, DuBois RN: Repression of prostaglandin dehydrogenase by epidermal 
growth factor and snail increases prostaglandin E2 and promotes cancer 
progression. Cancer Res 2006, 66(13):6649-6656. 
 
210. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J: 
Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory 
drug-induced regression in Apc(Min/+) mice. Cancer Res 2002, 62(2):403-408. 
 
211. Jaffe BM, Parker CW, Philpott GW: Immunochemical measurement of 
prostaglandin or prostaglandin-like activity from normal and neoplastic cultured 
tissue. Surg Forum 1971, 22:90-92. 
 
212. Sonoshita M, Takaku K, Oshima M, Sugihara K, Taketo MM: Cyclooxygenase-2 
expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 
2002, 62(23):6846-6849. 
 
213. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, 
Kobayashi M, Maruyama T, Kobayashi K et al: Involvement of prostaglandin E 
receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002, 62(1):28-32. 
 
214. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, 
Kobayashi M, Satoh K, Narita M, Sugimoto Y et al: Host prostaglandin E(2)-EP3 
signaling regulates tumor-associated angiogenesis and tumor growth. J Exp 
Med 2003, 197(2):221-232. 
 
215. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, 
Hla T: Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 
2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004, 
101(2):591-596. 
 
216. Cha YI, DuBois RN: NSAIDs and cancer prevention: targets downstream of 
COX-2. Annu Rev Med 2007, 58:239-252. 
 
217. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS: Prostaglandin 
E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling 
axis. Science 2005, 310(5753):1504-1510. 
 
225 
 
218. Shao J, Jung C, Liu C, Sheng H: Prostaglandin E2 Stimulates the beta-catenin/T 
cell factor-dependent transcription in colon cancer. J Biol Chem 2005, 
280(28):26565-26572. 
 
219. He TC, Chan TA, Vogelstein B, Kinzler KW: PPARdelta is an APC-regulated 
target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99(3):335-345. 
 
220. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN: Role of 
beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl 
Acad Sci U S A 2006, 103(5):1492-1497. 
 
221. Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D, 
Williams AC, Paraskeva C: Increased EP4 receptor expression in colorectal 
cancer progression promotes cell growth and anchorage independence. Cancer 
Res 2006, 66(6):3106-3113. 
 
222. Ma X, Kundu N, Rifat S, Walser T, Fulton AM: Prostaglandin E receptor EP4 
antagonism inhibits breast cancer metastasis. Cancer Res 2006, 66(6):2923-
2927. 
 
223. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN: 
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets 
for chemoprevention. J Clin Oncol 2005, 23(2):254-266. 
 
224. Shao J, Lee SB, Guo H, Evers BM, Sheng H: Prostaglandin E2 stimulates the 
growth of colon cancer cells via induction of amphiregulin. Cancer Res 2003, 
63(17):5218-5223. 
 
225. Buchanan FG, Wang D, Bargiacchi F, DuBois RN: Prostaglandin E2 regulates 
cell migration via the intracellular activation of the epidermal growth factor 
receptor. J Biol Chem 2003, 278(37):35451-35457. 
 
226. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS: 
Prostaglandin E2 transactivates EGF receptor: a novel mechanism for 
promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002, 
8(3):289-293. 
 
227. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat 
Med 2004, 10(8):789-799. 
 
228. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS: 
Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into 
mechanisms and implications for cancer growth and ulcer healing. Nat Med 
1999, 5(12):1418-1423. 
 
229. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon 
cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997, 
94(7):3336-3340. 
226 
 
 
230. Khayrullina T, Yen JH, Jing H, Ganea D: In vitro differentiation of dendritic cells 
in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes 
differentiation of Th17 cells. J Immunol 2008, 181(1):721-735. 
 
231. Wu Y, Zhou BP: Inflammation: a driving force speeds cancer metastasis. Cell 
Cycle 2009, 8(20):3267-3273. 
 
232. Wang S, Liu Z, Wang L, Zhang X: NF-kappaB signaling pathway, inflammation 
and colorectal cancer. Cell Mol Immunol 2009, 6(5):327-334. 
 
233. Klampfer L: The role of signal transducers and activators of transcription in colon 
cancer. Front Biosci 2008, 13:2888-2899. 
 
234. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP: Stabilization of snail 
by NF-kappaB is required for inflammation-induced cell migration and invasion. 
Cancer Cell 2009, 15(5):416-428. 
 
235. Yang J, Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of 
development and tumor metastasis. Dev Cell 2008, 14(6):818-829. 
 
236. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, 
Dinarello CA, Apte RN: IL-1 is required for tumor invasiveness and 
angiogenesis. Proc Natl Acad Sci U S A 2003, 100(5):2645-2650. 
 
237. Yu H, Kortylewski M, Pardoll D: Crosstalk between cancer and immune cells: 
role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7(1):41-
51. 
 
238. Zucker S, Vacirca J: Role of matrix metalloproteinases (MMPs) in colorectal 
cancer. Cancer Metastasis Rev 2004, 23(1-2):101-117. 
 
239. Mauchley DC, Lynge DC, Langdale LA, Stelzner MG, Mock CN, Billingsley KG: 
Clinical utility and cost-effectiveness of routine preoperative computed 
tomography scanning in patients with colon cancer. Am J Surg 2005, 
189(5):512-517; discussion 517. 
 
240. Copel L, Sosna J, Kruskal JB, Raptopoulos V, Farrell RJ, Morrin MM: CT 
colonography in 546 patients with incomplete colonoscopy. Radiology 2007, 
244(2):471-478. 
 
241. Mainenti PP, Romano M, Imbriaco M, Camera L, Pace L, D'Antonio D, Bucci L, 
Galloro G, Salvatore M: Added value of CT colonography after a positive 
conventional colonoscopy: impact on treatment strategy. Abdom Imaging 2005, 
30(1):42-47. 
 
227 
 
242. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, 
Wakelam MJ, Johnson PJ, Martin A: Identification of serum biomarkers for colon 
cancer by proteomic analysis. Br J Cancer 2006, 94(12):1898-1905. 
 
243. Fletcher RH: Carcinoembryonic antigen. Ann Intern Med 1986, 104(1):66-73. 
 
244. Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, Conca R, 
Miano ST, Marzocca G, Francini G: CEA and CA19.9 as early predictors of 
progression in advanced/metastatic colorectal cancer patients receiving 
oxaliplatin-based chemotherapy and bevacizumab. Cancer Invest 2012, 
30(1):65-71. 
 
245. Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, Pessi MA, 
Prochilo T, Quadri A, Gatta G et al: Colon cancer. Crit Rev Oncol Hematol 2010, 
74(2):106-133. 
 
246. Ueno H, Mochizuki H, Akagi Y, Kusumi T, Yamada K, Ikegami M, Kawachi H, 
Kameoka S, Ohkura Y, Masaki T et al: Optimal Colorectal Cancer Staging 
Criteria in TNM Classification. J Clin Oncol 2012. 
 
247. Hu H, Krasinskas A, Willis J: Perspectives on current tumor-node-metastasis 
(TNM) staging of cancers of the colon and rectum. Semin Oncol 2011, 
38(4):500-510. 
 
248. Newland RC, Chapuis PH, Pheils MT, MacPherson JG: The relationship of 
survival to staging and grading of colorectal carcinoma: a prospective study of 
503 cases. Cancer 1981, 47(6):1424-1429. 
 
249. Olson RM, Perencevich NP, Malcolm AW, Chaffey JT, Wilson RE: Patterns of 
recurrence following curative resection of adenocarcinoma of the colon and 
rectum. Cancer 1980, 45(12):2969-2974. 
 
250. Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius B, 
Haller D, Johnston P, Kerr D, Koehne CH et al: Adjuvant treatment of colorectal 
cancer (current expert opinion derived from the Third International Conference: 
Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer 2002, 
38(11):1429-1436. 
 
251. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, 
Haller DG: Colon cancer survival is associated with increasing number of lymph 
nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 
2003, 21(15):2912-2919. 
 
252. Prandi M, Lionetto R, Bini A, Francioni G, Accarpio G, Anfossi A, Ballario E, 
Becchi G, Bonilauri S, Carobbi A et al: Prognostic evaluation of stage B colon 
cancer patients is improved by an adequate lymphadenectomy: results of a 
secondary analysis of a large scale adjuvant trial. Ann Surg 2002, 235(4):458-
463. 
228 
 
253. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, 
Mueser M, Harstrick A, Verslype C et al: Cetuximab monotherapy and 
cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N 
Engl J Med 2004, 351(4):337-345. 
 
254. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, 
Berlin J, Baron A, Griffing S, Holmgren E et al: Bevacizumab plus irinotecan, 
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 
350(23):2335-2342. 
 
255. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, 
Llory JF, Letourneau Y, Coudert B et al: Phase III multicenter randomized trial of 
oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line 
treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18(1):136-147. 
 
256. Wagman LD, Kemeny MM, Leong L, Terz JJ, Hill LR, Beatty JD, Kokal WA, 
Riihimaki DU: A prospective, randomized evaluation of the treatment of 
colorectal cancer metastatic to the liver. J Clin Oncol 1990, 8(11):1885-1893. 
 
257. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux 
E, Couteau C, Buyse M, Ganem G et al: FOLFIRI followed by FOLFOX6 or the 
reverse sequence in advanced colorectal cancer: a randomized GERCOR 
study. J Clin Oncol 2004, 22(2):229-237. 
 
258. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, 
Lichinitser M, Yang TS, Rivera F et al: Randomized phase III study of 
capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus 
oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 
2008, 26(12):2006-2012. 
 
259. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, 
Kretzschmar A, Graeven U, Grothey A, Hinke A et al: Phase III study of 
capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus 
oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal 
Study Group. J Clin Oncol 2007, 25(27):4217-4223. 
 
260. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with 
advanced colorectal cancer improves with the availability of fluorouracil-
leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 
2004, 22(7):1209-1214. 
 
261. Cunningham D, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-
Jones R, Koralewski P, Bridgewater J, Mainwaring P, Wasan H et al: Two 
different first-line 5-fluorouracil regimens with or without oxaliplatin in patients 
with metastatic colorectal cancer. Ann Oncol 2009, 20(2):244-250. 
 
 
229 
 
262. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, 
Smith DB, Shepherd S, Maraveyas A, Ferry DR et al: Different strategies of 
sequential and combination chemotherapy for patients with poor prognosis 
advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. 
Lancet 2007, 370(9582):143-152. 
 
263. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, 
Carola E, Etienne PL, Rivera F et al: OPTIMOX1: a randomized study of 
FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced 
colorectal cancer--a GERCOR study. J Clin Oncol 2006, 24(3):394-400. 
 
264. Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, 
McArdle C, Cain D, Stephens RJ: Comparison of intermittent and continuous 
palliative chemotherapy for advanced colorectal cancer: a multicentre 
randomised trial. Lancet 2003, 361(9356):457-464. 
 
265. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, Aapro 
MS, Esser R, Loos AH, Siena S: Cetuximab plus irinotecan in heavily pretreated 
metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin 
Oncol 2008, 26(33):5335-5343. 
 
266. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, 
Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J et al: EPIC: phase III trial 
of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in 
patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(14):2311-2319. 
 
267. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, 
D'Haens G, Pinter T, Lim R, Bodoky G et al: Cetuximab and chemotherapy as 
initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 
360(14):1408-1417. 
 
268. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, 
Bodoky G, Cunningham D, Jassem J et al: Randomized, phase III trial of 
panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) 
versus FOLFOX4 alone as first-line treatment in patients with previously 
untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 
28(31):4697-4705. 
 
269. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, 
Van Laethem JL, Maurel J, Richardson G et al: Open-label phase III trial of 
panitumumab plus best supportive care compared with best supportive care 
alone in patients with chemotherapy-refractory metastatic colorectal cancer. J 
Clin Oncol 2007, 25(13):1658-1664. 
 
 
 
 
230 
 
270. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, 
Chan E, Lordick F, Punt CJ et al: Randomized phase III study of panitumumab 
with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI 
alone as second-line treatment in patients with metastatic colorectal cancer. J 
Clin Oncol 2010, 28(31):4706-4713. 
 
271. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye 
FJ, Lindeman N, Boggon TJ et al: EGFR mutations in lung cancer: correlation 
with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500. 
 
272. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan 
BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al: Activating mutations 
in the epidermal growth factor receptor underlying responsiveness of non-small-
cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139. 
 
273. Aparo S, Goel S: Evolvement of the treatment paradigm for metastatic colon 
cancer. From chemotherapy to targeted therapy. Crit Rev Oncol Hematol 2012, 
83(1):47-58. 
 
274. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell 
M, Sargent P, Piedbois P: Modulation of fluorouracil by leucovorin in patients 
with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004, 
22(18):3766-3775. 
 
275. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus 
administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J 
Clin Oncol 1998, 16(1):301-308. 
 
276. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni G, 
Agostara B, Pezzella G, Manzione L et al: Phase III randomized trial of FOLFIRI 
versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter 
study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005, 
23(22):4866-4875. 
 
277. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson 
SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of 
fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients 
with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 
22(1):23-30. 
 
278. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, 
Cortes-Funes H, Cervantes A, Freyer G et al: Leucovorin and fluorouracil with or 
without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin 
Oncol 2000, 18(16):2938-2947. 
 
 
 
231 
 
279. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, 
Ackland SP, Locker PK, Pirotta N et al: Irinotecan plus fluorouracil and 
leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J 
Med 2000, 343(13):905-914. 
 
280. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, 
Jandik P, Iveson T, Carmichael J, Alakl M et al: Irinotecan combined with 
fluorouracil compared with fluorouracil alone as first-line treatment for metastatic 
colorectal cancer: a multicentre randomised trial. Lancet 2000, 355(9209):1041-
1047. 
 
281. Tassi E, Wellstein A: The angiogenic switch molecule, secreted FGF-binding 
protein, an indicator of early stages of pancreatic and colorectal 
adenocarcinoma. Semin Oncol 2006, 33(6 Suppl 11):S50-56. 
 
282. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in 
tumor growth and angiogenesis. J Clin Oncol 2005, 23(5):1011-1027. 
 
283. El Zouhairi M, Charabaty A, Pishvaian MJ: Molecularly targeted therapy for 
metastatic colon cancer: proven treatments and promising new agents. 
Gastrointest Cancer Res 2011, 4(1):15-21. 
 
284. Ferrara N: Role of vascular endothelial growth factor in physiologic and 
pathologic angiogenesis: therapeutic implications. Semin Oncol 2002, 29(6 
Suppl 16):10-14. 
 
285. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. 
Endocr Rev 1997, 18(1):4-25. 
 
286. Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi 
C, Baldelli AM, Graziano F, Saba V et al: Expression of vascular endothelial 
growth factor can predict event-free survival in stage II colon cancer. Clin 
Cancer Res 2000, 6(7):2803-2807. 
 
287. Lee JC, Chow NH, Wang ST, Huang SM: Prognostic value of vascular 
endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 
2000, 36(6):748-753. 
 
288. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N: Regulation by vascular 
endothelial growth factor of human colon cancer tumorigenesis in a mouse 
model of experimental liver metastasis. J Clin Invest 1995, 95(4):1789-1797. 
 
289. Ellis LM: Mechanisms of action of bevacizumab as a component of therapy for 
metastatic colorectal cancer. Semin Oncol 2006, 33(5 Suppl 10):S1-7. 
 
290. Prat A, Casado E, Cortes J: New approaches in angiogenic targeting for 
colorectal cancer. World J Gastroenterol 2007, 13(44):5857-5866. 
 
232 
 
291. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, 
Lichinitser M, Yang TS, Rivera F et al: Bevacizumab in combination with 
oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal 
cancer: a randomized phase III study. J Clin Oncol 2008, 26(12):2013-2019. 
 
292. Wang TF, Lockhart AC: Aflibercept in the treatment of metastatic colorectal 
cancer. Clin Med Insights Oncol 2012, 6:19-30. 
 
293. Brave SR, Odedra R, James NH, Smith NR, Marshall GB, Acheson KL, Baker 
D, Howard Z, Jackson L, Ratcliffe K et al: Vandetanib inhibits both VEGFR-2 
and EGFR signalling at clinically relevant drug levels in preclinical models of 
human cancer. Int J Oncol 2011, 39(1):271-278. 
 
294. Sobrero AF, Bruzzi P: Vatalanib in advanced colorectal cancer: two studies with 
identical results. J Clin Oncol 2011, 29(15):1938-1940. 
 
295. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland 
EK, Haller DG, Lockhart AC, Rocha Lima CM et al: Phase II trial of sunitinib in 
patients with metastatic colorectal cancer after failure of standard therapy. J Clin 
Oncol 2007, 25(30):4793-4799. 
 
296. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, 
Blum H, Robertson J, Jurgensmeier JM et al: Phase I clinical study of AZD2171, 
an oral vascular endothelial growth factor signaling inhibitor, in patients with 
advanced solid tumors. J Clin Oncol 2007, 25(21):3045-3054. 
 
297. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, 
Koutsoukos A, Sun YN, Bass MB et al: Safety, pharmacokinetics, and efficacy of 
AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J 
Clin Oncol 2007, 25(17):2369-2376. 
 
298. Herbst RS: Review of epidermal growth factor receptor biology. Int J Radiat 
Oncol Biol Phys 2004, 59(2 Suppl):21-26. 
 
299. Marshall J: Clinical implications of the mechanism of epidermal growth factor 
receptor inhibitors. Cancer 2006, 107(6):1207-1218. 
 
300. Gibson TB, Ranganathan A, Grothey A: Randomized phase III trial results of 
panitumumab, a fully human anti-epidermal growth factor receptor monoclonal 
antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006, 6(1):29-
31. 
 
301. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska 
E, Sosman J, McDermott D, Bodrogi I et al: Temsirolimus, interferon alfa, or 
both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271-2281. 
 
 
233 
 
302. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon 
y Cajal S, Jones S, Vidal L et al: Dose- and schedule-dependent inhibition of the 
mammalian target of rapamycin pathway with everolimus: a phase I tumor 
pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 
2008, 26(10):1603-1610. 
 
303. Camidge DR, Gail Eckhardt S, Gore L, O'Bryant CL, Leong S, Basche M, 
Holden SN, Musib L, Baldwin J, Darstein C et al: A phase I safety, tolerability, 
and pharmacokinetic study of enzastaurin combined with capecitabine in 
patients with advanced solid tumors. Anticancer Drugs 2008, 19(1):77-84. 
 
304. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan 
R, Riddle J, Schmidt J et al: Phase I dose escalation and pharmacokinetic study 
of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced 
cancer. J Clin Oncol 2006, 24(25):4092-4099. 
 
305. Summy JM, Gallick GE: Treatment for advanced tumors: SRC reclaims center 
stage. Clin Cancer Res 2006, 12(5):1398-1401. 
 
306. Fujisaka Y, Onozawa Y, Kurata T, Yasui H, Goto I, Yamazaki K, Machida N, 
Watanabe J, Shimada H, Shi X et al: First report of the safety, tolerability, and 
pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese 
patients with advanced solid tumours. Invest New Drugs 2012. 
 
307. Wood KW, Cornwell WD, Jackson JR: Past and future of the mitotic spindle as 
an oncology target. Curr Opin Pharmacol 2001, 1(4):370-377. 
 
308. Luo L, Parrish CA, Nevins N, McNulty DE, Chaudhari AM, Carson JD, Sudakin 
V, Shaw AN, Lehr R, Zhao H et al: ATP-competitive inhibitors of the mitotic 
kinesin KSP that function via an allosteric mechanism. Nat Chem Biol 2007, 
3(11):722-726. 
 
309. Burris HA, 3rd, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L, Ho 
PT, Boerner SA, Lorusso P: A phase I study of ispinesib, a kinesin spindle 
protein inhibitor, administered weekly for three consecutive weeks of a 28-day 
cycle in patients with solid tumors. Invest New Drugs 2011, 29(3):467-472. 
 
310. Thomas MC, Chiang CM: The general transcription machinery and general 
cofactors. Crit Rev Biochem Mol Biol 2006, 41(3):105-178. 
 
311. Maston GA, Evans SK, Green MR: Transcriptional regulatory elements in the 
human genome. Annu Rev Genomics Hum Genet 2006, 7:29-59. 
 
312. Mees C, Nemunaitis J, Senzer N: Transcription factors: their potential as targets 
for an individualized therapeutic approach to cancer. Cancer Gene Ther 2009, 
16(2):103-112. 
 
234 
 
313. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff 
R, Hilsenbeck SG, Osborne CK et al: Inhibition of AP-1 transcription factor 
causes blockade of multiple signal transduction pathways and inhibits breast 
cancer growth. Oncogene 2002, 21(50):7680-7689. 
 
314. Eder IE, Hoffmann J, Rogatsch H, Schafer G, Zopf D, Bartsch G, Klocker H: 
Inhibition of LNCaP prostate tumor growth in vivo by an antisense 
oligonucleotide directed against the human androgen receptor. Cancer Gene 
Ther 2002, 9(2):117-125. 
 
315. Jean D, Bar-Eli M: Targeting the ATF-1/CREB transcription factors by single 
chain Fv fragment in human melanoma: potential modality for cancer therapy. 
Crit Rev Immunol 2001, 21(1-3):275-286. 
 
316. Dennis JH, Budhram-Mahadeo V, Latchman DS: The Brn-3b POU family 
transcription factor regulates the cellular growth, proliferation, and anchorage 
dependence of MCF7 human breast cancer cells. Oncogene 2001, 20(36):4961-
4971. 
 
317. Halmos B, Huettner CS, Kocher O, Ferenczi K, Karp DD, Tenen DG: Down-
regulation and antiproliferative role of C/EBPalpha in lung cancer. Cancer Res 
2002, 62(2):528-534. 
 
318. Abramovitch R, Tavor E, Jacob-Hirsch J, Zeira E, Amariglio N, Pappo O, 
Rechavi G, Galun E, Honigman A: A pivotal role of cyclic AMP-responsive 
element binding protein in tumor progression. Cancer Res 2004, 64(4):1338-
1346. 
 
319. Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, Chong GT, Nuckolls F, 
Giangrande P, Wright FA, Field SJ et al: The E2F1-3 transcription factors are 
essential for cellular proliferation. Nature 2001, 414(6862):457-462. 
 
320. Hashiya N, Jo N, Aoki M, Matsumoto K, Nakamura T, Sato Y, Ogata N, Ogihara 
T, Kaneda Y, Morishita R: In vivo evidence of angiogenesis induced by 
transcription factor Ets-1: Ets-1 is located upstream of angiogenesis cascade. 
Circulation 2004, 109(24):3035-3041. 
 
321. Takahashi A, Higashino F, Aoyagi M, Yoshida K, Itoh M, Kyo S, Ohno T, Taira 
T, Ariga H, Nakajima K et al: EWS/ETS fusions activate telomerase in Ewing's 
tumors. Cancer Res 2003, 63(23):8338-8344. 
 
322. Lee RY, Hench J, Ruvkun G: Regulation of C. elegans DAF-16 and its human 
ortholog FKHRL1 by the daf-2 insulin-like signaling pathway. Curr Biol 2001, 
11(24):1950-1957. 
 
 
 
235 
 
323. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C, Goldberg MA, Akita 
GY, Gregory RJ, Isner JM: Angiogenesis is induced in a rabbit model of hindlimb 
ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription 
factor. Circulation 2000, 102(18):2255-2261. 
 
324. Hatzi E, Murphy C, Zoephel A, Rasmussen H, Morbidelli L, Ahorn H, Kunisada 
K, Tontsch U, Klenk M, Yamauchi-Takihara K et al: N-myc oncogene 
overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis 
and suppresses neuroblastoma tumor growth. Oncogene 2002, 21(22):3552-
3561. 
 
325. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, 
Rajkumar SV, Srkalovic G, Alsina M, Alexanian R et al: A phase 2 study of 
bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348(26):2609-
2617. 
 
326. Bieche I, Tozlu S, Girault I, Onody P, Driouch K, Vidaud M, Lidereau R: 
Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast 
tumors: positive links to MMP2, NRG1 and CGB expression. Carcinogenesis 
2004, 25(3):405-411. 
 
327. Manshouri T, Yang Y, Lin H, Stass SA, Glassman AB, Keating MJ, Albitar M: 
Downregulation of RAR alpha in mice by antisense transgene leads to a 
compensatory increase in RAR beta and RAR gamma and development of 
lymphoma. Blood 1997, 89(7):2507-2515. 
 
328. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K: Celecoxib inhibits 
vascular endothelial growth factor expression in and reduces angiogenesis and 
metastasis of human pancreatic cancer via suppression of Sp1 transcription 
factor activity. Cancer Res 2004, 64(6):2030-2038. 
 
329. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM: 
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor 
activity. Oncogene 2005, 24(20):3236-3245. 
 
330. Leong PL, Xi S, Drenning SD, Dyer KF, Wentzel AL, Lerner EC, Smithgall TE, 
Grandis JR: Differential function of STAT5 isoforms in head and neck cancer 
growth control. Oncogene 2002, 21(18):2846-2853. 
 
331. Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA, Ji L: 
Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated 
wild-type p53 gene transfer in combination with docetaxel and radiation 
therapeutics in vitro and in vivo. Clin Cancer Res 2001, 7(9):2887-2897. 
 
 
 
 
236 
 
332. Arkin MR, Wells JA: Small-molecule inhibitors of protein-protein interactions: 
progressing towards the dream. Nat Rev Drug Discov 2004, 3(4):301-317. 
 
333. Stein CA, Benimetskaya L, Mani S: Antisense strategies for oncogene 
inactivation. Semin Oncol 2005, 32(6):563-572. 
 
334. Dykxhoorn DM, Palliser D, Lieberman J: The silent treatment: siRNAs as small 
molecule drugs. Gene Ther 2006, 13(6):541-552. 
 
335. Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofer M, Barton A: Novel 
single-stranded oligonucleotides that inhibit signal transducer and activator of 
transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. 
Mol Cancer Ther 2004, 3(10):1183-1191. 
 
336. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson 
DE, Huang L, He Y, Kim JD: Constitutive activation of Stat3 signaling abrogates 
apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 
2000, 97(8):4227-4232. 
 
337. Jing N, Zhu Q, Yuan P, Li Y, Mao L, Tweardy DJ: Targeting signal transducer 
and activator of transcription 3 with G-quartet oligonucleotides: a potential novel 
therapy for head and neck cancer. Mol Cancer Ther 2006, 5(2):279-286. 
 
338. Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ: G-quartet oligonucleotides: a 
new class of signal transducer and activator of transcription 3 inhibitors that 
suppresses growth of prostate and breast tumors through induction of apoptosis. 
Cancer Res 2004, 64(18):6603-6609. 
 
339. Bouwman P, Philipsen S: Regulation of the activity of Sp1-related transcription 
factors. Mol Cell Endocrinol 2002, 195(1-2):27-38. 
 
340. Schultz JR, Petz LN, Nardulli AM: Estrogen receptor alpha and Sp1 regulate 
progesterone receptor gene expression. Mol Cell Endocrinol 2003, 201(1-
2):165-175. 
 
341. Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde 
MP, Vyhlidal C, Safe S: Mechanisms of transcriptional activation of bcl-2 gene 
expression by 17beta-estradiol in breast cancer cells. J Biol Chem 1999, 
274(45):32099-32107. 
 
342. Duan R, Porter W, Safe S: Estrogen-induced c-fos protooncogene expression in 
MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex 
formation. Endocrinology 1998, 139(4):1981-1990. 
 
343. Murata Y, Kim HG, Rogers KT, Udvadia AJ, Horowitz JM: Negative regulation of 
Sp1 trans-activation is correlated with the binding of cellular proteins to the 
amino terminus of the Sp1 trans-activation domain. J Biol Chem 1994, 
269(32):20674-20681. 
237 
 
 
344. Courey AJ, Tjian R: Analysis of Sp1 in vivo reveals multiple transcriptional 
domains, including a novel glutamine-rich activation motif. Cell 1988, 55(5):887-
898. 
 
345. Kingsley C, Winoto A: Cloning of GT box-binding proteins: a novel Sp1 
multigene family regulating T-cell receptor gene expression. Mol Cell Biol 1992, 
12(10):4251-4261. 
 
346. Hagen G, Dennig J, Preiss A, Beato M, Suske G: Functional analyses of the 
transcription factor Sp4 reveal properties distinct from Sp1 and Sp3. J Biol 
Chem 1995, 270(42):24989-24994. 
 
347. Pascal E, Tjian R: Different activation domains of Sp1 govern formation of 
multimers and mediate transcriptional synergism. Genes Dev 1991, 5(9):1646-
1656. 
 
348. Bakovic M, Waite KA, Vance DE: Functional significance of Sp1, Sp2, and Sp3 
transcription factors in regulation of the murine CTP:phosphocholine 
cytidylyltransferase alpha promoter. J Lipid Res 2000, 41(4):583-594. 
 
349. Rotheneder H, Geymayer S, Haidweger E: Transcription factors of the Sp1 
family: interaction with E2F and regulation of the murine thymidine kinase 
promoter. J Mol Biol 1999, 293(5):1005-1015. 
 
350. Majello B, De Luca P, Lania L: Sp3 is a bifunctional transcription regulator with 
modular independent activation and repression domains. J Biol Chem 1997, 
272(7):4021-4026. 
 
351. Dennig J, Beato M, Suske G: An inhibitor domain in Sp3 regulates its glutamine-
rich activation domains. Embo J 1996, 15(20):5659-5667. 
 
352. Birnbaum MJ, van Wijnen AJ, Odgren PR, Last TJ, Suske G, Stein GS, Stein JL: 
Sp1 trans-activation of cell cycle regulated promoters is selectively repressed by 
Sp3. Biochemistry 1995, 34(50):16503-16508. 
 
353. Strom AC, Forsberg M, Lillhager P, Westin G: The transcription factors Sp1 and 
Oct-1 interact physically to regulate human U2 snRNA gene expression. Nucleic 
Acids Res 1996, 24(11):1981-1986. 
 
354. Karlseder J, Rotheneder H, Wintersberger E: Interaction of Sp1 with the growth- 
and cell cycle-regulated transcription factor E2F. Mol Cell Biol 1996, 16(4):1659-
1667. 
 
355. Pazin MJ, Sheridan PL, Cannon K, Cao Z, Keck JG, Kadonaga JT, Jones KA: 
NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of 
the HIV-1 enhancer in vitro. Genes Dev 1996, 10(1):37-49. 
 
238 
 
356. Chiang CM, Roeder RG: Cloning of an intrinsic human TFIID subunit that 
interacts with multiple transcriptional activators. Science 1995, 267(5197):531-
536. 
 
357. Gill G, Pascal E, Tseng ZH, Tjian R: A glutamine-rich hydrophobic patch in 
transcription factor Sp1 contacts the dTAFII110 component of the Drosophila 
TFIID complex and mediates transcriptional activation. Proc Natl Acad Sci U S A 
1994, 91(1):192-196. 
 
358. Ryu S, Tjian R: Purification of transcription cofactor complex CRSP. Proc Natl 
Acad Sci U S A 1999, 96(13):7137-7142. 
 
359. Ryu S, Zhou S, Ladurner AG, Tjian R: The transcriptional cofactor complex 
CRSP is required for activity of the enhancer-binding protein Sp1. Nature 1999, 
397(6718):446-450. 
 
360. Black AR, Black JD, Azizkhan-Clifford J: Sp1 and kruppel-like factor family of 
transcription factors in cell growth regulation and cancer. J Cell Physiol 2001, 
188(2):143-160. 
 
361. Philipsen S, Suske G: A tale of three fingers: the family of mammalian Sp/XKLF 
transcription factors. Nucleic Acids Res 1999, 27(15):2991-3000. 
 
362. Gollner H, Bouwman P, Mangold M, Karis A, Braun H, Rohner I, Del Rey A, 
Besedovsky HO, Meinhardt A, van den Broek M et al: Complex phenotype of 
mice homozygous for a null mutation in the Sp4 transcription factor gene. Genes 
Cells 2001, 6(8):689-697. 
 
363. Gollner H, Dani C, Phillips B, Philipsen S, Suske G: Impaired ossification in mice 
lacking the transcription factor Sp3. Mech Dev 2001, 106(1-2):77-83. 
 
364. Marin M, Karis A, Visser P, Grosveld F, Philipsen S: Transcription factor Sp1 is 
essential for early embryonic development but dispensable for cell growth and 
differentiation. Cell 1997, 89(4):619-628. 
 
365. Supp DM, Witte DP, Branford WW, Smith EP, Potter SS: Sp4, a member of the 
Sp1-family of zinc finger transcription factors, is required for normal murine 
growth, viability, and male fertility. Dev Biol 1996, 176(2):284-299. 
 
366. Oh JE, Han JA, Hwang ES: Downregulation of transcription factor, Sp1, during 
cellular senescence. Biochem Biophys Res Commun 2007, 353(1):86-91. 
 
367. Ammendola R, Mesuraca M, Russo T, Cimino F: Sp1 DNA binding efficiency is 
highly reduced in nuclear extracts from aged rat tissues. J Biol Chem 1992, 
267(25):17944-17948. 
 
239 
 
368. Kanai M, Wei D, Li Q, Jia Z, Ajani J, Le X, Yao J, Xie K: Loss of Kruppel-like 
factor 4 expression contributes to Sp1 overexpression and human gastric cancer 
development and progression. Clin Cancer Res 2006, 12(21):6395-6402. 
 
369. Safe S, Abdelrahim M: Sp transcription factor family and its role in cancer. Eur J 
Cancer 2005, 41(16):2438-2448. 
 
370. Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, Morita A, 
Nagawa H, Suzuki N: Up-regulation of DNA-dependent protein kinase activity 
and Sp1 in colorectal cancer. Int J Oncol 2004, 25(2):461-468. 
 
371. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li 
XC, Xie K: Constitutive Sp1 activity is essential for differential constitutive 
expression of vascular endothelial growth factor in human pancreatic 
adenocarcinoma. Cancer Res 2001, 61(10):4143-4154. 
 
372. Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G, D'Aiuto G, 
Stoppelli MP, Salvatore M: Coordinate up-regulation of Sp1 DNA-binding activity 
and urokinase receptor expression in breast carcinoma. Cancer Res 2000, 
60(6):1546-1551. 
 
373. Lou Z, O'Reilly S, Liang H, Maher VM, Sleight SD, McCormick JJ: Down-
regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits 
tumor formation. Cancer Res 2005, 65(3):1007-1017. 
 
374. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie 
K: Association between expression of transcription factor Sp1 and increased 
vascular endothelial growth factor expression, advanced stage, and poor 
survival in patients with resected gastric cancer. Clin Cancer Res 2004, 10(12 Pt 
1):4109-4117. 
 
375. Abdelrahim M, Baker CH, Abbruzzese JL, Sheikh-Hamad D, Liu S, Cho SD, 
Yoon K, Safe S: Regulation of vascular endothelial growth factor receptor-1 
expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer 
Res 2007, 67(7):3286-3294. 
 
376. Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, Filetti S: 
Increased expression of AP2 and Sp1 transcription factors in human thyroid 
tumors: a role in NIS expression regulation? BMC Cancer 2002, 2:35. 
 
377. Abdelrahim M, Samudio I, Smith R, 3rd, Burghardt R, Safe S: Small inhibitory 
RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene 
expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 
2002, 277(32):28815-28822. 
 
378. Courey AJ, Holtzman DA, Jackson SP, Tjian R: Synergistic activation by the 
glutamine-rich domains of human transcription factor Sp1. Cell 1989, 59(5):827-
836. 
240 
 
 
379. Hasleton MD, Ibbitt JC, Hurst HC: Characterization of the human activator 
protein-2gamma (AP-2gamma) gene: control of expression by Sp1/Sp3 in breast 
tumour cells. Biochem J 2003, 373(Pt 3):925-932. 
 
380. Safe S, Kim K: Nuclear receptor-mediated transactivation through interaction 
with Sp proteins. Prog Nucleic Acid Res Mol Biol 2004, 77:1-36. 
 
381. Pore N, Liu S, Shu HK, Li B, Haas-Kogan D, Stokoe D, Milanini-Mongiat J, 
Pages G, O'Rourke DM, Bernhard E et al: Sp1 is involved in Akt-mediated 
induction of VEGF expression through an HIF-1-independent mechanism. Mol 
Biol Cell 2004, 15(11):4841-4853. 
 
382. Onishi T, Yamakawa K, Franco OE, Kawamura J, Watanabe M, Shiraishi T, 
Kitazawa S: Mitogen-activated protein kinase pathway is involved in alpha6 
integrin gene expression in androgen-independent prostate cancer cells: role of 
proximal Sp1 consensus sequence. Biochim Biophys Acta 2001, 1538(2-3):218-
227. 
 
383. Banchio C, Schang LM, Vance DE: Phosphorylation of Sp1 by cyclin-dependent 
kinase 2 modulates the role of Sp1 in CTP:phosphocholine cytidylyltransferase 
alpha regulation during the S phase of the cell cycle. J Biol Chem 2004, 
279(38):40220-40226. 
 
384. Fojas de Borja P, Collins NK, Du P, Azizkhan-Clifford J, Mudryj M: Cyclin A-CDK 
phosphorylates Sp1 and enhances Sp1-mediated transcription. Embo J 2001, 
20(20):5737-5747. 
 
385. Haidweger E, Novy M, Rotheneder H: Modulation of Sp1 activity by a cyclin 
A/CDK complex. J Mol Biol 2001, 306(2):201-212. 
 
386. Huang W, Zhao S, Ammanamanchi S, Brattain M, Venkatasubbarao K, 
Freeman JW: Trichostatin A induces transforming growth factor beta type II 
receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 
to a Sp1.NF-Y complex. J Biol Chem 2005, 280(11):10047-10054. 
 
387. Ammanamanchi S, Freeman JW, Brattain MG: Acetylated sp3 is a 
transcriptional activator. J Biol Chem 2003, 278(37):35775-35780. 
 
388. Torigoe T, Izumi H, Wakasugi T, Niina I, Igarashi T, Yoshida T, Shibuya I, 
Chijiiwa K, Matsuo K, Itoh H et al: DNA topoisomerase II poison TAS-103 
transactivates GC-box-dependent transcription via acetylation of Sp1. J Biol 
Chem 2005, 280(2):1179-1185. 
 
389. Yang X, Su K, Roos MD, Chang Q, Paterson AJ, Kudlow JE: O-linkage of N-
acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. 
Proc Natl Acad Sci U S A 2001, 98(12):6611-6616. 
 
241 
 
390. Stoner M, Wormke M, Saville B, Samudio I, Qin C, Abdelrahim M, Safe S: 
Estrogen regulation of vascular endothelial growth factor gene expression in ZR-
75 breast cancer cells through interaction of estrogen receptor alpha and SP 
proteins. Oncogene 2004, 23(5):1052-1063. 
 
391. Jennings R, Alsarraj M, Wright KL, Munoz-Antonia T: Regulation of the human 
transforming growth factor beta type II receptor gene promoter by novel Sp1 
sites. Oncogene 2001, 20(47):6899-6909. 
 
392. Ammanamanchi S, Brattain MG: Sp3 is a transcriptional repressor of 
transforming growth factor-beta receptors. J Biol Chem 2001, 276(5):3348-3352. 
 
393. Liu Y, Zhong X, Li W, Brattain MG, Banerji SS: The role of Sp1 in the differential 
expression of transforming growth factor-beta receptor type II in human breast 
adenocarcinoma MCF-7 cells. J Biol Chem 2000, 275(16):12231-12236. 
 
394. Khan S, Abdelrahim M, Samudio I, Safe S: Estrogen receptor/Sp1 complexes 
are required for induction of cad gene expression by 17beta-estradiol in breast 
cancer cells. Endocrinology 2003, 144(6):2325-2335. 
 
395. Ngwenya S, Safe S: Cell context-dependent differences in the induction of E2F-
1 gene expression by 17 beta-estradiol in MCF-7 and ZR-75 cells. 
Endocrinology 2003, 144(5):1675-1685. 
 
396. Castro-Rivera E, Samudio I, Safe S: Estrogen regulation of cyclin D1 gene 
expression in ZR-75 breast cancer cells involves multiple enhancer elements. J 
Biol Chem 2001, 276(33):30853-30861. 
 
397. Samudio I, Vyhlidal C, Wang F, Stoner M, Chen I, Kladde M, Barhoumi R, 
Burghardt R, Safe S: Transcriptional activation of deoxyribonucleic acid 
polymerase alpha gene expression in MCF-7 cells by 17 beta-estradiol. 
Endocrinology 2001, 142(3):1000-1008. 
 
398. Xie W, Duan R, Chen I, Samudio I, Safe S: Transcriptional activation of 
thymidylate synthase by 17beta-estradiol in MCF-7 human breast cancer cells. 
Endocrinology 2000, 141(7):2439-2449. 
 
399. Xie W, Duan R, Safe S: Estrogen induces adenosine deaminase gene 
expression in MCF-7 human breast cancer cells: role of estrogen receptor-Sp1 
interactions. Endocrinology 1999, 140(1):219-227. 
 
400. Arinze IJ, Kawai Y: Sp family of transcription factors is involved in valproic acid-
induced expression of Galphai2. J Biol Chem 2003, 278(20):17785-17791. 
 
401. Zhu GH, Lenzi M, Schwartz EL: The Sp1 transcription factor contributes to the 
tumor necrosis factor-induced expression of the angiogenic factor thymidine 
phosphorylase in human colon carcinoma cells. Oncogene 2002, 21(55):8477-
8485. 
242 
 
 
402. Wu J, Ling X, Pan D, Apontes P, Song L, Liang P, Altieri DC, Beerman T, Li F: 
Molecular mechanism of inhibition of survivin transcription by the GC-rich 
sequence-selective DNA binding antitumor agent, hedamycin: evidence of 
survivin down-regulation associated with drug sensitivity. J Biol Chem 2005, 
280(10):9745-9751. 
 
403. Chae YM, Park KK, Magae J, Lee IS, Kim CH, Kim HC, Hong S, Lee JG, Choi 
IJ, Kim HS et al: Sp1-decoy oligodeoxynucleotide inhibits high glucose-induced 
mesangial cell proliferation. Biochem Biophys Res Commun 2004, 319(2):550-
555. 
 
404. Ishibashi H, Nakagawa K, Onimaru M, Castellanous EJ, Kaneda Y, Nakashima 
Y, Shirasuna K, Sueishi K: Sp1 decoy transfected to carcinoma cells suppresses 
the expression of vascular endothelial growth factor, transforming growth factor 
beta1, and tissue factor and also cell growth and invasion activities. Cancer Res 
2000, 60(22):6531-6536. 
 
405. Borgatti M, Lampronti I, Romanelli A, Pedone C, Saviano M, Bianchi N, Mischiati 
C, Gambari R: Transcription factor decoy molecules based on a peptide nucleic 
acid (PNA)-DNA chimera mimicking Sp1 binding sites. J Biol Chem 2003, 
278(9):7500-7509. 
 
406. Xu X, Hamhouyia F, Thomas SD, Burke TJ, Girvan AC, McGregor WG, Trent 
JO, Miller DM, Bates PJ: Inhibition of DNA replication and induction of S phase 
cell cycle arrest by G-rich oligonucleotides. J Biol Chem 2001, 276(46):43221-
43230. 
 
407. Gately S, Li WW: Multiple roles of COX-2 in tumor angiogenesis: a target for 
antiangiogenic therapy. Semin Oncol 2004, 31(2 Suppl 7):2-11. 
 
408. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl 
Cancer Inst 1998, 90(21):1609-1620. 
 
409. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer 
Inst 1998, 90(20):1529-1536. 
 
410. Abdelrahim M, Safe S: Cyclooxygenase-2 inhibitors decrease vascular 
endothelial growth factor expression in colon cancer cells by enhanced 
degradation of Sp1 and Sp4 proteins. Mol Pharmacol 2005, 68(2):317-329. 
 
411. Vane JR, Botting RM: Anti-inflammatory drugs and their mechanism of action. 
Inflamm Res 1998, 47 Suppl 2:S78-87. 
 
412. Ulrich CM, Bigler J, Potter JD: Non-steroidal anti-inflammatory drugs for cancer 
prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006, 
6(2):130-140. 
 
243 
 
413. Vane JR, Flower RJ, Botting RM: History of aspirin and its mechanism of action. 
Stroke 1990, 21(12 Suppl):IV12-23. 
 
414. Brown JR, DuBois RN: COX-2: a molecular target for colorectal cancer 
prevention. J Clin Oncol 2005, 23(12):2840-2855. 
 
415. Rigas B, Goldman IS, Levine L: Altered eicosanoid levels in human colon 
cancer. J Lab Clin Med 1993, 122(5):518-523. 
 
416. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson 
M, Moher D: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 
inhibitors for primary prevention of colorectal cancer: a systematic review 
prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007, 
146(5):376-389. 
 
417. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson 
M, Moher D: The use of aspirin for primary prevention of colorectal cancer: a 
systematic review prepared for the U.S. Preventive Services Task Force. Ann 
Intern Med 2007, 146(5):365-375. 
 
418. Dai Y, Wang WH: Non-steroidal anti-inflammatory drugs in prevention of gastric 
cancer. World J Gastroenterol 2006, 12(18):2884-2889. 
 
419. Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as 
anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl 
Cancer Inst 2002, 94(4):252-266. 
 
420. Baron JA, Sandler RS: Nonsteroidal anti-inflammatory drugs and cancer 
prevention. Annu Rev Med 2000, 51:511-523. 
 
421. Gupta RA, DuBois RN: Aspirin, NSAIDS, and colon cancer prevention: 
mechanisms? Gastroenterology 1998, 114(5):1095-1098. 
 
422. Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast 
cancer incidence in a prospective study. Epidemiology 1994, 5(2):138-146. 
 
423. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC: Non-steroidal 
anti-inflammatory drug use and the risk of gastric cancer: a systematic review 
and meta-analysis. J Natl Cancer Inst 2003, 95(23):1784-1791. 
 
424. Baron JA: Aspirin and NSAIDs for the prevention of colorectal cancer. Recent 
Results Cancer Res 2009, 181:223-229. 
 
425. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, 
Wakabayashi N, Saunders B, Shen Y, Fujimura T et al: The effect of celecoxib, 
a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 
2000, 342(26):1946-1952. 
 
244 
 
426. Matsuhashi N, Nakajima A, Shinohara K, Oka T, Yazaki Y: Rectal cancer after 
sulindac therapy for a sporadic adenomatous colonic polyp. Am J Gastroenterol 
1998, 93(11):2261-2266. 
 
427. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, 
Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal 
adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 
328(18):1313-1316. 
 
428. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM: Effects of long-
term sulindac therapy on colonic polyposis. Ann Intern Med 1991, 115(12):952-
954. 
 
429. Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tang BD, Bai AH, Sung JJ: 
Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004, 53(2):195-
200. 
 
430. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, Nagano K, Hori 
M: Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer 
xenografts via induction of apoptosis in nude mice. Am J Physiol 1998, 274(6 Pt 
1):G1061-1067. 
 
431. Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, 
Kinzler KW: Sulindac suppresses tumorigenesis in the Min mouse. 
Carcinogenesis 1996, 17(8):1757-1760. 
 
432. Tanaka T, Kojima T, Yoshimi N, Sugie S, Mori H: Inhibitory effect of the non-
steroidal anti-inflammatory drug, indomethacin on the naturally occurring 
carcinogen, 1-hydroxyanthraquinone in male ACI/N rats. Carcinogenesis 1991, 
12(10):1949-1952. 
 
433. Gupta RA, Dubois RN: Colorectal cancer prevention and treatment by inhibition 
of cyclooxygenase-2. Nat Rev Cancer 2001, 1(1):11-21. 
 
434. Chan AT, Ogino S, Fuchs CS: Aspirin use and survival after diagnosis of 
colorectal cancer. JAMA 2009, 302(6):649-658. 
 
435. Chan TA: Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer 
chemoprevention. Lancet Oncol 2002, 3(3):166-174. 
 
436. Chan TA, Morin PJ, Vogelstein B, Kinzler KW: Mechanisms underlying 
nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S 
A 1998, 95(2):681-686. 
 
437. Jana NR: NSAIDs and apoptosis. Cell Mol Life Sci 2008, 65(9):1295-1301. 
 
 
245 
 
438. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch 
R, Eisen G, Agrawal NM, Stenson WF et al: Gastrointestinal toxicity with 
celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and 
rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib 
Long-term Arthritis Safety Study. JAMA 2000, 284(10):1247-1255. 
 
439. Hinz B, Renner B, Brune K: Drug insight: cyclo-oxygenase-2 inhibitors--a critical 
appraisal. Nat Clin Pract Rheumatol 2007, 3(10):552-560; quiz 551 p following 
589. 
 
440. Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S: Molecular 
biology of sporadic gastric cancer: prognostic indicators and novel therapeutic 
approaches. Cancer Treat Rev 2004, 30(5):451-459. 
 
441. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, Kim HS, Nam DK, Lee KB, 
Kim HC: Increased expression of cyclooxygenase-2 protein in human gastric 
carcinoma. Clin Cancer Res 2000, 6(2):519-525. 
 
442. Soydan AS, Gaffen JD, Weech PK, Tremblay NM, Kargman S, O'Neill G, 
Bennett A, Tavares IA: Cytosolic phospholipase A2, cyclo-oxygenases and 
arachidonate in human stomach tumours. Eur J Cancer 1997, 33(9):1508-1512. 
 
443. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial 
cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 
83(3):493-501. 
 
444. Scorrano L, Penzo D, Petronilli V, Pagano F, Bernardi P: Arachidonic acid 
causes cell death through the mitochondrial permeability transition. Implications 
for tumor necrosis factor-alpha aopototic signaling. J Biol Chem 2001, 
276(15):12035-12040. 
 
445. Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM: Intracellular 
unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci U S A 2000, 
97(21):11280-11285. 
 
446. Hannun YA: Functions of ceramide in coordinating cellular responses to stress. 
Science 1996, 274(5294):1855-1859. 
 
447. Uefuji K, Ichikura T, Mochizuki H: Cyclooxygenase-2 expression is related to 
prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin 
Cancer Res 2000, 6(1):135-138. 
 
448. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas 
B: Effects of nonsteroidal anti-inflammatory drugs on proliferation and on 
induction of apoptosis in colon cancer cells by a prostaglandin-independent 
pathway. Biochem Pharmacol 1996, 52(2):237-245. 
 
246 
 
449. Soh JW, Weinstein IB: Role of COX-independent targets of NSAIDs and related 
compounds in cancer prevention and treatment. Prog Exp Tumor Res 2003, 
37:261-285. 
 
450. Zhang X, Morham SG, Langenbach R, Young DA: Malignant transformation and 
antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on 
cyclooxygenase-null embryo fibroblasts. J Exp Med 1999, 190(4):451-459. 
 
451. O'Neill EA: A new target for aspirin. Nature 1998, 396(6706):15, 17. 
 
452. Wong BC, Jiang X, Fan XM, Lin MC, Jiang SH, Lam SK, Kung HF: Suppression 
of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by 
cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 2003, 22(8):1189-1197. 
 
453. Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and 
salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 
396(6706):77-80. 
 
454. Kopp E, Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. 
Science 1994, 265(5174):956-959. 
 
455. Gu Q, Wang JD, Xia HH, Lin MC, He H, Zou B, Tu SP, Yang Y, Liu XG, Lam SK 
et al: Activation of the caspase-8/Bid and Bax pathways in aspirin-induced 
apoptosis in gastric cancer. Carcinogenesis 2005, 26(3):541-546. 
 
456. Ho CC, Yang XW, Lee TL, Liao PH, Yang SH, Tsai CH, Chou MY: Activation of 
p53 signalling in acetylsalicylic acid-induced apoptosis in OC2 human oral 
cancer cells. Eur J Clin Invest 2003, 33(10):875-882. 
 
457. Zhou XM, Wong BC, Fan XM, Zhang HB, Lin MC, Kung HF, Fan DM, Lam SK: 
Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells 
through up-regulation of bax and bak. Carcinogenesis 2001, 22(9):1393-1397. 
 
458. Redlak MJ, Power JJ, Miller TA: Role of mitochondria in aspirin-induced 
apoptosis in human gastric epithelial cells. Am J Physiol Gastrointest Liver 
Physiol 2005, 289(4):G731-738. 
 
459. Zimmermann KC, Waterhouse NJ, Goldstein JC, Schuler M, Green DR: Aspirin 
induces apoptosis through release of cytochrome c from mitochondria. 
Neoplasia 2000, 2(6):505-513. 
 
460. Pique M, Barragan M, Dalmau M, Bellosillo B, Pons G, Gil J: Aspirin induces 
apoptosis through mitochondrial cytochrome c release. FEBS Lett 2000, 480(2-
3):193-196. 
 
 
 
247 
 
461. Bellosillo B, Pique M, Barragan M, Castano E, Villamor N, Colomer D, 
Montserrat E, Pons G, Gil J: Aspirin and salicylate induce apoptosis and 
activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 1998, 
92(4):1406-1414. 
 
462. Dikshit P, Chatterjee M, Goswami A, Mishra A, Jana NR: Aspirin induces 
apoptosis through the inhibition of proteasome function. J Biol Chem 2006, 
281(39):29228-29235. 
 
463. Huang YC, Chuang LY, Hung WC: Mechanisms underlying nonsteroidal anti-
inflammatory drug-induced p27(Kip1) expression. Mol Pharmacol 2002, 
62(6):1515-1521. 
 
464. Luciani MG, Campregher C, Gasche C: Aspirin blocks proliferation in colon cells 
by inducing a G1 arrest and apoptosis through activation of the checkpoint 
kinase ATM. Carcinogenesis 2007, 28(10):2207-2217. 
 
465. Bock JM, Menon SG, Goswami PC, Sinclair LL, Bedford NS, Domann FE, Trask 
DK: Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative 
activity is mediated through p21-induced G1 arrest and E2F inhibition. Mol 
Carcinog 2007, 46(10):857-864. 
 
466. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, 
Ahnen DJ: Apoptosis primarily accounts for the growth-inhibitory properties of 
sulindac metabolites and involves a mechanism that is independent of 
cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 
1997, 57(12):2452-2459. 
 
467. Adachi M, Sakamoto H, Kawamura R, Wang W, Imai K, Shinomura Y: 
Nonsteroidal anti-inflammatory drugs and oxidative stress in cancer cells. Histol 
Histopathol 2007, 22(4):437-442. 
 
468. Gao J, Liu X, Rigas B: Nitric oxide-donating aspirin induces apoptosis in human 
colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci U S 
A 2005, 102(47):17207-17212. 
 
469. Tsutsumi S, Gotoh T, Tomisato W, Mima S, Hoshino T, Hwang HJ, Takenaka H, 
Tsuchiya T, Mori M, Mizushima T: Endoplasmic reticulum stress response is 
involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death 
Differ 2004, 11(9):1009-1016. 
 
470. Wong BC, Jiang XH, Lin MC, Tu SP, Cui JT, Jiang SH, Wong WM, Yuen MF, 
Lam SK, Kung HF: Cyclooxygenase-2 inhibitor (SC-236) suppresses activator 
protein-1 through c-Jun NH2-terminal kinase. Gastroenterology 2004, 
126(1):136-147. 
 
 
248 
 
471. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J: Sodium 
salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits 
tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein 
kinase activation. Proc Natl Acad Sci U S A 1997, 94(7):2869-2873. 
 
472. Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, Brenner DE, Lotan R, Fischer 
SM, Lippman SM: 15-LOX-1: a novel molecular target of nonsteroidal anti-
inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer 
Inst 2000, 92(14):1136-1142. 
 
473. Pasricha PJ, Bedi A, O'Connor K, Rashid A, Akhtar AJ, Zahurak ML, Piantadosi 
S, Hamilton SR, Giardiello FM: The effects of sulindac on colorectal proliferation 
and apoptosis in familial adenomatous polyposis. Gastroenterology 1995, 
109(3):994-998. 
 
474. Shiff SJ, Qiao L, Tsai LL, Rigas B: Sulindac sulfide, an aspirin-like compound, 
inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-
29 colon adenocarcinoma cells. J Clin Invest 1995, 96(1):491-503. 
 
475. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan 
HZ, Fischer SM, Lippman SM: The 15-lipoxygenase-1 product 13-S-
hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in 
colorectal cancer cells. Proc Natl Acad Sci U S A 2003, 100(17):9968-9973. 
 
476. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, 
Devchand P, Wahli W, Willson TM, Lenhard JM et al: Fatty acids and 
eicosanoids regulate gene expression through direct interactions with 
peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad 
Sci U S A 1997, 94(9):4318-4323. 
 
477. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, 
Borst P: The human multidrug resistance protein MRP4 functions as a 
prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory 
drugs. Proc Natl Acad Sci U S A 2003, 100(16):9244-9249. 
 
478. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB: Nonsteroidal anti-inflammatory 
agents differ in their ability to suppress NF-kappaB activation, inhibition of 
expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell 
proliferation. Oncogene 2004, 23(57):9247-9258. 
 
479. Andrews J, Djakiew D, Krygier S, Andrews P: Superior effectiveness of 
ibuprofen compared with other NSAIDs for reducing the survival of human 
prostate cancer cells. Cancer Chemother Pharmacol 2002, 50(4):277-284. 
 
480. Garg A, Aggarwal BB: Nuclear transcription factor-kappaB as a target for cancer 
drug development. Leukemia 2002, 16(6):1053-1068. 
 
249 
 
481. Mattson MP, Camandola S: NF-kappaB in neuronal plasticity and 
neurodegenerative disorders. J Clin Invest 2001, 107(3):247-254. 
 
482. Baeuerle PA, Baltimore D: NF-kappa B: ten years after. Cell 1996, 87(1):13-20. 
 
483. McCarty MF, Block KI: Preadministration of high-dose salicylates, suppressors 
of NF-kappaB activation, may increase the chemosensitivity of many cancers: 
an example of proapoptotic signal modulation therapy. Integr Cancer Ther 2006, 
5(3):252-268. 
 
484. Kim KM, Song JJ, An JY, Kwon YT, Lee YJ: Pretreatment of acetylsalicylic acid 
promotes tumor necrosis factor-related apoptosis-inducing ligand-induced 
apoptosis by down-regulating BCL-2 gene expression. J Biol Chem 2005, 
280(49):41047-41056. 
 
485. Stark LA, Reid K, Sansom OJ, Din FV, Guichard S, Mayer I, Jodrell DI, Clarke 
AR, Dunlop MG: Aspirin activates the NF-kappaB signalling pathway and 
induces apoptosis in intestinal neoplasia in two in vivo models of human 
colorectal cancer. Carcinogenesis 2007, 28(5):968-976. 
 
486. Din FV, Stark LA, Dunlop MG: Aspirin-induced nuclear translocation of 
NFkappaB and apoptosis in colorectal cancer is independent of p53 status and 
DNA mismatch repair proficiency. Br J Cancer 2005, 92(6):1137-1143. 
 
487. Reed JC: Cytochrome c: can't live with it--can't live without it. Cell 1997, 
91(5):559-562. 
 
488. Liu XH, Yao S, Kirschenbaum A, Levine AC: NS398, a selective 
cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 
expression in LNCaP cells. Cancer Res 1998, 58(19):4245-4249. 
 
489. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B: Role of BAX in the apoptotic 
response to anticancer agents. Science 2000, 290(5493):989-992. 
 
490. Zhu GH, Wong BC, Slosberg ED, Eggo MC, Ching CK, Yuen ST, Lai KC, Soh 
JW, Weinstein IB, Lam SK: Overexpression of protein kinase C-beta1 
isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial 
cells. Gastroenterology 2000, 118(3):507-514. 
 
491. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: 
destruction for the sake of construction. Physiol Rev 2002, 82(2):373-428. 
 
492. Orlowski RZ: The role of the ubiquitin-proteasome pathway in apoptosis. Cell 
Death Differ 1999, 6(4):303-313. 
 
493. Jana NR, Dikshit P, Goswami A, Nukina N: Inhibition of proteasomal function by 
curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 2004, 
279(12):11680-11685. 
250 
 
 
494. Drexler HC, Risau W, Konerding MA: Inhibition of proteasome function induces 
programmed cell death in proliferating endothelial cells. FASEB J 2000, 
14(1):65-77. 
 
495. Lopes UG, Erhardt P, Yao R, Cooper GM: p53-dependent induction of apoptosis 
by proteasome inhibitors. J Biol Chem 1997, 272(20):12893-12896. 
 
496. Bush KT, Goldberg AL, Nigam SK: Proteasome inhibition leads to a heat-shock 
response, induction of endoplasmic reticulum chaperones, and thermotolerance. 
J Biol Chem 1997, 272(14):9086-9092. 
 
497. Kaufman RJ: Orchestrating the unfolded protein response in health and disease. 
J Clin Invest 2002, 110(10):1389-1398. 
 
498. Pillinger MH, Capodici C, Rosenthal P, Kheterpal N, Hanft S, Philips MR, 
Weissmann G: Modes of action of aspirin-like drugs: salicylates inhibit erk 
activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci U S A 
1998, 95(24):14540-14545. 
 
499. Rigas B: The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in 
the chemoprevention of colorectal neoplasia. Curr Opin Gastroenterol 2007, 
23(1):55-59. 
 
500. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani 
BM, De Placido S, Bianco AR, Ciardiello F: Combination of a selective 
cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase 
inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor 
and antiangiogenic effect. Clin Cancer Res 2003, 9(4):1566-1572. 
 
501. Wagenaar-Miller RA, Hanley G, Shattuck-Brandt R, DuBois RN, Bell RL, 
Matrisian LM, Morgan DW: Cooperative effects of matrix metalloproteinase and 
cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer 2003, 
88(9):1445-1452. 
 
502. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois 
RN: Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal 
carcinoma growth. Gastroenterology 2001, 120(7):1713-1719. 
 
503. Kune GA, Kune S, Watson LF: Colorectal cancer risk, chronic illnesses, 
operations, and medications: case control results from the Melbourne Colorectal 
Cancer Study. Cancer Res 1988, 48(15):4399-4404. 
 
504. Bosetti C, Gallus S, La Vecchia C: Aspirin and cancer risk: an updated 
quantitative review to 2005. Cancer Causes Control 2006, 17(7):871-888. 
 
251 
 
505. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs 
CS: Aspirin dose and duration of use and risk of colorectal cancer in men. 
Gastroenterology 2008, 134(1):21-28. 
 
506. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, 
Fuchs CS: Long-term use of aspirin and nonsteroidal anti-inflammatory drugs 
and risk of colorectal cancer. JAMA 2005, 294(8):914-923. 
 
507. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE: 
Aspirin intake and survival after breast cancer. J Clin Oncol 2010, 28(9):1467-
1472. 
 
508. Lebeau B, Chastang C, Muir JF, Vincent J, Massin F, Fabre C: No effect of an 
antiaggregant treatment with aspirin in small cell lung cancer treated with 
CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 
patients. The "Petites Cellules" Group. Cancer 1993, 71(5):1741-1745. 
 
509. Creagan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, Flaum MA, 
Buroker TR, Geeraerts LH, Veeder MH, Gesme DH, Jr. et al: A randomized 
prospective assessment of recombinant leukocyte A human interferon with or 
without aspirin in advanced renal adenocarcinoma. J Clin Oncol 1991, 
9(12):2104-2109. 
 
510. Lipton A, Scialla S, Harvey H, Dixon R, Gordon R, Hamilton R, Ramsey H, Weltz 
M, Heckard R, White D: Adjuvant antiplatelet therapy with aspirin in colo-rectal 
cancer. J Med 1982, 13(5-6):419-429. 
 
511. Krymchantowski AV, Adriano M, Fernandes D: Tolfenamic acid decreases 
migraine recurrence when used with sumatriptan. Cephalalgia 1999, 19(3):186-
187. 
 
512. Eskerod O: Gastrointestinal tolerance studies on tolfenamic acid in humans and 
animals. Pharmacol Toxicol 1994, 75 Suppl 2:44-48. 
 
513. Isomaki H, Martio J, Kaarela K, Kajander A, Koota K, Lehtinen K, Luukkainen R, 
Martio T, Nissila M, Nuotio P et al: Comparison of the analgesic effect of ten 
nonsteroidal anti-inflammatory drugs. Br J Rheumatol 1984, 23(1):61-65. 
 
514. Keinanen S, Simila S, Kouvalainen K: Oral antipyretic therapy: evaluation of the 
N-aryl-anthranilic acid derivatives mefenamic acid, tolfenamic acid and 
flufenamic acid. Eur J Clin Pharmacol 1978, 13(5):331-344. 
 
515. Kim JH, Jung JY, Shim JH, Kim J, Choi KH, Shin JA, Choi ES, Lee SO, 
Chintharlapalli S, Kwon KH et al: Apoptotic Effect of Tolfenamic Acid in KB 
Human Oral Cancer Cells: Possible Involvement of the p38 MAPK Pathway. J 
Clin Biochem Nutr 2010, 47(1):74-80. 
 
252 
 
516. Basha R, Baker CH, Sankpal UT, Ahmad S, Safe S, Abbruzzese JL, Abdelrahim 
M: Therapeutic applications of NSAIDS in cancer: special emphasis on 
tolfenamic acid. Front Biosci (Schol Ed) 2011, 3:797-805. 
 
517. Gilpin RK, Zhou W: Infrared studies of the polymorphic states of the fenamates. 
J Pharm Biomed Anal 2005, 37(3):509-515. 
 
518. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S: Tolfenamic acid and 
pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl 
Cancer Inst 2006, 98(12):855-868. 
 
519. Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S: The nonsteroidal anti-
inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell 
and tumor growth by repressing erbB2 expression. Mol Cancer Ther 2009, 
8(5):1207-1217. 
 
520. Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh 
A, Baker C, Herrera L, Safe S: Tolfenamic acid inhibits esophageal cancer 
through repression of specificity proteins and c-Met. Carcinogenesis 2009, 
30(7):1193-1201. 
 
521. Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, 
Sheikh-Hamad D, Abudayyeh A, Alvarado B et al: Tolfenamic acid decreases c-
Met expression through Sp proteins degradation and inhibits lung cancer cells 
growth and tumor formation in orthotopic mice. Invest New Drugs 2011, 
29(1):41-51. 
 
522. Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha 
MR, Abdelrahim M: Tolfenamic acid enhances pancreatic cancer cell and tumor 
response to radiation therapy by inhibiting survivin protein expression. Mol 
Cancer Ther 2009, 8(3):533-542. 
 
523. Lee SH, Bahn JH, Choi CK, Whitlock NC, English AE, Safe S, Baek SJ: ESE-
1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal 
cancer cells. Mol Cancer Ther 2008, 7(12):3739-3750. 
 
524. Basha R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, Edwards JR, 
Holloway RW, Kaja S, Abdelrahim M: Tolfenamic acid inhibits ovarian cancer 
cell growth and decreases the expression of c-Met and survivin through 
suppressing specificity protein transcription factors. Gynecol Oncol 2011, 
122(1):163-170. 
 
525. Kakizawa H, Matsui F, Tokita Y, Hirano K, Ida M, Nakanishi K, Watanabe M, 
Sato Y, Okumura A, Kojima S et al: Neuroprotective effect of nipradilol, an NO 
donor, on hypoxic-ischemic brain injury of neonatal rats. Early Hum Dev 2007, 
83(8):535-540. 
 
253 
 
526. Gresele P, Momi S: Pharmacologic profile and therapeutic potential of NCX 
4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc 
Drug Rev 2006, 24(2):148-168. 
 
527. Thatcher GR, Bennett BM, Reynolds JN: NO chimeras as therapeutic agents in 
Alzheimer's disease. Curr Alzheimer Res 2006, 3(3):237-245. 
 
528. Kimura I: Medical benefits of using natural compounds and their derivatives 
having multiple pharmacological actions. Yakugaku Zasshi 2006, 126(3):133-
143. 
 
529. Zhang ZG, Zhang YH, Ji H, Qiu SG, Feng XC: [Design, synthesis and 
antiasthmatic activities of NO-donating seratrodast derivatives]. Yao Xue Xue 
Bao 2004, 39(9):705-710. 
 
530. Kaza CS, Kashfi K, Rigas B: Colon cancer prevention with NO-releasing 
NSAIDs. Prostaglandins Other Lipid Mediat 2002, 67(2):107-120. 
 
531. del Soldato P, Sorrentino R, Pinto A: NO-aspirins: a class of new anti-
inflammatory and antithrombotic agents. Trends Pharmacol Sci 1999, 20(8):319-
323. 
 
532. Rigas B: Novel agents for cancer prevention based on nitric oxide. Biochem Soc 
Trans 2007, 35(Pt 5):1364-1368. 
 
533. Kitagawa H, Takeda F, Kohei H: Effect of endothelium-derived relaxing factor on 
the gastric lesion induced by HCl in rats. J Pharmacol Exp Ther 1990, 
253(3):1133-1137. 
 
534. MacNaughton WK, Cirino G, Wallace JL: Endothelium-derived relaxing factor 
(nitric oxide) has protective actions in the stomach. Life Sci 1989, 45(20):1869-
1876. 
 
535. Ellis JL, Augustyniak ME, Cochran ED, Earl RA, Garvey DS, Gordon LJ, Janero 
DR, Khanapure SP, Letts LG, Melim TL et al: NMI-1182, a gastro-protective 
cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology 2005, 
12(5-6):521-534. 
 
536. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A: 
Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a 
proof of concept endoscopic study. Gastroenterology 2003, 124(3):600-607. 
 
537. Tesei A, Rosetti M, Ulivi P, Fabbri F, Medri L, Vannini I, Bolla M, Amadori D, Zoli 
W: Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a 
novel nitric oxide-releasing aspirin, in colon cancer cell lines. J Transl Med 2007, 
5:52. 
 
254 
 
538. Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, Patlolla JM, Simi B, 
Kopelovich L, Rigas B: Nitric oxide-releasing aspirin and indomethacin are 
potent inhibitors against colon cancer in azoxymethane-treated rats: effects on 
molecular targets. Mol Cancer Ther 2006, 5(6):1530-1538. 
 
539. Rosetti M, Tesei A, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Amadori D, Bolla 
M, Zoli W: Molecular characterization of cytotoxic and resistance mechanisms 
induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines. 
Apoptosis 2006, 11(8):1321-1330. 
 
540. Leonetti C, Scarsella M, Zupi G, Zoli W, Amadori D, Medri L, Fabbri F, Rosetti 
M, Ulivi P, Cecconetto L et al: Efficacy of a nitric oxide-releasing nonsteroidal 
anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in 
vitro and xenografts. Mol Cancer Ther 2006, 5(4):919-926. 
 
541. Fabbri F, Brigliadori G, Ulivi P, Tesei A, Vannini I, Rosetti M, Bravaccini S, 
Amadori D, Bolla M, Zoli W: Pro-apoptotic effect of a nitric oxide-donating 
NSAID, NCX 4040, on bladder carcinoma cells. Apoptosis 2005, 10(5):1095-
1103. 
 
542. Tesei A, Ulivi P, Fabbri F, Rosetti M, Leonetti C, Scarsella M, Zupi G, Amadori 
D, Bolla M, Zoli W: In vitro and in vivo evaluation of NCX 4040 cytotoxic activity 
in human colon cancer cell lines. J Transl Med 2005, 3(1):7. 
 
543. Huguenin S, Vacherot F, Fleury-Feith J, Riffaud JP, Chopin DK, Bolla M, 
Jaurand MC: Evaluation of the antitumoral potential of different nitric oxide-
donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human 
urological tumor cell lines. Cancer Lett 2005, 218(2):163-170. 
 
544. Royle JS, Ross JA, Ansell I, Bollina P, Tulloch DN, Habib FK: Nitric oxide 
donating nonsteroidal anti-inflammatory drugs induce apoptosis in human 
prostate cancer cell systems and human prostatic stroma via caspase-3. J Urol 
2004, 172(1):338-344. 
 
545. Huguenin S, Vacherot F, Kheuang L, Fleury-Feith J, Jaurand MC, Bolla M, 
Riffaud JP, Chopin DK: Antiproliferative effect of nitrosulindac (NCX 1102), a 
new nitric oxide-donating non-steroidal anti-inflammatory drug, on human 
bladder carcinoma cell lines. Mol Cancer Ther 2004, 3(3):291-298. 
 
546. Tesei A, Ricotti L, Ulivi P, Medri L, Amadori D, Zoli W: NCX 4016, a nitric oxide-
releasing aspirin derivative, exhibits a significant antiproliferative effect and 
alters cell cycle progression in human colon adenocarcinoma cell lines. Int J 
Oncol 2003, 22(6):1297-1302. 
 
547. Kashfi K, Ryan Y, Qiao LL, Williams JL, Chen J, Del Soldato P, Traganos F, 
Rigas B: Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the 
growth of various cultured human cancer cells: evidence of a tissue type-
independent effect. J Pharmacol Exp Ther 2002, 303(3):1273-1282. 
255 
 
 
548. Williams JL, Borgo S, Hasan I, Castillo E, Traganos F, Rigas B: Nitric oxide-
releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of 
human colon cancer cell lines more effectively than traditional NSAIDs: 
implications for colon cancer chemoprevention. Cancer Res 2001, 61(8):3285-
3289. 
 
549. Wink DA, Cook JA, Kim SY, Vodovotz Y, Pacelli R, Krishna MC, Russo A, 
Mitchell JB, Jourd'heuil D, Miles AM et al: Superoxide modulates the oxidation 
and nitrosation of thiols by nitric oxide-derived reactive intermediates. Chemical 
aspects involved in the balance between oxidative and nitrosative stress. J Biol 
Chem 1997, 272(17):11147-11151. 
 
550. Carini M, Aldini G, Orioli M, Piccoli A, Rossoni G, Maffei Facino R: Nitric oxide 
release and distribution following oral and intraperitoneal administration of 
nitroaspirin (NCX 4016) in the rat. Life Sci 2004, 74(26):3291-3305. 
 
551. Carini M, Aldini G, Orioli M, Piccoli A, Tocchetti P, Facino RM: 
Chemiluminescence and LC-MS/MS analyses for the study of nitric oxide 
release and distribution following oral administration of nitroaspirin (NCX 4016) 
in healthy volunteers. J Pharm Biomed Anal 2004, 35(2):277-287. 
 
552. Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, Kalala S, 
Traganos F, Benardini F, del Soldato P et al: NO-donating nonsteroidal 
antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently 
than traditional NSAIDs: a general pharmacological property? Biochem 
Pharmacol 2004, 67(12):2197-2205. 
 
553. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B: NO-
donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. 
Biochem Biophys Res Commun 2004, 313(3):784-788. 
 
554. Zhou H, Huang L, Sun Y, Rigas B: Nitric oxide-donating aspirin inhibits the 
growth of pancreatic cancer cells through redox-dependent signaling. Cancer 
Lett 2009, 273(2):292-299. 
 
555. Selvendiran K, Bratasz A, Tong L, Ignarro LJ, Kuppusamy P: NCX-4016, a nitro-
derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 
proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell 
Cycle 2008, 7(1):81-88. 
 
556. Ouyang N, Williams JL, Tsioulias GJ, Gao J, Iatropoulos MJ, Kopelovich L, 
Kashfi K, Rigas B: Nitric oxide-donating aspirin prevents pancreatic cancer in a 
hamster tumor model. Cancer Res 2006, 66(8):4503-4511. 
 
557. Rigas B, Kashfi K: Nitric-oxide-donating NSAIDs as agents for cancer 
prevention. Trends Mol Med 2004, 10(7):324-330. 
 
256 
 
558. Spiegel A, Hundley TR, Chen J, Gao J, Ouyang N, Liu X, Go MF, Tsioulias GJ, 
Kashfi K, Rigas B: NO-donating aspirin inhibits both the expression and catalytic 
activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. 
Biochem Pharmacol 2005, 70(7):993-1000. 
 
559. Williams JL, Ji P, Ouyang N, Liu X, Rigas B: NO-donating aspirin inhibits the 
activation of NF-kappaB in human cancer cell lines and Min mice. 
Carcinogenesis 2008, 29(2):390-397. 
 
560. Williams JL, Nath N, Chen J, Hundley TR, Gao J, Kopelovich L, Kashfi K, Rigas 
B: Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating 
aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell 
factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: 
implications for chemoprevention. Cancer Res 2003, 63(22):7613-7618. 
 
561. Gao J, Kashfi K, Liu X, Rigas B: NO-donating aspirin induces phase II enzymes 
in vitro and in vivo. Carcinogenesis 2006, 27(4):803-810. 
 
562. McIlhatton MA, Tyler J, Burkholder S, Ruschoff J, Rigas B, Kopelovich L, Fishel 
R: Nitric oxide-donating aspirin derivatives suppress microsatellite instability in 
mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. 
Cancer Res 2007, 67(22):10966-10975. 
 
563. Hagos GK, Abdul-Hay SO, Sohn J, Edirisinghe PD, Chandrasena RE, Wang Z, 
Li Q, Thatcher GR: Anti-inflammatory, antiproliferative, and cytoprotective 
activity of NO chimera nitrates of use in cancer chemoprevention. Mol 
Pharmacol 2008, 74(5):1381-1391. 
 
564. Wang D, Dubois RN: Prostaglandins and cancer. Gut 2006, 55(1):115-122. 
 
565. Halaschek-Wiener J, Wacheck V, Schlagbauer-Wadl H, Wolff K, Kloog Y, 
Jansen B: A novel Ras antagonist regulates both oncogenic Ras and the tumor 
suppressor p53 in colon cancer cells. Mol Med 2000, 6(8):693-704. 
 
566. Druesne N, Pagniez A, Mayeur C, Thomas M, Cherbuy C, Duee PH, Martel P, 
Chaumontet C: Diallyl disulfide (DADS) increases histone acetylation and 
p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 
2004, 25(7):1227-1236. 
 
567. Knowles LM, Milner JA: Diallyl disulfide induces ERK phosphorylation and alters 
gene expression profiles in human colon tumor cells. J Nutr 2003, 133(9):2901-
2906. 
 
568. Harrison LE, Wang QM, Studzinski GP: Butyrate-induced G2/M block in Caco-2 
colon cancer cells is associated with decreased p34cdc2 activity. Proc Soc Exp 
Biol Med 1999, 222(2):150-156. 
 
257 
 
569. Wargovich MJ, Chen CD, Jimenez A, Steele VE, Velasco M, Stephens LC, Price 
R, Gray K, Kelloff GJ: Aberrant crypts as a biomarker for colon cancer: 
evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol 
Biomarkers Prev 1996, 5(5):355-360. 
 
570. Hagos GK, Carroll RE, Kouznetsova T, Li Q, Toader V, Fernandez PA, 
Swanson SM, Thatcher GR: Colon cancer chemoprevention by a novel NO 
chimera that shows anti-inflammatory and antiproliferative activity in vitro and in 
vivo. Mol Cancer Ther 2007, 6(8):2230-2239. 
 
571. Chung HT, Pae HO, Choi BM, Billiar TR, Kim YM: Nitric oxide as a bioregulator 
of apoptosis. Biochem Biophys Res Commun 2001, 282(5):1075-1079. 
 
572. Pathi SS, Jutooru I, Chadalapaka G, Sreevalsan S, Anand S, Thatcher GR, Safe 
S: GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a 
reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. 
Mol Cancer Res 2011, 9(2):195-202. 
 
573. Szent-Gyorgyi A: Observations on the function of peroxidase systems and the 
chemistry of the adrenal cortex: Description of a new carbohydrate derivative. 
Biochem J 1928, 22(6):1387-1409. 
 
574. Svirbely JL, Szent-Gyorgyi A: The chemical nature of vitamin C. Biochem J 
1933, 27(1):279-285. 
 
575. King CG, Waugh WA: The chemical nature of vitamin C. Science 1932, 
75(1944):357-358. 
 
576. Banhegyi G, Braun L, Csala M, Puskas F, Mandl J: Ascorbate metabolism and 
its regulation in animals. Free Radic Biol Med 1997, 23(5):793-803. 
 
577. Verrax J, Calderon PB: The controversial place of vitamin C in cancer treatment. 
Biochem Pharmacol 2008, 76(12):1644-1652. 
 
578. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter 
E, Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer 
cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl 
Acad Sci U S A 2005, 102(38):13604-13609. 
 
579. Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA: Intravenous ascorbate as a 
tumor cytotoxic chemotherapeutic agent. Med Hypotheses 1995, 44(3):207-213. 
 
580. De Laurenzi V, Melino G, Savini I, Annicchiarico-Petruzzelli M, Finazzi-Agro A, 
Avigliano L: Cell death by oxidative stress and ascorbic acid regeneration in 
human neuroectodermal cell lines. Eur J Cancer 1995, 31A(4):463-466. 
 
258 
 
581. Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial 
of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol 
Interact 1974, 9(4):285-315. 
 
582. Golde DW: Vitamin C in cancer. Integr Cancer Ther 2003, 2(2):158-159. 
 
583. Cameron E, Pauling L, Leibovitz B: Ascorbic acid and cancer: a review. Cancer 
Res 1979, 39(3):663-681. 
 
584. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of 
cancer: reevaluation of prolongation of survival times in terminal human cancer. 
Proc Natl Acad Sci U S A 1978, 75(9):4538-4542. 
 
585. Padayatty SJ, Levine M: Reevaluation of ascorbate in cancer treatment: 
emerging evidence, open minds and serendipity. J Am Coll Nutr 2000, 
19(4):423-425. 
 
586. Wittes RE: Vitamin C and cancer. N Engl J Med 1985, 312(3):178-179. 
 
587. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM: High-
dose vitamin C versus placebo in the treatment of patients with advanced 
cancer who have had no prior chemotherapy. A randomized double-blind 
comparison. N Engl J Med 1985, 312(3):137-141. 
 
588. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, Frytak 
S: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with 
advanced cancer. A controlled trial. N Engl J Med 1979, 301(13):687-690. 
 
589. Cameron E, Rotman D: Ascorbic acid, cell proliferation, and cancer. Lancet 
1972, 1(7749):542. 
 
590. Mc CW: Cancer: a collagen disease, secondary to a nutritional deficiency. Arch 
Pediatr 1959, 76(4):166-171. 
 
591. Mc CW: Cancer: the preconditioning factor in pathogenesis; a new etiologic 
approach. Arch Pediatr 1954, 71(10):313-322. 
 
592. Cameron E, Pauling L: Ascorbic acid and the glycosaminoglycans. An 
orthomolecular approach to cancer and other diseases. Oncology 1973, 
27(2):181-192. 
 
593. Head KA: Ascorbic acid in the prevention and treatment of cancer. Altern Med 
Rev 1998, 3(3):174-186. 
 
594. Lee WJ: The prospects of vitamin C in cancer therapy. Immune Netw 2009, 
9(5):147-152. 
 
259 
 
595. Cameron E, Campbell A: Innovation vs. quality control: an 'unpublishable' 
clinical trial of supplemental ascorbate in incurable cancer. Med Hypotheses 
1991, 36(3):185-189. 
 
596. Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M: High-dose vitamin C (ascorbic 
acid) therapy in the treatment of patients with advanced cancer. Anticancer Res 
2009, 29(3):809-815. 
 
597. Block KI, Mead MN: Vitamin C in alternative cancer treatment: historical 
background. Integr Cancer Ther 2003, 2(2):147-154. 
 
598. Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena LR, Jr., Wang Y, 
Levine M: Pharmacokinetic model of ascorbic acid in healthy male volunteers 
during depletion and repletion. Pharm Res 1997, 14(9):1133-1139. 
 
599. Omaye ST, Skala JH, Jacob RA: Plasma ascorbic acid in adult males: effects of 
depletion and supplementation. Am J Clin Nutr 1986, 44(2):257-264. 
 
600. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, 
Levine M: Vitamin C pharmacokinetics: implications for oral and intravenous 
use. Ann Intern Med 2004, 140(7):533-537. 
 
601. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko 
J, Levine M: Pharmacologic doses of ascorbate act as a prooxidant and 
decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U 
S A 2008, 105(32):11105-11109. 
 
602. Shamim U, Hanif S, Ullah MF, Azmi AS, Bhat SH, Hadi SM: Plant polyphenols 
mobilize nuclear copper in human peripheral lymphocytes leading to oxidatively 
generated DNA breakage: implications for an anticancer mechanism. Free 
Radic Res 2008, 42(8):764-772. 
 
603. Halliwell B: Oxidative stress in cell culture: an under-appreciated problem? 
FEBS Lett 2003, 540(1-3):3-6. 
 
604. Clement MV, Long LH, Ramalingam J, Halliwell B: The cytotoxicity of dopamine 
may be an artefact of cell culture. J Neurochem 2002, 81(3):414-421. 
 
605. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, 
Pooput C, Kirk KL, Buettner GR et al: Ascorbate in pharmacologic 
concentrations selectively generates ascorbate radical and hydrogen peroxide in 
extracellular fluid in vivo. Proc Natl Acad Sci U S A 2007, 104(21):8749-8754. 
 
606. Englard S, Seifter S: The biochemical functions of ascorbic acid. Annu Rev Nutr 
1986, 6:365-406. 
 
607. Oberley TD, Oberley LW: Antioxidant enzyme levels in cancer. Histol 
Histopathol 1997, 12(2):525-535. 
260 
 
 
608. Davies KJ: The broad spectrum of responses to oxidants in proliferating cells: a 
new paradigm for oxidative stress. IUBMB Life 1999, 48(1):41-47. 
 
609. Riordan HD, Casciari JJ, Gonzalez MJ, Riordan NH, Miranda-Massari JR, 
Taylor P, Jackson JA: A pilot clinical study of continuous intravenous ascorbate 
in terminal cancer patients. P R Health Sci J 2005, 24(4):269-276. 
 
610. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, 
Rousseau C, Robitaille L, Miller WH, Jr.: Phase I clinical trial of intravenous 
ascorbic acid in advanced malignancy. Ann Oncol 2008, 19(11):1969-1974. 
 
611. Kimoto E, Tanaka H, Gyotoku J, Morishige F, Pauling L: Enhancement of 
antitumor activity of ascorbate against Ehrlich ascites tumor cells by the 
copper:glycylglycylhistidine complex. Cancer Res 1983, 43(2):824-828. 
 
612. Frei B, Yamamoto Y, Niclas D, Ames BN: Evaluation of an isoluminol 
chemiluminescence assay for the detection of hydroperoxides in human blood 
plasma. Anal Biochem 1988, 175(1):120-130. 
 
613. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G: Aspirin 
and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer 
2011, 105(8):1107-1113. 
 
614. Baron JA: Epidemiology of non-steroidal anti-inflammatory drugs and cancer. 
Prog  Exp Tumor Res 2003, 37:1-24. 
 
615. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G: Aspirin, salicylates, 
and cancer. Lancet 2009, 373(9671):1301-1309. 
 
616. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, 
Pipas JM, Karp DD, Loprinzi CL et al: A randomized trial of aspirin to prevent 
colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 
2003, 348(10):883-890. 
 
617. Chan AT, Ogino S, Fuchs CS: Aspirin use and survival after diagnosis of 
colorectal cancer. JAMA 2009, 302(6):649-658. 
 
618. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE: A large 
cohort study of long-term daily use of adult-strength aspirin and cancer 
incidence. J Natl Cancer Inst 2007, 99(8):608-615. 
 
619. Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, 
Stark L, Porteous ME, Campbell H, Dunlop MG: Effect of aspirin and NSAIDs on 
risk and survival from colorectal cancer. Gut 2010, 59(12):1670-1679. 
 
261 
 
620. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE: 
Aspirin intake and survival after breast cancer. J Clin Oncol 2010, 28(9):1467-
1472. 
 
621. Kim KM, Song JJ, An JY, Kwon YT, Lee YJ: Pretreatment of acetylsalicylic acid 
promotes tumor necrosis factor-related apoptosis-inducing ligand-induced 
apoptosis by down-regulating BCL-2 gene expression. J Biol Chem 2005, 
280(49):41047-41056. 
 
622. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM: 
Therapeutic levels of aspirin and salicylate directly inhibit a model of 
angiogenesis through a Cox-independent mechanism. FASEB J 2006, 
20(12):2009-2016. 
 
623. Shtivelband MI, Juneja HS, Lee S, Wu KK: Aspirin and salicylate inhibit colon 
cancer medium- and VEGF-induced endothelial tube formation: correlation with 
suppression of cyclooxygenase-2 expression. J Thromb Haemost : JTH 2003, 
1(10):2225-2233. 
 
624. Bos CL, Kodach LL, van den Brink GR, Diks SH, van Santen MM, Richel DJ, 
Peppelenbosch MP, Hardwick JC: Effect of aspirin on the Wnt/beta-catenin 
pathway is mediated via protein phosphatase 2A. Oncogene 2006, 25(49):6447-
6456. 
 
625. Din FV, Stark LA, Dunlop MG: Aspirin-induced nuclear translocation of 
NFkappaB and apoptosis in colorectal cancer is independent of p53 status and 
DNA mismatch repair proficiency. Br J Cancer 2005, 92(6):1137-1143. 
 
626. Din FV, Dunlop MG, Stark LA: Evidence for colorectal cancer cell specificity of 
aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer 2004, 
91(2):381-388. 
 
627. Pathi SS, Jutooru I, Chadalapaka G, Sreevalsan S, Anand S, Thatcher GR, Safe 
S: GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a 
reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. 
Mol Cancer Res  2011, 9(2):195-202. 
 
628. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S: Tolfenamic acid and 
pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl 
Cancer Inst 2006, 98(12):855-868. 
 
629. Abdelrahim M, Safe S: Cyclooxygenase-2 inhibitors decrease vascular 
endothelial growth factor expression in colon cancer cells by enhanced 
degradation of Sp1 and Sp4 proteins. Mol Pharmacol 2005, 68(2):317-329. 
 
630. Basha R, Baker CH, Sankpal UT, Ahmad S, Safe S, Abbruzzese JL, Abdelrahim 
M: Therapeutic applications of NSAIDS in cancer: special emphasis on 
tolfenamic acid. Front Biosci (Schol Ed) 2011, 3:797-805. 
262 
 
 
631. Abdelrahim M, Smith R, 3rd, Burghardt R, Safe S: Role of Sp proteins in 
regulation of vascular endothelial growth factor expression and proliferation of 
pancreatic cancer cells. Cancer Res 2004, 64(18):6740-6749. 
 
632. Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R, 3rd, Li X, Safe 
S: Curcumin decreases specificity protein expression in bladder cancer cells. 
Cancer Res 2008, 68(13):5345-5354. 
 
633. Chadalapaka G, Jutooru I, Burghardt R, Safe S: Drugs that target specificity 
proteins downregulate epidermal growth factor receptor in bladder cancer cells. 
Mol Cancer Res 2010, 8(5):739-750. 
 
634. Jutooru I, Chadalapaka G, Abdelrahim M, Basha MR, Samudio I, Konopleva M, 
Andreeff M, Safe S: Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate 
decreases specificity protein transcription factors and inhibits pancreatic tumor 
growth: role of microRNA-27a. Mol Pharmacol 2010, 78(2):226-236. 
 
635. Jutooru I, Chadalapaka G, Lei P, Safe S: Inhibition of NFkappaB and pancreatic 
cancer cell and tumor growth by curcumin is dependent on specificity protein 
down-regulation. J Biol Chem 2010, 285(33):25332-25344. 
 
636. Jutooru I, Chadalapaka G, Sreevalsan S, Lei P, Barhoumi R, Burghardt R, Safe 
S: Arsenic trioxide downregulates specificity protein (Sp) transcription factors 
and inhibits bladder cancer cell and tumor growth. Exp Cell Res 2010, 
316(13):2174-2188. 
 
637. Juarez Olguin H, Flores Perez J, Lares Asseff I, Loredo Abdala A, Carbajal 
Rodriguez L: Comparative pharmacokinetics of acetyl salicylic acid and its 
metabolites in children suffering from autoimmune diseases. Biopharmaceutics 
& Drug Disposition 2004, 25(1):1-7. 
 
638. Nollet F, Berx G, Molemans F, van Roy F: Genomic organization of the human 
beta-catenin gene (CTNNB1). Genomics 1996, 32(3):413-424. 
 
639. Yurochko AD, Mayo MW, Poma EE, Baldwin AS, Jr., Huang ES: Induction of the 
transcription factor Sp1 during human cytomegalovirus infection mediates 
upregulation of the p65 and p105/p50 NF-kappaB promoters. J Virol 1997, 
71(6):4638-4648. 
 
640. Wang YT, Chuang JY, Shen MR, Yang WB, Chang WC, Hung JJ: Sumoylation 
of specificity protein 1 augments its degradation by changing the localization and 
increasing the specificity protein 1 proteolytic process. J Mol Biol 2008, 
380(5):869-885. 
 
 
 
263 
 
641. Chintharlapalli S, Papineni S, Lei P, Pathi S, Safe S: Betulinic acid inhibits colon 
cancer cell and tumor growth and induces proteasome-dependent and -
independent downregulation of specificity proteins (Sp) transcription factors. 
BMC Cancer 2011, 11:371. 
 
642. Chimienti F, Seve M, Richard S, Mathieu J, Favier A: Role of cellular zinc in 
programmed cell death: temporal relationship between zinc depletion, activation 
of caspases, and cleavage of Sp family transcription factors. Biochem 
Pharmacol 2001, 62(1):51-62. 
 
643. Seve M, Chimienti F, Richard S, Mathieu J, Favier A: Intracellular zinc chelation 
induces apoptosis, caspases activation, and transcription factors degradation in 
Jurkat and HeLa cells. In: Trace Elements in Man and Animals 10. Edited by 
Roussel AM, Favier AE, Anderson RA. New York: Kluwer Academic/Plenum 
Publishers; 2000: 1003-1007. 
 
644. Hunt RH, Lanas A, Stichtenoth DO, Scarpignato C: Myths and facts in the use of 
anti-inflammatory drugs. Ann Med 2009, 41(6):423-437. 
 
645. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S: Betulinic acid inhibits 
prostate cancer growth through inhibition of specificity protein transcription 
factors. Cancer Res 2007, 67(6):2816-2823. 
 
646. Piedrafita FJ, Pfahl M: Retinoid-induced apoptosis and Sp1 cleavage occur 
independently of transcription and require caspase activation. Mol Cell Biol 
1997, 17(11):6348-6358. 
 
647. Baslas RK, Zamani R, Nomani AA: Studies on the metal-complex of acetyl 
salicylic acid (aspirin). Experientia 1979, 35(4):455-456. 
 
648. Kim EY, Chang SY, Chung JM, Ryu BR, Joo CK, Moon HS, Kang K, Yoon SH, 
Han PL, Gwag BJ: Attenuation of Zn2+ neurotoxicity by aspirin: role of N-type 
Ca2+ channel and the carboxyl acid group. Neurobiol Dis 2001, 8(5):774-783. 
 
649. Saito H, Sakai T, Ueno K, Kitagawa H: Influence of maternal drug metabolism 
on the fetal toxicity induced by acetylsalicylic acid. J Toxicol Sci 1982, 7(3):177-
184. 
 
650. Ghezzo F, Cesano L, Mognetti B, Pesce E, Pirro E, Corvetti G, Berta GN, 
Zingaro B, Di Carlo F: Salicylate inhibition of rat mammary carcinogenesis and 
angiogenesis in female rat compatible with misoprostol administration. Intl J 
Oncol 2005, 26(3):697-702. 
 
651. Wang D, Dubois RN: The role of COX-2 in intestinal inflammation and colorectal 
cancer. Oncogene 2010, 29(6):781-788. 
 
 
264 
 
652. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La 
Vecchia C, Meyskens F, Senn HJ et al: Aspirin and non-steroidal anti-
inflammatory drugs for cancer prevention: an international consensus statement. 
Lancet Oncol 2009, 10(5):501-507. 
 
653. Grosch S, Maier TJ, Schiffmann S, Geisslinger G: Cyclooxygenase-2 (COX-2)-
independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl 
Cancer Inst 2006, 98(11):736-747. 
 
654. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE: A large 
cohort study of long-term daily use of adult-strength aspirin and cancer 
incidence. J Natl Cancer Inst 2007, 99(8):608-615. 
 
655. Baron JA: Epidemiology of non-steroidal anti-inflammatory drugs and cancer. 
Prog Exp Tumor Res 2003, 37:1-24. 
 
656. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-
Eyssen G, Summers RW, Rothstein R, Burke CA et al: A randomized trial of 
aspirin to prevent colorectal adenomas. N Engl J Med 2003, 348(10):891-899. 
 
657. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, 
Pipas JM, Karp DD, Loprinzi CL et al: A randomized trial of aspirin to prevent 
colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 
2003, 348(10):883-890. 
 
658. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK: Randomized 
controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell 
proliferation in patients with familial adenomatous polyposis. Br J Surg 1993, 
80(12):1618-1619. 
 
659. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines 
C, Riddell R, Morton D, Lanas A et al: Cardiovascular events associated with 
rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 
352(11):1092-1102. 
 
660. Jutooru I, Chadalapaka G, Lei P, Safe S: Inhibition of NFkappaB and pancreatic 
cancer cell and tumor growth by curcumin is dependent on specificity protein 
down-regulation. J Biol Chem 2010, 285(33):25332-25344. 
 
661. Jutooru I, Chadalapaka G, Abdelrahim M, Basha MR, Samudio I, Konopleva M, 
Andreeff M, Safe S: Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate 
decreases specificity protein transcription factors and inhibits pancreatic tumor 
growth: role of microRNA-27a. Mol Pharmacol 2010, 78(2):226-236. 
 
662. Jutooru I, Chadalapaka G, Sreevalsan S, Lei P, Barhoumi R, Burghardt R, Safe 
S: Arsenic trioxide downregulates specificity protein (Sp) transcription factors 
and inhibits bladder cancer cell and tumor growth. Exp Cell Res 2010, 
316(13):2174-2188. 
265 
 
 
663. Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe SH: Betulinic 
Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-dependent 
Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer. Mol Cancer Ther 2012. 
 
664. Tatsukawa H, Sano T, Fukaya Y, Ishibashi N, Watanabe M, Okuno M, Moriwaki 
H, Kojima S: Dual induction of caspase 3- and transglutaminase-dependent 
apoptosis by acyclic retinoid in hepatocellular carcinoma cells. Mol Cancer 2011, 
10:4. 
 
665. Chimienti F, Seve M, Richard S, Mathieu J, Favier A: Role of cellular zinc in 
programmed cell death: temporal relationship between zinc depletion, activation 
of caspases, and cleavage of Sp family transcription factors. Biochem 
Pharmacol 2001, 62(1):51-62. 
 
666. Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D: Sp1, a new 
biomarker that identifies a subset of aggressive pancreatic ductal 
adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2008, 17(7):1648-1652. 
 
667. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, Xie K: 
Transcription factor Sp1 expression is a significant predictor of survival in human 
gastric cancer. Clin Cancer Res 2003, 9(17):6371-6380. 
 
668. Adrian GS, Seto E, Fischbach KS, Rivera EV, Adrian EK, Herbert DC, Walter 
CA, Weaker FJ, Bowman BH: YY1 and Sp1 transcription factors bind the human 
transferrin gene in an age-related manner. J Gerontol A Biol Sci Med Sci 1996, 
51(1):B66-75. 
 
669. Chintharlapalli S, Papineni S, Lee SO, Lei P, Jin UH, Sherman SI, Santarpia L, 
Safe S: Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells 
by drugs that decrease specificity proteins. Mol Carcinog 2011, 50(9):655-667. 
 
670. Chadalapaka G, Jutooru I, Burghardt R, Safe S: Drugs that target specificity 
proteins downregulate epidermal growth factor receptor in bladder cancer cells. 
Mol Cancer Res 2010, 8(5):739-750. 
 
671. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S: Betulinic acid inhibits 
prostate cancer growth through inhibition of specificity protein transcription 
factors. Cancer Res 2007, 67(6):2816-2823. 
 
672. Rejholec V, Vapaatalo H, Tokola O, Gothoni G: Tolfenamic acid in the treatment 
of rheumatoid arthritis. Scand J Rheumatol Suppl 1979(24):9-12. 
 
673. Dinarello CA: Anti-inflammatory agents: present and future. Cell 2010, 
140(6):935-950. 
 
 
266 
 
674. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, 
Chaussade S, Baron JA: Aspirin for the chemoprevention of colorectal 
adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009, 
101(4):256-266. 
 
675. Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, 
Ahnen DJ, Gui J, Summers RW, Baron JA: Nonsteroidal anti-inflammatory drug 
use after 3 years of aspirin use and colorectal adenoma risk: observational 
follow-up of a randomized study. J Natl Cancer Inst 2009, 101(4):267-276. 
 
676. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese 
JA, Oxenius B, Horgan K, Loftus S et al: A randomized trial of rofecoxib for the 
chemoprevention of colorectal adenomas. Gastroenterology 2006, 131(6):1674-
1682. 
 
677. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, 
Gerletti P, Tang J et al: Celecoxib for the prevention of colorectal adenomatous 
polyps. N Engl J Med 2006, 355(9):885-895. 
 
678. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, 
Rosenstein RB, Wittes J, Corle D et al: Celecoxib for the prevention of sporadic 
colorectal adenomas. N Engl J Med 2006, 355(9):873-884. 
 
679. Ouyang N, Williams JL, Rigas B: NO-donating aspirin inhibits angiogenesis by 
suppressing VEGF expression in HT-29 human colon cancer mouse xenografts. 
Carcinogenesis 2008, 29(9):1794-1798. 
 
680. Bratasz A, Selvendiran K, Wasowicz T, Bobko A, Khramtsov VV, Ignarro LJ, 
Kuppusamy P: NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-
resistant human ovarian xenograft tumors to cisplatin by depletion of cellular 
thiols. J Transl Med 2008, 6:9. 
 
681. Kashfi K, Rigas B: The mechanism of action of nitric oxide-donating aspirin. 
Biochem Biophys Res Commun 2007, 358(4):1096-1101. 
 
682. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, Couturier D, 
Coste T, Little J, Chaussade S: Daily soluble aspirin and prevention of colorectal 
adenoma recurrence: one-year results of the APACC trial. Gastroenterology 
2003, 125(2):328-336. 
 
683. Chintharlapalli S, Papineni S, Abdelrahim M, Abudayyeh A, Jutooru I, 
Chadalapaka G, Wu F, Mertens-Talcott S, Vanderlaag K, Cho SD et al: 
Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-
dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells. Int J Cancer 2009, 
125(8):1965-1974. 
 
 
267 
 
684. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S: The oncogenic microRNA-
27a targets genes that regulate specificity protein transcription factors and the 
G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007, 
67(22):11001-11011. 
 
685. Costoya JA: Functional analysis of the role of POK transcriptional repressors. 
Brief Funct Genomic Proteomic 2007, 6(1):8-18. 
 
686. Tillotson LG: RIN ZF, a novel zinc finger gene, encodes proteins that bind to the 
CACC element of the gastrin promoter. J Biol Chem 1999, 274(12):8123-8128. 
 
687. Levine M, Espey MG, Chen Q: Losing and finding a way at C: new promise for 
pharmacologic ascorbate in cancer treatment. Free Radic Biol Med 2009, 
47(1):27-29. 
 
688. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH, Chen S, Corpe C, Dutta 
A, Dutta SK et al: Vitamin C as an antioxidant: evaluation of its role in disease 
prevention. J Am Coll Nutr 2003, 22(1):18-35. 
 
689. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of 
cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad 
Sci U S A 1976, 73(10):3685-3689. 
 
690. Verrax J, Delvaux M, Beghein N, Taper H, Gallez B, Buc Calderon P: 
Enhancement of quinone redox cycling by ascorbate induces a caspase-3 
independent cell death in human leukaemia cells. An in vitro comparative study. 
Free Radic Res 2005, 39(6):649-657. 
 
691. Casciari JJ, Riordan NH, Schmidt TL, Meng XL, Jackson JA, Riordan HD: 
Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in 
vitro tumours. Br J Cancer 2001, 84(11):1544-1550. 
 
692. Park CH, Amare M, Savin MA, Hoogstraten B: Growth suppression of human 
leukemic cells in vitro by L-ascorbic acid. Cancer Res 1980, 40(4):1062-1065. 
 
693. Prasad KN, Sinha PK, Ramanujam M, Sakamoto A: Sodium ascorbate 
potentiates the growth inhibitory effect of certain agents on neuroblastoma cells 
in culture. Proc Natl Acad Sci U S A 1979, 76(2):829-832. 
 
694. Verrax J, Calderon PB: Pharmacologic concentrations of ascorbate are 
achieved by parenteral administration and exhibit antitumoral effects. Free Radic 
Biol Med 2009, 47(1):32-40. 
 
695. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, 
Riordan NH: Pharmacokinetics of vitamin C: insights into the oral and 
intravenous administration of ascorbate. P R Health Sci J 2008, 27(1):7-19. 
 
268 
 
696. Duarte TL, Almeida GM, Jones GD: Investigation of the role of extracellular 
H2O2 and transition metal ions in the genotoxic action of ascorbic acid in cell 
culture models. Toxicol Lett 2007, 170(1):57-65. 
 
697. Hu J, Fang J, Dong Y, Chen SJ, Chen Z: Arsenic in cancer therapy. Anticancer 
Drugs 2005, 16(2):119-127. 
 
698. Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S: Mechanisms of 
action of arsenic trioxide. Cancer Res 2002, 62(14):3893-3903. 
 
699. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph 
WW, Waxman S, Pelicci PG, Lo Coco F et al: Arsenic trioxide as an inducer of 
apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia 
cells. J Natl Cancer Inst 1998, 90(2):124-133. 
 
700. Dynan WS, Tjian R: The promoter-specific transcription factor Sp1 binds to 
upstream sequences in the SV40 early promoter. Cell 1983, 35(1):79-87. 
 
701. Lee YJ, Shacter E: Hydrogen peroxide inhibits activation, not activity, of cellular 
caspase-3 in vivo. Free Radic Biol Med 2000, 29(7):684-692. 
 
702. Lee YJ, Shacter E: Oxidative stress inhibits apoptosis in human lymphoma cells. 
J Biol Chem 1999, 274(28):19792-19798. 
 
703. Kumar S, Sun X, Wiseman DA, Tian J, Umapathy NS, Verin AD, Black SM: 
Hydrogen peroxide decreases endothelial nitric oxide synthase promoter activity 
through the inhibition of Sp1 activity. DNA Cell Biol 2009, 28(3):119-129. 
 
704. Wang X, Wang J, Lin S, Geng Y, Jiang B: Sp1 is involved in H2O2-induced 
PUMA gene expression and apoptosis in colorectal cancer cells. J Exp Clin 
Cancer Res 2008, 27:44. 
 
705. Dasari A, Bartholomew JN, Volonte D, Galbiati F: Oxidative stress induces 
premature senescence by stimulating caveolin-1 gene transcription through p38 
mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich 
promoter elements. Cancer Res 2006, 66(22):10805-10814. 
 
706. Chu S, Ferro TJ: Identification of a hydrogen peroxide-induced PP1-JNK1-Sp1 
signaling pathway for gene regulation. Am J Physiol Lung Cell Mol Physiol 2006, 
291(5):L983-992. 
 
707. Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD, Neve R, Ratan RR: 
Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in 
cortical neurons. J Neurosci 2003, 23(9):3597-3606. 
 
 
  
269 
 
VITA 
Name:   Satya Sreehari Pathi 
Mailing Address:  Department of Veterinary Physiology & Pharmacology 
   4466 TAMU, College Station, TX 77843-4466 
Education:    
August 2012  Doctor of Philosophy in Toxicology 
   Texas A&M University, College Station, TX   
December 2008  Master of Science in Biology 
   Texas A&M University, Kingsville, TX 
   Thesis: Functional analysis of zRICH, a nerve regeneration 
   related protein in zebrafish 
   Thesis Advisor: Rafael Perez-Ballestero 
December 2005 Bachelor of Veterinary Medicine (equivalent to DVM) 
   Acharya N. G. Ranga Agricultural University, India 
    
